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ABSTRACT 
 
This thesis contrasts vaccine innovation efforts in the cases of poliomyelitis and 
HIV/AIDS. It addresses the question of why some fields of human endeavour can be seen 
to yield positive change more quickly than others. 
 
The thesis develops a perspective that views innovation as a cumulative learning process. It 
employs the notion of a ‘testing regime’ to draw attention to the role of testing in driving 
this carefully managed learning process during the development of vaccines. Repeated 
testing, under conditions that are varied using instruments and skill, generates knowledge 
that is reliable and robust for technological purposes. Governance is needed to co-ordinate 
this process of testing to ensure the resulting knowledge growth is shared and cumulative. 
This lens is used to explore the creation of intermediate conditions, the development of 
instrumentalities, and the role of governance in vaccine innovation processes. 
 
The thesis uses the notion of ‘social visions’ to explore how attention directed to 
poliomyelitis contrasted with neglect and apathy afforded to AIDS in its early 
manifestations. Shared, rather than competing, visions are found to play a significant role in 
setting the vaccine innovation process in motion. However, the thesis finds that key 
pathogenic features of the virus and certain ethical and safety stances make learning and the 
accumulation of technological knowledge inherently difficult. Importantly, the thesis finds 
policy measures can mitigate or exacerbate these learning challenges considerably. Whilst 
greater market support and increased research funding tend to be positive contributions to 
vaccine development, this research shows they are only part of what is needed to take ideas 
through to innovation. 
 
The empirical evidence gathered in this thesis, when viewed through the testing regime 
lens, suggests that science and innovation are distinct activities but their inter-relationships 
can be enhanced with the development of an infrastructure focussed on nurturing skills, 
fostering the use of new techniques, encouraging the development of new instruments, and 
implementing governance measures to co-ordinate testing efforts and resources. 
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‘The demand for higher levels of food consumption, greater life expectancy, the elimination 
of infectious disease, and the reduction of pain and discomfort, have presumably existed 
indefinitely in the past, but they have been abundantly satisfied only in comparatively 
recent times. It seems reasonable to suppose that the explanation is to be found in terms of 
supply side considerations. It is unlikely that any amount of money devoted to inventive 
activity in 1800 could have produced modern, wide-spectrum antibiotics, any more than 
vast sums of money at that time could have produced a satellite capable of orbiting the 
moon. The supply of certain classes of inventions is, at some times, completely inelastic - 
zero output at all levels of prices… On the other hand, the purely demand-oriented 
approach virtually assumes the problem away. The interesting economic situations surely 
lie in that vast intermediate region of possibilities where supply elasticities are greater than 
zero but less than infinity!’ (Rosenberg 1974:106). 
 
 
 
‘All effects follow not with like certainty from their supposed causes. Some events are 
found, in all countries and all ages, to have been constantly conjoined together: Others are 
found to have been more variable, and sometimes to disappoint, our expectations; so that, 
in our reasonings concerning matter of fact, there are all imaginable degrees of assurance, 
from the highest certainty to the lowest of moral evidence’ (Hume 1748/2007:Part I iii). 
 
 
 
‘Theories are not verifiable, but they can be corroborated. A theory can be the better 
corroborated the better testable it is’ (Popper 1959:248, 268). 
 
 
 
‘People have been talking vaccine, vaccine, vaccine for public consumption, and I have 
said it too. But I always scratch my head and say this [AIDS] is not the kind of situation 
where it is going to be easy to do the testing’ (Unnamed US public health official, quoted in 
Altman 1986). 
 
 
 
 
Chapter 1 
 
Introduction 
 
What will it take for an HIV vaccine to be developed? Why is there not yet a vaccine after 
nearly 30 years of research? With treatment and prevention programmes alone unable to 
end the pandemic and with 15,000 new infections daily, how can vaccine discovery be 
accelerated? Some believe that HIV vaccine innovation suffers from a lack of money; 
others view it as a virus posing unusual scientific challenges. 
 
Whilst economics and biology certainly reveal difficulties, as recognised and investigated 
in the thesis, these are not the only barriers. The thesis contends that a different set of 
difficulties is exposed when vaccine innovation is analysed as a learning process. 
Examining the path from science to innovation reveals that learning is controlled, co-
ordinated and cumulative; and most importantly, this process can benefit from policy 
intervention. Policies are needed to support not only the generation of scientific knowledge, 
but also the accumulation of specific knowledge required for vaccine innovation. The thesis 
suggests that, in the case of HIV vaccine development efforts, weaknesses in science and 
technology policies may have hampered innovation. 
 
There is a keen sense to let the ‘power of science’ overcome the challenges of HIV vaccine 
innovation (IAVI 2008b:3). This optimism is based on the idea that innovation has 
generally become more related to science1. This would argue that any public policy that 
strengthens science will inevitably support vaccine innovation too. However, as this thesis 
identifies, experience suggests this is far from the case. 
 
The hope that scientists can turn their discoveries into products, in a simple and linear way, 
runs against research on the relationship between science and technology by historians of 
science, historians of technology, sociologists, scientists, engineers, patent and bibliometric 
                                                 
1
 See for example, Dosi (1988b:222) or Freeman (1982:31). However, Freeman notes that ‘the expression 
science-related, is usually preferable to the expression science-based’ (1982:29). 
 2 
analysts. As Nightingale (1997:1) puts it, ‘scientists may like to think that technology is 
just applied science, but engineers know better’. 
 
If the complexities of the science-technology relationship mean that simply funding science 
is not enough to generate vaccines, what else is needed? This thesis seeks to make this 
question clearer for policy makers by providing a framework for conceptualising the 
production and accumulation of vaccine knowledge. 
 
The thesis starts by observing that some vaccines are made quickly, whilst others are not 
made at all. It argues that socio-economic theories provide incomplete explanations of this 
variation, and that an analysis of the way knowledge is accumulated further up the vaccine 
innovation process is required. The thesis draws on historical experiences in vaccine 
innovation, and reflects on the record of HIV research. 
 
A recurrent theme emerges from this analysis: technologists must be able to generate 
knowledge that is reliable, robust and shared in order for it to accumulate and yield 
innovations. Moreover, there is an identifiable system underlying this process. 
Technologists test ideas with instruments and skill, under varying conditions, according to 
widely accepted standards and co-ordinating institutions. Together, the thesis calls this 
conceptualisation a ‘testing regime’. 
 
The testing regime is intended for use as an expository device to gain insights into the 
problems faced during vaccine development efforts. The thesis characterises the role of a 
testing regime in the context of vaccine innovation, locates the testing regime in key 
innovation theory, and applies the testing regime to explore the cases of poliomyelitis and 
HIV vaccine efforts. The thesis shows that certain components of the testing regime are 
potentially fertile – but largely unrecognised – areas for public policy to accelerate and 
improve vaccine innovation. 
 
The rest of this chapter proceeds in six sections. The first section underscores the need for 
policies that support vaccine innovation. The second section preludes a later chapter on the 
 3 
economics of vaccines, and discusses the funding situation for HIV vaccine R&D. The 
third section argues that an ‘upstream’ analysis of vaccine innovation is required. This 
looks at the source of new ideas and how they are taken-up into development. The fourth 
section defines the focus of the thesis, and how it aims to explain the accumulation of 
technological knowledge. The fifth section outlines a broader science policy back-drop to 
this focus and the sixth outlines the remainder of the thesis. 
 
1.1 The need for vaccines 
 
It is difficult to overstate the desirability of vaccines. They have prevented more premature 
deaths, permanent disability and suffering than any other medical discovery or intervention2 
(WHO 2000; Andre 2001:2206). And they are cheap per life saved. For example, the 
cluster of vaccines against polio, diphtheria, pertussis and tetanus that are delivered by the 
WHO’s Expanded Programme on Immunization can together be given for less than about 
$20 per year of healthy life gained in low-income countries (Jamison, Breman et al. 2006). 
 
Vaccines are cost effective when the costs of treatment, hospitalisation and lost working 
days are taken in to account (IOM 2000; Bloom, Canning et al. 2005). For every dollar 
spent on the measles, mumps and rubella vaccine, $21 is saved in direct medical costs 
(IOM 1997). Similarly, the diphtheria, tetanus and pertussis vaccine saves $6.21 for every 
$1 spent (CDC 1999). The WHO has estimated that poliomyelitis eradication will save 
governments $1.5bn per year in treatment and rehabilitation costs (Barrett 2004). The 
elimination of smallpox is thought to have saved $275m per year in direct health costs 
(GAVI 2003) and the $100m invested in eradicating the disease after 1967 ‘saved the world 
about $1.35bn a year’ (Barrett 2004:640). The US alone saves the total of all its 
contributions to the smallpox eradication programme every 26 days (Rappuoli, Miller et al. 
2002). An influential World Bank report, Investing in Health (1993), concluded that child 
immunization is one of the most cost-effective health interventions available. 
 
                                                 
2
 I consider technologies that provide clean water and sanitation to be a likely exception to this claim. 
 4 
Vaccines have positive externalities of group immunity, where people who are not 
immunised also benefit because of the reduced transmission of the pathogen (Ramsay, 
Andrews et al. 2003; Fine 2004). Thus, suffering caused by the spread of communicable 
disease is reduced in addition to the prevention of suffering for the vaccinated product-user. 
Vaccines are easier to administer than many drugs, especially compared to the complicated 
drug regime in AIDS therapy, and some vaccines require only one dose, placing less 
pressure on health infrastructures and budgets. 
 
Immunisation also reduces poverty and inequality (Andre, Booy et al. 2008). These impacts 
stem from the fact that immunisation protects individuals not only against an illness, but 
also against long term effects of that illness on their physical, emotional and cognitive 
development. Enduring poor health through certain phases of life may be especially 
conducive to entering chronic poverty (Yaqub 2002; 2004:125). In contrast, improved 
health has a positive effect on economic productivity, savings and investment, and workers 
to dependents ratios (Bloom, Canning et al. 2004). Health inequalities within countries (let 
alone across the world) still persist but vaccines present us with a tool with which to 
promote equity in health (Bishaia, Koenig et al. 2003; Anand, Peter et al. 2005). 
 
It is not surprising then that a vaccine to stem the HIV pandemic is so sought after. The 
UNDP’s Human Development Report considers HIV to have inflicted a major reversal in 
human development (UNDP 2005). The workforce of entire countries are being decimated 
as they are laden with sickness, or lost altogether to death. Victims, and those around them, 
often suffer social and psychological costs, and the effects of discrimination are deeply 
detrimental to the economy. There are about 40 million people living with HIV/AIDS, 95% 
of them in developing countries3 (WHO/UNAIDS 2006). 
 
So far, the potential contributions of more than 25 million people have been lost to 
HIV/AIDS; their deaths have left 12 million children orphaned in sub-Saharan Africa alone 
(WHO/UNAIDS 2008). In some of those countries, one in five working age adults have 
HIV, and life expectancy has dropped to 30 years, the level of a century ago (CGDev 
                                                 
3
 Combating HIV/AIDS is the sixth Millennium Development Goal (IAVI 2005; UNDP 2005). 
 5 
2006). The loss of household bread-winners and parents to HIV/AIDS has cost sub-Saharan 
Africa about 12% of its GNP (Sachs, Ahluwalia et al. 2001). 
 
1.2 Funding for vaccine innovation 
 
Given that an HIV vaccine is needed so much, one might expect significant private 
investments. However, their investments remained less than $25m in 1993, and only 
managed to reach $50m in 19994 (IAVI 2004a:3). 
 
This led to suggestions of market failure and the need for corrective ‘pull’ policies. They 
include strengthening tax and intellectual property incentives, making advanced purchase 
commitments, offering tiered/differential pricing and the establishment of prizes (Danzon 
1998; Kremer 2001; Kremer 2002; Kremer and Glennerster 2004; Kremer and Snyder 
2004; Kremer, Glennerster et al. 2005; Kremer, Glennerster et al. 2006). Despite the 
assortment of ‘pull’ options, annual private investment in HIV vaccine R&D has never 
exceeded 10% of the global total (UNAIDS 2008:14). 
 
In contrast the most prominent ‘push’ mechanism is funding research directly (IAVI 
2004b)5. For 1993, total global funding for HIV vaccine R&D was less than $160m (IAVI 
2004a:3). Several authors recognised this to be very low and called for increased funding 
using the global public goods argument (Archibugi and Bizzarri 2004; Arnold 2005; Barder 
2005). 
 
In the absence of private investment, governments funded 89% of total global investment in 
HIV vaccine R&D between 2000 and 2007 (UNAIDS 2008:14). Funding R&D is a 
relatively blunt policy tool because the outcomes are so uncertain, but it has been 
                                                 
4
 This compares to around $5bn in 2001 for worldwide expenditure on cancer research by the private sector 
(UICC 2006). 
5
 Other ‘push’ policies include regulatory ‘streamlining’, tax credits, and liability protection (IAVI 2004b). 
 6 
increasingly deployed. Total global investment in HIV vaccine R&D has increased steadily 
from $327m in 2000 to $961m in 20076 (UNAIDS 2008:12). 
 
With an annual expenditure of almost a billion dollars, it is difficult to consider HIV 
vaccine development as a neglected effort, especially when compared to other diseases  that 
have been ‘neglected’7 (Trouiller, Olliaro et al. 2002; Vogel 2006). Total worldwide 
spending on malaria vaccine R&D was only $42m in 1999 and $65m in 2003 (MVI 2004)8. 
For tuberculosis vaccine R&D, it was even less, estimated to have been between $100m 
and $150m over the 1990s (WHO 2002)9. That was the equivalent of spending less than a 
cent over the entire decade for every person infected with tuberculosis. 
 
Funding for neglected disease R&D has increased in recent years to $2bn in 2004 (Morel, 
Acharya et al. 2005) and $2.5bn in 200710 (Moran, Guzman et al. 2009:142). Despite the 
increases, expenditure on HIV vaccine R&D still only represents a small part of the $20bn 
total annual spend on AIDS treatment R&D; and an even smaller part of the $70bn annual 
spend on all health product development (IAVI 2007). 
                                                 
6
 A considerable part of that increase is explained by a $100m donation to IAVI by the Gates Foundation in 
2002. 
7
 The Commission on Health Research for Development (1990) showed that about 10% of health research 
funding is allocated to 90% of the world’s health problems (the ‘10/90 gap’). This includes neglect by public 
expenditure. Medicins Sans Frontieres (2001) estimated that in 2000, non-commercial research was less than 
$100m for TB, malaria, trypanosomiasis, and leishmaniasis combined, compared to $3.1bn public expenditure 
devoted to cancer in the US alone. At the level of research activity, Lanjouw and Cockburn (2001) find that 
references to tropical diseases (which have 99% of their burden in poor countries) occurred in less than 1.5% 
of all citations in 1998. Closer to the product level, Pecoul et al (1999) find that 0.5% of total pharmaceutical 
patents in 1996 relate to these diseases. Only 8 out of 1,393 drugs licensed anywhere in the world between 
1975 and 1997 were developed specifically for tropical diseases. Of these, five were intended for veterinary 
purposes and two were for military purposes. 
8
 It is set to increase following the Gates Foundation’s donation of $107m over six years to the Malaria 
Vaccine Initiative. Donation made on 30/10/2005. See 
http://www.gatesfoundation.org/StoryGallery/GlobalHealth/SGGHMalariaMVI-011019.htm 
9
 According to the WHO’s ‘Global Plan to STOP TB 2006-2015’, it is set to increase to around $200m per 
year over the next decade (WHO 2006). 
10
 Around 80% of these totals have been focussed on HIV, tuberculosis and malaria, whilst other equally 
high-burden diseases (as measured by disability-adjusted life years), such as pneumonia and the diarrhoeal 
illnesses, collectively received less than 6% (McCoy, Kembhavi et al. 2009; Moran, Guzman et al. 2009). 
Much of this concentration in funding is due to the priorities and policies of the Gates Foundation, as 90% of 
total neglected disease funding is provided by public and philanthropic sources (McCoy, Kembhavi et al. 
2009; Moran, Guzman et al. 2009). This emphasizes the importance of the role for public policy in neglected 
diseases. 
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1.3 Uncertainties of the early innovation process 
 
‘If, by doubling research and development spending over the coming five to 10 years we 
could bring forward the discovery of an Aids vaccine, we could save millions of lives’ 
(Brown 2005). 
 
The difficulty with the view put forward by Gordon Brown is that successful innovation is 
not only a function of the amount of money spent on the project, especially in its early 
stages. It is a correct but incomplete view of innovation. Accordingly, one can observe 
immense heterogeneity in vaccine innovation. Table 1 shows that some vaccines have been 
developed in a decade whilst others have eluded development for over a century. 
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Table 1: High variation in the number of years to develop some vaccines 
Infectious Agent 
(disease) 
Agent linked to 
disease 
Vaccine licensed in 
U.S. 
Years elapsed 
Measles virus 
(measles) 
 
1953 1963 10 
Hepatitis B virus 
(hepatitis) 
 
1965 1981 16 
Human 
papillomavirus 
(cervical cancer) 
1981 2006 25 
Rotavirus 
(diarrheal disease) 
 
1973 2006 33 
Bordetella pertussis 
(whooping cough) 
 
1906 1948 42 
Varicella zoster virus 
(chickenpox) 
 
1953 1995 42 
Poliovirus (polio) 
 
 
1908 1955 47 
Haemophilus 
influenzae 
(meningitis) 
1889 1981 92 
Salmonella Typhi 
(typhoid fever) 
 
1884 1989 105 
HIV (AIDS) 
 
 
1983 2018, 
a minimum estimate* 
35+ 
Human 
cytomegalovirus 
(birth defects, 
mononucleosis) 
1960  
- 
48+ 
Mycobacterium 
tuberculosis 
(tuberculosis) 
1882 1927, 
BCG** 
126+ 
Plasmodium spp. 
(malaria) 
 
1880  
- 
128+ 
Source: International AIDS Vaccine Initiative (IAVI 2008a:14). *Two thirds of leading AIDS scientists 
believe that a vaccine will not be developed for at least another ten years (Connor and Green 2008). 
**Although BCG vaccine is widely used in children, it is not as effective in tropical countries, and is not 
effective in adults. 
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Explanations of this wide variation have focused on downstream issues concerning product 
innovations. Economists have emphasised demand-side issues for vaccine products (Pauly, 
Robinson et al. 1995; GAVI 2007) or have analysed issues around the trade-offs in vaccine 
efficacies, costs and development times (Tangcharoensathien, Phoolcharoen et al. 2001; 
Esparza, Chang et al. 2003; Cropper, Haile et al. 2004). Sociologists are concerned with 
anti-vaccination movements (Blume 2006; Dempsey, Zimet et al. 2006), delivery and 
access (Aston 2001; IOM 2003) and selection of vaccine products (Blume 2005; Blume and 
Zanders 2006). 
 
Explaining why something did not occur is obviously methodologically difficult. A focus 
on downstream issues has the weakness that it essentially attempts to explain the non-
existence of a product at the end of the innovation process, by comparing with products that 
do exist. This does not pay attention to how the knowledge that drives the process is 
generated. A deeper analytical approach would involve exploring further upstream in the 
innovation process to trace the unpredictable turns that characterise the evolution of 
knowledge, the historical circumstances in which certain research paths were taken and 
others abandoned, and the local context in which technologies are developed11. 
 
Economic notions of market failure and sociological notions of neglected diseases are 
relatively silent on why HIV vaccine innovation is difficult. HIV vaccine research is well 
funded, has a potential market and is supported by a coalition of prominent social groups12. 
This thesis provides an alternative explanation that builds on innovation theory, draws on 
vaccine history, and is consistent with the HIV vaccine research record. 
 
The first two sections of this chapter highlighted an urgent need for an HIV vaccine, and 
the substantial R&D investments being made for it. This section noted a wide variance in 
the innovation timeline. The next section discusses an important missing variable in 
                                                 
11
 Processes at work before the ‘moment of invention’ must not be neglected from analysis, partly because the 
notion of invention is itself so blurry and arbitrary. Invention is inseparably part of a broader process of 
innovation, the analysis of which unavoidably involves a critical and detailed analysis of the work and 
findings of scientists. This can make social scientists uncomfortable with the burden of mundane 
technicalities, and natural scientists uncomfortable with the possibility that their work might be sullied by 
political, social and economic influences. 
12
 Possibly to the neglect of many other important diseases. 
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explaining that timeline: technological knowledge. Greater understanding of processes that 
create technological knowledge could be used to identify policy levers to accelerate vaccine 
innovation. 
 
1.4 Focus of thesis: Technological knowledge accumulation 
 
This thesis argues that vaccine innovation requires technological knowledge. This 
knowledge cannot be obtained ‘as-is’ from scientific knowledge, but has to be specifically 
generated and accumulated through its own dedicated and deliberate steps. Generating 
technological knowledge involves repeated testing. The purpose of testing is to align 
knowledge to the environment where the technology will actually be used. This requires 
varied, measured and controlled manipulation of experimental conditions with instruments, 
skills and experience. These allow a series of conditions that can mark milestones, or act as 
stepping stones in the path to an innovated product. 
 
But central to the concern of this thesis is that intermediate conditions can range from the 
highly artificial, where it is easier to learn, to the highly relevant, where it is more reliable 
for the purposes of technological use. The creation of these intermediate conditions 
depends on what instruments, skills and experience are available and how they have been 
developed and used. A research process that lacks the basis for creating intermediate 
conditions has to advance in ‘lumpy steps’. This can lead to researchers facing large leaps 
in selecting research strategies. The factors that determine intermediate conditions can be 
crucial in shaping the research and development path. 
 
The manipulation of intermediate conditions needs to be governed so that the emergent 
knowledge is robust. Institutions are required to ensure the knowledge is true, shared and 
integrated. This is to recognise that the accumulation of technological knowledge is a social 
process. Critical instruments and skills are the foundations of the design of intermediate 
conditions and need to be made available or even developed. After a range of testing 
conditions have been developed, they also need to be institutionally standardised for more 
intensive testing. 
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The thesis brings these arguments about the accumulation of technological knowledge 
together in a conceptual framework it calls a ‘testing regime’. It argues that the testing 
regime lens can provide important insights into the vaccine innovation process and, in 
doing so, may be used to help explain some of the variation seen in vaccine innovation. For 
vaccines against different viruses, in different instrumental, social and institutional 
contexts, the propensity to innovate varies systematically, and the testing regimes device 
may be able to characterise this variation to some extent. 
 
Whilst traditional, decentralised ‘peer review’ governance of science may be cumulative for 
the growth of scientific knowledge, it may also contribute to fragmented output that 
increases uncertainty throughout the innovation process. The thesis therefore also needs to 
consider the role of institutions in contracting out targeted research projects, or co-
ordinating investigator-initiated research, for the accumulation of technological knowledge. 
 
1.5 Broader implications of the testing regime for science policy 
 
Whilst the central focus of the thesis is the accumulation of technological knowledge, the 
notion of exploring technological change using the testing regime lens raises a set of wider 
questions within the governance of science. The issue of societal benefits of research and 
professional autonomy may be regarded as a notable back-drop to this study, which 
suggests why testing regimes may have been neglected in the past and why policies to 
support them may be resisted. 
 
Sarewitz (1996) argues the notion that researchers are best left alone to work 
autonomously, because any scientifically reasonable line of research into fundamental 
natural processes is as likely to yield social benefit as any other, is a ‘myth of unfettered 
research’. The argument is aimed at ideas such as Polanyi’s ‘Republic of Science’ (1962), 
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Elzinga’s view that external corruption of science leads to ‘Epistemic Drift’ (1985), and 
more recently Ziman’s ‘Real Science’13 (2000a). 
 
In principle, maximum autonomy in HIV/AIDS research would be achievable if science 
justified itself in terms of the cultural value of understanding a pathogen and disease that 
ravages society. As a cultural entity, there are no criteria by which to judge the merits of 
scientific work, so scientists can be left to decide amongst themselves what deserves 
support (Ronayne 1984). However, if science was justified on such grounds then it would 
merit no more support than the arts. 
 
The noted increases in research funding, however, have not been based on such grounds. 
Rather, increased funding has been provided by governments principally for the purposes 
of making a vaccine. In recognising that technological innovation will require the 
embodiment of new knowledge, funding has been released for R&D. When science justifies 
itself in such practical utility terms it opens the activities of scientists to external control 
(Ronayne 1984). This is because technological concerns, such as those mentioned by 
economists and sociologists in section 1.3, and the role of institutions in testing regimes 
outlined in section 1.4, typically require more management and social organisation than 
scientific endeavours (Pavitt 1999). This gives rise to a tension between professional 
autonomy and accountability as summed up by MacLeod: 
 
‘In our day, we have become accustomed to situations where scientists urge the utility of 
science when asking for public money but defend the social autonomy of science whilst 
spending it’ (cited in Balmer 1993:29). 
 
Therefore the idea of guiding research towards innovation, in the form of testing regimes, 
can find itself meeting resistance, as part of a concern to defend the autonomy and political 
legitimacy of science. However, as will be seen in the next chapter, innovation literature 
from beyond vaccines, and beyond the platitudes of ‘pure’ scientists, indicates that research 
                                                 
13
 These arguments are responses largely to a movement in the 1930s led by JD Bernal (1939) who argued 
that science should serve the needs of the state. 
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can be directed towards innovation and that such tensions can be managed alongside more 
traditional models of science. 
 
‘Despite the uncertain and apparently random nature of the innovation process, it is 
possible to find an underlying pattern of success. Not every innovation fails, and some 
[organisations] appear to have learned ways of responding and managing it such that, while 
there is never a cast iron guarantee, at least the odds in favour of successful innovation can 
be improved’ (Tidd, Bessant et al. 2001:45). 
 
For the purposes of innovation then, certain steps can be taken to complement science and 
make the innovation process more consistent. This key message - that science on its own is 
not enough to secure persistent innovation - seems to have been misunderstood by 
policymakers of recent, and turned on its head to mean that the institutions of science are in 
need of whole-scale reform14 rather than in need of further investment alongside policies to 
develop a skilled industrial workforce (OECD 2003; Dosi, Llerena et al. 2006; EC 2007). 
 
                                                 
14
 Reforms such as encouraging universities to patent and commercialise their research through intellectual 
property licensing deals are often framed in the context of a ‘European Paradox’, where Europe has a 
supposedly strong science base but is unable to turn it into business (see especially European Commission 
Green Paper 1995). 
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1.6 Outline of the thesis 
 
The thesis is developed in nine more chapters. Chapters 2 and 3 introduce the idea of the 
testing regime in two steps: first, by discussing the innovation literature it draws on and 
second, by presenting it as an exploratory framework to analyse technological change. 
Chapter 6 applies it to poliomyelitis vaccine innovation and Chapters 7-9 to HIV vaccine 
innovation efforts. The analysis of HIV vaccine efforts is split into three chapters that use 
the testing regime lens to explore three fundamental aspects of innovation respectively: rate 
of technological change, direction of technological change and decision-making under 
uncertainty. Chapter 4 discusses methodology. Chapter 5 sets the background for the 
empirical chapters by discussing the economics and the biology of vaccine research and 
development. 
 
Chapter 2 reviews evolutionary theories of technological change. This highlights 
shortcomings in ‘push-pull’ models of innovation and policies based on them. The chapter 
discusses how technological paradigms and their trajectories can help characterise 
innovation process in a much more realistic and policy relevant way. Whilst these concepts 
appear later in the empirical chapters, there is a notable issue in the literature in terms of 
understanding why some technological paradigms are overtly more powerful than others. 
The chapter suggests that future theoretical development might address this underlying 
question by focussing on how the deliberate development of instruments and skills in 
crafting varying intermediate conditions affects technological change. 
 
Chapter 3 develops a framework to explore technological knowledge growth. Within this 
framework, the chapter introduces the notion of a ‘testing regime’, specifying its 
characteristics and suggesting its role in innovation. The chapter identifies three dimensions 
of the testing regime in terms of relevant learning conditions, instruments to manipulate 
them, and institutional roles in ensuring cumulative output. The discussion of the testing 
regime builds upon, and is presented in relation to, the theories discussed in chapter 2. The 
chapter also adds the concepts of social vision and operational principle to analyse disease 
construction and vaccine design respectively. 
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Chapter 4 explains the methods used. Recognising that historical and detailed case study 
approaches are useful for addressing process-oriented issues such as innovation, the thesis 
re-constructs the innovation of the poliomyelitis vaccines and HIV vaccine efforts, but with 
a new lens provided by the concept of the testing regime. Details are provided in this 
chapter of how cases were selected and built up. The difficulties of analysing contemporary 
cases, such as HIV vaccine research, and the strategy of synthesising secondary data are 
also discussed. 
 
Chapter 5 analyses the economics of vaccine innovation and highlights the strengths and 
weaknesses of such an approach. It finds that a more detailed examination of the 
technological knowledge underlying vaccine innovation is needed. The second part of the 
chapter outlines basic concepts in immunology and vaccinology necessary to understand 
the biological parameters that define the innovation task.  
 
Chapter 6 analyses the history of two successful poliomyelitis vaccines, and analyses the 
development of its testing regime. A coordinated vision helped encourage provision and 
development of instruments to improve learning conditions. The chapter shows how these 
conditions were related to the selection and development of approaches towards 
poliomyelitis vaccines. Research governance is discussed for its role in the accumulation of 
technological knowledge and in mediating differences in opinion between different 
research groups. Finally, the chapter also notes how differences across countries affect 
vaccine choice and use. 
 
Chapter 7 uses testing regimes to explore the rate of HIV vaccine development. It draws a 
contrast between the strong social vision that drove poliomyelitis research and the weaker 
one in HIV research. The chapter explains how characteristics of HIV make the testing 
regime appear weak and describes under-explored efforts to strengthen it using animal 
models. 
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Chapter 8 applies testing regimes to discuss the direction of HIV vaccine development. It 
tracks the emergence of multiple HIV vaccine efforts in both private and public sectors. It 
explains how, for different vaccine designs, the learning conditions were either realistic but 
difficult, or simple but irrelevant. It suggests how instruments may help change these 
conditions, and highlights the importance of governance in taking up these instrumental 
opportunities to arrive at a vaccine with suitable and appropriate characteristics. 
 
Chapter 9 uses the testing regime idea to focus on decision-making under uncertainty with 
respect to launching HIV vaccine clinical efficacy trials, the most expensive set of testing 
conditions in vaccine development. The chapter shows how the testing regime could, in 
principle, reveal ways to help reduce uncertainties around decisions to undertake such tests 
by drawing out how different decisions about the creation of testing conditions have 
different implications for the rate and direction of innovation. It questions not simply 
whether society really wants (or can have) a vaccine, but also what kind of vaccine it might 
want (or get). Conversely, the testing regime can highlight weaknesses that exist in HIV 
vaccine research policy and can be seen to exacerbate uncertainties. Clinical trials are not 
simply about testing if a vaccine works, but as discussed in the chapter, involve complex 
inter-relationships between the design of the trial and the research approach that led to the 
trial; and these can have effects on the final characteristics of the vaccine15. 
 
Chapter 10 summarises evidence in chapters 6-9 on poliomyelitis and HIV vaccine 
innovation. It then draws ‘cross-cutting’ conclusions across chapters about the use of 
testing regimes to explore innovation. Overall, the thesis suggests that the ideas embedded 
and emphasised by the testing regime lens play important roles in the accumulation of 
technological knowledge, which, if not anticipated and addressed, is likely to hinder 
vaccine innovation further. The chapter suggests that there are three principles which policy 
can follow, which broadly correspond to the three elements of the testing regime: supply 
and development of instruments and skills, supply and development of animal models, and 
strong institutional leadership and co-ordination. 
                                                 
15
 For example, it explains why there is an important distinction to be made between HIV vaccines and AIDS 
vaccines (discussed further in section 9.6). 
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Chapter 2 
 
Evolutionary Theories of Technical Change: A review 
 
This chapter will review evolutionary theories of technological change and their 
explanation of knowledge growth. It argues the field would benefit by including the 
development of instruments, a necessary but under-emphasised foundation for learning. 
The next chapter will take this argument further to suggest the notion of testing regimes be 
used as a lens through which technological change in vaccines can be explored. 
 
2.1 ‘Science-push’ or ‘Demand-pull’? 
 
The birth of innovation studies is typically dated to the 1950s when economic growth 
models1 were left with a ‘residual’, unexplainable by the growth of labour and capital. This 
large leftover was attributed to ‘technical advance’ and referred to as ‘a measure of our 
ignorance’ (Abramovitz 1956; Solow 1957). Explaining technological change became a 
central research challenge. 
 
Post-war science and technology policy drew on Bush’s (1945) manifesto for public 
funding of free and fundamental science. Although his model left room for nuances, it 
encouraged a linear conception of innovation, where scientific discoveries feed directly into 
industrial engineering departments2. Early work in economics provided post-hoc 
justification for policy, by focusing on weak incentives to invest in basic research (Nelson 
1959; Arrow 1962). Social returns to R&D were greater than private returns due to the low 
appropriability of knowledge. Knowledge as a non-rivalrous and non-excludable 
                                                 
1
 Aside from growth accounting exercises, economic historians also emphasised the importance of studying 
the effects of technological change. For example, a landmark text by Landes (1969) succeeds in placing 
technological change at the centre of industrial development, but is weaker in explaining where the new 
technologies came from, preferring to cast science and technology as autonomous entities, largely free from 
the influence of the social, political and economic institutions he so excellently detailed. 
2
 The linear model is rooted in the successes of wartime projects, especially the Manhattan Project. 
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commodity meant that it could leak out of firms without them reaping the full benefits. 
Thus, science represented a market failure that required government intervention. 
 
In contrast, Schmookler (1966) suggested that changes in demand determined innovation 
by showing that shifts in demand preceded shifts in inventive activity3. Marquis (1969) 
found that approximately 75% of 500 innovations were stimulated by ‘demand pull’. Later, 
studies pointed to the importance of paying attention to users’ needs (Rothwell, Freeman et 
al. 1974), the role of users in developing innovations (von Hippel 1988), and the skills and 
informal mobility of researchers between science and industry (Gibbons and Johnston 
1974). 
 
In addition, many examples existed to suggest that science benefited from, rather than 
pushed, technological change, such as investments in the steam engine driving advances in 
thermodynamics (see Rosenberg 1982a for more examples). Such findings may have 
implied that technological change and science4 are determined, rather than influenced, by 
demand. Accordingly, in the 1970s and 1980s, science and technology policies around the 
world - especially those supporting ‘blue sky’ research in the UK - were reined in to make 
for a leaner state that relied more on markets than ‘wasteful’ subsidies (Balmer 1993:64; 
von Tunzelmann, Malerba et al. 2008:472). 
 
Rosenberg (1976; 1982b) was a key opponent of this extreme emphasis on the determinacy 
of market forces: ‘…we are compelled to consider the rates at which different sciences have 
progressed. Many important categories of human wants have long gone either unsatisfied or 
very badly catered for in spite of a well established demand’ (Rosenberg 1976:276). He 
argued science, research and knowledge are important variables in themselves. For him, 
economic forces can only operate within a framework of scientific and technical constraint 
and his historically based work drew attention to what exactly gets invented or attempted. 
                                                 
3
 Demand was measured by investment levels whilst inventive activity was measured by patent applications. 
4
 See for example, Bernal’s (1939) ‘The Social Function of Science’. 
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He argued that it is deeply unsatisfactory to consign technology to a black box and study it 
by quantifying input resources and output efficiency gains5. 
 
Mowery and Rosenberg (1979) identified methodological flaws in demand-pull studies6. 
Explaining innovation by market demand requires more than merely showing its existence: 
it requires evidence that innovation was stimulated by a shift in demand only, rather than a 
shift in demand and knowledge supply together. They also identified theoretical flaws. 
They argue that the concept of demand is invoked inconsistently as the market cannot 
accurately evaluate demand for a future product of which it has incomplete knowledge. 
This is revealed especially by examples of revolutionary new products such as telephones 
and computers7. Furthermore, Schmookler concentrates on mechanical sectors where 
innovations are close to investment and neglects other sectors where the link is likely to be 
weaker. And most importantly, he neglects to analyse how the state of technological 
knowledge influences the choice and method of technical problems that are even attempted. 
 
Mowery and Rosenberg’s influential conclusion was that demand was necessary but not 
sufficient for innovation. Perhaps because they were so focussed on testing the demand-pull 
movement, they did little to explain the vast differences in technical change that were 
emerging from the empirical evidence8 (Pavitt 1984). A new perspective was needed to 
appreciate innovation as an ongoing process9 rather than an event that can be simply pushed 
or pulled. 
 
                                                 
5
 As a result, Rosenberg (1976:278) finds ‘the interesting economic situations… lie in that vast intermediate 
region of possibilities where supply elasticities [of technology] are greater than zero but less than infinity.’ 
6
 As Martin and Nightingale (2000:xvi) note, when the demand pull hypothesis was re-tested, using 
Schmookler’s data and new data, significantly weaker relationships were found. 
7
 In 1943, Thomas Watson as head of IBM, stated, “I think there is a world market for about five computers.” 
Western Union declined the opportunity purchase Alexander Bell’s telephone patent when ‘it was offered to 
them for a mere $100,000!’ (Rosenberg 1986:24; 1994). ‘This ‘telephone’ has too many shortcomings to be 
seriously considered as a means of communication. The device is of inherently no value to us’ (Western 
Union internal memorandum 1876, cited in Yates, Wilkinson et al. 2008:112). 
8
 For example, science-push could be important in the early stages of an industry and economic factors more 
important in later stages; different classes of industry have their own distinctive sources and stimuli for 
technical change. 
9
 Prior to evolutionary theories of innovation, Donald Campbell (1960) also did much to establish the growth 
of knowledge as a process of ‘blind variation and selective retention’. 
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2.2 Evolutionary theories: Moving beyond push-pull debates 
 
A defining feature of evolutionary theory was its stress on bounded rationality and inherent 
uncertainty throughout the ‘groping’ R&D process10. Nelson and Winter (1982:46) 
advocated ‘appreciative theorising’ in order to take into account ‘ignorant uncertainty’ 
where possible outcomes as well as their likelihoods were both unknown11. Such a 
conception of uncertainty cannot be used in elegantly bounded formal probability 
distributions (Nelson 2006). The result was a deliberate blurring between choosing how to 
execute or develop a technique and deciding what technique to use. The essence of the 
evolutionary argument is that these choices can be readily understood as a reflection of the 
past (as opposed to a rational decision making process). 
 
The degree to which variations on the past are blind processes or deliberate goal seeking 
actions was left largely unanswered (see section 2.5). Suffice to say here that, in its early 
manifestations, evolutionary theory emphasised the disorderly and error-ridden nature of 
innovation (leaning to the blind) by amassing empirical studies into the details of the 
innovation process, and increased the appreciation of its diversity, complexity and immense 
uncertainty (Rosenberg 1976; 1982b; Clark and Fujimoto 1991; Pisano 1996). 
 
Thus, the evolutionary perspective developed a more dynamic and differentiated 
perspective of technological change. Nelson and Winter’s ‘technological regimes’ 
(1977:57; 1982:258) reformulated push and pull factors to explain the nature of 
technological knowledge as distinct from well-codified information: it was specific, tacit 
and embodied in people and organisations. They drew on behavioural theories of the firm 
(March and Simon 1958; Cyert and March 1963) to argue that firms do not optimise or 
maximise in their activities; instead they ‘satisfice’ (try to reach definable, realistic targets) 
through the establishment of ‘routines’ (heuristics, habits, rules of thumb) for action and 
                                                 
10
 As a result of the complexity and uncertainty emphasised by evolutionary theory, firms or governments are 
not able to explain fully or predict accurately either the outcomes of their innovative activities, or the 
technical performance of innovations. Another consequence is an emphasis on processes and institutions other 
than market organisation. 
11
 Stirling (1998) developed Knight’s (1921) conception of uncertainty into distinctions between risk, 
uncertainty, ignorance and ambiguity. 
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decision making. Importantly these included search routines for exploring technological 
improvements, which made it a theory of change that regarded the historical accumulation 
of skills and experience as very important. 
 
The importance of tacitness was incorporated into the generation and flows of knowledge. 
Firms, industries and countries were differently able to innovate, and innovation was 
analysed inside the firm as well as outside. Firms were not just information 
processing/coordinating organisations, they were dynamic learning ones too. Firms’ 
variation in rate and direction of learning depended on their accumulated competencies and 
search routines as well as their technological and market opportunities, and their ability to 
appropriate the benefits of their activities (Klevorick, Levin et al. 1995). 
 
Thus, while technological knowledge was still thought costly to create, it was no longer 
assumed to be costless to transmit and re-use. Firms were not considered to be homogenous 
maximisers; moreover, they were thought to play critical and distinctive roles in the way in 
which new technological knowledge is embodied in artefacts. 
 
2.3 Constraints and structure in the growth of technical knowledge 
 
Dosi (1982) developed the evolutionary theory further by suggesting how technology 
changes in ways that cannot be characterised in terms of supply and demand. He applied 
Kuhn’s (1962) ideas about paradigms in science, to technical change. His notion of an 
overarching ‘technological paradigm’12 highlighted that the innovation process does not 
just produce new artefacts and practices; it also generates its own body of growing 
knowledge, restricting innovation and the growth of technological knowledge to a path-
dependent ‘technological trajectory’13. 
 
                                                 
12
 Nelson and Winter (1977) identified a similar concept of ‘technological regime’, mentioned earlier, but did 
not relate it to the opportunities afforded by Kuhn’s (1962) notion of paradigm shifts. 
13
 See David (1985) and Arthur (1989) for alternative explanations of ‘lock-in’ and path-dependence in 
technological change. 
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The incremental accumulation of technological knowledge is constrained by its inherently 
tacit and specific nature, by the emergence of technological tasks from other or older 
technologies, by technology’s links to scientific principles and by the physical materials 
required for solving a technical problem. Perceptions of these factors influence what tasks 
are possible and how they are solved, the identification of dead ends and likely routes to 
success, and shape how new knowledge can be learnt from existing technological practice. 
 
Dosi’s theory emphasised that investments in research would not, on their own, be 
sufficient to yield innovations. Innovations were unlikely to emerge directly from academic 
research without considering concerns highlighted by Dosi, such as problem solving skills. 
It provided a more realistic model for exploring the substantial (but incomplete) role of 
science in innovation than the alternative focus on ‘spill-overs’, which carried an implicit 
but obvious linear assumption of catching and applying science emerging from universities 
(von Tunzelmann, Malerba et al. 2008). 
 
By highlighting that technology had its own growing body of knowledge, and that it links 
to science, Dosi implied that there were two separate bodies of knowledge to link together. 
Thus, Dosi built on work by previous scholars who had argued that science and technology 
were distinct, and therefore, it was their relationship that needed clarification (von Hayek 
1945; Polanyi 1958; Price 1965; Layton 1972; 1974; 1976; Vincenti and Rosenberg 1978). 
This contrasts with authors who have preferred to try and show science and technology to 
be essentially equivalent, or ‘symmetrical’ (Bloor 1976; Latour and Woolgar 1986; Latour 
1987)14. 
 
Taking stock of technological regimes, paradigms and trajectories, (five) stylised facts of 
innovation emerged (1988a:222): uncertainty is inherent; there is increasing reliance on 
                                                 
14
 Microstudies by sociologists studying the social shaping of technology have provided a refined analysis of 
demand and user groups by taking into account class, gender, power and control (MacKenzie and Wajcman 
1985; Bijker, Hughes et al. 1987). These models initially look useful for analysing the developments efforts 
for a vaccine that affects the poor and marginalised, but the theories are difficult to operationalise because 
they try to explain the social construction of, not only technology but also, science, knowledge and facts, all 
under the same ‘symmetrical’ framework of truth and falsity (Pickering 1984; Latour and Woolgar 1986). For 
a rebuttal of social constructivism, see Vincenti (1995). ‘[Technologies] …must conform to real-world 
constraints, such as laws of nature, that are not open to alteration by human agency’ (Vincenti 2000:174). 
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scientific opportunities; search activities are undertaken by formal organisations; these 
organisations learn much by doing and using; and innovation is a cumulative activity and 
competences are built up over time. 
 
2.4 Knowledge flows between science and technology 
 
We have seen that attempts to explain changes in knowledge through needs, even when 
expressed as effective market demand, were problematic (likened to pushing a piece of 
string in Pavitt 1991). Since markets alone could not explain the relationship between 
science and technology, different aspects of technological regimes, paradigms and 
trajectories were explored by examining their knowledge flows across and within 
organisational and institutional boundaries. 
 
R&D departments have remained close to manufacturing firms and production departments 
(Pavitt 1999). Where they have not, networks of people providing feedback and 
collaboration are especially important (Hicks 1995), forming ‘national systems of 
innovation’ (Lundvall 1992; Nelson 1993; Edquist 1997; Freeman 2008) or ‘sectoral 
systems of innovation’ (Malerba 2002; 2004). Whilst universities may be seen as 
knowledge producers and industry as innovators, in systems of innovation it is the 
knowledge flows and linkages between universities and industry that are most significant15 
(Mansfield 1995; Narin, Hamilton et al. 1997; Geuna, Salter et al. 2003). 
 
In order to examine knowledge flows and linkages, a distinction is often made between 
products and their broader underlying bodies of knowledge in order to understand how the 
increasingly specialised production of knowledge is integrated by organisations, 
institutions, and governance for cumulative and persistent innovation (Granstrand, Patel et 
al. 1997; Pavitt 1998; 2002). This is because the division of labour between companies in 
production cannot be mirrored by an equivalent division of labour in knowledge: ‘firms 
                                                 
15
 Indeed, some have suggested that such diffused ‘mode 2’ knowledge production should be studied as a new 
form (Gibbons, Nowotny et al. 1994) whilst others have encouraged a ‘triple helix’ of academia, industry and 
government (Etzkowitz and Leydesdorff 2000). Both the ontological and normative claims of the two groups 
respectively have been contested (Dasgupta and David 1994; David, Foray et al. 1999). 
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know more than they make’ so that they can co-ordinate and integrate for innovation 
(Brusoni, Prencipe et al. 2001)16. 
 
2.4.1 Learning from outside the firm 
 
The production of increasingly specialised knowledge and complex artefacts requires 
integrating an increased range of fields of knowledge that contribute to innovation (Pavitt 
1999). The knowledge required to innovate is often acquired from external sources in a 
form that cannot be easily applied. So R&D has ‘two faces’, one where it enables firms to 
produce new technology, but another where it has to be undertaken in order to understand 
external sources of information and acquire an ‘absorptive capacity’17 (Cohen and 
Levinthal 1989; 1990). 
 
This second external face of R&D is significant because underlying fields of knowledge do 
not advance at the same rate. Their uneven progress cannot be tracked solely by monitoring 
codified information. Tacit competencies, such as the ability to use and refine instruments 
developed elsewhere, must be retained in house to ‘assimilate and exploit externally 
available information’ (Cohen and Levinthal 1989:593). 
 
So, as noted by the concepts of technological regimes, paradigms and trajectories, 
knowledge is highly idiosyncratic at the firm level. It does not diffuse automatically and 
freely through the system; rather, it has to be absorbed by firms through their differential 
capabilities accumulated over time. This raises deeper questions of why some knowledge 
fields are able to grow faster than others (Nelson 2003), and why some technological 
paradigms are less powerful than others in yielding innovations when demand is strong 
(Nelson 2008b). 
 
                                                 
16
 Thus products are becoming increasingly multi-technology and firms increasingly multi-product. 
17
 Similar explanations were put forward by others (Rosenberg 1990; Pavitt 1991), with strong supporting 
empirical evidence (Gambardella 1992; Malerba 1992; Hicks 1995). For example, Project SAPPHO 
highlighted factors common to successful innovation, many of which related to the external environment. 
Firms need to access external know-how, fundamentally incorporate users’ needs into design and 
development, acquire skills and human capital readily, and need product champions and gatekeepers 
(Rothwell 1992; 1994). 
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2.4.2 Learning inside the firm 
 
The way firms adapt to changes in their external knowledge environment and associate 
them with appropriable market opportunities is affected by their internal ‘core 
competencies’, ‘core rigidities’ and ‘dynamic capabilities’ (Henderson and Cockburn 1994; 
Prahalad and Hamel 1994; Leonard-Barton 1995; Teece, Pisano et al. 1997)18. Along with 
absorptive capacity, these concepts resonate strongly with the view that the firm’s primary 
role is knowledge integration. 
 
This knowledge-based approach to understanding firms has a long history, with Penrose 
(1959:78) arguing that the application of knowledge to produce goods and services requires 
the bringing together of many areas of specialised knowledge. The production process is 
not simply the transformation of inputs into outputs, but the creation of value by combining 
an array of knowledge specialisms in a co-ordinated, non-random way19. 
 
Knowledge integration can be recognised as an activity that defines the firm’s existence. 
Injecting market incentives within the firm can be detrimental to intra-organisational 
learning and knowledge integrating capabilities because these activities require a high 
degree of co-operation and teamwork in the delivery of products and services (Kogut and 
Zander 1992). Accumulating increments in an existing stock may depend not just on the 
level of that knowledge stock, but also on the level of other (complementary or 
interconnected) stocks (Dierickx and Cool 1989). For accumulating new knowledge inside 
a firm, market incentives have inherent limits. So, to provide excessively strong individual 
incentives would in fact be destructive of the very advantages that a firm can bring for 
knowledge integration. 
 
Nelson (1998; 2000) divides bodies of knowledge into two distinct but complementary and 
interacting bodies. ‘Bodies of understanding’ reflect competence in a specific technological 
                                                 
18
 This resonates with a long held view that the firm’s primary role is to combine existing but heterogeneous 
sources of knowledge (Penrose 1959:78). These features are central to determining the way firms strike a 
balance between exploiting existing knowledge, and exploring for new knowledge (March 1991). 
19
 Penrose states that the practice of combining specialised knowledge and the ‘inherent heterogeneity in 
resources’ allows the exploitation of ‘productive opportunities’. 
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field. They are less dependent on the immediate context of products and are easier to codify 
and generalise, so they often give rise to publishing and patenting. ‘Bodies of practice’ are 
more esoteric, context specific, and tacit because they are based on experience and skills 
(see also Nelson and Winter 1982:74). As such they are closely related to design, 
development, production and marketing. 
 
Firms are developing and bringing these bodies of knowledge together differently. Practice 
and skills play an important constraining role. This is supported by empirical findings 
showing that whilst firms’ knowledge capabilities are diversifying, their product focus is 
increasing (Gambardella and Torrisi 1998). Firms can move into areas that utilise new 
bodies of understanding, but their production remains constrained by what they already 
know in terms of their bodies of practice. Pavitt (1998:442) takes this to indicate ‘clear 
cognitive limits on what firms can and cannot do’. Thus, the direction in which firms’ 
search activities seek to improve bodies of understanding is strongly influenced by their 
bodies of practice and what they actually make. In this way, electronics firms have moved 
into semiconductor technology (but not biotechnology), and pharmaceutical firms have 
moved into biotechnology (but not semiconductor technology) (Patel and Pavitt 1997). 
 
Recent research has examined firms’ techniques for improving their bodies of 
understanding. It frames learning as a cognitive process that is not only constrained by past 
activities, but one that generates new questions and new knowledge as solutions to 
problems (Nightingale 1998). Drawing on cognitive psychology literature, Padua (2008) 
has suggested that problems can be well defined or ‘ill defined’. Mahdi (2002; 2003:246) 
has gone further in developing a taxonomy of technological search dependent on three 
factors: firstly, the degree to which technological problems can be ‘parsed’ into simpler 
sub-tasks; secondly, the level of ‘rational’ understanding of cause-effect relations; and 
lastly, the costs of experimentation with ‘multiple’ possible solutions. Analysis along these 
dimensions has been very revealing about the growth of bodies of understanding, 
presenting it as a cumulative, step-by-step cognitive advance involving incremental puzzle 
solving. 
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So, firms’ bodies of understanding can be improved in a step-by-step fashion, but this 
cognitive advance is often constrained by bodies of practice. However this perspective 
underplays the possibility of firms strategically changing their bodies of practice so that it 
links up with their bodies of understanding better. There are some indications in the 
literature suggesting that instruments could play a vital role in this endeavour; in particular, 
the role of instruments in recognising when something valuable has been found in a search 
for new understanding. ‘It is almost trite to point out that if you wish to achieve some 
material effect, your tools, not the theories, are the instrumentalities. A theory cannot be 
used directly to move or change something’ (Price 1984b). Despite the importance of 
instrumentation (Price 1984a; 1984c; Rosenberg 1992; Irvine, Martin et al. 1997) it remains 
remarkably under-represented in current innovation literature in terms of how and why it is 
important. 
 
2.4.3 Learning through instrumentation 
 
This section argues that the use and development of instrumentation is a vital and deliberate 
aspect of technological change that deserves more focus. Whilst individual scientists may 
have distinct styles and perspectives of objectivity in bodies of understanding, their 
description at the socially aggregated level is more stable; scientific explanations share 
sufficient common ground for overlapping discoveries and contests over their priority to 
exist (Price 1984b:5). This may lead some to hypothesise that knowledge grows along 
universal paths that are determined by a process of cognitive cumulation. 
 
However such a view of knowledge growth along a unitary path leaves little room for 
science and technology policy, because it implies that the paths of knowledge growth are 
largely predetermined. Kuhn’s paradigm shifts (1962) leave an attractive loophole out of 
this pre-determinacy problem where knowledge growth is still constrained, but might be 
opened up to non-cognitive factors. Kuhn thought of shifts as emerging when, in order to 
accommodate a seemingly incomparable finding, an entire system of thought requires 
radical re-structuring. Major cognitive leaps are necessitated by incommensurable 
observations, which in turn may have important social or economic contingencies. 
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Unfortunately, there are difficulties in relying on paradigm shifts to explain technological 
discontinuities in this way. The history of technology can be structured into paradigmatic 
patterns (Dosi 1982)20, but major technical shifts, that represent considerable cognitive 
advance, do not necessarily acquire the seminal importance that shifts brought on by lesser 
cognitive advance do. For example, silly putty and the Concorde jet were technical 
triumphs brought on by considerable cognitive advance respectively, but they did not 
acquire the importance of the supermarket or the printer, which required less cognitive 
advance. ‘They are just not the type of event that can serve as even the thin end of a wedge 
to open the closed cumulation of science to the social, economic and general utilitarian 
determination that such theorists seek’ (Price 1984b:5). Thus, relying on paradigmatic 
cognitive processes of cumulation to explain shifts in the socio-economic arena clearly has 
tight limitations. 
 
Price notes that rather than simply testing theories and replicating experiments, a great deal 
of laboratory work involves developing ‘instrumentalities’. These involve practicing old 
techniques for doing something; producing a new technique by tinkering and fiddling with 
it; then perfecting, extending and using it on everything in sight. Usually this only yields 
new results that fit very well with prior expectations. But occasionally, it is hoped, the 
experimenter will produce, by luck or clever judgement, results other than those readily 
comprehensible within the paradigms of previous knowledge. 
 
For example, Price noted how the telescope provided the conditions in which Galileo made 
his contributions, an experience which Price delightfully termed ‘artificial revelation’ 
                                                 
20
 This is not what Dosi’s paper aimed to do; rather, as reviewed earlier, it was a theoretical persuasion that 
technological trajectories can exist. I do however believe this claim is supportable (see also subsequent 
evolutionary studies such as Ziman 2000b). For example, an IT expert expresses sentiment of almost 
inescapable progression, ‘Precious little has happened over the past five years… steady increases in processor 
speed and storage size have become as predictable as child’s growth… just as the computer industry is 
predicated on Moore’s Law – that chips will double in speed every 18 months, which companies can literally 
plan on – the telecom industry can be predicated on the transparent network… change is routine and 
uneventful… the fiber-optic backbone has joined the microprocessor on a steady predictable climb. 
Processing speeds will double every 18 months. Bandwidth will quadruple every two years’ (Steinberg 
1998:80-84, cited in Pavitt 1998). 
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(1984b:9)21 . The telescope provided ‘unnatural conditions’ that extended the common 
experience of the senses. ‘Galileo realized that he had manufactured for himself a 
revelatory knowledge of the universe that made his poor brain mightier than Plato and 
Aristotle and all the Church Fathers put together….by clothing the naked eye…. His insight 
was that the new aid to the senses was generalisable to other experiences’ and relevant to 
the real world (1984a:108, 110). This was not the testing of theories, but rather the trying 
out of new practices and techniques to create new conditions, hoping for learning 
opportunities, and then relating them to the world outside of these ‘unnatural conditions’. 
 
Price advocates the use of the term ‘instrumentality’ to carry the general connotation of a 
laboratory method for doing something to nature or to data in hand. But the significant 
point about instrumentalities ‘is that they are not of themselves part of the knowledge 
system of science. They are clearly technology, an understanding of the way to do things, 
and often in their beginning, as with the telescope and voltaic pile, no one properly 
understands how and why they do work as they do, but only that they work and that they 
produce something new’ (Price 1984b:13). The key point is that whilst instrumentalities 
may provide a means of doing something new in the laboratory, they might also conjointly 
do so for the world outside. 
 
Price (1965) had suggested that science and technology move in linked but largely 
independent ways, related like a pair of dancers. Upon realising the significance and 
potential of studying the role of instruments in change, Price revised the imagery by 
arguing that what keeps science and technology linked is that both dance to the music of 
instrumentalities. ‘Normal science begets more normal science. Normal technology begets 
more normal technology. But an adventitiously new instrumentality can make for a change 
in the paradigm within science, and an invention leading to new innovation within 
technology’ (Price 1984a:113). 
 
                                                 
21
 Artificial Revelation: ‘The term is not used lightly. Galileo was not so conceited as to think he was brighter 
than all previous authorities; he knew that he had been presented with decisive new evidence of the structure 
of nature’ (Price 1984b:9). 
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Therefore, particularly for the purposes of analysing innovation that draws heavily on 
science, this thesis suggests that a fruitful line of enquiry would be to combine analysis of 
cognitive learning factors with an examination of how instrumentalities develop, within an 
institutional context that facilitates accumulation (rather than fragmentation) of socially 
produced knowledge. It is with these three incisors (learning, instrumentalities and 
governance) that the next chapter sets out a conceptual framework for exploring 
technological change in vaccine innovation, aspiring to incorporate science, as well as 
technology, in models of innovation and change. 
 
2.5 From bounded to blinded-rationality: fertile ground for new theory 
 
This section develops the notion of a testing regime, ahead of a more formal exposition of 
the analytical framework of the thesis. It reviews existing ideas on variation in evolutionary 
theory and situates instrumental testing processes within them. 
 
Evolutionary theory is perhaps our most tactile approach to dealing with empirical 
challenges in studies of technological change22. This is particularly the case for sectors that 
deal with highly complex, systemic and difficult to predict patterns of behaviour such as 
biopharmaceuticals23. However, evolutionary theory tends to understate the extent to which 
deliberate and purposeful testing processes drive change. Testing processes are integral to 
                                                 
22
 The explanatory potential of evolutionary theory is suggested not only by the burgeoning empirical studies 
in this stream (for example Ziman 2000a) but also by the fact that historians of technology and scholars 
studying growth of knowledge have also arrived at similar points of view, acknowledging some form of 
variation-selection mechanism at work (Campbell 1987; Hull 1988; Vincenti 1990; Constant 2002). In 
particular, it has allowed us to account for enormous accumulated technical change in the past; for if we 
accept that variations are heritable and that selection allows some to be retained, previously unimaginable 
distances can be traversed given time. Adopting such a view makes us less prone to underestimating the 
potential future impact of long term technological change (Rosenberg 1986). ‘In living bodies, variation will 
cause the slight alterations, generation will multiply them almost infinitely, and natural selection will pick out 
with unerring skill each improvement. Let this process go on for millions on millions of years; and during 
each year on millions of individuals of many kinds; and may we not believe that a living optical instrument 
might thus be formed as superior to one of glass as the works of the Creator are to those of man?’ (Darwin 
1859/1994:chapter iv). 
23
 Biopharmaceuticals is a category of medical biotechnology (EC 2009:7). Biotechnology is defined as ‘the 
application of science and technology to living organisms, as well as parts, products and models thereof, to 
alter living or non-living materials for the production of knowledge, goods and services’ (OECD 2005:9). 
Biotechnology can be used for agricultural, industrial and medical purposes. Medical biotechnology is further 
categorised into devices, diagnostics and biopharmaceuticals (treatments and preventatives) (EC 2009:7). 
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any scientific or technological endeavour by selecting what ideas and approaches are 
prioritised or discarded; but less readily recognised is that the tests’ design, set-up, and 
execution provide sources of new ideas and approaches for developing them. As the 
empirical chapters will show, testing concerns feature much earlier in the generation and 
development of ideas than is commonly assumed. 
 
Crucial to all evolutionary theories has been the notion that variation is to some extent 
blind24. The emphasis on uncertainty in R&D served as an important reminder that it is not 
adequate to assume agents rationally devise and choose what they are doing from a large 
range of alternatives with known outcomes. But blind does not necessarily mean random or 
just effects of luck. Dosi (1982) and Nelson and Winter (1977; 1982) did much to show that 
the evolution of technical knowledge was not just serendipitous and a result of chance. In 
this sense, evolution was made less blind with the development of constraining concepts, 
technological paradigms and trajectories. Further advances have been made by scholars 
developing the bounded-rationality notion and highlighting cognitive limits (Gavetti 2005; 
Nelson 2008a). 
 
However, as Dougherty (2007:265) finds25, there remain difficulties in applying theory 
outside the ‘old’ world of ‘autos, computers, and chemicals’ where models emphasise 
‘linear, decomposable, scalable, and path-dependent processes that obey the laws of 
physics.’ In contrast, ‘many 21st century innovation challenges involve non-linear, non-
decomposable, non-scalable and pathless activities that obey the ‘laws’ of life sciences and 
social sciences’. As a result, ‘after more than a year’ of trying, Dougherty sees ‘patterns 
lurking in [her] data but cannot grab them conceptually’ (2007:265). So theoretical 
refinements to the blindness concept are needed for analysing modern empirical data better, 
and ‘people working on drug discovery [using bioinformatics for example] are figuring out 
limits to blind search the hard way’ (2007:267). 
                                                 
24
 ‘In going beyond what is already known, one cannot but go blindly. If one can go wisely, this indicates 
already achieved wisdom of some general sort’ (Campbell quoted in Vincenti 1990:48). 
25
 See also Pisano (2006) who recognizes there are difficult innovation challenges being faced by the 
biotechnology sector, but notes that, recently, the sector has become structured so that research is increasingly 
separated from production and marketing activities. He argues the sector will continue to struggle to remain 
innovative unless these activities are brought closer together again and co-ordinated more carefully. 
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There is a need to further particularise our models of R&D and innovation to take into 
account the diversity of holistic26 knowledge systems, in particular the distinctive 
contributions of science and technology. Dougherty’s findings indicate that industrial life 
scientists ‘proceed in an emergent, stepwise, but deliberate fashion to feel out the 
possibilities in a way that preserves the whole problem space but begins to zero in on 
options’ (2007:267). Simply acknowledging uncertainty is not helpful in such situations, 
where organisations need to engage in deliberate learning activities (Zollo and Winter 
2002). 
 
The need for evolutionary theory to adapt its models to challenging new forms of empirical 
data has been noted. Nelson (2007:31) suggests a new agenda. ‘..too much of the research 
within this tradition has stayed too close to certain features of the early work, which I think 
is causing the endeavour to run into sharply diminishing returns… we played down the role 
of cognition, understanding, and conscious-problem-solving… in effect we were playing 
down the importance of human knowledge in the advance of know-how, and in particular 
were repressing the important roles that the advance of science had played in the evolution 
of practice… It is time to build more closely into economic evolutionary models the nature 
and evolution of the knowledge that guides attempts to improve practice.’ By deferring too 
much to behaviouralists (March and Simon 1958; Cyert and March 1963), evolutionary 
theory lacks agency and struggles to explain change, especially radical change (for example 
in bio-pharmaceuticals). Agency, on its own however, cannot explain the persistent and 
cumulative change that is consistently achieved. 
 
Nelson’s call to redress the balance is highly germane but, as the thesis discussed, it 
remains tied to what is essentially a cognition driven perspective. In contrast, the 
perspective put forward here seeks to emphasise strategic learning through testing with 
instrumentalities. The tests may still be designed by agents of bounded-rationality, but 
testing activities are nevertheless considered intentional, shaped by institutional forces and 
                                                 
26
 Dougherty (2007:268) notes that most pharmaceutical companies are reorganising into multi-disciplinary 
therapy teams to capture interdependencies since the life system cannot be decomposed. 
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built on previous knowledge and habits (Constant 1983). The question that emerges is how 
results from such tests can be and are applied to the innovation process. 
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Chapter 3 
 
Testing Regimes: A lens to explore vaccine innovation 
 
This chapter presents some building blocks from innovation theory with which to explore 
the inventive efforts documented in the empirical chapters of this thesis. It focuses on the 
production of technological knowledge in order to contrast with other explanations of 
vaccine innovation that emphasise the role of the market in vaccine innovation. 
 
One can imagine a Schmooklerian (1966) explanation for poliomyelitis vaccine innovation. 
It would emphasise that the expectation of profit drove industry to allocate its resources 
towards inventive activity. Similarly, it might argue that the lack of an HIV vaccine is due 
to meagre expectations of profit relative to the risks of investment. This thesis will argue 
that such views are problematic because, firstly, industry involvement was limited in 
poliomyelitis vaccine innovation and, secondly, considerable resources have been invested 
into HIV vaccine efforts. 
 
Following Rosenberg’s studies (1976; 1982b), an exploration of technical details in 
upstream vaccine innovation processes is required for a more complete analysis. However 
this chapter also seeks to develop a lens for organising these details into technological 
paradigms (Dosi 1982) so that the empirical chapters should not simply be seen  as a review 
of ‘the science’ underlying vaccine innovation. It uses the concept of operational principles 
as a device that explicitly distinguishes between science and technology, and opens up the 
possibility for exploring technical, path-dependent trajectories in vaccine development. The 
chapter defines testing regimes, charts its role in modern innovation and outlines some of 
its characteristics. 
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3.1 Operational principles in technology 
 
Innovation is an iterative process in which problems are selected, and their solutions are 
generated and selected (Constant 1980; Laudan 1984; Vincenti 1990). Once a problem is 
selected, potential solutions are generated either by using existing knowledge and problem 
solving skills or by engaging in a process of testing and learning. Potential solutions 
become solutions through failure, revision and re-testing. Effective and established 
solutions can then be thought of as operational principles. 
 
Operational principles are defined by Polanyi (1958:328) as ‘how [a technology’s] 
characteristic parts… fulfil their special function in combining to an overall operation 
which achieves the purpose’. The technological problem provides the function the device 
must fulfil (purpose) whilst the operational principle is defined by the way the device will 
perform (function). As such, Vincenti (1990:209) argues, it incorporates features of 
knowledge beyond science1. Thus, science is often necessary but never sufficient for 
innovation, and the technological knowledge needed for innovation cannot be obtained ‘as-
is’ from scientific knowledge. 
 
For example Sir George Cayley’s 1809 statement of the operational principle of the fixed-
wing aircraft is: ‘to make a surface support a given weight by the application of power to 
the resistance of air’ (quoted in Vincenti 1990:208). This separates lift from propulsion. ‘It 
says that an airplane operates by propelling a rigid surface forward through the resisting air, 
thus producing the upward force required to balance the airplane’s weight. It was 
fundamental in that it freed designers from the previous impractical notion of flapping 
wings. All designers have this concept in the back of their minds’ (Vincenti 1990:208). 
 
                                                 
1
 The operational principle ‘originates outside the body of scientific knowledge and comes into being to serve 
some innately technological purpose. The laws of physics may be used to analyse such things as airfoils… 
once their operational principle has been devised, and they may even help in devising it; they in no way 
however contain or by themselves imply the principle’ (Vincenti 1990:209). Similarly Polanyi states, ‘The 
physico-chemical topography of the object may in some cases serve as a clue to its technical interpretation, 
but by itself would leave us completely in the dark [about its operational purpose]… The complete knowledge 
of a machine as an object tells us nothing about it as a machine.’ This detail is recognised by patent law in its 
distinction between discovery and invention (Polanyi 1958:177). 
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Tacit appreciation of the form and purpose of operational principles is crucial. ‘These 
concepts may exist only implicitly in the back of the designer’s minds, but they must be 
there. They are givens for the project, even if unstated. They are absorbed by engineers in 
the course of growing up, perhaps even before entering formal training’ (Vincenti 
1990:208). This also applies to how components are arranged or ‘configured’ to embody 
the operational principle. For example, ‘automobile designers of today usually (but not 
invariably) assume without much thinking about it that their vehicles should have four (as 
against three) wheels and a front-mounted, liquid cooled engine’2 (Vincenti 1990:210). 
 
Engineering design is decomposable into a multi-level and hierarchical set of problems3. 
Successive stages ‘resolve’ problems ‘into smaller manageable sub-problems, each of 
which can be attacked in semi-isolation. Problems at the upper level tend to be conceptual 
and relatively unstructured. People outside engineering think of design primarily in such 
terms; historians tend to focus predominantly on project definition and overall design. At 
the lower levels, where the majority of engineering effort takes place, problems are usually 
well defined and activity tends to be highly structured’ (Vincenti 1990:9). However, the 
notion of decomposability should be employed with caution, particularly in bio-
pharmaceuticals, where patterns of behaviour are highly complex, systemic and difficult to 
predict (Dougherty 2007). 
 
Normally, operational principles and their configuration are well established throughout the 
hierarchy. Most technology is well understood and the challenge is to make steady 
incremental improvements at the lower hierarchical levels. Constant refers to this as 
‘normal technology’ and Vincenti calls the process ‘normal design’4. ‘The engineer 
engaged in such design knows at the outset how the device in question works, what are its 
customary features, and that, if properly designed along such lines, it has a good likelihood 
                                                 
2
 ‘They doubtless assume other things as well. Other features may be left open to be decided in the course of 
the design (whether for instance power is to be applied via the front wheels, the rear wheels, or all four). 
Whatever the details, the preferred configuration for a given device with a given application is knowledge that 
has to be learned by the engineering community, usually by experience with different configurations in the 
early stages of a technology’ (Vincenti 1990:210). 
3
 See Vincenti (1990:9) and Constant (1984:24-27, 33) for examples of multi-level and hierarchical design. 
4
 Normal technology is what Constant’s technological communities usually do – ‘the improvement of the 
accepted tradition or its application under ‘new or more stringent conditions’… like Kuhn’s normal science of 
‘puzzle solving’’ (Constant 1980:10). 
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of accomplishing the desired task’ (Vincenti 1990:7). 
 
But for radical design, or perhaps even normal design in bio-pharmaceuticals, familiarity 
with such design concepts cannot be assumed. ‘How the device should be arranged or even 
how it works is largely unknown. The designer has never seen such a device before and has 
no presumption of success. The problem is to design something that will function well 
enough to warrant further development’ (Vincenti 1990:8). Simply, operational principles 
are yet to be developed and the challenge is to find one that works at all in terms of 
function and purpose. 
 
Despite the need for holistic approaches in bio-pharmaceuticals noted by Dougherty (2007), 
routines for establishing operational principles are likely to be dynamic and hierarchical; 
where progressively lower levels are sequentially fleshed out as a line of development or 
operational trajectory. This is because when there is uncertainty at a given level of 
operation, lower levels are also subject to the same or more uncertainties. As one 
operational principle is established, another needs to be established further down the design 
hierarchy. Solutions to one set of problems go on to define a new set of problems further 
along the design process (Laudan 1984:84; Vincenti 1990:9). 
 
However, as operational trajectories proceed, designers learn about probable efficacy 
through preliminary tests. This means that the trajectory is not completely linear with time, 
and that knowledge acquired about lower hierarchical levels feeds back up to higher levels 
too. The degree to which testing, learning and feedback is possible within the operational 
trajectory is therefore a key factor in the rate of technological change. We return to how 
operational trajectories are selected later. 
 
3.2 Formalised testing regimes 
 
Testing and learning in the innovation process have perhaps become more common in 
recent times because the feasibility of inventions can be trialled more easily before going 
into full scale operation. An increase in the number of trained scientists in the workforce, 
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organisations that have accumulated capabilities in testing prototypes, technical and 
instrumental developments focused on testing, may all have contributed to a new 
environment that makes indirect testing more favourable than in the past (Nightingale 
2000). 
 
Situations where there is less scope for indirect trial still likely remain, for example an 
artisan working from conception through to fabrication with little more than the resolving 
eye and the skilful hand5. Whilst this form of technical development may have many 
favourable artistic attributes, products emerging from craftsmanship are likely to be of high 
unit cost, low standardisation and relatively low complexity. Learning and product 
refinement is largely confined until after the product is introduced to the environment 
directly. Knowledge accumulation and transmission relies heavily on traditions, rituals and 
apprenticeship, acquired mainly through interactions in person, involving tacit or 
procedural knowledge and skills transfer (Constant 1980). 
 
These aspects of knowledge accumulation are still important for innovation where there is 
scope to trial products before exposing them to their environments. However, other 
characteristics of technological change start to emerge more prominently when knowledge 
specifically dedicated to testing is embodied in people (communities and organisations) and 
artefacts (equipment, tools and instruments). 
 
For example, the rate of technical change can be markedly more rapid when designs are 
exposed to the environment vicariously through indirect testing and when feedback is 
quicker. Where vicarious development is not possible, such as craftwork, selection has to 
take place by direct trial in the environment, and traced back to which ‘skilled master’ 
introduced it, before imitation and distribution. So useful design improvements might be 
overlooked, and many of them may not be incorporated into cumulative and systemic 
change. 
 
                                                 
5
 Nightingale (2007) personal communication. 
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Dedicated testing regimes reflect a greater organised division of labour. For example, 
engineers and architects plan on paper by conceptualising their ideas visually (Ferguson 
1977). With drawings, they transmit their ideas to workmen and labourers who build, 
construct, and might also add further creativity (von Hippel 1988). Crucially, plans can be 
refined and modified on paper because design and production is separated to a greater 
extent. 
 
Testing regimes can be yet more formalised. Indeed, a prominent feature of many modern 
engineering sectors is a highly formalised testing regime with communities that are 
dedicated to their development through routinised and systematic testing practices. 
Constant goes so far as to suggest that ‘bold total-systems conjecture and rigorous testing to 
large scale, complex, multilevel systems beginning in the nineteenth century created a 
fundamentally novel category of knowledge and knowledge processes distinct both from 
science proper and from craft technology’ (Constant 1980:21). This form of organised 
engineering, with divided labour exploring the environment indirectly, is capable of much 
faster and more cumulative change than craft based technology and paper-planned design 
(Constant 1980; Constant 1987; Brusoni 2001; Brusoni, Prencipe et al. 2001). Their 
products are typically more sophisticated, standardised and of lower unit cost. 
 
The various degrees of testability and testing regimes described in this section can be 
depicted as different modes of innovation process (see figure 1), where the route to 
innovation can range from the direct to the highly punctuated with several intervening 
steps. It should be noted that important and complex feedback loops have been omitted for 
the purposes of illustrative clarity. The diagram resonates strongly with recent evolutionary 
theory about ‘offline’ development (Nelson 2008a; Nelson 2008b). 
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Figure 1: Increasing indirectness of innovation 
 
 
However, the advantages of increasingly being able to disconnect technical change from its 
environment need be to set against some important disadvantages. Industries that exhibit 
formalised testing regimes can be susceptible to large degrees of unresponsiveness to 
rapidly changing environments. Inflexibility and path-dependency can have harmful effects 
for society (Dosi 1982; David 1985; Blume 2005). Thus a central feature of testing regimes, 
vicarious ‘offline’ testing, can make possible an increasing intensity of production but can 
also limit choices about the direction of technological development by reducing direct 
engagement with the environment (Stirling 2009). 
 
The questions that emerge are: ‘What is it that is ‘modern’ about modern technology?’ 
(Rosen cited in Vincenti 1990:256). What then do we mean by a formal testing regime? 
And how have they had such a profound effect on the rate and direction of technological 
change? 
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3.3 Constitution of a testing regime 
 
The testing regime is defined in this thesis as a system made up of intermediate conditions, 
instrumentalities, and institutional structure. These core terms are in turn defined as 
follows: 
 
1/. Intermediate conditions – A set of environments in which experiments are undertaken to 
learn and develop technology. 
 
2/. Instrumentality – A way of carrying out an experiment, a skill or technique used in 
conjunction with an instrument or tool to create specific intermediate conditions. 
 
3/. Institutional structure – An important context that provides problems to be worked on 
and influences ways of working. 
 
Each of the components of a testing regime is examined in more detail below but it is 
important to note that these core concepts are highly interactive. When we examine a 
‘testing regime’ we must be aware that we are dealing with an ensemble of all three 
elements. 
 
3.3.1 Intermediate Conditions: the reduction of uncertainty 
 
New operational principles are built up in a series of iterative and recursive steps, whilst 
complex phenomena are broken down and simplified (Nightingale 2000)6. This is 
conducted with a background, tacit knowledge of how an operational principle works and 
whether actors can intervene to create artificial conditions more suitable for analysing 
patterns of behaviour (Nightingale 1997). This analysis involves a process of recognising, 
mapping and theorising patterns of behaviour. Patterns of behaviour caused by features of 
the world that are external to the operational principle can be removed, in the mind first 
(during experimental design) and then in reality (experimental set-up). This leaves behind 
the explanatory factors that are of most interest. In this way, the strength and extent of key 
                                                 
6
 Mahdi (2002) refers to this breakdown of phenomena as problem parsing. 
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causal relationships can be assessed for their reliability; and the robustness of a new 
operational principle can be extended into practice. 
 
Initial explanations formed in protected and purified laboratory experiments may not 
necessarily remain relevant in the more messy and unpredictable world outside the 
laboratory (Nightingale 2004). The ability to learn is facilitated by modifying and creating 
simplified conditions, where specific causal mechanisms can be isolated and tested 
(Hacking 1983). However, the resulting experimental knowledge needs to be iterated back 
and forth into more complex conditions of application to ensure relevance outside the 
laboratory. Thus, the development of new operational principles is permeated by constant 
trade-offs between conditions that facilitate the ease of learning and conditions that are 
relevant to the non-laboratory world7. Figure 2 depicts this trade-off. 
 
Figure 2: A trade off in which the innovation process goes back and forth 
 
 
Presenting intermediate conditions as a scale adds to Nelson’s (2008a; 2008b) concept of 
‘offline’ or ‘online’ development by indicating that there may in principle be a continuous 
spectrum of conditions that lie in between offline and online8. 
 
3.3.2 Instrumentalities: the manipulation of intermediate conditions 
 
The ability to tinker with these conditions so that ideas work and become operational 
principles is important for knowledge growth. Its importance has been noted by several 
                                                 
7
 When a balance can be struck between the two, Nightingale (2004:1264) refers to such environments as 
‘artificially purified conditions where theories and the world coincide.’ 
8
 For example, temperature is often part of experimental conditions in biology and biotechnology, but it is not 
a discrete variable that can either be offline or online. It can be held constant or variable, but when it is 
variable it can be more, or less, realistic relative to the designer’s intended operating environment of the 
technology in development. 
x number of intermediate conditions 
Simple 
conditions 
facilitate 
learning 
Complex 
conditions 
reflect 
realism 
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scholars referring to ‘research technologies’, ‘standardised packages’, ‘epistemic 
machinery’, and ‘thing knowledge’ (Fujimura 1992; Rosenberg 1992; Knorr-Cetina 1999; 
Joerges and Shinn 2001; Baird 2004). Their use and application rely on tacit skills and 
techniques (Nelson and Winter 1982:74; Senker 1995; Hopkins 2004:15). 
 
The impact of instrumentalities on technology is being explored, for example in the nano-
materials sector (Rafols 2007; Olsen 2009); although, why they can have such immense 
impacts on the development process is not directly examined. Nelson (2008b:488) argues 
that the ability to ‘identify, control and replicate’ conditions influences progress along 
technological trajectories. Whilst variable conditions may enable learning and the 
development of theories, this does not, on its own, facilitate the development of a 
technology. Rather it is the intended and deliberate manipulation of these conditions with 
instrumentalities (Price 1984b:13) to allow the variation and selection of alternative 
explanations (Deutsch 1997). 
 
The notion of instrumentalities has not been overly specified and tightly defined because it 
is intended for flexible application in empirical contexts. Its value is likely to lie in the way 
that it draws consistent attention across varying empirical contexts to the distinctive 
contribution of technological knowledge to innovation, as distinct from scientific 
knowledge. Instrumentalities: the use of certain objects (artefacts) in certain ways (skilled 
techniques), can be useful for learning in a laboratory9, but it may also be conjointly useful 
for the world outside. In such circumstances, instrumentalities are critical for the creation of 
a set of intermediate conditions that lie in between the laboratory and the world outside, 
where the production of technological knowledge is most intense. 
 
Instrumentalities provide a link between experiment and application by allowing iteration 
along intermediate points of conditions. Technologies develop as instrumentalities reduce 
uncertainty by winnowing the number of possible explanations for behaviour. This helps 
select out a large proportion of possible explanations. As Deutsch (1997) notes, while there 
                                                 
9
 For science, the ability to adjust our ideas for given conditions is given more primacy than our ability to 
adjust conditions to make ideas work. 
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are an infinite number of possible explanations for a phenomenon, there are only a finite 
number of actual ones. Technologies increasingly are too complex to explore unaided, and 
instrumentalities allow conditions to be created for a subpopulation of possible 
explanations to be selectively explored, analysed and tested. A well developed set of 
instrumentalities allows a more focused set of explanations from which to choose, reducing 
search time and costs. 
 
Instrumentalities help technology to be reliable (in the sense that they function repeatedly) 
and valid (in the sense that they function across varied conditions). These selected 
characteristics of knowledge are implicated when instrumentalities allow the creation of a 
series of intermediate conditions in which realistic sets of explanations can be formed. 
Thus, instrumentalities allow rapid recursion between reliability and validity, resulting in 
‘strongly corroborated’ but not necessarily ‘true’ knowledge (Constant 2000:221). 
 
Learning and innovation can therefore be facilitated by improving the resolving power of 
instrumentalities, such that they increase the number of intermediate conditions. The 
greater their number, the easier it is to make reliable inductive inferences that can be shared 
across different sites with the minimum of ‘tinkering’. This effect is appreciated by 
engineers, ‘About half of the Institution of Electrical and Electronic Engineers annual list of 
the 200 top innovations is devoted to testing equipment’ (Constant 1980:276). Since 
experimental conditions are created locally, their co-ordination requires the use of 
specialised technology, shared tinkering or standard operating procedures. 
 
Cumulative learning is affected by how observations emerging from instruments are 
categorised. The technologist (and scientist) has to constantly make decisions over whether 
to take a new reading as highly significant or whether to put the observation down as an 
error in procedure or protocol (Polanyi 1964)10. Inevitably these personal judgements are 
                                                 
10
 These observations need to be related to the complexity and relevance of conditions but observations, often 
borrowed explicitly from science, are always laden with theoretical assumptions (Hanson 1958; Feyerabend 
1987). They can serve to frame observations either as potential breakthroughs or as rendered contaminants. 
Instrumental equipment and criteria are therefore calibrated according to such assumptions and frames. For 
example, in order to keep the data output at manageable levels, the new Hadron Collider (particle accelerator) 
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subject to cultural, educational and social conditioning. We can, but only to a certain extent, 
protect against such subjective judgements by repeating and varying tests as many times as 
resources allow (Nightingale 2000; Nightingale and Mahdi 2006). 
 
Cumulative innovation relies on instrumentalities being used to gather prescriptive, as well 
as descriptive, knowledge (see table 2 and figure 3)11. Procedural knowledge involves 
knowing what to design for, as opposed to knowing how to design to a given requirement. 
Amorphous, ill defined, qualitative goals must be translated into specifiable, attainable, 
quantitative goals couched in definite technical terms. Without such technical performance 
specifications, the designer cannot contrive the details that are ultimately required. For the 
designer these quantities are objective ends, for everyone else they are objective means to 
an associated subjective end. 
 
Table 2: Description and Prescription 
Descriptive Knowledge Prescriptive Knowledge 
Describes things as they are Prescribes how things should be to attain a 
desired end 
It is knowledge of fact or actuality; judged 
in terms of veracity or correctness 
It is knowledge of procedure or practice; 
judged in terms of effectiveness, degree of 
success/failure 
While it may be more or less precise, it is 
not subject to wilful adjustment by 
engineers to serve their needs 
Can be altered at will to be more or less 
effective 
Source: Compiled from a summary of Vincenti (1990:197-8, 216-7, 236-7). 
 
                                                                                                                                                     
is being fine tuned and calibrated to detect and allow for certain observations predicted by string theory 
(Shiga 2007). 
11
 As earlier scrutiny of operational principles suggested, a full descriptive understanding of the way things 
are is not sufficient for technology. Prescriptive and tacit elements are necessary, which indicate: in order to 
accomplish this, arrange things this way. 
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Figure 3: Explicit and procedural knowledge 
 
Source: Taken from Vincenti (1990:198). 
 
For example, applying this to vaccine development, criteria need to be set in the 
development of vaccines. The qualitative goal of immunity must be translated into 
quantitative goals such as the proportion of antibodies that need to be neutralised, or the 
number of T cells that must be activated, or the required concentration of immune system 
support molecules such as cytokines or chemokines. Specifications about what is meant by 
a ‘working vaccine’ are required. Vaccines can be designed to provide immunity quickly 
for a short length of time, or can be designed to become gradually more effective through 
the use of boosters to provide immunity for longer periods of time. 
 
For technology, observations emerging from instruments need to be framed within a set of 
theories that may not, accurately, be called science. They are distinct because they are 
‘device specific, have little explanatory power or scientific standing… Engineers devise 
them because they must get on with their job and the phenomena in question are too poorly 
understood or too difficult to handle otherwise… They are used because they work, 
however imperfectly, and because no better analytical tools are available’ (Vincenti 
1990:214). Even more expedient tools exist but these are ‘too crude even to be dignified as 
theories.’ They are often realised to be wrong and used for practical reasons because they 
are known from experience to give conservative or otherwise acceptable results.12 
 
                                                 
12
 The role of these tools is merely to establish a relative order between observations that need not be absolute. 
Properties of the technological systems (such as size, weight and conformation, composition) measurable or 
observable by instruments are related to predictable and unpredictable conditions to make ‘educated,’ 
experienced guesses about function and failure. The exact number of antibodies is not as important, as 
establishing when they are more or less, and critically when they are enough. 
Explicit knowledge 
Procedural knowledge 
Tacit knowledge Prescriptive knowledge Descriptive knowledge 
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3.3.3 Governance in testing regimes: coordinating instrumentalities 
 
Leadership of, and co-ordination between, research and development groups completes the 
triad, by ensuring that the new knowledge arising from experimental practice with 
instruments is accumulated, assimilated and utilised. For the purposes of a research and 
development community, the testing regime is a ‘shared utility’ that forms an important 
part of the ‘invisible’ research infrastructure (Nightingale 2004) because testing regimes do 
not develop autonomously alongside technological opportunities. They are created at high 
fixed cost and need governance to set up and maintain. 
 
Testing regimes exist in an institutional context where there are ‘basic rules of the game’ 
derived from laws, norms, customs and costs for organising labour and transactions 
(Granovetter 1985; Williamson 1985; Hodgson 1988; North 1990). Within that context, as 
noted in section 3.2, testing regimes develop technologies in niches protected from these 
direct market and social forces (to varying degrees). As a consequence, governance is 
needed to organise the division of labour, coordinate the distribution of testing materials, 
allocate resources for testing, ensure comparability of methods and results, and make 
choices about the development of parallel R&D paths. 
 
The particular set of governing structures required for establishing and maintaining a 
testing regime requires further separate characterisation. Instrumentalities are ‘physical 
technologies’, but the way in which work is divided and coordinated across multiple parties 
using instrumentalities can be conceived as ‘social technologies’ (Nelson 2008c). The two 
technologies co-evolve but the social is more difficult to direct and control than the 
physical (Nelson 2008c), and so it is likely that the testing regime changes slower than the 
technology it tests and develops. 
 
Variations in experimental practice and instruments can mean that comparison is not 
possible; conditions or standards between tests may be different, accuracy and relevance 
may be checked with different instruments. With low comparability, the interpretation of 
testing data in order to eliminate less suitable trajectories becomes subject to intense social 
negotiation as interests form around particular trajectories. Governance structures can either 
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co-ordinate various activities and instruments to increase comparability across conditions or 
it can provide leadership that mediates arguments about how the instruments are calibrated 
and the criteria for success or failure (this forms part of the procedural knowledge). 
 
Standard-setting is a principal way to divide labour and co-ordinate activities dimensions; 
one can set certain quality standards to aim for, use technical standards to compare across, 
and establish reference standards to track progress13 (David and Greenstein 1990). 
Processes of standard setting, both within and across organisations, can result in standards 
being explicitly published or remaining ‘private’ (Farrell and Saloner 1988; Hawkins, 
Mansell et al. 1995). One can imagine that technologies can still develop in contexts of 
privately held standards, but as Steinmueller (2003:134) notes, the standards literature has 
not yet analysed such contexts. 
 
Governance is also needed to play a strategic role in selecting between possible operational 
trajectories. It is of course possible to conduct development on parallel trajectories to hedge 
against uncertainties about function and purpose, but this quickly becomes impossible as 
the costs of developing multiple trajectories become too expensive to maintain and choices 
must be made along the way (Nelson 1961; Scherer 1967; Arditti and Levy 1980; Scherer 
2007). Where costs allow, parallel trajectories may survive all the way through to full 
development, such that broader market or socio-political forces have greater impact on 
choice. 
 
The testing regime itself can take on alternative trajectories of development and may raise 
issues in need of policy guidance. Testing regimes and technological change are 
bidirectionally related, and can be conjointly or independently dynamic. Sometimes to 
unlock innovation, the development of the testing regime needs to be addressed directly. 
Policies might be put in place to encourage the development of techniques and skills, and 
                                                 
13
 Instruments can also be calibrated or designed to provide a way for standardisation. For example, rulers can 
be designed and distributed to allow distance to be measured in centimetres and not inches. Similarly, time 
can be measured by radioactive half life, but the watch is a more practical way of providing measurements in 
minutes and hours. In some cases of technological development, the range of instruments available for use 
may be wide, the scope for manipulating conditions large and the number of possible intermediate conditions 
high. In these circumstances governance becomes even more important. 
 49 
instruments and analytical tools so that test results feed back quickly. Efforts might be 
directed towards reducing the costs of supplying prototypes and models so that testing can 
be high volume. These are overt governance challenges and attention to the evolution of 
such supporting infrastructure can be easily overlooked if a particular innovation is being 
zealously pursued. 
 
3.4 Application to vaccine innovation 
 
This section situates the notion of testing regimes within the specific context of vaccine 
innovation. In the vaccines literature, Blume’s focus has been largely sociological, 
Muraskin’s largely political and Galambos’ on the private firm. Focusing on the gradual 
and persistent accumulation of technological knowledge is likely to complement social, 
political and industrial analyses of vaccine innovation, rather than duplicate them. The 
section will then highlight pertinent questions about the way testing regimes affect vaccine 
development. 
 
3.4.1 Incorporating revolutionary technologies into existing knowledge 
 
Many authors have written about revolutions (impending or past) in vaccine science and 
technology (Galambos and Sewell 1995; Muraskin 1998; Galambos 1999; Andre 2001; 
Plotkin 2005a). These perspectives tend to emphasise science as the major contributor to 
vaccine innovation. The biotechnology revolution and, more specifically, the ideal of 
‘reverse vaccinology’ through rational design (Pizza, Scarlato et al. 2000; Capecchi, 
Serruto et al. 2004; Danzig 2006) envisage potential vaccine targets being identified from 
the genome sequence rather than pathogen cultivation or manipulation (see chapter 5). 
 
Perspectives that emphasise the revolutionary potential of new scientific breakthroughs 
often come at the cost of overlooking the broader technological context into which they 
must enter, where there is considerable prior accumulated knowledge that also needs to be 
integrated. In effect, they are prone to understating the additional research and development 
that is required to bridge the gap between science and innovation. As such, breakthroughs 
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that were expected to revolutionise the pharmaceutical sector have on their own failed to 
reinvigorate product pipelines and are yet to yield a windfall of new therapeutics 
(Nightingale and Martin 2004; Hopkins, Martin et al. 2007). Thus, many of the divisions 
between past revolutions or cycles seem artificial or even arbitrary because past strategies 
continue to be useful rather than completely displaced. 
 
The impacts of major discontinuities need to be related to and assimilated into a system of 
old technologies for cumulative technological change. Even where old is completely 
displaced by new, the origins of revolutions can be traced. ‘…‘creative destruction’ is no 
more prevalent than ‘creative accumulation’ since revolutionary new technologies either 
grow out of old technologies, or must be combined with changes in them in order to 
develop useful artefacts’14 (Pavitt 1999:xv). This thesis does not seek to identify the next 
revolutionary technology to sweep the vaccine industry; instead it focuses on the steady 
accumulation of technological knowledge as it leads up to innovation15. 
 
International efforts to encourage vaccine innovation have tended to overlook the steady 
cumulative aspects of the process. The Children’s Vaccine Initiative was created on the 
hopes of a biotechnology revolution and on fears that the market place was responding only 
to effective demand16 (Muraskin 1998). The CVI was founded to improve communications 
throughout the vaccine innovation system, from basic research and product development 
through to supply delivery. At its core was the assumption that better co-ordination of 
                                                 
14
 Pavitt here is discussing the nature of the micro-electronics revolution, but Constant (1980) holds and 
almost identical view with regard to what is termed ‘the turbojet revolution’. 
15
 This thesis therefore reflects scepticism about the extent of the discontinuities generated by ‘revolutionary’ 
technologies. Revolutionary changes in understanding rarely make redundant all of the techniques that feed 
into –and are necessary for - a complete product. ‘A new paradigm does not discredit and displace all of the 
knowledge generated in earlier paradigms, but instead adds to them. Newtonian physics still has major 
theoretical and practical uses, and at least a quarter of all the new technology created today is still in 
mechanical engineering. The development and commercial exploitation of technological discontinuities turns 
out to be a more cumulative process than is often supposed’ (Pavitt 1998:443). The thesis emphasises that 
innovation draws on stocks of knowledge other than science and represents more than the application of pure 
science. 
16
 The CVI was founded to develop new improved vaccines by bringing together actors in the health 
community network. These included scientists, health bureaucrats (national and international) foreign aid 
donors, and vaccine manufacturers (private and public). The network communicated with each other through 
personal links, publications and conferences but rarely worked together. The kind of private public sector 
switching that occurs in science was not thought to occur as much with administrative officials (Muraskin 
1998). 
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economic information about the biotechnology revolution and about social demand would 
solve the problem, a static view that understates the role of dynamic tacit and technological 
knowledge growth. 
 
The CVI was initially focussed on developing an oral tablet that protects against a dozen 
diseases (a ‘magic bullet’), before turning its mission to field delivery of existing vaccines. 
The CVI was considered unsuccessful and disbanded17. But the reasons put forward for its 
failure have been centred on various polities, overlooking the need for organisations that 
engender tacit skills and infrastructure capable of accumulating technological knowledge 
(Muraskin 1998). Muraskin’s Machiavellian analysis of turf wars and political infighting 
serves to underscore the need for effective governance in a testing regime that may cross 
political borders. 
 
3.4.3 The industrial organisation of the vaccine system 
 
The most prevalent organisational context for testing regimes has been firms, which 
dominate the development and marketing of vaccines (Douglas 2004). Galambos and 
Sewell (1995) provide detailed insight into industrial vaccine innovation at Merck, and 
some of the organisational capabilities required to undertake innovation18, but do not afford 
explicit attention to the testing regimes at work. 
 
Galambos and Sewell (1995) find that a number of ‘cycles’ of revolutionary technologies 
and vaccines have emerged from a mixed system of public, profit and non-profit making 
institutions. By focussing on the varying incentives and disincentives for inventive efforts 
at Merck, they suggest that threatening the market conditions faced by private sector actors 
                                                 
17
 In the late 1990s, the CVI was replaced with a new initiative called The Global Alliance for Vaccines and 
Immunization (GAVI), which focused on ensuring equity in access to new vaccines (Muraskin 2004; Hardon 
and Blume 2005). 
18
 Galambos and Sewell (1995) focus on Merck’s ability to read signals from scientific and medical networks, 
forge new links and ultimately manage the firm through a changing knowledge environment, where many 
others failed. Some of Merck’s absorptive capacity resided in the fact that the executive leadership used to be 
research leaders themselves, such as Maurice Hilleman, who turned out to be a crucial catalyst for innovation. 
Although the authors do not make any reference, their description of Hilleman may well fit that of the 
network builder or the systems leader (Hughes 1983). 
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would cause a fundamental and detrimental shift in the tripartite system that has so far 
fostered vaccine innovation19. 
 
The role that public policies might play in strengthening a testing regime is left largely 
unexplored by Galambos and Sewell (1995). This is particularly significant because, since 
their caution about altering the status quo, two conspicuous shifts in the pharmaceutical 
industry have emerged. Firstly, the industry has become increasingly disaggregated ( 
McKelvey and Orsenigo 2006). Secondly, and perhaps relatedly, public-private 
partnerships have become more prevalent (for example Chataway and Smith 2006). The 
next section discusses some implications of these shifts in turn. 
 
3.4.4 The role of the public sector in shaping norms, values and choice 
 
Whilst the pharmaceutical industry continues to be dominated by large firms undertaking 
most of their innovative activity in house, recent decades have seen significant vertical 
restructuring of the industry such that firms increasingly rely on externally sourced R&D 
coming from small biotechnology firms (McKelvey and Orsenigo 2006). The causes of this 
restructuring of R&D activity are complex, ranging from changes in patent law and practice 
that have extended exclusionary IPRs further ‘upstream’ in science (Heller and Eisenberg 
1998; Mazzoleni and Nelson 1998), financial market innovations that have eased access to 
venture capital for early stage companies (Hall and Lerner 2009), and the development of 
institutions20 that have encouraged universities and public laboratories to actively promote 
commercialization (Debackere and Veugelers 2005; Candemir and Van Lente 2007). 
 
One consequence of these changes is that a larger market for knowledge has emerged 
where knowledge is traded between small technology firms and large integrating firms 
                                                 
19
 ‘The private firms read a combination of scientific/technical and market signals; the professional 
institutions read scientific/technical signals and blend them with signals about their members’ functional 
concerns; the public institutions blend political signals from the electorate, interest groups, and governmental 
bureaucracies with information of a scientific, technical and professional nature. The public interest in disease 
control is best served, we believe, by having all of those signals read and responded to by an innovative, 
mixed system’ (Galambos and Sewell 1995:250). 
20
 Examples of such organisations are science parks, technology transfer offices, incubators, spin-offs, 
contract research consultancies (EC 2004:10). Much of the literature resorts to referring to them as bridges or 
intermediaries to cross undefined regions between university and industry (Webster 1994; Bozeman 2000). 
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(Brusoni and Geuna 2003). Pharmaceutical innovation now exhibits a complex network of 
contractual agreements linking a variety of actors at various stages of the development 
process. Empirical evidence on strategic technology alliances also shows an explosion of 
collaborative activity since the early 1990s, with many of these alliances spanning national 
boundaries21 (Powell, Koput et al. 1996; Powell, Koput et al. 1999; Roijakkers and 
Hagedoorn 2006). 
 
Even where there are weak market incentives, private firms (both small and large) still 
interject because R&D networks extend to public sector research organisations. Public-
private partnerships, particularly those involving philanthropic entities, have emerged as a 
dominant solution to co-ordinating R&D activities in neglected diseases, where markets are 
weak (Buse and Waxman 2001; Widdus 2003; Arnold 2005; Moran 2005; Chataway and 
Smith 2006; Chataway, Brusoni et al. 2007). 
 
Many authors view these changes in the industry as a worrying trend that is systematically 
undermining public sector competences (Gréco 2001:1609; Yamey 2002a; Yamey 2002b; 
Foladori 2003; Barder 2005; Lorenz 2007). However, one author goes further in suggesting 
that these shifts change the nature of products emerging from testing regimes (for example 
Blume and Zanders 2006). This thesis seeks to build on work by Blume in particular, 
whose histories focus on the nature and social acceptability of the vaccines that are 
produced. By disclosing the values, assumptions and social negotiations through which 
vaccines are endowed with particular features22, Blume aims to show that gradual 
privatisation of public sector activities and services is detrimental for public health and 
social welfare. 
 
An important step in this argument is to show that industrial restructuring and public-
private partnerships results in a shift in social values, norms and assumptions. By 
                                                 
21
 Between 1963 and 1999 over one-third of new drugs approved originated in industrial alliances (Danzon, 
Nicholson et al. 2005). 
22
 In this way, Blume’s work resonates with the social construction of technology literature, which carries 
strong differences in emphasis when explaining rate and direction of technical change to the literature 
reviewed in chapter 2. For example, Blume pragmatically avoids drawing explicit boundaries between science 
and technology. 
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examining rival theories of knowledge production (Gibbons, Nowotny et al. 1994; David, 
Foray et al. 1999), Blume and Geesink (2000b) find that ‘vaccinology’ is now highly 
privatised and fits the more diffused ‘mode 2’ model. They suggest that privatisation has a 
detrimental shift in the values, norms and incentives that structure existing disciplines and 
institutions of vaccine R&D. Although, they do not go as far as David et al. (1999), who 
argue that ‘mode 2’ skews incentives in ‘parasitic’ way, drawing resources away from 
traditional scientific work; Blume and Geesink (2000b) remain more concerned by the 
impact on vaccine technology in society. 
 
Another step in the argument is to show how the changes take effect on the nature of 
vaccines and their incorporation into social systems. Blume and Zanders (2006) argues that 
under new organisations of vaccine R&D, such as public-private partnerships, public sector 
competencies are undermined and ultimately, the scope for vaccine choice is diminished. 
The paper suggests the need to critically examine the implications of having various 
nations’ public sectors under increasing encroachment by a globalised and privatised 
vaccine industry. An over-dependence on the private sector may develop as public sector 
competencies in evaluating, developing or manufacturing vaccines are lost. A growing and 
concentrated industry has an interest in standardised products that can be marketed 
globally. Increasingly vocal advocacy groups are in tune with global opinions, where 
individual rights and responsibilities have acquired much greater emphasis over collective 
interest. Blume shows that these forces are now impinging heavily on public health officials 
and consequently health policy outcomes. 
 
The importance of coupling vaccine development and production to a national vaccination 
programme, and insulating them from such collective forces is illustrated in a series of 
papers (Blume and Geesink 2000a; Blume and Lindner 2004; Blume 2005). Blume uses 
histories of poliomyelitis vaccines and the shaping of vaccine policy to show why public 
sector vaccine institutes should respond to quite different incentives to innovate than do 
multinational pharmaceutical companies23. 
                                                 
23
 Drawing on the concept of lock in and path-dependence (David 1985; Arthur 1989; Arthur 1994), these 
papers by Blume highlight the influence of national characteristics and institutions on vaccine selection and 
deployment. By comparing vaccine policy in the USA with that in the Netherlands, he charts the practices and 
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Two of the themes Blume identifies in his exploratory paper (1998), safety and data 
collection, are explored in more detail in this thesis. Blume (1998:170) views questions 
such as ‘can the next step be justifiably taken?’ as reflections of a relative process of 
negotiation between social groups. This thesis adds to these views by emphasising that such 
questions are also an indication of an inherently iterative process of using instruments to 
guide cognitive processes in garnering technological, as distinct from scientific, knowledge. 
Institutional norms play an important role in the testing regime, but even if social 
negotiations could somehow be quenched, such questions about taking ‘the next step’ 
would still arise, where instruments and testing play key roles. 
 
3.4.5 Diagnosis, expectations and visions 
 
Expectations have been argued to be a crucial part of technology dynamics because 
promises are vital to network formation24 (van Lente 1993). They are seen as a resource for 
actors when they legitimize arguments and mobilise funds and attention. In his cyclical 
model, ‘opportunities presented as promises, get accepted and become part of an agenda; 
and are subsequently converted into requirements that guide search processes’ (1993:198). 
It is an inherently forward looking perspective that sees technological change as essentially 
ideas being turned into world-altering actions through expectations that are either pre-
existing or constructed. Whilst expectations are important, focussing analysis on it detracts 
from how, through testing processes, we may unexpectedly learn from the world to change 
our ideas about how a technology should or can function. 
 
However, the notion of a ‘social vision’ of the future (Blume 1992:64-70) is important for 
vaccine innovation. The ‘Tyranny of Diagnosis’ (Rosenberg 2002) highlights how the 
specification of disease concepts has played a pivotal role in ‘how we organize health care 
delivery, think about ourselves, debate and formulate social policy, and define and manage 
                                                                                                                                                     
interests that was likely to have ‘locked out’ one of the vaccines that was later improved and found to be very 
useful were it not for the strength of the Dutch public sector health institutions. 
24
 Van Lente (1993:37) defines promises or expectations as explicit statements uttered in public or written 
down in order to stress their social and shared character. Expectations have a performative element to them as 
they transform statements into actions. ‘The statement alters social reality; it creates, reinforces, or destroys a 
social connection or linkage’ (1993:191). 
 56 
deviance’ (2002:236). By providing an essentialist taxonomy, the act of diagnosis has 
allowed the development of specialised bodies of clinical knowledge and medical 
technologies to address mechanisms of disease. Employing definitions of disease is also the 
link through which clinicians can use these technologies (and bring institutions to bear) on 
patients in a routinised and predictable way. 
 
Thus, the construction of a vision for the technological community depends on an 
essentially scientific endeavour of establishing an observable causal relationship, hence the 
technological importance of an accepted explanation of disease. Once a cause is 
established, the notion of developing a vaccine (or other technological strategies) becomes 
possible. Following Thagard (1999), there are two stages before experimentation and 
mechanism elaboration where such an approach to developing medical technologies can 
break down. 
 
First, before a causal inference can get underway, there needs to be a disease to be 
explained (Thagard 1999:20). Characterisation (Thagard 1999:129) is harder for diseases 
which have many different symptoms (typically called syndromes). It is easier when 
symptoms are distinct and do not change much over time. The indeterminacy of symptoms 
can be a serious impediment to diagnosis, and hence the development of causal 
understanding. Second, for cause specification (1999:130), there can be too many causes to 
sort out and a disease may correlate with many possible causes. Or the causal factor may 
not have the power to impose a readily observable effect with current diagnostic 
instruments (1999:117). Or there may be background theories (such as religious disease 
concepts) that impede the recognition of plausible causes (Thagard 1999:22; Hilleman 
2000b:1436). 
 
3.4.6 Laboratories, animals and humans 
 
This section identifies emerging questions to lead the empirical analysis. 
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Following Thagard and Charles Rosenberg, a social vision is formed as a disease is 
characterised, its causes established, and resources and institutions reorganised towards 
developing a solution to the problem. The key questions that inform this vision are: 
 
• What are the causes and origins of the disease? 
• Are resources and institutions being reorganised? 
 
In the case of vaccines, there are essentially two operational principles new vaccine 
knowledge may build on: a passive immunisation, or active immunisation with a live or 
killed pathogen (see chapter 5). The testing regime can either be weak or strong in terms of 
accumulating this technological knowledge. Subjective goals are translated into more 
feasible, objective and specifiable criteria (Vincenti 1988). One can expect the development 
process to go back and forth between intermediate conditions, and the transitions to be 
difficult. The jumps from concept to animal modelling, and from animal modelling to 
clinical trials, are likely to be fruitful points of analysis. They will involve making 
inferences and judgements as conditions vary between artificially simplified learning 
conditions, and real and complex technological conditions (Nightingale 2004). The most 
crucial questions that emerge are: 
• How does a testing regime help accumulate technological knowledge? 
• What makes a testing regime weak or strong? 
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3.5 Summary 
 
The previous chapter reviewed how evolutionary theories of innovation moved debates 
beyond science-push and demand-pull explanations. This chapter builds on that stream of 
theory (Nelson 2008a; Nelson 2008b) by exploring how a testing regime may affect the 
power of technological paradigms and trajectories to accumulate its own knowledge. 
Together, the chapters emphasise that knowledge growth is not only a cognitive process, 
but that knowledge is also socially accumulated. They argued that cognitive perspectives 
could be usefully augmented with analysis of how instruments develop and interact with 
the innovation process. 
 
This chapter presented the testing regime as a lens for exploring the empirical chapters. The 
testing regime consists of instrumentalities for the creation of intermediate conditions, and 
governance for shared learning and technical development. 
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Chapter 4 
 
Appreciative Synthesis: Methods and methodology 
 
This chapter discusses why a case study approach was adopted, why poliomyelitis and 
AIDS were selected as cases, the challenges of studying a contemporary case, and the 
benefits of analysing data through synthesis. 
 
4.1 Reasons for adopting a case study approach 
 
4.1.1 Getting ‘dirty’ with the details 
 
The development of a new vaccine tends to be seen as an event transpiring in a ‘black 
box’1. Innovation can either be pushed by science, or markets can be corrected to exert 
stronger demand pull forces2. This thesis recognises the importance afforded by these 
policies to vaccine innovation, but seeks to open up and examine the contents of the black 
box, into which vaccine innovation has been consigned3. I believe this will not only allow 
for further complimentary innovation policies to be developed, but will also illuminate why 
there are differences in rate and direction of technical change. This is because specific 
characteristics (of viruses, techniques, instruments, and science policies), together with 
historical contingencies and tendencies, have ramifications that cannot be understood 
without a close and detailed examination of those characteristics. 
 
As Rosenberg explains (1976:2), we must be willing to ‘dirty one’s hands’ in acquiring a 
familiarity with the relevant details of the technology itself. Only in this way is it possible 
to develop an appreciation for the characteristics of particular technologies and the 
                                                 
1
 As Latour (1987) explains, the now widely used black box concept is borrowed from cybernetics, where 
they were customarily used as a short hand way of alluding to some complex process. If it is deemed 
unnecessary to get into the details, one denotes this by simply drawing a box with the inputs and outputs. 
2
 Similarly, for sociological explanations of vaccine innovation, diseases can either affect relevant or 
irrelevant social groups (Bijker, Hughes et al. 1987). Precisely what makes them irrelevant to the vaccine 
innovation process is less well understood, and remains ‘black-boxed’. 
3
 See sections 1.3 and 5.1 for examples of such consignments. 
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consequences that flow (or fail to flow) from them. It is not possible to analyze the effects 
of technological change independent of the particular context within which it appears, for 
the availability of the same technology will exercise very different kinds of consequences 
in societies that differ with respect to their institutions, their values, their resource 
endowments, and their histories’ (1976:2). Rosenberg is certainly not alone in this view and 
this study follows in the tradition of many other scholars’ contributions in this way 
(Constant 1980; Hughes 1983; Vincenti 1990; Blume 1992). 
 
The thesis draws on my understanding and experience acquired through prior studies in 
biochemistry in order to detail the role of certain biological and chemical processes. 
However, references to well known textbooks were often necessary to better appreciate 
findings in journal articles (Stryer 1997; Murray, Rosenthal et al. 1998; Madigan, Martinko 
et al. 2000; Alberts, Johnson et al. 2002; Levine, Kaper et al. 2004; Plotkin and Orenstein 
2004; Voet and Voet 2004; Janeway, Travers et al. 2005). 
 
4.1.2 For complex questions, context counts 
 
The case study method is appropriate for this thesis because the ‘how’ and ‘why’ nature of 
its goals are too complex to be able to use survey or experimental methods (Yin 1994:6). 
Survey methods are unsuitable because such questions do not seek to determine the 
prevalence of established phenomena and experimental methods are unsuitable because we 
have no control over behavioural events. 
 
The complexity and breadth of human activities involved in innovation renders suspect 
attempts to discuss vaccine innovation in highly aggregated quantitative ways4. The 
working assumption has been that while policy and social science literature treats vaccines 
as an almost homogenous category, the scientific literature makes a series of important 
distinctions in their work, that have yet to be brought into the social science or policy 
discourse (for example, natural sterilising immunity is an important consideration in 
                                                 
4
 ‘After all, man is, in his ordinary way, a competent knower, and qualitative common-sense knowing is not 
replaced by quantitative knowing… This is not to say that such common-sense naturalistic observation is 
objective, dependable, or unbiased. But it is all we have. It is the only route to knowledge- noisy, fallible and 
biased thought it be’ (Campbell 1975:191 quoted in Flyvbjerg 2001:73). 
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vaccine design; see section 7.2). A detailed study approach will be able to do this and 
explore the currently unknown consequences for theory and policy. 
 
Theory formulation in vaccine innovation is difficult because there is such wide variety in 
the outcomes of innovative efforts. The heterogeneous phenomenon under study is assumed 
to interact with its context in many ways, blurring the boundaries between the two making 
them virtually indistinguishable. Therefore a study in vaccine innovation processes should 
not, and cannot, be readily divorced from its context. Yin (1993:3) highlights some 
challenges of studying such a situation, ‘First, the richness of the context means that the 
ensuing study will likely have more variables than data points5. Second, the richness means 
that the study… will likely need to use multiple sources of evidence. Third, distinctive 
strategies will be needed for research design and for analysis.’ 
 
4.2 Case study as a tool for context-based learning 
 
The aim of the thesis is a critical exploration of the concept of innovation in vaccines, 
highlighting its substantial variation and historical contingencies. The emphasis is on 
developing context-based theory because developing predictive theories and universals in 
the study of human affairs is difficult. For Flyvbjerg (2001:73), ‘concrete, context-
dependent knowledge is therefore more valuable than the vain search for predictive theories 
and universals’. 
 
Case studies on their own are not supposed to be broadly generalised to populations or 
universes, but act with theory to provide to an adjusted understanding about innovation that 
may be generalised in tandem with other evidence. Yin (1994:30) characterises this process 
as making ‘level two inferences’ through ‘analytic’ rather than ‘statistical generalisation.’ 
 
The thesis is in keeping with Mayr (1976:664) who ‘is fundamentally inductive rather than 
deductive; it begins with microscopic research done in depth and detail on the level of 
                                                 
5
 With less than a hundred vaccines invented (Plotkin and Orenstein 2004), ‘more variables than data points’ 
is a very likely situation. 
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individual episodes, in hopes that the empirical data thus gathered will lead to 
generalisations on some higher level’ (quoted in Vincenti 1990:10). 
 
This study does not, however, reach for completely grounded and empirically-led theory; it 
proceeds more by appreciative theorising (Nelson and Winter 1982:46). In grounded 
theorising, the researcher (supposedly) has no preconceptions guiding the research at all 
(Strauss and Corbin 1998); this leaves the researcher with data from which new theory may 
not necessarily emerge. Although I do not have a detailed preconceived theory already set 
out, I have developed a basic framework with which to expect a reasonable theoretical 
contribution. 
 
Theoretical contributions are appreciative because the thesis seeks to iterate back and forth 
with triangulated empirical data, which is used to test hypotheses about testing regimes. As 
Balmer (1993:55) notes, ‘there is therefore a two-fold research objective: to use theory to 
say something about the data and to use the data to say something about the theory’. 
 
4.3 Case selection and data collection 
 
4.3.1 Disease as a unit of analysis 
 
The ‘disease’ was chosen as the unit of analysis because it is assumed that inventive efforts 
coalesce around the symptoms, tragedies, and challenges posed by the diseases we are 
faced with. For example, most pharmaceutical companies are now organising their efforts 
into therapeutically focussed teams (Dougherty 2007:268). Public policies and programmes 
are structured around single diseases such UNAIDS, STOP TB, and Roll Back Malaria. 
 
‘Disease’ is taken to be a discrete unit of analysis because vaccine innovation processes are 
necessarily targeted at disease-causing agents such as viruses (rather than disease 
symptoms). Viruses, in turn, are assumed to be sufficiently different enough to warrant the 
development of unique innovation systems. Although most vaccines are developed for a 
single disease, some are available for multiple diseases, such as measles, mumps and 
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rubella. However, these are essentially combinations of single vaccines developed from 
earlier innovation processes (Levine, Kaper et al. 2004; Plotkin and Orenstein 2004). 
 
4.3.2 Importance of ‘failure’ in case selection 
 
The two cases I selected, poliomyelitis and AIDS, were primarily chosen to represent 
variation across the dimension that informed my preliminary judgements the most. AIDS 
affected socially neglected groups, poliomyelitis affected all social classes; so innovation 
(or lack thereof) was socially determined in these cases, and they would be amenable to 
social analysis. 
 
Case selection was also driven by two other concerns6. I selected diseases caused by viruses 
in order to avoid unnecessary biological differences, and I was influenced by the 
availability of data. Vaccines against poliomyelitis virus and HIV were two of the major 
research programmes of the last century, and consequently, much has been written about 
those efforts. They seem ready for theory building through a close inspection of their ‘black 
boxes’7. 
 
Poliomyelitis was widely documented as an ‘American success story’ (Oshinsky 2005) 
driven by the determination of a popular US President (akin to the goal of landing on the 
moon) (Gallagher 1985). Such Panglossian histories indicated to me that the case was 
probably in need of further critical review, or at least one that incorporated other powerful 
social groups. 
 
In contrast, HIV/AIDS by the turn of the century had rapidly gained broad media coverage 
as a disease of inequity, with antiretroviral drugs being accessible to some but not others 
                                                 
6
 Screening out other potential cases represented a significant portion of my research effort. 
7
 I considered malaria and tuberculosis, which are also major killers of neglected populations. However, in 
addition to not being viruses, considerably less financial resources were committed to them, compared to 
AIDS and poliomyelitis vaccine efforts (see chapter 1). I studied them to a certain depth and this has informed 
my views. 
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(McGreal 2000; Boseley 2001; Boseley and Astill 2001)8. Indeed, vaccines were hardly 
mentioned at all, except to say that they were a neglected technical option that needed more 
funding (Archibugi and Bizzarri 2004). Moreover, there was an increasing awareness that 
global health inequities were being exacerbated by a broader lack of R&D for neglected 
diseases (Trouiller, Olliaro et al. 2002). In this context my preconception that innovation 
was socially determined seemed reasonable. However, my studies in biochemistry and 
awareness of the challenges faced by natural scientists in these neglected diseases piqued 
suspicions that this was neither a full nor sufficient explanation of innovation in this field. 
 
The methodological strength of the cases selected lies in replication, not sampling, logic 
(Yin 1994:46). According to sampling logic, a small set of cases is assumed to ‘represent’ a 
larger universe. In contrast, the reliability of this study is rooted in replication logic which 
aims to use the same method across the cases, such that similar results are predicted (literal 
replication) or contrasting results are produced but for predictable reasons (theoretical 
replication). This study follows the latter, where one case of successful innovation and 
another of not-yet successful innovation will be examined with ‘maximally similar 
methods’9 (Campbell and Fiske 1959; Campbell 1969). 
 
The importance of such a strategy has been noted by many scholars referring to ‘failure’ 
but has not been followed up with as much conviction (Staudenmaier 1985). This is strange 
because analysis has focussed on successful innovations despite abundant empirical 
evidence indicating that the majority of innovation attempts result in failure (Freeman 
1982) and cogent theoretical arguments about the importance of failures in engineering10 
(Petroski 1992; 2005). 
 
                                                 
8
 This ‘Dying for drugs’ series of newspaper articles were highly influential on the development of my 
thoughts at the time as a biochemistry student. It would not be an exaggeration to say that they led me to 
studies in the social sciences, particularly in innovation policy. 
9
 Campbell conceives reliability as ‘the agreement between two efforts to measure the same trait through 
maximally similar methods’ whereas validity is ‘represented in the agreement between two attempts to 
measure the same trait through maximally different methods’ (cited in Constant 2000:200). Constant argues 
that recursive practice aiming for consistency and convergence lead to increasingly reliable and valid 
knowledge as Campbell conceives it. 
10
 Petroski’s conception of failures in engineering bears similarities to Popper’s notion of falsification in the 
growth of knowledge. Technologies can be seen as hypotheses waiting to be disproved and corrected. 
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Given the emphasis on failure by the scholars above, the case of AIDS seemed pertinent as 
significant resources and inventive effort are now committed to it (see chapter 1). While it 
may be more accurate to describe the case as ‘not yet successful’, it is certainly difficult to 
currently consider it ‘successful’ when prominent AIDS researchers remark, “the virus is 
winning” and “HIV is currently beating the crap out of us” (Hilleman 1992:1052). 
 
It should be noted, however, that the cases were not selected with the aim of answering a 
counterfactual question: ‘why did innovation ostensibly not occur in this case?’ This would 
involve consideration of, potentially, an infinite number of rival theories. Instead, as 
Rosenberg emphasises, much can be learnt about the innovation process from the 
difficulties and challenges encountered in less innovative endeavours, such as the AIDS 
vaccine efforts. ‘It is highly relevant to ask why it took so long to do certain things, and 
why inventors failed for so long at some inventive efforts while they succeeded quickly at 
others… If we want to probe the relations between science, technology and inventive 
activity more deeply, we must learn much more about what was not possible as well as 
what was possible. We need to understand what scientific and technological discoveries 
were needed for key breakthroughs in invention. For knowledge not only permits - it also 
constrains. For this reason we can learn much from the study of unsuccessful attempts to 
invent something for which the market was perceived to be ready. In this respect, the study 
of failure is essential to a determination of the precise role of supply side variables in the 
inventive process’ (Rosenberg 1976:278). 
 
4.3.3 Flexible data collection 
 
Although the study was rooted in theoretical replication logic, where the aim was to use 
similar methods for both cases, greater weight has been given to AIDS in terms of its 
empirical and analytical content. This was to draw out features of the AIDS virus which 
presented vaccine designers with unique sets of challenges. The implications required 
further research and analysis in order to build appreciative theory. This resulted in the rapid 
expansion of the AIDS case and has to a certain extent led to its characterisation as a 
deviant or extreme case. 
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These case studies are not primarily intended to unveil new historical data, but to test 
certain theoretical concepts by bringing together sources on a wide range of topics. Data 
validity was corroborated using a triangulation approach with a varied range of sources. 
Secondary sources of data used were reviews of the scientific literature, histories, 
biographies, contemporary journals such as Vaccine, Virology, Nature and Science, reports 
by policy makers, newspaper articles and publications by non-governmental organisations 
such as advocacy groups and charity foundations. It should be stressed that many of the 
eminent scientists and key actors involved with the poliomyelitis and AIDS vaccine 
endeavours were known personally by the authors of the histories I have drawn on11. In 
some instances they themselves are the authors. 
 
This method of data collection leaves the study prone to several forms of bias (Becker 
1958; 1967; Thatcher 2006). The first is secondary bias, effectively a recycling of the 
primary author’s inaccuracies or prejudices. In order to minimise this effect, documents 
were carefully used and not readily accepted as universal truths or as literal recordings of 
events that have taken place. As mentioned before, multiple sources were used to gain a 
consistent picture. When they were contradictory rather than corroboratory, it was used as a 
signal for further investigation. 
 
The second is researcher bias, a tendency to affirm rather than falsify my own assumptions 
and biases. I have tried to be reflexively careful about this by being alert to it and resisting 
simplistic verification where possible. It should be noted that my preliminary views about 
AIDS as a neglected disease have altered during the course of the research. This may not 
qualify as falsification proper, since there were no formal hypotheses at the outset, but does 
suggest that this investigation was open to the possibility of falsification. 
 
A third form of bias may be geographical. Most of the sources used to build both case 
studies focus entirely on the US, and the convenience of access to this data may have 
skewed the analysis. At first sight, epidemiology does not seem to justify the US focus. As 
                                                 
11
 For example, John Paul, Jonas Salk, Richard Carter, Saul Benison, Frederick Robbins, Stanley Plotkin, 
Robert Gallo, Jon Cohen, Maurice Hilleman, Patricia Thomas, Myron Levine. 
 67 
hygiene and welfare standards improved globally, poliomyelitis epidemics broke out across 
the globe, not just in the US (Carter 1965; Paul 1971). For AIDS, two thirds of all cases 
(and 80% of female cases) live in sub-Saharan Africa (deCock and Weiss 2000; Piot, 
Bartos et al. 2001). The region is home to ten out of the eleven people who contract HIV 
every minute (Kalipeni, Craddock et al. 2003). 
 
However, most vaccines have been developed, produced and funded in the US (Pauly, 
Robinson et al. 1995; Levine, Kaper et al. 2004; Plotkin and Orenstein 2004). For HIV 
vaccine R&D, the US accounted for 85 to 90% of public sector funding between 2000 and 
2004 (UNAIDS 2005:10). About two-thirds of total global HIV vaccine R&D funding was 
disbursed by the US’s NIH alone between 1999 and 2007 (Batson and Ainsworth 
2001:721; UNAIDS 2008:13). A closer examination of epidemiological trends also reveals 
an American focus. Hygiene standards improved foremost in the US and, as such, faced 
severe poliomyelitis epidemics before most other countries. For example, by the time the 
1957 poliomyelitis epidemic struck the Soviet Union, two vaccines had already been 
developed in the US (Carter 1965:359; Paul 1971). A few vaccines are developed in 
Europe, but the rate of AIDS in the US in the mid-nineties was 8 times higher than that of 
the UK or Germany, and 3 times higher than that of France or Switzerland (deCock and 
Weiss 2000:3). By 1999, the US had more than 3 times the total number of cases in Europe 
(deCock and Weiss 2000:6). 
 
4.4 Difficulties of examining contemporary events 
 
Soderqvist (1997) identifies a temporal imbalance in the history of science where 
contemporary science heavily outweighs earlier historical periods in terms of size and 
activity12. Recent science is more ‘dense’ and poses the problem of ‘documentary overload’ 
to the historical researcher. Hughes (1997) therefore emphasises the need to tighten and 
restrict the scope of the study. 
 
                                                 
12
 See also Ziman (1994). 
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However, this approach is less easy in a policy environment, where the unit of analytical 
concern is necessarily large, like the disease. Decomposing the unit into variables divorced 
from their context is likely to hinder the policy relevance of the findings. Therefore, large 
bodies of literature were used, but they were managed by using review articles and histories 
to identify and triangulate key papers. Over the course of this study I was able to recognise 
significant actors and became familiar with key researcher names. 
 
Secondly, the danger of exaggerating the documentary overload can lead to the neglect of 
other problems such as the politics of history. Hughes argues that history is always 
contested by competing interests and partisan accounts, but that this problem is especially 
pertinent in contemporary history. ‘History is never for itself; it is always for someone’ 
(Jenkins quoted in Hughes 1997:26; see also Tatarewicz 1997). Fee and Fox (1989:307) 
explain why this is so: ‘In dealing with the distant past, historians have only the dead and 
each other with whom to contest their interpretations; in dealing with the recent past and 
the present, they must also confront the living – who have memories of their experience, 
and who may also have powerful and perhaps partisan explanations of the same events. The 
political and ideological struggles over interpretation of the present are usually waged with 
a special intensity rarely displayed in arguments over the more distant past’13. 
 
Thirdly, there are problems associated with being temporally too close to the events being 
studied. ‘Contemporary history is the most interesting thing. In my time it used to be called 
journalism’ (Hennessy cited in Hughes 1997:19). Whig history is criticised for interpreting 
past events in today’s context but the main critique of contemporary studies is that the lack 
of temporal perspective compromises one’s ability to analyse rigorously or be able to judge 
which events are (most) significant. However a counter side to this argument can be made. 
Close temporal proximity means that it is not just the history of ‘successful’ technologies 
that is told, but the much richer story of failures is also told. Contemporary studies of 
innovation have the advantage of not knowing which technological option will emerge 
successfully and are therefore able to provide a fuller account of events as they happened. 
 
                                                 
13
 It is interesting to note that Fee and Fox make their point by using the case of AIDS. 
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Even with this advantage however, several well known works on the AIDS epidemic (for 
example Shilts 1987; for example Grmek 1993; Thomas 2001) succumb to a teleological 
account of events, reading history backwards by projecting the certainties of hindsight back 
onto past events. So some events that were important at the time but later emerged to be 
non critical are often omitted or events that were thought to be unimportant at the time are 
invoked with greater emphasis and intensity. They tend to cast actors as either heroes or 
villains and rarely move beyond the position that if only science and technology were free 
from politics and society, everything would be fine. This view contrasts sharply with 
theoretical perspectives of science and technology presented in chapter 2. This thesis is 
careful to highlight contingencies, uncertainties and failures where they were apparent and 
resists re-constructing scientific developments to follow a rational order. 
 
4.5 Analysis through Synthesis 
 
In comparison to the natural sciences, progress in the social and behavioural sciences ‘has 
been exceedingly slow’ (Rosenthal 1991:3). Rosenthal identifies two sources of pessimism 
in social science: problems of ‘poor cumulation’ and ‘small effects’. Although the thesis 
partly argues that the natural sciences have problems of cumulativeness of their own, better 
cumulativeness might be achieved in social research if more effort was spent on analysing 
and conceptualising the data that already exists. This is particularly the case for a 
phenomenon that is so acute, the burgeoning literature has led to establishment of a 
biannual Aids Book Review Journal. Rather than to search for a few major determinants of 
social phenomena, synthesising existing evidence of small effects on variation may 
combine to provide a better overall picture of variability and heterogeneity (Scott 2004; 
NESTA 2006:6). 
 
The importance of quantitative meta-analyses and systematic reviews has been recognised 
by organisations such as the Cochrane and Campbell Collaborations that promote ‘evidence 
based’ medicine and social policy (Sackett, Rosenberg et al. 1996; Chalmers 2003). 
Systematic review techniques have been developed there to pool the results of randomised 
controlled trials, such as meta-analysis (Chalmers and Altman 1995). However, researchers 
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have also begun to explore methods that allow the synthesis of qualitative research (Pope 
and Mays 1996). One such method, used in this thesis, is narrative synthesis, which seeks 
to go beyond summarising studies and highlighting recorded events by attempting to 
integrate them into a narrative analysis. These syntheses aim to identify key themes and 
threads that run through the collected evidence (Greenhalgh 2004). 
 
The synthesised data was analysed using two forms of pattern matching: ‘non equivalent 
dependent variables’ and ‘rival explanations’ (Yin 1994:106). In the first, one seeks to find 
a variety of outcomes that are consistent with an argument and in the second, one takes the 
outcome as given but focuses on how and why the outcome occurred. These methods are 
not very precise and, until better methods are developed, Yin (1994:110) discourages 
postulating very subtle patterns. However, the strong differences between the cases in this 
thesis, combined with synthesised sources that are stable (allowing the investigator to 
assume reliability by revisiting repeatedly) and varied (allowing the investigator to assume 
validity by visiting multiple sources), have allowed me to identify relatively nuanced 
patterns. 
 
4.6 Summary of methods used 
 
I adopted an exploratory case study approach in order to subject the black box of vaccine 
innovation to a detailed examination, using prior experience in biochemistry. I sought to 
develop contextualised theory by making analytical generalisations to the growth of 
knowledge standard. I used disease as the unit of analysis, and selected poliomyelitis and 
AIDS from a range of viruses because they provided interesting technical similarities and 
social contrasts. Importantly, they provided a contrast between ‘success’ and ‘failure’ in 
vaccine innovation. I synthesised a variety of documentary sources, using a 
multidisciplinary approach, to build case validity and reliability. The methods minimised 
secondary bias, researcher bias, geographical bias and difficulties in contemporary studies. 
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Chapter 5 
 
Contextual Analysis of Vaccines: Economic and technical dynamics 
 
This chapter aims to establish a context in which to situate the forthcoming empirical 
chapters. The first part will show how economists have focused on the nature of the vaccine 
market and its effect on industry incentives to invest in R&D for new and improved 
vaccines. The perspective may help to understand why blunt science-push and demand-pull 
explanations of vaccine innovation have dominated policy formulations. The second part 
will provide a basic introduction to the technicalities of vaccines so that the reader may 
engage with ‘the details of the technology’ (Rosenberg 1976:2) in chapters 6-9. 
 
An economic analysis of the vaccine sector 
 
Economic models seem to underlie most analysis and policy discussions about vaccine 
innovation1 (Grabowski and Vernon 1997; Barrett 2004; Finkelstein 2004; Milstien and 
Candries 2005; Kremer, Glennerster et al. 2006; Stephenne and Danzon 2006). ‘There is a 
common root to most of the problems [in vaccines]: economic fundamentals’ 
(Vandersmissen 2001:1612). And the World Health Report states, ‘You cannot make real 
changes in society unless the economic dimension of the issue is fully understood’ (WHO 
1999:viii). This section will highlight some of the strengths and weaknesses of this 
approach. 
 
Most economists have argued that poor market conditions, together with certain industry 
characteristics have led to less than desirable levels of vaccine innovation. They tend to do 
this by splitting the factors into supply and demand. ‘Two avenues can be considered: one 
can attempt to solve the problem by addressing the supply side, to ensure plentiful 
availability. Alternatively one can strengthen demand, to provide the incentive of an 
                                                 
1
 The references to HIV/AIDS as a threat to notions of progress and economic growth in section 1.3 support 
this assertion further. 
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attractive market’ (Vandersmissen 2001:1614). Aside from the problems of divorcing 
interacting factors in this way, such categorisation is also rather arbitrary because all of the 
characteristics listed below as supply may easily be considered part of market conditions as 
a whole, perhaps excepting rising R&D costs. Nevertheless, the categorisation below 
should be sufficient for gaining a familiarity with the broad context of vaccine innovation. 
 
Section 5.1 will examine the demand for vaccines by exploring certain characteristics of the 
market. It notes that the vaccine market is considerably smaller than that of pharmaceuticals 
and the following sections examine why this might be. It examines the centralised way in 
which vaccines are often purchased, varying disease environments, and social resistance to 
vaccination. 
 
Section 5.2 will examine the supply of vaccines by exploring certain characteristics of the 
industry. It notes the importance of limited liability and regulation, and strong intellectual 
property protection in the context of rising R&D costs. It suggests that in the absence of 
these factors many companies have exited the sector, leaving vaccine supply largely in the 
hands of a few manufacturers. 
 
5.1 Demand for vaccines: the vaccine market 
 
5.1.1 Small market size relative to pharmaceuticals 
 
Worldwide annual vaccine sales have been growing from about $1bn in 1980 to $6bn in 
2001 and $10bn in 2005. The market is expected to continue growing by 10 to 12% per 
year; to $17bn in 2010 (Gréco 2001; Gréco 2002; NIH and NIAID 2002; Vandersmissen 
2002; Douglas 2004; Costello 2007; NIH and NIAID 2007). Despite such rapid growth 
rates, the vaccine market still only represents about 1.5% of the pharmaceutical market2.  
For example, the global market for a major cholesterol lowering agent was $10.3bn in 
2003, exceeding the entire vaccine market for the year (NIH and NIAID 2007). 
                                                 
2
 In 2001, the pharmaceutical market was estimated to be $350bn (Gréco 2001; Gréco 2002; NIH and NIAID 
2002; Vandersmissen 2002). In 2006, it grew to $650bn (IMSHealth 2006). These figures suggest that the 
relative size of the vaccine market has remained largely unchanged. 
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Small market size is significant because it reduces incentives to invest in R&D. As 
Acemoglu and Linn (2004:1084) suggest with a temptingly direct link between demand and 
supply, ‘a 1 percent increase in the potential market size for a drug category leads to 
approximately a 4 percent growth in the entry of new non-generic drugs and new molecular 
entities.’ The small size of the vaccine market may be due to the presence of oligopsony, 
distinct disease environments, and social resistance, which are examined further below. 
 
5.1.2 Oligopsony: centralised public demand 
 
The introduction of a new vaccine to the market typically follows a 20 year pattern (Gréco 
2001). In the early stages, fragmented sales are made predominantly to the private market at 
low quantities but high prices. The market as a whole grows, but the private market is 
gradually displaced by public procurement. In the later stages, sales are almost exclusively 
to governments and a few organisations (such as UNICEF, PAHO, WHO, GAVI) at high 
quantities but lower prices. 
 
In the US, the Centers for Disease Control estimate that up to 80% of paediatric vaccines 
are purchased by government. Given that paediatric vaccines represent 50 to 70% of the 
vaccine market (Gréco 2001; Scrip 2002), centralised government purchases have 
considerable concentrated purchasing power to lower aggregate demand. Whilst private 
prices are set by manufacturers, public prices are negotiated and purchased below those 
paid by the private sector (see table 3). 
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Table 3: Public-Private Vaccine Prices ($) in the US by year and vaccine 
 DTP MMR OPV/IPV 
Year Private Public Private Public Private Public 
1985 2.8 2.21 13.53 6.85 6.15 0.80 
1995 5.54 1.40 21.43 11.27 10.18 1.92 
2005 22.04 12.75 40.37 16.67 21.80 10.42 
Source: National Centers for Disease Control and Prevention3. DTP is diphtheria-tetanus-pertussis vaccine; 
MMR is measles-mumps-rubella vaccine; OPV is oral poliomyelitis vaccine; IPV is injected poliomyelitis 
vaccine. 
 
Perhaps because of the product-market cycle identified by Greco, there is an expectation 
that all vaccines will eventually be abundantly available at low prices, and the role of 
centralised purchasers should be to accelerate this process. However, it is unlikely that the 
prices being paid by the end of the cycle, or even over the whole cycle, really reflect the 
full value of vaccines to society when considering the reduction in health care costs and 
related costs, suffering, and death (see chapter 1). 
 
Many have argued that pricing is critical to protecting vaccine innovation incentives 
because R&D costs are compensated for by large profits (Grabowski and Vernon 1997); 
profitability and R&D outlays were found to be strongly correlated in the pharmaceutical 
industry (Scherer 2001; Giaccotto, Santerre et al. 2005; Vernon 2005). Frank (2001) adds a 
more dynamic dimension by emphasising that the link is more specifically to do with R&D 
investment today and expected - but uncertain - future profits. Since vaccine companies are 
often subsidiaries of pharmaceutical companies, vaccines must compete with other product 
areas for resources in this context of uncertainty (Vagelos and Galambos 2004; 2006). 
 
Internationally, centralised purchasing and public pressure continue to depress prices. The 
growth of the global vaccine market is driven by new vaccines sold to North America and 
Europe, which represent 70% of the market by dollar sales (Gréco 2001). The impact on the 
direction of innovation is therefore heavily geographic and disease specific. 
 
                                                 
3
 http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm 
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5.1.3 Different disease environments 
 
Distinct disease environments and specific epidemiologies can segment or shrink a market. 
Whilst developing countries have obtained substantial benefits from pharmaceuticals 
developed originally for rich country markets (Scherer and Watal 2002), little research is 
conducted on diseases that primarily affect poor countries. 
 
For some diseases, at least 99% of cases are located in low- and middle-income countries4 
(Lanjouw and Cockburn 2001). In 1998 alone, these ‘tropical’ or ‘neglected’ diseases are 
estimated to have caused the loss of almost 200 million DALYs5, and over five million 
lives, a large share of them children. The A-strain of the HIV virus is also particularly 
widespread in poor countries but not in the developed world. For these diseases there is 
simply no free ride. 
 
Estimates suggest that infectious and parasitic diseases account for only 3% of the disease 
burden in high-income countries (WHO 2006). Yet this figure rises to one-third in low-
income countries and to nearly one half in Africa. In contrast, 83% of the disease burden in 
high-income countries is made up of non-communicable conditions such as cancer and 
cardiovascular disease. This impacts on vaccine innovation because the people who would 
benefit the most from vaccines (developing countries with high communicable disease 
burdens) are the people who can least afford it, and offer satisfactory returns to firms’ R&D 
investments. 
 
Even for diseases that affect developed countries as well as developing countries (such as 
cancer), characteristics of poor countries make the products designed for developed markets 
unsuitable. Developing countries have weak infrastructure and so for example, need 
vaccines that can withstand breaks in refrigerated distribution chains and survive a long 
shelf life. Vaccine candidates that are potentially cheap, but are technically less effective, 
may not be acceptable to rich consumers and hence not be developed by firms even though 
                                                 
4
 For the disease list see Lanjouw and Cockburn (2001). 
5
 Disability-adjusted life years (DALYs) are estimates of years of life lost or lived with a disability, adjusted 
for its severity. Mortality and DALY figures are found in WHO (1999). 
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they would be of great benefit to poor consumers. Developing countries have weaker health 
care systems and so for example, need products that do not require intense supervision by 
medical personnel. Whilst Europe has 39 trained physicians per ten-thousand people and 
the US has 27, sub-Saharan Africa has only 1 (World Bank 2001). In addition, new 
vaccines may not provide immunity to some strains prevalent in developing countries. 
 
Thus whilst developing countries benefit from products based on other countries’ R&D 
efforts, few products are tailored to the specific needs of the developing world. For the 
vaccine manufacturer, the key implication of these differences between developed and 
developing country disease environments is a reduction in available market size. 
 
5.1.4 Social resistance 
 
Social and cultural factors that centre on risks and benefits of vaccines also affect the 
popularity of vaccines as a product. This is likely to have a diminishing effect on market 
size. As they succeed in dissipating disease, vaccines become a more feared entity (Gréco 
2001). The prevalence of disease and that of anti-vaccine attitudes therefore have an inverse 
relationship, presumably because populations become unaccustomed to the ravages of 
disease and overestimate risks of vaccines while underestimating their benefits. 
 
Even if an effective AIDS vaccine were available, Brandt (1988) raises the issue that it is 
highly unlikely that a sufficient number of people will identify themselves at risk and 
actually use the vaccine. Furthermore, some may oppose the vaccination of others arguing 
that it would alter social behaviours, such as the use of recreational drugs or the practice of 
deviant or promiscuous sexual activity. Brandt draws on the history of other sexually 
transmitted diseases such as syphilis to show that where there is fear, hostility and 
intolerance of a group affected by a disease, attitudes to vaccination are likely to be 
especially negative. The recent difficulties in encouraging parents to vaccinate their 
children against cervical cancer seem to support this, with some parents believing that 
vaccination will encourage sexual activity in their children (Dempsey, Zimet et al. 2006). 
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Vaccines currently feature heavily in the media and interest seems to have been driven by 
safety concerns. Using the Lexis-Nexis Professional database, I searched for ‘major 
mention’ to the words ‘vaccine’ or ‘vaccines’. The search covered all UK national 
newspapers, but excluded newswires. The graph below shows the results of the search and 
its secondary bars show that between 10 to 25% of these articles were exclusively about 
safety issues. 
 
Figure 4: Vaccine safety in the media 
UK Newspaper articles about vaccines
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Source: Compiled from Lexis-Nexis database. 
 
Table 4 provides a brief list of reasons why vaccines may be perceived as excessively risky. 
Although generalizations are made in the table, it should be noted that many non-
vaccinating parents have their own localized knowledge systems with which public health 
officials need to engage if vaccine uptake is to be maintained (Blume 2006; Leach and 
Fairhead 2007). 
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Table 4: Risks in vaccination 
Generalisations from the Risk literature Attributes of vaccines/vaccination 
pertinent to risk perception 
A risk accepted voluntarily causes less 
dread than one which is required by 
obligation, law or coercion. 
Vaccinations are sometimes regarded as 
obligatory and some are required by law. 
When the consequences of accepting risk 
are immediate, there is less fear than when 
the consequences lie at some indeterminate 
time in future. 
The risks of vaccination are immediate but 
the benefits of vaccination may or may not 
be needed in the future.  
People seem to be more acquiescent to a 
risk which is presented as the only 
possibility, rather than a risk that may not 
necessarily be incurred because there is an 
alternative course of action. 
The increasing popularity of Alternative 
Medicine (Ernst 2000) suggests that 
vaccines are not seen as the only way of 
avoiding disease, making vaccination seem 
less obligatory. 
If a risk is regarded as essential, it is more 
acceptable than one which is regarded as 
unnecessary. 
At the time of vaccination, it does not seem 
essential as the putative vaccinee is well 
and free from disease. The vaccine effect 
may not be perceived because it will only 
be apparent by the expression of the normal 
healthy state of the individual and the 
absence of disease. This is in stark contrast 
to therapeutic interventions, where risks are 
tolerated more readily. 
When the consequences of having been 
exposed to a risk are reversible, that risk is 
more countenanced than one where the 
effects are irreversible. 
Vaccination is seen as an irreversible health 
choice and there is a sense of dread at the 
vaccinial contamination of a clean, pure 
and healthy body. 
Source: Compiled from Stirling (2003) and Spier (2001). 
 
A key characteristic of vaccination, known as herd immunity, is that the reduction in 
susceptibility for one person benefits all unvaccinated persons (see chapter 1). So not all 
members of the community need to be vaccinated in order for everyone in the community 
to be protected (Ramsay, Andrews et al. 2003; Fine 2004). Thus, the externalities of 
vaccination mean that it is possible for individuals to free ride on the costs and risks 
incurred by other members of the community. It is likely that increasingly consumerist 
cultures centred on the individual, prevalent in North America, have contributed to some of 
the difference in immunization rates across America and Europe through an under-
appreciation of the benefits of vaccination to wider society. 
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This is of concern to the democratic political process because once half the population is 
vaccinated, it would not be possible to obtain majority approval for any increases in 
vaccination rate, assuming that non-altruistic parents of vaccinated children cease to place 
any value on vaccination of other children. 
 
Many unsubstantiated claims have endangered vaccination programmes in many countries 
(Andre 2003). The origin of these claims, usually promoted by a few zealous champions, is 
often country specific. For example, social amplification models have been applied to the 
rapid spread of autism claims regarding MMR vaccine in the UK6 (Hillman 2001). A non-
exhaustive list of such beliefs with their sources is shown in table 5. It is worth noting that 
the origins and causes of these health conditions, often claimed to be directly caused by the 
implicated vaccine, are (or were) not well understood. 
 
Table 5: Vaccine Safety debates 
Health condition Vaccine implicated Source 
Neurological damage DTP Scotland 
Unexplained death DTP Japan 
Chronic fatigue syndrome Hepatitis B Canada 
Sudden infant death DTP France 
Multiple sclerosis Hepatitis B France 
Crohn’s disease MMR UK 
Autism MMR UK 
Diabetes Hib US 
AIDS OPV A US journalist (Hooper 1999; 
2000) 
Mental retardation / Autism Thiomersal US 
Arthritis Lyme US 
vCJD Bovine serum UK 
Immune overload Combinations US 
Source: Based on Andre (2003). 
 
It is important to acknowledge that vaccines can indeed cause unwanted side effects. Even 
if such adverse reactions are difficult to establish scientifically (temporal associations with 
vaccinations does not necessarily mean causality) serious errors have occurred more than 
                                                 
6
 Following the 1998 autism claims, MMR vaccination rates in the UK dropped to under 80%. In 2006 and 
2007, there were more cases of measles than in the previous ten years put together. One of the cases led to the 
first measles death in 14 years. ( http://www.dh.gov.uk/en/News/Recentstories/DH_086861 ) 
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once in the past. Examples are the Cutter incident, when one batch of killed poliomyelitis 
vaccine that had not been properly inactivated caused many cases of paralytic 
poliomyelitis, or the Lubeck disaster when the use of pathogenic mycobacteria for the 
production of BCG vaccine was responsible for cases of tuberculosis. Mass immunization 
programmes mean that such errors involve large numbers of people. Errors are acute and 
conspicuous because those affected are otherwise healthy children. As the section below 
notes, exposure to liability is a major disincentive for the vaccine industry. 
 
5.2 Supply of vaccines: characteristics of the vaccine industry 
 
5.2.1 Liability and Regulation 
 
Whilst the liability of products should promote efficient levels of product safety, 
misdirected liability efforts are argued to be harmful to innovation because they increase 
the cost of R&D (Viscusi and Moore 1993). This effect is seen across most manufacturing 
sectors but there is evidence to suggest that liability costs are a particularly important 
consideration in the vaccine sector (Vandersmissen 2002; Sloan, Berman et al. 2004; 
Hinman 2005). One reason the vaccine sector is prone to high liability costs is because, 
unlike most drugs, vaccines are usually administered to healthy and young people. 
 
Evans et al. (2004) report that the litigious atmosphere of the early 1980s brought a series 
of lawsuits against vaccine manufacturers. When the lawsuits were successful, they often 
exceeded the gross sales of all vaccines in a year. Vaccine suppliers decreased and prices 
rose sharply. DTP vaccine went from $0.19 in 1980 to $12.00 in 1986. 
 
In response to lobbying by medical and biological professionals, as well as industry, a 
reluctant Reagan administration passed the National Childhood Vaccine Injury Act in 1986. 
The program was essentially a way to compensate vaccine victims quickly and easily 
without punishing vaccine manufacturers. Negligence and blame was removed under a 
quite unusual ‘no fault system.’ Although similar schemes were already in place in other 
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countries (for example the UK’s 1979 Vaccine Damage Payments Act7), the United States’ 
scheme represented a significant improvement in the legal situation for vaccine 
manufacturers since this was where the majority of claims were being made. 
 
However, the scheme has reportedly been plagued by money shortages (Cohen 1992c) and 
the solution would not be applicable for adult vaccines such as AIDS. In addition, the 
varying stringency of the California liability regime correlated with companies’ entry, exit, 
re-entry, and re-exit from AIDS vaccine development. Interview evidence with 
Genentech’s lawyer indicated that the alternating leniency in liability was directly affecting 
their investment decisions (Cohen 1992c). 
 
Another factor argued to be responsible for depressing vaccine innovation by increasing 
R&D costs has been the role of an increasingly complex regulation (Gréco 2001; 
Vandersmissen 2001; Gréco 2002; Vandersmissen 2002; Douglas 2004). Recently, for 
pharmaceutical drugs, this link between strict regulation and lowered innovation has been 
directly and persuasively criticised (Abraham 2008). 
 
Relative to pharmaceuticals however, it is likely that regulations for vaccines are more 
stringent, and have been increasing in their complexity. Significant shifts have occurred in 
the interpretation and intensity of enforcement of those guidelines by the Food and Drug 
Adminstration8 over the last decade or more (IOM 2003). For example, acceptable levels of 
Thimerosal (ethyl mercury) were suddenly changed in 1999 after the FDA reassessed the 
risk and required its removal from all paediatric vaccines (Freed, Andreae et al. 
2002:1154). This decision necessitated major alterations in production and bottling 
processes and resulted in an estimated 20 to 30 % losses on various vaccines. 
 
Whilst manufacturers may try to suggest that the FDA’s decisions are heavily influenced by 
an irregular, unpredictable and powerful media and anti-vaccination movement, this author 
considers it more likely that such inconsistencies reflect limited knowledge of the ways in 
                                                 
7
 The UK scheme has recently been strengthened (Government, UK Dept of Pensions 2002). 
8
 The Center for Biologics Evaluation and Research (CEBR) of the FDA is responsible for regulating 
vaccines in the US. 
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which vaccines work. The evolution of the vaccine safety system has been shaped in large 
parts by lessons learnt from past experiences and controversies rather than on a strict 
understanding of vaccine development (Abraham 1995; Ball, Ball et al. 2004). Modern 
challenges for regulation principally focus on the vast array of changing technologies used 
in developing and manufacturing vaccines (Baylor, Midthun et al. 2004; Levine, Kaper et 
al. 2004; Plotkin and Orenstein 2004). 
 
5.2.2 Rising R&D costs 
 
Studies investigating the overall costs of developing a new vaccine have not been 
undertaken in the systematic way that they have for drugs; as such, estimates vary widely. 
However, they do indicate that similar amounts are spent on developing vaccines and 
drugs, despite vaccines having a much smaller market. DiMasi et al. (1991; 2003) estimate 
that drug costs have risen from $231m in 1991 to $900m in 20019. Estimates for bringing a 
new vaccine to market currently range from $600m to $800m (Douglas 2004; Plotkin 
2005b), although a recent influenza vaccine cost more than $1bn (NIH and NIAID 2007)10. 
 
Clinical development involves studies of the effects of vaccines on patients for safety and 
efficacy typically over a longer period of time than that of drugs (Ebbert and Mascolo 
2004). This is due to the preventative nature of vaccines where proving a negative 
occurrence for the purposes of satisfying regulatory conditions is difficult and takes longer. 
As a result of this difficulty, more indicators and proxies are often required for vaccine 
trials (Levine, Kaper et al. 2004). Because clinical trials take longer, they are more 
expensive too. A commonly quoted figure for trials was $30m (Batson and Ainsworth 
2001:723), but a recent HIV vaccine trial that enrolled just 8000 volunteers cost $130m 
alone (NIH and NIAID 2007). 
 
Manufacturing plants are also expensive costing between $50m and $200m, and unique 
manufacturing requirements usually mean they are suitable for only one product (Douglas 
                                                 
9
 1991 figure based on 1987 dollars; 2001 figure based on 2000 dollars. 
10
 Next to these figures, the expenditure of a billion dollars per year on HIV vaccine R&D (chapter 1) seems 
particularly noteworthy. 
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2004). Outlays for production plants need to be committed early on, 4 or 5 years before 
licensing if there is to be no gap between the product’s licensing and its market launch. 
Choosing to commit such large funds represents an uncertain decision with large financial 
risk. Moving to manufacturing plants is a difficult process, often requiring long 
investigations on how laboratory procedures can be transferred to mass production 
techniques with consistency and safety (Pisano 1996). Since vaccines are biological (rather 
than chemical) products, their essential components work in more complex ways that 
cannot be measured (or reduced) easily. As such, they require more assays that must be 
validated for each stage of manufacture, which adds to costs and makes schedules harder to 
follow. 
 
Pisano’s (1996) case studies show that changes in multiple manufacturing tasks must be 
timed carefully because they need to be approved by regulatory authorities. This means that 
strong management systems and controls are needed, and clinical and process development 
tasks must be closely co-ordinated (Pisano and Slack 2001; Douglas 2004; Pisano 2006). 
This is perhaps why the later stages of development have remained intact through current 
trends of industry disintegration. 
 
5.2.3 Intellectual property regime 
 
For more than 50 years, large empirical studies from across the world have found 
consistently that patents are extremely important for the pharmaceutical sector 11. Indeed 
the sector is somewhat unusual in valuing patents so highly (Schankerman 1998). It is 
estimated that pharmaceutical R&D outlays would be reduced by 64% in the absence of 
patent protection; while for other industries, the corresponding reduction was only 8% 
(Grabowski 2002). 
                                                 
11
 The largest empirical surveys into IP are drawn from the UK (Taylor and Silberston 1973), the US (Scherer 
1959; Mansfield 1986; Levin, Klevorick et al. 1987; Cohen, Nelson et al. 2000), Japan (Cohen, Goto et al. 
2002) and Europe (Arundel, van de Paal et al. 1995; Arundel and Kabla 1998; Arundel 2001). Other factors 
for appropriating benefits from research-intensive innovations included trade secrecy, first mover advantages 
and associated brand loyalty, establishment of effective production, sales and marketing functions, and the 
complexity of the learning curve and production technology. Silberston’s (1987) follow-up categorised survey 
responses and analyses of patent and R&D intensities into 3 groups, where patents are ‘essential’, ‘very 
important’ or ‘less important’. He concluded that the first group ‘consists of only one industry - 
pharmaceuticals’. 
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The reason why patents are so critical to pharmaceutical firms in appropriating the benefits 
from innovation lies principally in the characteristics of the pharmaceutical R&D process. 
New drugs cost in the region of $1bn and take around a decade to develop and gain 
regulatory approval (see above). In the absence of patent protection, imitators can free-ride 
on the innovator’s regulatory approval and duplicate the compound for a small fraction of 
the originator’s costs. 
 
Imitation costs in the pharmaceutical industry are exceptionally low, relative to the 
innovator’s costs for discovering and developing a new product12. Generic compounds need 
only demonstrate that they are bio-equivalent to the pioneering brand in order to receive 
market registration. This process only takes a few years and costs $1m to $2m (Reiffen and 
Ward 2006). Furthermore, the prospect of success is very likely, as reflected by the fact that 
many generic firms typically receive FDA approval and enter the market within a short 
time of the patent expiration of the pioneer brand. The case of Praziquantel – which was 
discovered, developed and licensed by Bayer, then immediately copied, improved and sold 
at a lower price by a Korean pharmaceutical company – is illustrative of this (Reich and 
Govindaraj 1998). 
 
Patents are similarly important for vaccines but probably less than for drugs. As vaccines 
are more complex biological products than drugs, it is likely that more tacit knowledge 
would be required to imitate innovators. Furthermore, the small market size of vaccines 
reduces the incentives to imitate and ‘production, control and regulatory constraints will 
keep the barriers to entry high’ (Gréco 2001:1609). Nevertheless, strong - but of limited 
scope - patent protection may still be useful as part of a package of policies to improve 
innovation and access across the world. 
 
                                                 
12
 While R&D may cost in the region of $1bn and take longer than a decade, imitation costs are around $1m 
and can be undertaken in a year. There are few other comparable industries where there is such a large 
disparity between the costs and dynamics of innovation and imitation. 
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5.2.4 Oligopoly: concentrated industrial structure and wider actors 
 
The industry has been increasing in concentration such that only a small number of 
companies are left producing vaccines. In 1967, there were twenty-six companies with US 
vaccine licenses; by 1980 there were seventeen; and by 2002 there were twelve (Cohen 
2002b). The exodus began as half of all commercial vaccine producers stopped 
manufacturing vaccines between 1966 and 1977 (IOM 2003). In 1996 there were six firms 
producing recommended childhood vaccines for the US market (Sing and William 1996); 
and by 2002 an oligopoly of only four remained (IOM 2003). 
 
Part of the decrease in number of suppliers can be explained by mergers and acquisitions13. 
Such a trend towards increasing industry concentration has worried many observers about 
the stability of vaccine supply (Cohen 2002a; Sloan, Berman et al. 2004; Hinman, Schwartz 
et al. 2005; Salinsky and Werble 2006). It is argued by these authors that a fragile vaccine 
supply is a sufficiently serious public health risk to warrant the formulation of policies to 
address this directly. Underlying their arguments is the discussion over what factors 
influenced the consistent exit of firms out of the industry. Regulatory costs, liability costs, 
and poor returns relative to pharmaceutical and other products in the corporate portfolio 
seem to be the key factors.  
 
Danzon (2005; 2006) goes further by suggesting that the inherent nature of the vaccine 
market is such that only one or very few suppliers can exist at any point in time. Small and 
concentrated demand for standardised products mean that competition between firms with 
large sunk costs and low marginal costs is likely to drive down prices to marginal cost, 
leading ultimately to the exit of all but one producer. 
 
However, such an orthodox view overlooks two important features of industrial 
organisation highlighted by innovation scholars. First, innovation is a key factor to 
changing the structure of industries. Second, the knowledge required for innovation is 
                                                 
13
 Greco (DeNoon 1998) listed several examples of industrial concentration, of which one is: Merieux 
Institute and Pasteur Vaccines became Pasteur Merieux Serums & Vaccines. Then, Pasteur Merieux Serums 
& Vaccines and Connaught became Pasteur Merieux Connaught. 
Pasteur Merieux Connaught joined with Merck's European division to create Pasteur Merieux MSD. 
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socially distributed across multiple institutions and not just private companies. A closer 
look at the innovative dynamics and the broader actors in the network suggest that the 
vaccine supply need not be as inevitably fragile as Danzon suggests, provided a strong 
public infrastructure can be maintained. The innovation systems perspective (Lundvall 
1992; Freeman 2008) notes the significance of deliberate investements in intangibles – 
specifically, learning activities – in a variety of institutions (firms, schools, and 
universities) and links among them. Highlighting knowledge flows between different 
institutions allows for an explicit appreciation of industrial change, and such a view 
emphasises that the accumulation of vaccine development skills and capabilities may not 
necessarily occur within the confines of a single organisation developing vaccines. 
 
Although there are few vaccine producers, there are many more small firms undertaking 
vaccine R&D, whose primary source of funding is risk capital from private investors but 
who may have spun off from public research or universities (Sisk 1995:177). Innovation 
drawing on the public sector seems to be a common way for private newcomers to gain 
entry. Once entry is gained, another route, similar to the rest of the pharmaceuticals and 
medical device industry (Powell, Koput et al. 1999; Malerba and Orsenigo 2002), is for 
small firms involved in vaccine R&D to seek merger or acquisition when what they have 
developed demonstrates some commercial viability (for example Chiron). 
 
There are several government departments in the US that play important roles in vaccine 
research and development (Douglas 2004). Their relative contribution to the vaccine 
network is depicted in table 6 below. The National Institutes of Health is a major funding 
agent of research, usually in academic institutions. The Food and Drug Administration is 
the regulatory body, charged with licensing new products. It establishes standards for 
manufacturing processes, facilities, and clinical studies to ensure that licensed vaccines are 
safe and effective. It also maintains some research capacity to assist in its evaluations. The 
Center for Disease Control and Prevention conducts epidemiological studies and evaluates 
the public health impact of disease in order to establish public health priorities for vaccine 
R&D. This department is an important factor in determining the demand for a vaccine and 
how profitable a vaccine can be. It exerts its influence in two ways. Firstly, it makes 
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recommendations for vaccine usage (along with other professional organisations), and 
secondly, it is responsible for most of the public purchases. Some additional directed 
research is also supported by two other departments, the Department of Defense and the US 
Agency for International Development, on vaccines that might be relevant to military 
service and on vaccines for children in developing countries respectively. 
 
Table 6: Relative contributions of US government departments 
 Research Development 
 Basic/Related Targeted Process Clinical Manufacture Postlicensure 
studies 
NIH +++ +++  ++   
CDC      ++ 
FDA  + + +  + 
DOD + + + +  + 
USAID  +  +   
Large 
company 
+ +++ +++ +++ +++ +++ 
Small 
company 
+ +++ +- +- +-  
Academia +++ +++  +++   
NGOs  +  +   
Source: Reproduced from Marcuse et al. (1997:1017). +++, major; ++, intermediate; +, minor; +-, varies by 
company. NIH is National Institutes of Health; CDC is Centers for Disease Control and Prevention; FDA is 
Food and Drug Administration; DOD is Department of Defense; USAID is US Agency for International 
Development; NGO is non-governmental organization. 
 
5.3 Shortcomings of an economic approach 
 
Vaccines tend to be overshadowed by pharmaceuticals because vaccines are produced by 
pharmaceutical companies and the vaccine sales market is much smaller than that of 
pharmaceuticals. The consternation of most public health officials and analysts is that the 
vaccine market is much smaller than their social value. Economic models dominate policy 
discourse by emphasising oligopsony effects on prices, and highlighting social resistance 
and disease categories as factors that shrink the market. However, the models are weak on 
explaining where the social resistance comes from or why and how disease categories 
shrink the market. 
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Economic models are also often invoked by pharmaceutical companies to identify ‘ever 
increasing regulatory, quality [liability] and R&D costs’ (Gréco 2001:1609) as 
unfavourable barriers to industrial innovation. These rising supply side costs are not 
explained easily and indeed explanations are not often attempted. This thesis argues that 
this is largely due to a failure to appreciate the product complexity of vaccines. Thus R&D 
costs may be high, and there may be resultant intellectual property issues, but the causes of 
these effects should not be relegated to ‘exogenous factors’ and excluded from analysis. 
 
Without a more thorough investigation of the technological knowledge underlying 
vaccines, its growth and socially distributed nature, the ability to develop economic policies 
to stimulate and shape the innovation process in the pre-market phases will be limited. 
Whether of a ‘demand-pull’ or ‘science-push’ type, they are not sensitive enough to capture 
the dynamics of technological change or the subtleties in the relationship between science 
and technology. Dependence on such models is likely to lead to the development of blunt 
policy tools. 
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Technical dynamics of vaccines 
 
This part of the chapter introduces how vaccines work. The first section introduces some 
important background concepts in immunology that are exploited by vaccines. It then 
presents a short history of vaccination outlining its principles. The second section compares 
and provides an overview of the types of immunisations that are currently possible. And the 
final section comments on the possibility of genomics as the platform for future vaccines. 
 
5.4 Principles in immunology and vaccination 
 
5.4.1 Two distinct arms of the immune system 
 
Pathogens are handled by two distinct arms of the immune system. When a pathogen enters 
the bloodstream, the immune system responds, firstly, to prevent it from infecting cells and, 
secondly, to eliminate any cells that do become infected. These two aspects are called the 
humoral and cellular responses respectively. 
 
The humoral response aims to prevent entry into cells. The immune system’s B 
lymphocytes (B cells) secrete antibodies which patrol the bloodstream and intercellular 
spaces. Antibodies are Y shaped proteins that can identify foreign substances in the blood 
and lock onto them in a highly specific fit. (The model of antibody-antigen binding 
commonly used is of the two arms of the Y locking on to the point of a V, with key-like 
ridges interspersed along the interfaces providing specificity.) With antibodies latched onto 
it, a pathogen cannot infect cells readily and is rendered inert. The memory B cells stored in 
the lymph nodes ‘remember’ the conformation of the pathogen so that if the immune 
system were to come across it again, its antibody response would be even swifter. Killed 
vaccines (see below) tend to be effective at training B cells to perform these functions 
(Nathanson and Mathieson 2000). 
 
If the pathogen finds shelter inside cells, it is beyond the reach of the antibodies, so a 
different arm of the immune system’s response is engaged. The cellular response or cell 
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mediated immunity is used. T cells scrutinize the exterior of cells looking for traces of 
infections. For example, after a virus infects a cell, it copies itself. During replication, bits 
and pieces of its proteins (viral debris) are moved to the cell surface (exocytosis) where 
they work as warning flags for T cells to detect. 
 
There are two routes to the cell surface resulting in two different kinds of signal for the T 
cells. Both routes involve specialized MHC (Major Histocompatibility Complex) 
molecules. In the first disposal mechanism, MHC Class I molecules attach to viral antigens 
and make them visible to a specific kind of T cell, the killer T cell (cytotoxic T lymphocyte 
or CTLs). Killer T cells take on the infected cell by ingesting it (phagocytosis) and 
releasing extremely potent cytotoxic chemicals. Once killer T cells are primed to a 
particular pathogen, they kill every cell infected by that pathogen they can find. Copies of 
different kinds of killer T cells are archived and can be reactivated if the same antigen ever 
returns. In the second disposal mechanism, MHC Class II molecules take the viral antigens 
and display them in a way that is recognizable to helper T cells (CD4 T lymphocytes). 
Having recognized the antigens, helper T cells do not attack the virus directly. Instead 
helper T cells signal a general siren that boosts production and localisation of antibodies 
and killer T cells. 
 
Live vaccines (see below) tend to be effective at stimulating the cell mediated arm of the 
immune system because they exploit the normal way T cells learn to find and destroy 
infected cells. Live vaccines can infect cells and express the proteins that, via the MHC, 
signal T cell activation (Desrosiers 2004). Killed vaccines, in contrast, penetrate cells much 
less and are more limited in their ability to express proteins, but the antibody response is 
stronger. 
 
5.4.2 Vaccination in historical perspective 
 
A vaccine is a substance sufficiently like the organism to generate a specific response in the 
immune system, but sufficiently different that the vaccine itself does not cause the 
infectious disease. The response in the immune system that is looked for is one that will 
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protect from future infections, known as acquired immunity14 (Murray, Rosenthal et al. 
1998; Madigan, Martinko et al. 2000). 
 
Acquired immunity (as opposed to innate immunity) can be achieved in several ways. The 
early strategy was to deliberately cause a mild infection with unmodified pathogen (Plotkin 
and Plotkin 2004a). This was the principle of variolation, established in 1798, in which 
inoculation of a small amount of dried material from a smallpox pustule would cause a mild 
infection followed by long lasting protection against reinfection. However, infection after 
variolation was not always mild: fatal smallpox ensued in about 3% cases (Jenner 
1798/1966). 
 
Jenner’s achievement was realising that infection with a bovine analogue of smallpox, 
vaccinia (L. vacca, cow) which caused cowpox, would provide protective immunity against 
smallpox in humans without the risk of significant disease. He named the process 
vaccination15, and as a tribute to him, Pasteur later extended the term to the stimulation of 
protection to other infectious agents (Plotkin and Plotkin 2004a). Humans are not a natural 
host of vaccinia, which establishes only a brief and limited subcutaneous infection. But it 
contains antigens that stimulate an immune response that is cross reactive with smallpox 
antigens and thereby confers protection from the human disease (Elgert 1996). 
 
This established the underlying principles for safe and effective vaccination, but they lay 
fallow until late the 19th century, when the germ theory of disease was established16 
(Hilleman 2000b). Both of these were, in large part accomplished by Louis Pasteur (Plotkin 
and Plotkin 2004a). However, Pasteur was far more interested in preventing disease than 
studying it. Before leaving on holiday, Pasteur accidentally left a chicken cholera culture 
out on the shelf for two weeks. On his return, he noticed that the culture, weakened by 
exposure to air, provided immunity to the disease rather than cause the disease itself (Elgert 
1996). 
                                                 
14
 Acquired immunity is also known as adaptive immunity (Janeway, Travers et al. 2005). 
15
 In this thesis, the terms vaccination and immunisation are used interchangeably. 
16
 The germ theory suggested that disease is caused by microorganisms rather than by an imbalance of body 
humors or the position of the moon (Elgert 1996). 
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Pasteur’s contribution was recognising17 that attenuation had occurred. The principle was 
the same as Jenner’s but attenuation had been achieved in a different way. Using a 
weakened form of chicken cholera itself to prevent disease was preferable to using a related 
organism in the Jennerian way because it may provide better immunity and less chance of 
transmitting other diseases. The idea was quickly developed into a chemically attenuated 
rabies vaccine five years later (Plotkin and Plotkin 2004a). Thus, the modern concept of 
immunisation, involving the development of vaccines in the laboratory using the same 
agent that caused the disease, was really introduced by Pasteur. 
 
The next major step in vaccine development was the killed vaccine concept, where bacteria 
are killed by heat (Hilleman 2000b). In the space of a decade, this approach yielded 
vaccines against typhoid, cholera and plague (Plotkin and Plotkin 2004a). The focus on 
bacteria and antibodies in the late 19th century originated from key discoveries in immunity 
that were being made by no less than four Nobel prize winning scientists. 
 
In 1890, Robert Koch established procedures for proving that a particular living agent was 
the source of a specific disease18. This was by identifying agents through staining and 
growing single strains of bacteria (pure culture). These procedures are known as ‘Koch’s 
postulates’19. In 1883, Elie Metchnikoff was the first champion of cellular immunity and 
his studies uncovered the central role of phagocytes in host defence (Janeway, Travers et al. 
2005). In 1897, Paul Elrich’s receptor theory of immunity was an equally strong 
contribution to vaccine development because it pointed out the difference between active 
and passive forms of acquired immunity (Hilleman 2000b). In 1890, Emil von Behring’s 
work defined the origin and role of antibodies, which established the field of passive 
immunotherapy (Elgert 1996). Elrich’s development of methods for specific quantification 
of antibodies made von Behring’s passive immunity a practical reality. Elrich’s concepts 
                                                 
17
 Pasteur is quoted to have said “Chance favours the prepared mind” (Elgert 1996). 
18
 Koch isolated both the cholera and tubercle bacilli as the causal organisms of the respective diseases. 
19
 The postulates consist of four requirements. First, the causal agent must be found in all cases of the disease. 
Second, the agent must be isolated from a carrier and grown in pure culture. Third, when the culture is 
injected into a susceptible laboratory animal, the animal must contract the disease. Finally, the causal agent 
must then be recovered from the diseased animal. 
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for specific complementarity of cellular side chains with chemicals and with other proteins 
gave birth to what was later called specific receptor-ligand binding (Stryer 1997). This 
concept dominates modern understanding of biochemistry and underpins all technological 
assets related to immunology. 
 
The majority of the fundamental concepts of vaccinology had been introduced by the end of 
the 19th century. Vaccine development in the early 20th century followed two empirical 
roads, gradually refining these theoretical underpinnings. The first was the search for live 
attenuated organisms with reduced pathogenicity, which would stimulate protective 
immunity; the second was the development of vaccines based on whole inactivated 
organisms that would be as effective as using live organisms (see table 7 below). 
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Table 7: Learning and instrumentalities in vaccines since 1798 
Disease causation and 
instrumentalities 
Live, Attenuated Killed, Whole Protein or 
polysaccharide 
Genetically 
engineered 
18th Century 
Gods and devils cause 
disease until… 
Germ theory of disease 
Smallpox (1798)    
19th Century 
Focus on bacteria and 
antibodies. Pasteur 
(attenuation), Koch’s 
postulates, von Behring 
(antibodies), 
Metchnikoff 
(phagocytes), Elrich 
(specific receptor 
binding) 
Rabies (1885) Typhoid (1896) 
Cholera (1896) 
Plague (1897) 
  
Early 20th Century 
Antibody mechanisms 
described, 
Immunotherapy 
dominates field 
Tuberculosis 
(1927)(BCG) 
Yellow Fever (1935) 
Pertussis (1926)(whole 
cell) 
Influenza (1936) 
Rickettsia 
(1938)(typhus) 
Diptheria (1923) 
Tetanus (1927) 
 
Post World War II 
New culture techniques, 
Goodpasture (fertile 
eggs), Enders et al 
(human cell culture) 
 
Conjugation technology 
 
Adjuvant technology 
 
Recombinant genetic 
technology 
Polio (oral) (1958) 
Measles (1963) 
Mumps (1967) 
 
Rubella (1969) 
Adenovirus  
Typhoid (1990) 
Varicella 
Rotavirus (1998) 
Cold adapted influenza 
Polio (injected) (1955) 
Rabies  
Japanese encephalitis 
(1965) 
 
Tick borne encephalitis 
(1937,1980) 
Hepatitis A (1991) 
Cholera 
Pneumococcus (1972) 
Meningococcus (1976) 
H. influenzae (1988) 
Hepatitis B (plasma 
derived protein) (1981) 
Typhoid 
Acellular pertussis 
Anthrax (in 
development, 
bioterrorism act) 
Hepatitis B 
recombinant (yeast or 
mammalian cell 
derived) (1986) 
Acellular pertussis 
(some components) 
Lyme (E.coli 
recombinant) (1998) 
Sources: (Andre 2003), (Hilleman 2000b), (Plotkin and Plotkin 2004b) 
 
Although the instrumentalities are not clearly defined in table 7, the table does serve to 
confirm suggestions made in chapters 2 and 3; the development of instrumentalities have 
been crucial influences in the rate and direction of vaccine innovation. Significant changes 
and achievements throughout the history of vaccination against viruses have been subject to 
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the co-evolution of instruments and techniques for growing them20. The initial challenge 
was due to viruses requiring living and multiplying cells for their growth, so no inanimate 
growth media (such as agar gel, used to grow bacteria) would suffice, no matter how it was 
enriched. It was not until the first decade of the 20th century, when cells could be cultivated 
in vitro, that the possibility of culturing viruses opened up. Even as cell culture techniques 
became good enough to grow cells seemingly forever (immortal cell lines), viruses did not 
grow and some even began to doubt their existence (Paul 1971:371). 
 
In 1931, Ernest Goodpasture introduced the use of embryonated hens’ eggs for growing 
viruses (Plotkin and Plotkin 2004a). This technique represented a major advance, because 
until then human viruses could only be grown in expensive animals, such as horses and 
sheep (Markel 2007). ‘Nearly all the later practical advances in the control of virus diseases 
of men and animals sprang from this single discovery’ (Burnet cited in Chase 1982:286). It 
facilitated the production of a crude influenza vaccine, as well as vaccines against rickettsia 
and yellow fever. 
 
Then in 1949, Enders, Weller and Robbins propagated poliovirus in human tissue (see 
section 6.3.2). The ability to grow human viruses outside a living host, in a relatively easy 
and safe way, led to a flood of creative activity in vaccinology. This technique, in addition 
to greater knowledge of pathogens and host responses, led to what Plotkin and Plotkin 
(2004a:6) call the ‘golden age of vaccine development’ in the 1950s and 1960s, the 
development of effective viral vaccines against poliomyelitis, measles, mumps and rubella. 
 
The eradication of smallpox through a global vaccination campaign in the late 1970s is one 
of the most important accomplishments of medical science21. It returned vaccines to the 
spotlight as an indispensable tool for public health administrators and provided an impetus 
for the development of new vaccines (Muraskin 1998). This optimism renewed interest in 
discoveries made in the 1930s which fell by the wayside for forty years due to the success 
of antibiotics (Plotkin and Plotkin 2004a). The discoveries showed that the immunogenicity 
                                                 
20
 This seems to be consistent with Hopkins’s thesis (2004) that technological change in medicine can be 
‘technique-led.’ 
21
 Poliomyelitis and measles, whose only reservoir is human beings, have also been targeted for eradication. 
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of a capsular polysaccharide, which is generally a poor immunogen, could be increased by 
chemically binding (conjugation) to a carrier protein (PRP) (Janeway, Travers et al. 2005). 
This new protein conjugation technology was finally developed in the 1970s and 1980s 
yielding three effective bacterial vaccines: a meningococcal vaccine, a pneumococcal 
vaccine, and a Haemophilus Influenza type b vaccine22 (Plotkin and Plotkin 2004a). 
 
In addition to conjugation technology, the use of adjuvants is another important approach to 
enhancing the immunogenicity of vaccines. Purified antigens do not usually trigger a strong 
immune response on their own, and most acellular vaccines require the addition of 
adjuvants to boost their immunogenicity (Madigan, Martinko et al. 2000). Adjuvants use 
bacterial cell wall components, synthetic polymers, or liposomes and they influence the 
type of immune response induced by the vaccine (Madigan, Martinko et al. 2000)23. 
 
In 1981, a hepatitis B vaccine, made from surface antigen derived from human plasma, was 
licensed, and this was followed in 1986 by a recombinant hepatitis B vaccine, the first of its 
kind (Hilleman 2000b). As will be discussed, the advent of molecular biology and the 
development of new techniques in genetic manipulation and recombination greatly 
expanded the number of possible approaches for vaccine development. 
                                                 
22
 These were important improvements over previous non-conjugated vaccines because children under the age 
of two, who are most at risk from these diseases, cannot make good antibody responses and could not be 
effectively vaccinated by polysaccharides vaccines (Janeway, Travers et al. 2005). New conjugated vaccines 
meant that children could be vaccinated by having their immune systems recognise the protein and launching 
a cellular response. 
23
 For example, tetanus vaccines often contain aluminium salts, which bind polyvalently to the immunogen by 
ionic interactions and stimulate antibody responses (Janeway, Travers et al. 2005). Pertussis toxin has 
adjuvant properties in its own right and, when given mixed with tetanus and diphtheria immunogens, not only 
vaccinates against pertussis but also acts as an adjuvant for the other two immunogens (Janeway, Travers et 
al. 2005). This mixture makes up the DTP triple vaccine. 
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5.5 Types of immunisation and their development 
 
This section reviews and compares the types of immunisations that are possible (figure 5). 
 
 
Figure 5: A typology of immunisations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sources: Stryer (1997); Murray et al. (1998). 
 
The injection of purified antibody or antibody containing serum for the rapid, temporary 
protection or treatment of a person is termed ‘passive immunisation’ (Murray, Rosenthal et 
al. 1998). It can be used to prevent disease after a known exposure, to alleviate the 
symptoms of an ongoing disease, to protect immune suppressed patients like those infected 
with HIV, or to block the action of bacterial toxins and prevent the diseases they cause (for 
example diphtheria antitoxin grown in horses (Markel 2007). Immune serum globulin 
preparations are derived from humans (preferred) or animals. 
Types of Immunisation 
Passive Active 
Immune serum globulin Specific immunoglobulins Monoclonal antibodies 
Human 
Equine 
Inactivated Live DNA 
Killed bacterium or virus 
Subunit 
Peptide or polysaccharide 
Toxoid 
Virulent strains 
Hybrid viruses 
Attenuated mutants 
Limited host range 
Temperature sensitive 
Cold adapted 
Genetically manipulated 
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‘Active immunisation’ occurs when an immune response and immunological memory are 
stimulated in response to a challenge with an immunogen (Elgert 1996). Such 
immunisation occurs after each exposure to an infectious agent (natural immunisation) and 
through exposure to microbes or their antigens in vaccines. 
 
Inactivated vaccines, rather than live vaccines, are used to confer protection against most 
bacteria and the viruses that may be too virulent or that can cause recurrent infection 
(Janeway, Travers et al. 2005). Inactivated vaccines can be produced through the chemical 
or heat inactivation of bacteria, bacterial toxins, or viruses or through the purification of the 
components or subunits of the pathogen. These vaccines are usually administered with an 
adjuvant, which boosts their immungenicity (Madigan, Martinko et al. 2000). Inactivated 
vaccines are generally safe, except in people who have allergic reactions to vaccine 
components (Murray, Rosenthal et al. 1998). However, even with adjuvants, the immune 
response evoked by the inactivated vaccines is much more limited than that evoked by live 
vaccines (Madigan, Martinko et al. 2000). The immunity is not usually life-long, may be 
limited to humoral (molecular) and not cell-mediated (cellular) immunity, requires booster 
shots, and requires a larger dose of an inactivated vaccine than of a live vaccine (Madigan, 
Martinko et al. 2000). 
 
A subunit vaccine can be developed after identification of the bacterial or viral components 
that elicit a protective immune response.  Either the immunogenic component is isolated 
from the bacterium, virus, or virus-infected cells by biochemical means or the vaccine is 
prepared through genetic engineering involving the expression of cloned viral genes in 
bacteria or eukaryotic cells.  Vaccines against H. influenzae B, N. meningitidis, S. typhi and 
S. pneumoniae are prepared from capsular polysaccharides enhanced by conjugation to a 
protein carrier, such as diphtheria toxoid (inactivated toxin) or N. meningitides outer 
membrane protein (Madigan, Martinko et al. 2000). 
 
Live vaccines are prepared with organisms limited in their ability to cause disease 
(avirulent or attenuated). Most live vaccines are used to protect people against viral 
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diseases, especially infections caused by enveloped viruses, which can require T-cell 
immune responses for the infection to resolve (Elgert 1996). Immunisation with a live 
vaccine resembles the natural infection and elicits both the humoral and cellular immunity. 
It generates an immunity that is generally long lived and can mimic the normal immune 
response to the infecting agent (Murray, Rosenthal et al. 1998). 
 
However, there are two problems with live vaccines: (1) the vaccine may still be dangerous 
for immunosupressed people or pregnant women who do not have the immunological 
resources to resolve even a weakened virus infection, and (2) the vaccine may revert to a 
virulent form, a process that is rare. It is hoped that these shortcomings will be alleviated 
with the application of recombinant DNA technology to the development of live attenuated 
vaccines, making them safer24 (Janeway, Travers et al. 2005). 
 
Live virus vaccines consist of less virulent mutants (attenuated) of the wild type virus, 
viruses from other species that share antigenic determinants, or genetically engineered 
viruses lacking virulence properties (Madigan, Martinko et al. 2000). Wild type viruses are 
attenuated by growth in embryonated eggs or tissue culture cells at non-physiological 
temperatures (32˚C to 34˚C) and away from the selective pressures of the host immune 
response. These conditions select for or allow the growth of viral strains (mutants) that are 
less virulent because they grow poorly, do not replicate well in any human cell, or can 
replicate at a benign site but do not disseminate, bind, or replicate in the target tissue 
affected by the disease (Madigan, Martinko et al. 2000). 
 
5.5.1 Reverse vaccinology 
 
Recent breakthroughs in life, and information, sciences have opened up a radically new 
approach to developing vaccines. This approach has been termed ‘reverse vaccinology’ 
because potential vaccine targets are identified from the genome sequence rather than 
elucidated from the pathogen cultivation. Genome sequences are fed into computer 
                                                 
24
 One example of this is Salmonella typhi, the causative agent of typhoid, which is manipulated to develop a 
live vaccine. Specific genes are targeted for mutation that makes the bacteria dependent on an external supply 
of an essential nutrient. These bacteria grow poorly in the gut but survive long enough as a vaccine to induce 
an effective immune response (Janeway, Travers et al. 2005). 
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software that can provide a list of possible antigens - without needing to grow pathogens in 
vitro and empirically derive which parts of the pathogen are antigenic. Although no 
vaccines have been developed in this way yet, the reverse vaccinology approach has been 
applied recently to Meningococcus B25 to focus efforts more precisely (Pizza, Scarlato et al. 
2000; Capecchi, Serruto et al. 2004; Danzig 2006). 
 
Reverse vaccinology may be able to generate a range of possibilities, but it does not select 
them for us. Software might be able to screen or prioritise some of the possibilities for us, 
but that software in turn needs to be designed, with programmatic assumptions that are 
likely to have been derived from empirical labour as well as genomic analysis. There is 
nothing inherent in genomes that will, by itself, indicate a social purpose – a vaccine – 
without human interpretation, based on tacit knowledge and empirical testing. The 
immense challenge of developing assays, measurements and efficacy tests (and then 
codifying them into programs!) will therefore still remain. Developing these tests is 
especially problematic in cases where there is a lack of natural sterilising immunity, such as 
HIV, TB and malaria. In these cases, we cannot readily observe a natural immunity, and 
then use it to illuminate a design pathway for us by developing a body of tacit and 
empirically tested knowledge. This is supported by the fact that the HIV, TB and malaria 
pathogen genomes have all been sequenced for many years now, but successful vaccines 
have not been developed. 
 
As shown in the empirical chapters, broader genetic recombination techniques may also 
help to develop better delivery (vector) technologies. However, the value of knowing 
‘what’ to present to the immune system, as well as how to present it, is unlikely to be 
diminished by these technologies. They do not represent an unequivocal, all competence 
destroying, technological revolution in vaccines. 
                                                 
25
 The pioneer case of reverse vaccinology was Meningococcus B (Pizza, Scarlato et al. 2000). As its genome 
was being sequenced, computer software was used to screen the genome for putative pathogen-surface 
exposed or pathogen-secreted proteins (2158 possibilities). These proteins are then screened again for 
potential antigens (600 possibilities). Of the potential antigens, only half could be expressed and purified 
(350). These were tested in bactericidal assay, an assay which is known to correlate with protection in humans 
(91). The antigens that were able to induce bactericidal antibodies (29) are then subjected to immugenicity 
testing in mice. This left us with 15 promising vaccine candidates for developmental investigation, a number 
greater than the total number of candidates found over the previous 40 years. 
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5.6 Reflecting on technical dynamics 
 
The first part of this chapter analysed shortcomings in an economic approach to vaccine 
innovation issues. 
 
The second part of the chapter discussed biological principles in immunology and basic 
concepts in vaccine development. It noted that the immune system has separate responses 
for when the pathogen is inside or outside cells, known as the cellular and humoral 
responses respectively. Live vaccines tend to exploit the cellular response more effectively, 
whilst killed vaccines tend to exploit the humoral response more effectively. 
 
A historical perspective was used to outline how the knowledge of vaccination has 
accumulated over time (rather than simply changed). The role of instrumentalities was 
emphasised by highlighting the co-evolution of instruments and techniques. New 
instrumentalities were integrated into existing bodies of knowledge. Thus, the early 
strategies of killed pathogen and live attenuation have remained useful over time, despite 
200 years of knowledge accumulation. 
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Chapter 6 
 
Knowledge Accumulation in the Road to Poliomyelitis Vaccines 
 
This chapter proceeds in seven sections. The introductory section explains why 
poliomyelitis drew attention and became recognised as a problem. It describes the 
construction of a vision, led by a US President, as well as by scientists establishing a cause 
for the disease. The second section describes some of the failures and barriers faced by 
researchers, which might otherwise be overlooked in a history of poliomyelitis successes. 
The third section describes the development of a testing regime, which involved improving 
learning conditions, instrumentalities, and knowledge co-ordination and integration. The 
fourth section describes the development of field-based testing capabilities to manage the 
move out of the laboratory. The fifth and sixth sections follow the development of two 
different operational principles, disagreements between people working on the different 
approaches, and the significance of ethics and path-dependency to certain testability issues. 
A final section concludes the chapter. 
 
6.1 The emergence of a problem and the vision of a solution 
 
Poliomyelitis was eventually given its name as a disease in the middle of the 19th century1 
after physicians learnt to associate a distinctive paralysis with damaged spinal cords in 
children. This formed the basis for early clinical recognition (Paul 1971:26). It was 
sometimes fatal, and the damage was found to be inflammation (itis) of the grey (polios) 
matter of the spinal cord (myelos) (Paul 1971:7). Initially, it was thought to be caused by 
teething (Carter 1965:8), perhaps due to the temporal proximity of the events. The 
                                                 
1
 The earliest evidence of poliomyelitis is an Egyptian stone carving depicting a man with a deformed limb 
dated to 1500BC (see Paul 1971:15 for an image of the stone). The disease was given a series of changing 
names as the characterisation of the condition became increasingly specific. For example, names range from 
morning paralysis in 1843, to tephromyelitis anterior acuta parenchymatose in 1872 and later, infantile 
paralysis (Paul 1971:5). 
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clustering of cases in single households however, suggested the disease was of an infectious 
nature. 
 
6.1.1 A vision for the technological community 
 
In 1908, Landsteiner and Popper, showed more conclusively that poliomyelitis was spread 
by an infectious agent (Robbins 2004:17). The researchers caused monkeys to develop the 
disease by inoculating their brains with spinal cord tissue taken from a human who had died 
of the disease2 (Paul 1971:98). The following year, Flexner and Lewis went further by 
passing the human infection from monkey to monkey (Carter 1965:9). Although the 
infectious agent responsible for poliomyelitis could not be seen under microscope, the 
flurry of experiments between 1908 and 1910 showed it conclusively to be a living parasitic 
microorganism3, able to reproduce in the cells of its victims. 
 
This line of enquiry was likely to have been informed by Koch’s postulates, which had laid 
the foundations of germ theory4 (Paul 1971:100). The Metropolitan board of health in New 
York had recently formed, and was keen to exploit such freely available ideas (Mullan 
1989). It allowed public health officials to be less concerned with intractable environmental 
tasks such as cleaning up the city, ridding pests and animals, promoting personal hygiene 
and sanitation, or dealing with overcrowded slums, hunger and poverty (Tomes 1990). The 
establishment of a causal agent also helped initiate a shift in disease management policies 
away from quarantinism (Baldwin 1999). 
 
For the technical community, the discovery of a disease causing agent for poliomyelitis 
allowed them to search for past experience of similar situations. They were able to conceive 
a solution based on Jenner’s and Pasteur’s vaccines, which tackle diseases known by then 
                                                 
2
 It is important to note that the animal model was not a perfect simulation of humans. The monkeys only 
contracted paralytic poliomyelitis if the agent was injected directly into their central nervous systems (Paul 
1971:98). 
3
 The infectious agent was recognised to be a virus because it could pass through the finest filters (Carter 
1965). The relationship between infectious agent and disease is relatively simple for poliomyelitis. As we 
shall see, the relationship between HIV and the onset of AIDS is more complex and when modelling in 
monkeys, SIV infection, not HIV infection, is needed to bring about AIDS-like disease in monkeys. 
4
 Pasteur had already applied these principles a few decades earlier for vaccine protection against anthrax, 
cholera and rabies (see chapter 5). 
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to also be caused by a specific agent. The poliomyelitis researcher Hortsmann (1985) 
wrote, ‘Recovering the etiologic agent of a disease immediately conjures up dreams of 
developing a vaccine to prevent the infection. This was as true in 1908 when Landsteiner 
reported the isolation of poliovirus as it is today, when the identification of HTLV3 [the 
early term for HIV] as the probable cause of AIDS burst on the horizon.’ However, beyond 
having a target to take aim at, the operational principles such a poliomyelitis vaccine might 
have were completely unknown, and further knowledge about the epidemiology of the 
poliovirus was needed to assert that the notion of a vaccine was a technological possibility. 
 
By 1910 it was demonstrated that monkeys that survived poliomyelitis often resisted re-
infection. It was also shown that the blood of surviving monkeys contained a substance that 
neutralised virus in a test tube (Paul 1971:108). This served as further clues to the 
possibility of a vaccine, and ensured that further work towards the idea of a vaccine was not 
eliminated as unworthy of resources. In 1911 Flexner issued a press release declaring that 
within six months5 a specific remedy would be announced, ‘We have already discovered 
how to prevent the disease, and the achievement of a cure, I may conservatively say, is not 
far distant’ (full press release in Paul 1971:116). For Flexner the nut had already been 
cracked and all that was needed was to turn the laboratory discovery into a fully developed 
and tested technology. He was appealing to a common intuition in which the difficulties of 
moving from science (of establishing cause) to innovation (of a vaccine) were 
underestimated. Perhaps this was necessary in order to sustain the belief that the vision or 
proposed idea is not ridiculed as a technological impossibility6. 
 
However, there were several early obstacles to establishing operational principles (aside 
from world wars). Laboratory diagnosis of poliomyelitis was dependent on testing spinal 
fluid, obtained through a painful and dangerous procedure that few physicians could 
perform. So serum harvested from the blood of sick patients or animals remained scarce 
and unreliable, and was critically dependent on skilled people (Paul 1971; Rogers 1992). 
                                                 
5
 A similar, more public, announcement was made by Margaret Heckler, US secretary of health, about the 
time needed (a couple of years) to develop an AIDS vaccine (Shilts 1987; Cohen 2001b). 
6
 The eminent polio researcher John Paul concedes, ‘[Flexner] can be forgiven for making mistakes about 
poliomyelitis’ (Paul 1971:125). 
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As such, accumulating knowledge about the properties of the virus (and viruses generally) 
was slow. Little was known about how poliomyelitis established itself in man 
(pathogenesis), or how it was transmitted (Robbins 2004:17). 
 
It is now known that various types of poliovirus may enter through the mouth and nose 
from droplets such as saliva or microscopic pieces of faeces (Paul 1971:2). The virus then 
slides into the gut where it reproduces. Normally the immune system can limit this 
infection before it causes serious disease, but on rare occasions the virus travels through the 
blood and into the central nervous system, causing meningitis. Paralysis occurs only if the 
virus then enters nerve cells. It is estimated that in an unvaccinated population, poliovirus 
paralyses 1-2% of the people it infects (Madigan, Martinko et al. 2000). 
 
This model of polio-pathogenesis accounts for the transmission of its immunity, as well as 
the patterns of disease spread during epidemics. Before poliomyelitis epidemics emerged, 
poliovirus was usually spread by faecal contact. Paradoxically, increasing sanitation and 
better standards of hygiene promoted its spread because children were less exposed to mild 
forms making them more susceptible to severe infection (and also because mothers did not 
pass immunity to foetuses7)8. 
 
The model postulated by Flexner in 1913 was significantly different and, in short, mistaken 
(Rogers 1992). In this incorrect model, poliomyelitis was caused by only one type of virus, 
which travelled through the sinuses directly to the brain and spine, and grew in living 
nervous tissue. These assumptions led to problematic inferences. First, it mistakenly led 
researchers down the path of aiming to culture (grow) virus in nervous tissue, rather than 
any other kind of culture medium. Second, if the poliovirus did not enter the bloodstream, 
there was little point in trying to put any antibody there. Furthermore, monkeys that 
recovered from the disease did not develop noticeable amounts of antibody in their blood 
                                                 
7
 However, Immunoglobulin A, which contains antibodies, is passed on to newborns in the colostrums in their 
mothers’ milk (Chase 1982). 
8
 The general implication is that our pathogenic environment is constantly evolving in response to our 
behaviour and in turn new health technologies will need to ‘keep up’ in order to remain effective. The most 
important innovations in healthcare then are not one-off vaccines, but instead lie in the processes that can 
consistently innovate and a system that can sustain the distribution of such innovations. It is with this in mind 
that we explore which aspects of the vaccine innovation process were important. 
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until long after recovery. Antibodies were therefore seen as a by-product of illness rather 
than of central significance to immunity. 
 
The early work that followed Landsteiner and Flexner was expensive and produced unclear 
results. Experiments were often confusing because researchers did not know they were 
dealing with multiple types of virus at the same time. Furthermore, the only polio-
susceptible animal was the monkey, ‘a cranky, expensive creature, which in those days 
(prior to antibiotics) had a way of succumbing to other diseases before the researcher could 
measure its responses to polio. No laboratory combined sufficient interest with enough 
funds to buy and maintain all the monkeys needed for thorough study of the poliovirus and 
the disease it caused’ (Carter 1965:19). Apart from a few researchers like Flexner and 
Lewis, the consensus of the scientific community in 1913 (and up to 1935) was that a 
vaccine was possible and desirable, but not likely (Carter 1965:58; Paul 1971:113). 
 
6.1.2 Finding wider support and a war chest to chase the vision 
 
By 1916, the annual incidence of paralytic poliomyelitis in the United States was over 
27,000, killing more than 7,000. New York, in particular, was panicked where there were 
9000 cases with over 2000 deaths that year (Rogers 1992:10). Reported cases had never 
exceeded 7.9 per 100,000 but in 1916 the rate jumped to 28.5 (Paul 1971:148; Rogers 
1992:10). Hospitals refused to admit cases for fear of infecting others, and some cities 
began insect control programmes with DDT whilst others impounded cats and dogs, all of 
which authorities mistakenly thought could transmit the infectious agent discovered by 
Landsteiner (Paul 1971:149, 291). Parents sealed their windows and refused to let their 
children play outside (Oshinsky 2005). By 1953, poliomyelitis afflicted more than 20 per 
100,000 (Robbins 2004:17). 
 
Although the rate was not as high as some other diseases, such as measles, much public 
concern was generated by the media portrayal of poliomyelitis because of its seasonal 
occurrence, its disfiguring nature and its propensity for paralysing the respiratory muscles 
(Oshinsky 2005). The disease was highly visible because paralysed patients often needed 
help breathing with large apparatus dubbed ‘the iron lung’ (Paul 1971:327). In addition, the 
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disease was visible to all social classes because, unlike other leading causes of infant 
mortality and infectious diseases (such as tuberculosis), it was not restricted to the poor. 
Given Landsteiner’s finding, public health officials are likely to have known that the 
middle and upper classes could not be insulated from poliomyelitis very well using current 
methods (such as quarantine). 
 
In 1921, Franklin Roosevelt9 was struck by poliomyelitis aged 39 (Carter 1965:11; Paul 
1971:301; Gallagher 1985; Oshinsky 2005). Roosevelt’s condition altered public perception 
of poliomyelitis and boosted scientific research. His misfortune was beneficial not only to 
poliomyelitis victims but also to those with other disabilities too because physical 
handicaps were judged harshly. Afflicted individuals were kept out of sight by families that 
felt ashamed (Longmore 1987). An influential orthopaedic text of the time supported the 
idea that disabilities are punishments from God, stating, ‘…a cripple is detestable in 
character, a menace and burden to society, who is only apt to graduate into the mendicant 
and criminal classes…’ (Longmore 1987:357). 
 
Roosevelt’s public relations were carefully coordinated so that he would appear less like 
the cripple described above and more as a triumphant hero despite being burdened with 
physical limitations; this significantly contributed to the transforming structure of disabled 
identity (Gallagher 1985). The lack of photographs of Roosevelt in a wheelchair support 
this notion and contribute to what Gallagher (1985) calls ‘FDR’s magnificent deception’. In 
1924, after it was reported in newspapers that he bathed in Warm Springs, Georgia, to ease 
his paralysis, many other sufferers made their way there. Roosevelt spent two thirds of his 
personal fortune renovating, and expanding it to become the Warm Springs Foundation 
(Gallagher 1985). It was directed by his former law partner, Basil O’Connor, whose 
commitment was further reinforced by his daughter’s death from poliomyelitis (Oshinsky 
2005:271). 
 
                                                 
9
 Although Roosevelt’s presidency did not begin until 1933, he had by then already risen to national 
prominence. He was born into a wealthy and powerful family. In 1905 he married his cousin, who was the 
niece of the then President Theodore Roosevelt. By 1920, he had won his party’s Vice-presidential 
nomination (Gallagher 1985). 
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In 1934 Roosevelt staged nationwide charity balls on his birthday ‘to dance so others may 
walk’ (Carter 1965:14) and also to relieve debts accruing at Warm Springs (Rose 2003). 
Given the stock market crash of 1929, the campaign achieved extra-ordinary success (Rose 
2003). It raised $1m that year10, $0.75m the following year and it reserved $100,000 to 
‘stimulate and further the meritorious work being done in the field of infantile paralysis’ 
(Carter 1965:14,15 and 18). The first sixteen research grants totalled $250,000, one of 
which, for $65,000, was distributed to Maurice Brodie (Carter 1965:20; Benison 1967:179). 
 
6.2 Brodie-Kolmer vaccine failures: A weak testing regime in need of strengthening 
 
Part of Flexner’s bold optimism was based on the successes of tetanus and diphtheria 
vaccines, which by 1910 had rapidly saved millions of lives11. This passive immunisation 
was achieved by using immune sera drawn from the blood of horses previously immunised 
with graded doses of bacteria. Flexner and Lewis attempted to repeat the achievement with 
polioviruses but had to report ‘the failure to produce neutralising serum in the horse by 
repeated injections of filtrate… The horse serum, when mixed with the virulent filtrate and 
incubated [as in monkeys], displayed no power whatever to inhibit the action of the virus. 
The monkeys injected with the mixture of horse serum and virus became paralysed in the 
same average period as the controls’ (cited in Chase 1982:302). Poliovirus could not be 
grown in horses, or any other animal12, and further research and development would have 
to involve either humans or monkeys. 
 
6.2.1 Failure of ‘witches’ brew’ 
 
Despite the confusing data emerging from monkeys, the overall vision was strong and 
stable enough for two investigators to overlook the problems. They independently 
conducted field trials of ill-conceived vaccines prepared from spinal cord of infected 
monkeys in 1936 (Chase 1982; Robbins 2004). They envisaged rudimentary operational 
                                                 
10
 All dollar figures in this thesis, unless stated otherwise, have not been adjusted for inflation. 
11
 For example, the United States’ death rate for diphtheria halved between 1900 and 1909 (Chase 1982:302). 
12
 Although, in 1939, a poliovirus strain was adapted for certain rodents, its growth was limited and rare (Paul 
1971:276; Robbins 2004:19). Humans and monkeys seemed the only alternatives. 
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principles and wanted to test them promptly to refine them into a vaccine. Brodie and Park 
used a formalin-treated preparation of mashed up spinal cord, whilst Kolmer used live virus 
from spinal cords which he treated with chemicals and refrigeration to achieve immunity. 
In retrospect Kolmer’s was probably the more dangerous of the two, described by some as 
‘a veritable witches’ brew’ (Paul 1971:258). 
 
The investigators wanted to progress quickly with tests, and using what Paul (1971:259) 
refers to as ‘kitchen chemistry’, the two hurried their ‘vaccines’ into perceived readiness, 
each fearing the other would succeed first. The rivalry was perhaps all the more intense 
since Kolmer was not funded by Warm Springs money. The failure killed and paralysed 
many of 12,000 children he ‘vaccinated’ (Paul 1971; George 1996). In a public health 
association meeting, Kolmer is reported to have said “Gentlemen, this is one time I wish 
the floor would open up and swallow me” (Paul 1971:260; Chase 1982:284). Many have 
alleged that Brodie killed himself four years after the trials (Paul 1971:261), but his death 
certificate only offers thrombosis as the cause (Chase 1982:284). 
 
The failures stifled vaccine development and dampened enthusiasm to an extent that Paul 
considers ‘blown out of proportion’. The impact of the experience traumatised researchers 
and sparked ‘a wave of revulsion against human vaccination attempts in poliomyelitis’ that 
lasted for two decades (Paul 1971:260). 
 
6.2.2 Learning from failure with a testing regime 
 
The failed efforts are indicative of the norms and traditions of those testers. They saw 
vaccinology largely as an empirical art, and if the vaccine worked, it worked. Vaccines for 
diseases such as smallpox and rabies had been developed without formal identification and 
characterisation of their infectious agents. How or why a vaccine protected a human was 
relevant but not all important. Their aim was to protect public health and livestock; if 
understanding was improved along the way, so much the better. 
 
But if the vaccine did not work in a single attempt, as in this instance, the testing regime 
needs to be able to ensure that researchers have a way of finding out why the test failed. 
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The knowledge generated from these trials did not accumulate and further social investment 
in the testing regime would be needed. The failures served to highlight that more 
systematically gained know-how was needed before injecting people. 
 
The testing regime was weak for three reasons. Firstly, feedback loops were weak because 
there was so little virus available to work with. Few were skilled at diagnosing infection 
quickly by extracting spinal fluid, so most researchers had to wait for symptoms when 
testing for any immunity. Secondly, iterations, refinements and adjustments could not be 
made, because monkeys were so difficult to use and they were not used intensively because 
they were so expensive13. Thirdly, the community did not establish the types of 
poliomyelitis virus they were working with before trialling. Each of these three issues 
needed to be addressed for successful vaccine innovation as the next section shows. 
 
The failures moved Roosevelt to abandon the Birthdays Balls after 1937 and rename the 
Warm Springs Foundation to the National Foundation for Infantile Paralysis (Rose 2003). 
Its mission was not just to ‘make every effort to ensure that every possible research agency 
in the country is adequately financed to carry out investigations into the cause of infantile 
paralysis and the methods by which it may be prevented’ (Carter 1965:15). But 
significantly, Roosevelt also announced that the Foundation would, ‘lead, direct, and unify 
the fight of every phase of this sickness’ (Markel 2005:1408) [my italics]. It would form a 
major institutional part of the testing regime for poliomyelitis vaccine development, and it 
formed a focal point for the co-ordination of resources – fiscal, labour, skills and materials. 
 
The first fund raiser held by the Foundation was a radio promotion. One of the radio 
promoters enthused ‘we could ask people to send their dimes directly to the White 
House…think what a thrill people would get…we could call it the march of dimes’ (Carter 
1965:16). The Foundation received over $1.8m in a week and with each new campaign the 
proceeds increased. For example, the 1945 receipts totalled $18m, and 1955 contributions 
                                                 
13
 Brodie only tested his vaccine on 20 monkeys before trialling with 300 children whilst Kolmer only tested 
on a few monkeys, himself, his children and 22 others before distributing the vaccine to physicians around the 
country (Paul 1971). 
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totalled $67m (Carter 1965:26). A considerable war chest was established for the research 
and development of vaccines14 (Carter 1965; Paul 1971:312). 
 
Figure 6: March of Dimes Posters 
 
Sources: US FDA15 
 
6.3 The construction of a more sophisticated testability regime 
 
In 1947, Harry Weaver was appointed as Director of Research at the Foundation. With the 
support of O’Connor, and to the resistance of many others, he went about directing 
poliomyelitis research much in the style of large war time projects. Weaver began by 
inviting leading poliomyelitis researchers to conferences and had the Foundation publish 
their remarks in regular reports (Carter 1965; Smith 1990). He instituted a series of round 
table discussions with the Foundation’s grantees. The more long term purpose of this was 
to ‘encourage communication and intellectual cross-fertilisation in a field notable for its 
lack of both’ (Carter 1965:57). The more short term goal was to bring himself up to speed 
with the current wisdom about poliomyelitis. 
 
In this way, Weaver immediately played an important co-ordinating role between different 
groups of scientists. With O’Connor, Weaver would also play an intermediary role between 
                                                 
14
 Between 1938 and 1962, the Foundation’s overall income was $630m. 59% was spent on hospital and 
patient support (treatment and care), 13% was spent on fund-raising and advertising, 8% on educational 
programmes, and 11% ($69m) was spent on vaccine R&D (Paul 1971:312). 
15
  www.fda.gov/cber/summaries/cent092302pp.htm and http://polioclinic.com/history/dimes.htm  
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the scientific community and the wider public interest. The Foundation was entrusted with 
co-ordinating the scientific community and preventing the failures of the 1930s vaccines 
resurfacing, but it was also constantly in the media spotlight and funded by mothers with 
tins collecting door-to-door. With Weaver, the Foundation was able to juxtapose scientific 
concerns with those of the technology-demanding public. Researchers wanted incremental 
advances of certainty, and poliomyelitis sufferers wanted tangible advances urgently. 
 
The tensions between these two aims quickly became apparent to Weaver. The round table 
discussions and conferences led Weaver to the view that whilst researchers who are free of 
direction establish more certainties about a disease, they often choose to investigate 
questions of little practical application. Weighing up the field Weaver wrote to O’Connor, 
 
‘Only an appalling few…were really trying to solve the problem of poliomyelitis in 
man….If real progress were to be made, more exact methods of research would have to be 
clearly defined, procedures and techniques would have to be developed to permit attaining 
those objectives and individual groups of workers would have to sacrifice to some extent 
their inherent right to roam the field, and concentrate their energies on one, or at most, a 
few of the objectives’ (Carter 1965:57). 
 
Prior to Weaver’s appointment, the National Foundation simply funded projects that 
independent researchers chose (Benison 1967; Smith 1990), similar to many of the 
foundations of today (Arnold 2005:34; Boddington 2008; McCoy, Kembhavi et al. 2009; 
Moran, Guzman et al. 2009), upholding the traditional view that burdening scientists would 
suffocate their creativity and output. Weaver believed that part of the problem was allowing 
this form of investigator-initiated research to dominate the research agenda at the expense 
of more carefully co-ordinated research. As Weaver was a doctor of philosophy and not of 
medicine (Carter 1965:58), he set up a Scientific Research Committee with whom he could 
direct research at the technical level. The head of this Committee was Dr Thomas Rivers, 
who shared Weaver’s view of targeted research, 
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‘During the first year of the Foundation’s existence, the Scientific Research Committee 
received any number of applications from individual investigators and, while many were 
worthwhile in themselves, together they did not seem to be going anywhere. They were too 
haphazard for a program and I thought that the Foundation would be better served if a 
committee surveyed the field of polio research and blocked out problems that needed 
solution. With such a guide in hand, I felt that the committee should seek out the men and 
institutions capable of researching such problems and support them with grants’ (Benison 
1967:231). 
 
‘Several members of the committee didn’t like my idea.... They felt that the Foundation 
would be better advised if it simply continued to give grants to competent investigators of 
accredited institutions who voluntarily expressed their wish to do research into causes and 
prevention of polio’ (Benison 1967:232). For example, one prominent Foundation grantee 
wrote, ‘Are we now employees who are ordered about?’ (Paul 1971:405). 
 
Despite the resistance to such interference in research, Rivers and Weaver led the enterprise 
‘by seeking out men and institutions’ to undertake an 11 point research plan they felt 
needed doing16. To begin with, there were three major impediments to poliomyelitis 
vaccine development which Weaver tackled directly. Firstly, Weaver felt that a monkey 
shortage had delayed poliomyelitis research. Secondly, it was not known how many wild 
types of poliovirus existed against which a prospective poliomyelitis vaccine would need to 
protect. Thirdly, it was not possible to grow viruses successfully in the laboratory; they had 
to be grown in living animals, in the brains of monkeys. This was time consuming, 
expensive and of low yield. 
 
6.3.1 “Monkey Business”: Co-ordinating the supply of Testing Resources 
 
Weaver complained to O’Connor that ‘experiment after experiment had been botched by 
scientists who used too few monkeys or made the error of reusing monkeys whose systems 
                                                 
16
 The eleven priorities are fully listed by Benison (1967). 
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were misleadingly immune to one or another type of the virus.’ O’Connor resolved, “We’ll 
go into the monkey business” (Carter 1965:73). 
 
After decades of trying, researchers had been unsuccessful (except in a very limited way) in 
giving poliomyelitis to mice, rats, rabbits and other small, inexpensive and readily available 
laboratory animals (Robbins 2004). They could do it with monkeys, but working with 
monkeys was expensive, messy, and sickly. Even with the ethics of animal research being 
less high profile compared to today, working with monkeys was still troublesome. Monkeys 
required special animal quarters distinct from the usual cages or bins for smaller laboratory 
animals such as guinea pigs and mice (Paul 1971:101). 
 
Aside from the extra space required, monkeys needed an entirely different kind of care 
from that of smaller animals. ‘Salk had spent a significant proportion of his time arranging 
the housing and feeding of his monkeys, as well as placating the assistants who had to work 
with them’ (Smith 1990:123). For it was these skilled keepers who had to watch for their 
welfare and keep up their spirits, whilst also cleaning their messes and feeding them. They 
were skilled in handling them, exercising them and observing their behavioural tendencies. 
They also had to contend with the constant threat of bites and thumps, as well as the chance 
of catching disease from them. The possibility was frightening enough for Salk to request 
from the Foundation ‘a $10,000 life insurance policy for each of the individuals in this 
extra-hazardous work’17 (Carter 1965:75). 
 
Despite these difficulties, laboratory demand for monkeys outstripped supply. Capture of 
wild monkeys was not always a simple affair, free of outside considerations18. Many 
                                                 
17
 One physician working with monkeys suffered a fatal case of encephalitis. The Foundation referred Salk to 
University administration on his request for insurance against such fatalities. 
18
 Cynomolgous monkeys suffered from poliomyelitis in ways that were close to human and their 
temperament made them easier to work with, but their extreme scarcity meant they were very expensive 
imports from the Philippines and Indonesia (Time 1954; Smith 1990). Rhesus monkeys, the type most 
commonly used for laboratory research, were abundant in India, but they are sacred to Hindus, regarded as 
incarnations of the monkey God Hanuman (Lutgendorf 2007). Only Muslims, (or other non-Hindus) would 
catch monkeys and then only during specific seasons, for example not over the month of Ramadan (Time 
1954). Supplies were also susceptible to Indian government regulations and restrictions rooted in Hindu 
religious pressure groups, fears about what they were being used for, or concerns about mistreatment in transit 
(Time 1958). 
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researchers complained about monkeys arriving dead or diseased. Salk complained to a 
supplier, ‘In addition to the three monkeys from the first shipment that were dead on arrival 
(in one instance there was obvious head trauma), we have lost three more. I wonder… 
whether you will replace the animals that die… The monkeys of the 18th seem to be much 
cleaner, more content and evidently well fed; however they seem very small’ (Carter 
1965:75). 
 
O’Connor established Okatie Farms to address these problems. Weaver would organise 
massive monkey ‘airlifts’ from India and Indonesia (Time 1954:7) and have them sent 
directly to the Farms. There they would rest, recover their bearings, and recuperate from 
whatever diseases they might have had. Only when they were nursed back to health would 
they be dispatched to laboratories. In this way, the Farms saved laboratory time, effort and 
space. 
 
Smith (1990:121) describes the Farms as ‘a rehabilitation facility that was also a center 
[sic] for research in the solution of problems nobody else much cared about.’ The Farms 
developed carefully formulated dry monkey feed in conjunction with researchers like Salk, 
‘I am wondering if the low cost of your [monkey] diet is not due to the fact that there has 
been some substitution in content’ (Carter 1965:76). The Farms also provided instructions 
on how to mix the feed and tips on when and how to get the monkeys to eat it. Among the 
tips were to divide the rations so that the monkeys would not have enough in one go ‘to 
fling around and mash into each other’s ears and stuff down drains and such like’ (Smith 
1990:122). In all, there are considerably long correspondences regarding the minutiae of 
delivering, feeding, handling and disposing of monkeys (Carter 1965). 
 
6.3.2 Tissue Culturing: a new technique for growing virus 
 
The effort to develop better methods for propagating the virus was attempted by various 
investigators throughout the 1930s, but failed to find a solution (Robbins 2004). By the end 
of the decade two exceptional groups reported the growth of poliovirus in cultures of 
human embryonic brain tissue, however they failed to take the technique further with cells 
from non-nervous system tissues (Sabin and Olitsky 1936; Burnet and Jackson 1940:373; 
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Paul 1971). Robbins (2004:18) laments on their efforts, ‘Unfortunately, they did not pursue 
these findings; otherwise the vaccine might have been available almost a decade earlier.’ 
 
Their failure to persist was in part due to the orthodoxy that poliovirus was essentially a 
nervous system virus, which occasionally spilled over into the blood. Unfortunately their 
findings served only to reinforce the notion that poliovirus was more neurotropic than it 
really was. Thus it was thought that a poliomyelitis vaccine was highly impractical because, 
if it would only grow in the nervous systems of monkeys, it was impossible to remove all of 
the animal-nerve cells when harvesting the virus for vaccine preparation. This in turn meant 
that a vaccine would be very dangerous for humans because, when they are injected with 
foreign nervous tissue, they may suffer fatal allergic inflammations of the brain, or 
encephalitis (Rogers 1992). 
 
However, some other Foundation grantees made significant findings about virus growth. 
Paul and Trask observed the presence of virus in human faeces, implying it could reproduce 
in the alimentary tract (Paul 1971:281). In 1940, Bodian and Howe gave chimpanzees 
poliomyelitis by feeding them the virus and, in 1947, Melnick and Hortsmann demonstrated 
that the animals developed antibody and resistance to re-infection after such feeding (Paul 
1971:287). This provided strong indications that poliomyelitis was an intestinal infection. 
 
Then, with Weaver at the helm, the Foundation funded a more persistent effort on tissue 
culturing than before. The Foundation provided funds for training personnel to acquire 
practice and skills in culturing. In order to achieve good yields, cultures have to be kept at 
precise temperatures, in very clean containers, of the right shape and size, with the right 
kind of lids and stoppers (Smith 1990). Sourcing the tissue with which to culture was not a 
straightforward matter either. The Foundation kept laboratories in close contact with local 
maternity hospitals because embryonic tissue grows much faster than that of adults, and is 
less prone to disease, so it is the preferred tissue. Given the contentious nature of acquiring 
genuine embryonic tissue, the closest the Foundation could get was to acquire small 
quantities of foreskins from circumcisions of newborn boys. Placentas, miscarriages and 
 117 
still-born tissue were also used but the supply of these sources were less predictable and 
were also quite controversial (Smith 1990). 
 
The Foundation commissioned a group at Harvard University, who had been developing 
culturing techniques on mumps virus and chicken pox virus with considerable success, and 
supplied them with abundant poliovirus and funding to match (Chase 1982:292). In this 
attempt, Enders, Weller and Robbins succeeded in making the breakthrough most eagerly 
sought by the Foundation – that is, cultivating poliovirus in human non-nervous tissues (in 
human embryonic skin muscle). It was not long before poliomyelitis was found to 
propagate in cells from a variety of tissues (Robbins 2004:18). 
 
Initially, the scientist John Paul undervalued the breakthrough. ‘For the moment, I was 
stupidly unaware of the implications that this finding held. At least it did not appear to me 
as an electrifying piece of news. Instead, I visualised it as just another repetition of the 
results which Sabin and Olitsky had reported twelve years earlier…However remarkable 
their technical triumph was, it hardly seemed to me to be a trick... How utterly mistaken 
was my preliminary judgment of this discovery to prove!’ (Paul 1971:373). Their technique 
marked the start of the tissue culture era. 
 
Tissue culture transformed the testing regime by providing a safer and simpler environment 
to learn in, with tighter feedback loops with new knowledge derived from tests 
accumulating quickly. Firstly, the tissue culture era did not simply represent a method of 
growing more of the virus. It was a source of better quality virus because it was relatively 
free of protein and, crucially, it could be free of nerve cells, which meant it removed the 
chief safety concern of encephalitis (Robbins 2004:18). 
 
Secondly, tissue cultures drastically reduced the need for monkeys which were being 
imported at great financial and temporal expense (Chase 1982). In 1953, human embryonic 
tissue was substituted with the testicles or kidneys of monkeys, a single one of which, 
according to Salk, could provide enough tissue culture for two hundred test tubes (Carter 
1965:114). One monkey, then, did what used to require two hundred. ‘Worse than the costs 
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of buying and maintaining these animals were the temporal limits they placed on the 
investigative progress’ (Chase 1982:286). With the need for experimental animals vastly 
reduced, feedback loops were much shorter. More ideas could be tested, and the results of 
such tests could be assessed quicker. Thus testing became dramatically cheaper and 
quicker. 
 
Thirdly, tissue cultures were used to set up standards and criteria. It was observed that early 
in the course of poliovirus cultivation, infected cells were rapidly destroyed (Chase 
1982:292; Robbins 2004:19). This cytopathic effect was used as an indicator of viral 
replication, meaning that the presence of viruses were observable with microscopes rather 
than with monkeys. With some technical modifications, tissue cultures were also used for 
virus titration, antibody quantification, virus isolation from clinical specimens and antigenic 
typing of virus isolates (Paul 1971:374; Robbins 2004:19). 
 
Robbins (2004:18) reflects, ‘There is no ready explanation as to why [our] experiments 
succeeded whereas those of Sabin and Olitsky did not. The principal technical difference 
was that, in Enders’ laboratory, the cultures were maintained for a longer time, with 
periodic changes of nutrient medium…’. Sabin himself acknowledged this at a Danish 
conference (Carter 1965:115). Persistence and simply trying harder and for longer, 
however, were not the only reasons they succeeded. Rivers also saw the experiments as 
very similar, as he recounted, ‘[Sabin and Olitsky’s] work was so meticulously done that I 
believed it was absolutely correct… I read [Enders’] paper over and over looking for a 
flaw. In the end I had to believe he was right. It wasn’t easy because I damn well knew that 
Olitsky and Sabin were also right’ (Carter 1965:90). But Rivers realised that whilst Enders 
was supported by the Foundation in the form of grants and supply with plenty of virus, the 
other groups were not. He reasoned that Sabin and Olitsky’s technical downfall had been 
the virus they had used. As Sabin subsequently proved, possibly at Rivers’ suggestion, the 
MV virus was the only poliovirus that would not grow in non-nervous tissue. Rivers noted, 
‘If Olistky and Sabin had worked with another strain… the chances are that… we would 
have had a breakthrough of major proportions in making a vaccine [much earlier]’ (Carter 
1965:91). 
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So Rivers felt that working without a clear cataloguing of the various poliomyelitis strains 
had impeded vaccine development by delaying tissue culturing. 
 
6.3.3 Virus typing: $1.37m for a “dull” and “menial” program 
 
In 1948, Weaver pushed forward this important, but theoretically unexciting, strategic 
research project. For a long time it was suspected that multiple strains of poliovirus 
existed19 but to establish this with more certainty would involve a long and systematic 
effort. It would entail immense cost in terms of laboratory space, monkeys, technical 
personnel, and equipment. Weaver was aware that senior researchers would be reluctant to 
take on such ‘drudgery’ (Carter 1965:61) because it would involve giving over their 
laboratories and several years to mechanical and boring work. 
 
John Paul (1971:318) says of the co-operative typing program, ‘This was not exploration; 
rather it was the application of established methods to solve a specific problem. In the 
planning and implementation of this type of medical ‘research and development,’ the 
foundation was at its best’ (Paul’s inverted commas). 
 
The protocol of immunological testing was difficult, imprecise and time consuming. A 
group of monkeys was infected with a strain of poliovirus, say Type I virus. After waiting 
for them to get sick, and waiting for them to recover (if they did recover), they were then 
challenged with ‘standard’ doses of unknown viruses and their responses were charted. If 
this group of monkeys that was infected with known Type I virus and then subsequently 
infected with a virus of unknown type, got sick again on the second infection, one infers 
that the unknown virus is a different strain from Type I, say Type II or Type III. This 
different strain of virus can then be injected into another group of monkeys known to have 
recovered from infection with Type II virus. If there were no ill effects, the unknown strain 
can be confirmed as Type II, but if the monkeys got sick the procedure is repeated with 
another group of monkeys known to resist Type III viral infection so that the unknown 
                                                 
19
 There were indications that monkeys immune to one strain of poliovirus could still be infected by another 
strain (Burnet 1931, cited in Chase 1982:284). 
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virus can eventually be confirmed as a Type III virus strain when the monkey shows no ill 
effects (Smith 1990). 
 
The whole protocol, even when executed perfectly and with a lot of luck, would have 
required a lot of monkeys to confirm immunological test results. But there are many 
inaccuracies in making the deductions. Preparing ‘standard’ doses, also known as challenge 
stock, was a delicate, time consuming and frustratingly immense job because the viruses 
differed greatly in pathogenicity and infectivity. Thus the standard dose was significantly 
different for just about every virus strain and it could be miscalculated easily given such 
high variance. Too weak a dose and one might mistake a very mild infection for prior 
immunity. Too strong a dose and the monkeys end up dead, which would reduce the 
efficiency of monkey use. To guard against such miscalculations, each step of the process 
needed to be repeated with dozens of monkey groups (Smith 1990). Only then can a 
challenge stock database be compiled and shared with other groups as a sort of ‘public 
good’ of knowledge for further research. 
 
Weaver set up an eminent advisory committee to lead the virus typing project but the task 
itself did not inspire any of them so Weaver went looking for other young and fresh 
researchers. An ambitious Jonas Salk had just set up a new laboratory of his own after 
having worked on a formalin-inactivated influenza20 vaccine with his mentor, Thomas 
Francis, for the US Armed Forces (Carter 1965; Galambos and Sewell 1995:47). Salk was 
looking for his laboratory’s first grant when Francis encouraged him to take on lucrative 
work being offered by the Foundation (Carter 1965; Smith 1990). This project was seen by 
Salk as ‘a dull but dependable investment that would provide a regular dividend of money 
for his lab’ (Salk quoted in Smith 1990:117). Smith writes ‘The Foundation’s virus typing 
program would be menial but liberating [Salk] told himself – a simple job… and a means to 
expand both the size and the equipment of his laboratory in ways that would remain long 
after… The Foundation directors who had chosen Salk’s laboratory didn’t mind a bit of 
careerist greed as long as it got the job done’ (1990:110). 
                                                 
20
 The Army were interested in influenza vaccines because more people died from the influenza epidemic of 
1918 than were killed in combat (Crosby 1976). 
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The large scale experiment spanned four universities and two years, classified over 200 
clinical strains of poliovirus isolated from patients all over the world, cost $1.37m and used 
up 30,000 monkeys21 imported at great expense (Chase 1982). It showed conclusively that 
there were three, and only three22, immunologically distinct types of poliomyelitis virus 
(Bodian 1949). 
 
This was crucial information for developing a vaccine that was fully protective and not just 
partially protective against local strains. The virus typing set another standard for all future 
vaccine candidates to be compared against. Indeed when successful results were announced 
to the public in Francis’ final evaluation report, it was in terms of this standard; Salk’s 
vaccine was ‘60-70% effective against disease caused by Type I virus and 90% or more 
effective against that of Type II and Type III virus…’ (Carter 1965:275). The Foundation 
also devoted significant funds to epidemiological studies which established which of the 
three strains were prevalent and where the strains were distributed across the country. Such 
epidemiological data would be useful in deciding where to locate field trials of future 
vaccines (Paul 1971:357). 
 
6.3.4 Summary 
 
Weaver ensured that the Foundation worked to open channels for communicating research 
results, encourage the sharing of unpublished data and establish criteria and specifications 
with which to frame those results. The Foundation’s scientific advisors, led by Rivers, 
commissioned the development of key research tools such as tissue culturing, and 
important epidemiological studies such as identifying and classifying the three strains of 
virus. 
 
On the one hand, tissue culturing drastically reduced the need for monkeys but on the other 
hand, the virus typing programme offset that reduction and made the need for monkeys 
                                                 
21
 To put the figure in context, the US Department of Agriculture reported the use of 52,000 monkeys, 
chimpanzees and other primates in 2002 for the all R&D http://www.aphis.usda.gov/ac/ar2002.html  
22
 The three strains were named Lansing, Prunhilde and Leon strains (Time 1953). 
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even more intense than it was before23. Weaver’s careful watch on monkey procurement 
from Asia and O’Connor’s efforts in the establishment of Okatie Farms relieved scientists 
of many of the administrative and handling problems associated with monkeys. 
 
The community was well prepared to appreciate any new ideas and, following these key 
advances, were well positioned to start thinking about how they might test and assess them 
in monkeys and, eventually, people. With the chances of making a poliomyelitis vaccine 
much improved, a number of groups worked towards that goal but with different 
operational trajectories. Hammon chose to pursue a passive immunisation approach, whilst 
Salk and Sabin successfully pursued active immunisation approaches24. Salk took the line 
of a formalin-inactivated vaccine, whilst Sabin chose to pursue a live attenuated vaccine. 
 
6.4 Passive immunisation: Testing for design and field-based capabilities 
 
By the 1950’s, the emphasis shifted from establishing these operational trajectories in 
monkeys, to creating learning conditions in humans. These conditions would be more 
relevant and realistic, but this section highlights how the associated complexity was 
managed through governance so that testing resources were co-ordinated and tests on 
humans resulted in the accumulation of technological knowledge. A critical part of the 
vaccine design process is also described as a difficult and uncertain translation of 
qualitative goals into objective ones. I begin by outlining the feasibility of passive 
immunisation as an operational principle, before analysing considerations made about 
vaccine design and organisational capabilities during the move to human testing. 
 
Hammon believed that gamma globulin, an antibody obtained from pooled plasma with 
known neutralising activity, might protect against natural infection. His immediate goal 
was to prevent poliovirus causing disease on the nervous system, rather than infection in 
                                                 
23
 The Virus typing program used 30,000 monkeys but before the program, 17,500 monkeys were used in 
tests (Carter 1965; Chase 1982). 
24
 Passive immunisation refers to injection of blood gamma globulins that transfer specific antibodies to the 
virus, in contrast to active immunisation, in which an antigenic substance is injected that induces specific 
antibodies to the virus. See chapter 5. 
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the first occurrence (Carter 1965; Paul 1971; Plotkin and Vidor 2004). Permanent immunity 
through repeated infection might be achieved, but without the symptoms of poliomyelitis. 
The idea carried weight in part because passive administration of serum achieved some 
success against measles virus (MRC 1948). 
 
In 1948 Morgan and Bodian were able to protect monkeys from one type of poliomyelitis25 
(Carter 1965:64; Paul 1971:405). By using graded doses of virus with the purpose of 
producing varying levels of antibody, they effectively constructed an index of the degree of 
immunity in monkeys. This represented an improvement in the knowledge infrastructure 
because future antibody experiments could be compared to this index. Hammon argued that 
the role of antibody was still uncertain in humans, and that the antibody index would allow 
a safe start to ascertaining ‘how much was enough for humans?’ and ‘how long do they last 
in the blood?’. 
 
The Foundation created a ‘Committee on Immunization’ to manage strategic and logistic 
aspects of human vaccine trials26 (Carter 1965:125; Paul 1971:407). It was a daring role 
given the traumatic failures of the Brodie-Kolmer trials two decades earlier. Fear about 
using killed or live virus was a common theme voiced by Sabin and coloured the views of 
most in the field (Rinaldo 2005). However, Hammon’s vaccine did not contain any virus 
and answered Rivers’ call for boldness, ‘I think it is time that we got ready to go 
somewhere, and somebody ought to come up with some concrete experiments that will be 
done in human beings on a small scale in order to get going’ (Carter 1965:126). 
 
Hammon’s preliminary field trial showed that relatively low levels of antibody could 
prevent invasion of the central nervous system27 (Hammon, Corriel et al. 1953). The results 
provided vaccine designers pursuing different operational trajectories, such as Salk and 
Sabin, not only with the confidence that infection could be prevented, but also a tangible 
                                                 
25
 Although the following year the Foundation’s virus typing committee (of which Hammon was a member) 
found that there were three types. 
26
 Members included most of the eminent virologists of the time: Bodian, Enders, Francis, Hammon, Howe, 
Paul, Rhodes, Sabin, Salk (Carter 1965:125; Paul 1971:407). 
27
 This indicated that Hammon’s lower goal, of preventing disease rather than infection, may have been 
excessively modest. 
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performance criterion. The subjective aim of immunity had become an objective goal of 
putting antibodies in the blood28. The testing regime had a bar, against which potential 
designs could be compared. 
 
Questions of how quickly and safely immunity could be established in the blood, and how 
long it would last for in the blood under various conditions remained. Antibodies produced 
by the body through active stimulation were thought to last longer than those passively 
given to the body. Hammon argued the other operational trajectories’ also provided only 
transient immunity29. In addition, he noted their safety concerns and their need for multiple 
injections, saying that with his gamma globulin, its effect would be immediate and would 
represent no danger to any child’ (Hammon 1950:702). 
 
Although passive immunisation might not need multiple injections, Hammon apparently 
overlooked the fact that passive immunisation would require up to 10cc of gamma globulin 
given in the buttocks, a painful and taxing task (Rinaldo 2005). Although he cited the 
availability of gamma globulin as an advantage (Hammon 1950), his subsequent clinical 
trial seriously depleted all reserves of gamma globulin30. A further trial with more people, 
and hence more slightly varied conditions, was needed to address these issues of speed, 
durability and quality of immunity31. 
 
The Foundation funded Hortsmann (1952) and Bodian (1952) to see if passive 
immunisation protected monkeys from very high, lethal doses of poliovirus of all three 
                                                 
28
 By helping to ascertain how much antibody was needed to prevent infection, Hammon effectively provided 
what can be called a correlate of immunity. Many HIV vaccine researchers lament on the lack of correlates of 
immunity (see section 7.2.2). 
29
 In support of this view, Morgan (1948) had showed that repeated large doses of formalin-inactivated virus 
induced only temporary immunity in monkeys. 
30
 The limited availability of gamma globulin restricted its use. Obtaining gamma globulin was an expensive 
and time consuming process and depended on voluntary blood donations. At the same time, the Korean War 
and hospital needs were drawing on supplies. O’Connor warned that there was not enough to provide ‘even 
temporary protection to the 46 million children and adolescents most susceptible to poliomyelitis’ (Rinaldo 
2005:795). Nevertheless, the Foundation spent $7m boosting gamma globulin production and a further 
million children were protected in the poliovirus season of 1953 (Rinaldo 2005). 
31
 The Immunization Committee initially turned down Hammon’s request for a larger scale controlled trial 
(Rinaldo 2005). They wanted to see more animal and human data before embarking on a complicated and 
expensive clinical trial (the trial ultimately cost the Foundation $1m). They were also concerned about using 
placebo controls, which had never been used before, and its moral and social acceptability (Rinaldo 2005). 
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strains. Compared to Morgan’s experiment in 1948, these conditions were more stringent, 
more technologically relevant, and perhaps even scientifically less interesting because the 
theoretical concept of neutralising antibodies had already been established. The protection 
achieved under these conditions convinced the panel to fund a pilot study of 5000 children. 
Panel members realised that this size would not yield statistically significant results, rather 
the study’s purpose was ‘to gain experience in organisation and administration, as well as 
to evaluate the public’s and medical profession’s reaction to such a trial’ (Rinaldo 
2005:793). 
 
The details of the trial which needed to be organised were very broad and included how to: 
blind the vaccine vials, select a type of control inoculum, source and set dosage of gamma 
globulin, types of syringes, packaging, venue, injection administration site on the body, 
consider legal aspects such as written informed consent, select geographical areas 
undergoing epidemics of a suitable magnitude, gain approval by local population, manage 
publicity and preparation of clinics, and follow up studies to identify incidence cases. Most 
critical was ‘the definition of the severity of the paralytic disease, for which they used a 
carefully graded scale of muscle function loss’ (Rinaldo 2005:793). This is another 
example where the Foundation set up an infrastructure to compare future observations to a 
set of known conditions, thereby ensuring that those observations would contribute to 
cumulative knowledge growth. It might otherwise have been seen as a chore, with little, if 
any, scientific merit. 
 
The pilot results were encouraging and public support was very strong, with hundreds of 
volunteers being turned away by day four (Hammon, Corriel et al. 1953). Problems 
included such issues as lack of access to large autoclaves to sterilise the syringes and 
needles. A larger trial was quickly approved, which involved 55,000 children. The result of 
this trial was considered, ‘conclusive evidence of a very significant reduction in the total 
number of cases of paralytic poliomyelitis’ (Hammon, Corriel et al. 1953:758). 
 
Hammon concluded that, ‘perhaps the greatest contribution of the gamma globulin trials… 
demonstrated that a very low concentration of antibodies will protect man’ (Hammon, 
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Corriel et al. 1953:1283). Aside from taking this design standard from monkeys and 
establishing it in human conditions, a graded scale of paralytic disease was also developed. 
The trials were seized as an opportunity for the Foundation to build up organisational 
capabilities in acquiring local knowledge for testing outside laboratory conditions, and co-
ordinating people, resources, logistics and public support. The Foundation had already 
begun setting up the organisational decision-making process for moving, potentially, more 
dangerous vaccines to trial in humans. 
 
6.5 Killed vaccines: Testing regimes for taking ‘calculated risk’ 
 
This section discusses how a more risky vaccine was tested, and selected to be tested, in 
humans. The vaccine was more risky than Hammon’s because it contained killed virus, but 
less risky than using live vaccine. The initial risk appears to have been borne by certain 
sections of society, who provided the conditions that were both relevant for technological 
development and suitable for learning. Key techniques used to ensure these conditions for 
knowledge growth was the design of double-blind, placebo-controlled trials, and 
institutional leadership to mediate differences of opinion. This was critical for choosing 
which of the different operational trajectories to test. 
 
By 1953, Salk had showed that poliovirus could be inactivated by formaldehyde (Salk 
1953). Moreover, he determined how much formalin affected inactivation, and conducted 
safety and immungenicity studies in animals (Benison 1967; Robbins 2004). If there was 
any doubt as to whether such animal findings could be translated to children, Howe’s 
(1952) paper made it clear, entitled ‘Antibody response of chimpanzees and human beings 
to formalin inactivated Trivalent poliomyelitis vaccine’. 
 
Howe tested six children at the Rosewood school, whom he noted as, ‘low-grade idiots or 
imbeciles’ (1952:265), and was able to report that ‘both children and chimpanzees develop 
readily demonstrable neutralising antibodies at comparable levels following the injection of 
small quantities of clarified monkey cord suspensions containing formalin inactivated 
poliomyelitis virus’ (1952:265). Salk, too, had started preliminary studies in humans which 
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showed that antibodies could be increased to relatively high titres in children already 
infected at the Watson Home for Crippled Children32. But these advances, aside from any 
modern day ethical testing concerns, were leading to a somewhat problematic vaccine. 
 
Conventional wisdom held that only a live-attenuated vaccine could confer long lasting 
immunity because it more closely mimicked a true infection (Carter 1965; Klein 1976; 
Smith 1990). Several of the Committee’s senior virologists, including the Nobel Laureate 
John Enders and Albert Sabin, in particular questioned the relation of antibodies to 
permanent immunity and doubted the safety of a vaccine prepared from virulent poliovirus, 
regardless of ‘inactivation’ method, especially after the failed vaccines of the 1930s (ibid). 
Enders cautioned, ‘the ideal immunising agent against any virus infection should consist of 
a living agent exhibiting a degree of virulence so low that it may be inoculated without 
risk’33 (Enders 1954:88). 
 
But, for Salk, the notion that only natural infection, or a vaccine made of living pathogen, 
could offer durable protection was nonsense. Salk felt the orthodoxy was based on 
unverified lore received from the past, conflicted with some observed realities and 
premised on the idea that the effectiveness of a vaccine depended not on chemistry but on 
some occult life force. Salk therefore saw his challenge to orthodoxy as not only 
experimental but an ideological claim for empiricism and pragmatism in science34 (Carter 
1965; Klein 1976; Smith 1990). 
 
                                                 
32
 Like Howe, Salk tested children who were not infected but were ‘mentally retarded’ and found that the 
levels of antibody production were equally encouraging (Chase 1982). 
33
 This adheres to the classic Jenner-Pasteur model where a live, but attenuated, strain creates immunity by 
producing less severe form of the real disease. It is notable that the development of such attenuated strains in 
animals was extremely time consuming and difficult but the feasibility of this operational trajectory was now 
vastly improved by the culturing techniques that Enders developed (see above). It is understandable then that 
Enders would want to see his technique be used in the development of the final poliomyelitis vaccine. 
34
 It is likely that Salk’s deviation from the orthodoxy resulted from his newness to the field of poliomyelitis 
prophylaxis. In fact, his previous experience in developing inactivated influenza vaccine most probably 
directed his choice of approach to the poliomyelitis problem (Galambos and Sewell 1995:47). Brodie and 
Kolmer had tarnished the killed approach and Salk was careful in his relations with the public to set apart his 
methods from theirs; for example, a Time magazine article pointed out, in unusual technical detail, that Salk’s 
vaccine used purified mineral oils to hold the vaccine in the body for longer as a way of distinguishing his 
from previous efforts (Time 1953). 
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The professional controversies directed at Salk’s unconventional vaccine were ‘waged with 
the intensity that man usually reserves for his holy wars’ (Carter 1965:6). Sabin persistently 
objected that a massive investment of time, money and public faith in a [killed] vaccine of 
only temporary use would hurt efforts to find a live virus that would really solve the 
problem (Smith 1990). Flexner declared that ‘only an infectious vaccine compounded of 
living virus could protect’ (Carter 1965:86). Enders is even quoted as having confronted 
Salk and calling his work, “quackery” (Carter 1965:88). 
 
Members of the Foundation did their best to calm such ‘sharp differences between this 
group of opinionated scientists’ in the Immunization Committee (Paul 1971:407). For 
example, regarding the concerns about the lack of certainty over whether an inactivated 
poliomyelitis vaccine really was inactivated, Rivers said at a Committee meeting, “I think 
we will all admit that there is no test to be sure the stuff is inactive. Why not just accept 
that? Why kid ourselves? Why use the word inactive? Why not just say, ‘safe for use?’ It 
won’t produce disease, and that’s all there is to it” (Carter 1965:126, my italics). 
 
Such ‘nervous brawling’ often crippled progress (Carter 1965:129). So, in 1953, the 
Foundation set up a new and smaller committee because, as Weaver is quoted as saying, 
‘The immunization committee was not able to function with the necessary dispatch. It could 
get entangled for months in technical debates. Furthermore, its members were virologists 
and the decisions on which we needed help were not exclusively virological. The Vaccine 
Advisory Committee with experienced public health men… was a far more efficient group’ 
(Carter 1965:176; Paul 1971:411). The need for a second committee suggests that the 
design of tests is not an entirely objective and technical matter, and includes broader 
considerations. It was also established in part to limit conflicts of interest that may arise 
from having competing designers playing the role of ‘architect, carpenter and building 
inspector’ all at once (Weaver quoted in Carter 1965:179). 
 
Supporting Salk’s vaccine into trials was a difficult choice made under conditions of high 
uncertainty and social conscience. A member of the Vaccine Advisory Committee said, “I 
think… progress can be made even in the light of the fact we have so little knowledge. It 
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would seem to me the time has come to really go at the inactivated material… The live 
virus is fine, but if you think about it as a public health measure, it is a difficult thing to 
use… I don’t think you have a good excuse morally to go into infectious material until we 
have shown that inactivated material was unsatisfactory” (Carter 1965:128). 
 
Salk recalls the arbitrary nature of deciding when to test. “We did not have a vaccine yet. 
There really was not a vaccine until an arbitrary decision was made prior to the national 
field trials of 1954, and the vaccine, so to speak, was not developed until later than that. In 
1952 all we had were several dozen experimental preparations, some with adjuvant, some 
without, some containing one type of virus, some another or a third or all three, some made 
with monkey tissue, some with testes, some inactivated for ten days, some for thirteen, 
some for twenty one” (Carter 1965:130). Although, Salk here attests to the landmark 
significance of the major clinical trial, the possible permutations of experimental conditions 
he describes seem endless, and arriving at any one combination to test in a ‘major field 
trial’ is likely to have been subject to a series of many tests prior to that point in 
development. 
 
Salk seemed initially uncomfortable with being pushed into a state of readiness by 
members of the Foundation. Salk insisted, ‘I don’t know that we even have a vaccine yet. 
That term was used, but I think it should be understood that we are using it as a colloquial 
expression. We have preparations which have induced antibody formation in human 
subjects’ (Carter 1965:152). 
 
Rivers asked, “Wouldn’t it be silly to wait 50 years or to wait 10 years to develop the ideal 
vaccine when there is the possibility of a vaccine being developed very rapidly that will 
last, say, for two or three years with one injection perhaps? We don’t know anything about 
that, but have we the right to wait until the ideal vaccine comes along?” (Carter 1965:151). 
Salk emphasised the trade-off in a telegram to convince sceptics, ‘It is said that to await 
certainty is to await eternity’ (Smith 1990:295). Despite the many and strong objections, 
Weaver and O’Connor believed that the Foundation had a mandate from its volunteers and 
donors to proceed and, although Rivers thought the Salk vaccine was ‘something slightly 
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better than gamma globulin, something by definition imperfectible,’ he felt it was ‘worth a 
try’ (Carter 1965:152). The Foundation began to plan for a major field trial. 
 
Harry Weaver wrote, ‘The practice of medicine is based on a calculated risk…the physician 
elects to follow the course that provides the greatest benefit with the least risk of incurring 
any untoward effects… If [we wait until more] research is carried out, large numbers of 
human beings will develop poliomyelitis who might have been prevented from doing so… 
our work must be governed by scientific and sociological concerns’ (Carter 1965:147; 
Benison 1967). This implies that the vaccine development process was not simply a 
scientific puzzle, with a technical solution that could be found and optimised; rather, the 
urgency of the historical and social context of the actors played important roles in their 
decisions about an ‘imperfectable’ vaccine. 
 
In the design of the trial, the planned use of placebo controls was problematic, but the 
precedent seemed necessary. Initially, Weaver sought simplicity and economy, and 
suggested that the poliomyelitis rate be compared between vaccinated and non-vaccinated 
school-children of the same age (Carter 1965:176). However, the Vaccine Advisory 
Committee suggested that socioeconomic differences between those who volunteered and 
those who did not would weaken the study.35 
 
Salk felt that his vaccine was not up to such a stringent test, and lapses in the manufacturing 
process or unimpressive results of a double-blind test might scupper the opportunity to 
improve it (Carter 1965:178). I quote him at length in the paragraphs below to show that 
the design of the tests was at the centre of his concerns at the time, and that the parameters 
of the tests left an indelible mark on the nature and characteristics of the vaccine most 
widely used. 
                                                 
35
 High income, well educated families were more likely to submit their children to experimentation of this 
kind. In contrast, less well educated families living in poorer areas were less susceptible to paralytic 
poliomyelitis, tending to contract the non-paralytic form in infancy and gaining immunity. Thus, a project to 
vaccinate all volunteers, would immunize the children most susceptible. The poliomyelitis rate might be 
unimpressively similar to that among the unvaccinated. Therefore the vaccine might be good, but the test 
would not have the resolving power to prove its efficacy. In addition, poliomyelitis diagnosis was still 
difficult despite the scale developed in the Hammon trials, and any biases emerging from knowing who had 
been vaccinated and who had not, would serve to exacerbate the problem. 
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“The sensible thing, I thought, was to accept the urgencies of the situation 
and continue improving the vaccine. I thought the field trial should be 
designed to permit this, not prevent it… I thought we should concentrate on 
polio prevention and be less concerned about making epidemiological 
history with an elegant double-blind study. I was afraid that, for some 
people, the kind of test had become more important than the kind of 
protection the vaccine might be able to provide.” 
 
“I wanted a field trial not only because it was simpler but because it was 
suited to the realities. I wanted to know who had been vaccinated so that 
blood samples could be taken promptly. If tests then showed that a certain 
batch of vaccine was producing unsatisfactory results, the children could be 
revaccinated with better material. At the same time, we could be taking steps 
to improve the manufacturing process and avoid new batches of inferior 
vaccine. Finally I was uncomfortable about giving placebo shots to children, 
depriving them of immunity in what might turnout to be an epidemic year. 
Many public health officials agreed with me on this.” 
 
“The issue of field-trial design was typical. Here you had someone like 
myself, trying to adapt to the needs and circumstances, and there you had 
this rigid insistence that a ‘product’ be submitted forthwith for ceremonious 
testing. The emphasis on ‘product’ and on ritual and on looking good in the 
eyes of certain elements in the scientific community was being allowed to 
obscure the real purpose of everyone’s work, which was the prevention of 
polio. For arguing this as often as I did I earned scorn as an eccentric 
nuisance. My desire to continue my experiments so that the vaccine might 
be as close to 100 per cent effective as possible was considered intolerably 
presumptuous. What a dreadful inconvenience to impose on designers of 
field trials and on pharmaceutical manufacturers and on government 
officials!” (Carter 1965:178). 
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Salk went on to describe the use of placebos as ‘a fetish of orthodoxy… a ‘beautiful 
epidemiologic’ experiment over which the epidemiologist could become quite ecstatic but 
would make the humanitarian shudder and would make Hippocrates turn over in his 
grave… the worship of science involves the sacrifice of humanitarian principles on the alter 
of rigid methodology’ (Carter 1965:192). In order to address the concerns of parents, 
teachers, and such ‘humanitarians’ O’Connor announced that an observed control plan 
would be used, in which children would not be injected but only observed (Meldrum 1998). 
 
The Foundation asked the nation’s health officers for advice and support, who suggested 
that the Foundation may not be able to maintain impartiality in such evaluation (Meldrum 
1998). So O’Connor appointed Thomas Francis to head the evaluation of the trials, a 
critical but unglamorous task, based on ‘his deft direction of complex field trials of 
influenza virus vaccines during World War II’ (Markel 2005:1408). However, Francis 
would not accept until he manoeuvred between health officers, paediatricians, clinical 
poliomyelitis specialists, statisticians and virologists to engineer a change in the trial design 
(Meldrum 1998). He suggested a placebo design run in some areas at the same time as an 
observed design run in other areas. 
 
Addressing concerns about volunteer recruitment in the placebo plan, the evaluation group 
decided that it could rely on the widespread fear of the disease; members agreed that ‘it 
would not be difficult to sell as there is a high attack rate… [and] there would still be a 50% 
chance of a child receiving the vaccine’ (Meldrum 1998:1235). Francis compromised with 
Salk and others to a certain extent with observed design in some areas, but his insistence on 
the placebo plans in other areas was particularly important in the context of the vociferous 
criticisms from Enders, Sabin and others about the validity of the killed-vaccine concept. 
 
Firstly, results emerging from double blind trials might be more convincing, and facilitate 
quicker and more widespread vaccine adoption. Secondly, it was important given the 
possible conflict of interest arising from the Foundation evaluating a vaccine they, as an 
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organisation, developed and sponsored. Thirdly, the placebo plans were also a part of the 
Foundation’s effort to legitimise an institution governed by non-experts. 
 
The trial for the vaccine went ahead in 1954 and was the largest of its kind to be run. It was 
not a cheap gamble, grants for the field trial and its evaluation cost the Foundation a total of 
$7.5m. The results of nearly 2 million children were presented on 12th April 1955, and the 
vaccine was found to be safe and 70% effective (Smith 1990). Although not completely 
effective, the breakthrough cases36 were judged to be less severe (Smith 1990). With 
financial guarantees from the Foundation, industrial production facilities were already built 
and ready to operate (Blume and Geesink 2000a). The Foundation paid a further $7.5m to 
the manufacturers for 10 million Salk vaccine doses (Chase 1982). The products of six 
producers were licensed within days, one of whom was Cutter Laboratories in Berkeley37 
(Offit 2005a). Poliomyelitis cases dropped from 58,000 in 1952 to 5,600 in 1957. 
 
Writing of the 1935 and 1955 vaccines, Paul, whose career in poliovirus research spanned 
both eras, noted how different the testing regimes were. ‘The situations were in no way 
comparable, for the Brodie-Kolmer vaccines had been launched in the face of colossal 
ignorance, whereas the Salk-type vaccine had been promoted under circumstances which 
from the start almost guaranteed success. And yet one cannot help feeling a twinge of 
sympathy for the two figures of 1935 who were so alone in the midst of their disgrace, in 
contrast to the powerful forces of the National Foundation, the US Public Health Service, 
and innumerable advisory committees that stood back of the Salk type vaccine’ (Paul 
1971:420). 
 
                                                 
36
 Cases where volunteers are diagnosed with poliomyelitis despite being vaccinated in the trial. 
37
 The Cutter incident represented ‘one of the worst pharmaceutical disasters in history’ (Offit 2005b:1411). 
In a batch of Salk vaccine manufactured by Cutter, there remained some active virus which had not been 
killed. It caused over two hundred cases of poliomyelitis, of which 150 were paralytic and 11 were lethal 
(Nathanson and Langmuir 1963). The error paralysed 15 times more children than the earlier Brodie and 
Kolmer vaccines combined. 
 134 
6.6 Live vaccines: in the shadow of the killed vaccine 
 
This section reviews how improvements to the testing regime enabled the establishment of 
live vaccine operational trajectory. The section emphasises the path-dependency of such 
trajectories by highlighting the role of non-fiscal testing resources. It also emphasises how 
context-dependent such operational principles become by highlighting testability 
constraints, and different decisions taken by public health authorities in the USSR and 
USA. 
 
As he had done with the yellow fever virus, Max Theiler passaged the poliovirus 
continuously through the brains of living mice until, without losing its capacities to produce 
antibodies, the attenuated virus no longer caused paralysis (Chase 1982). He reported it to 
the Foundation in 1946, which then funded research to demonstrate that poliovirus could 
also lose its ability to infect the central nervous system on repeated passage through non-
nervous system tissues (Robbins 2004). The idea of attenuating the poliovirus, rather than 
killing it outright, appealed to many because it was presumed to mimic the natural situation 
more effectively, resulting in a longer and more effective immunity38. 
 
The live attenuated poliomyelitis vaccine approach was feasible only with the possibility of 
intense empiricism because it relied so much on striking a balance between efficacy and 
safety (see section 8.5.3). This entailed searching for virus that is not pathogenic (disease 
causing) but retains some of its virulence (ability to infect). By strengthening the testing 
regime, the Foundation reduced barriers to empiricism. The development of tissue culture 
techniques39 facilitated the rapid emergence of variation in strains, whilst the availability of 
monkey models allowed designers to select for pathogenicity and virulence traits, and the 
typing project allowed putative vaccine preparations to be challenged without added 
                                                 
38
 However, Salk, and other proponents of killed vaccine, resisted the notion that immunity provided by live 
vaccine would be somehow longer lasting. ‘One cannot say how long immunity may last, one can report only 
how long it has lasted’ (Carter 1965:377). 
39
 Viral culture techniques were significantly improved by Dulbecco and Vogt (1954). Adapting techniques 
for growing bacteria, they grew virus in microscopically thin mono-layers of chick embryo tissue cells. The 
colonies proliferating from the growth of a single viral particle could be identified, counted and isolated. This 
made it easier to purify specific lines of virus, which was extremely valuable for those looking to prepare a 
live vaccine (Paul 1971:406; Robbins 2004:19). 
 135 
confusion. Selecting strains with monkeys meant that live vaccine development did not 
need to rely on few and imprecise in-vitro markers of virulence, such as growth at higher 
temperature (Paul 1971:458). Instead, a more authoritative test for neurovirulence, adopted 
as the standard by the regulatory agencies, was devised where monkeys had to be 
inoculated through their central nervous system (Robbins 2004:20). 
 
6.6.1 Scarcity of testing resources 
 
Sabin was one of several groups40 working in this way (Paul 1971; Robbins 2004). In light 
of the improvements to the testing regime noted above, the Foundation provided him with 
$1.2m between 1953 and 1961, and $2m in total (Carter 1965:357; Chase 1982:303). In 
1955, Sabin began a trial on inmates in Chillicothe Federal Prison in Ohio (Carter 
1965:357; Smith 1990:301). His vaccine was successful, but the Foundation saw little 
reason to take chances with a larger scale trial of an infectious live vaccine when Salk’s 
field trial had demonstrated efficacy the previous year. Large scale trials of Sabin’s 
vaccine, and those of others, would be difficult to interpret because the Salk vaccine had 
been licensed and was being used widely. For example, when, in 1959, Herald Cox had the 
opportunity to test his live vaccine in Miami, Florida, Sabin dismissed any excitement by 
pointing out that too many people had taken Salk vaccine for the test to mean anything 
(Carter 1965:365). 
 
There is clearly a strong path-dependency element to testing processes in vaccines (see also 
Blume 2005), but I would like to draw attention to a slightly different view. In the early 
experiments, poliomyelitis researchers faced a shortage of virus; Evans and Green, who 
were beaten to the Nobel Prize, faced shortage of human embryonic tissue; Hammon faced 
issues with a shortage of gamma globulin; whilst Sabin faced a shortage of people to test 
on. These cases represent a scarcity of testing resources. These resources are not fiscal, as is 
commonly emphasised in health and vaccine development literature (see for example 
Archibugi and Bizzarri 2004; Barder 2005), but can be anything from the availability of 
                                                 
40
 Other groups were led by Hilary Koprowski at the Wistar Institute, Herald Cox at Lederle Laboratories, and 
Joseph Melnick at Yale, all of whom tested their prototype live vaccines on institutionalised children (Chase 
1982). 
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monkeys, gamma globulin, primary isolates, to simply people as test subjects. They were 
unlikely to have been resolved by policies that focussed on pecuniary issues alone. 
 
6.6.2 Testing to see which vaccine is better 
 
The safety concerns to this approach extended beyond simply whether the virus in the 
vaccine was sufficiently attenuated to prevent it from causing disease. The major concern 
centred on its genetic stability and whether the attenuated virus would remain safely 
attenuated. One of the advantages of the live vaccine was that after it passed through the 
intestines and was excreted by the vaccinee, it might then go on to confer immunity to 
someone else in the community. But the same advantage became a disadvantage for those 
who thought that, after several passages through the community, the altered vaccine strain 
might undergo progressive genetic changes such that it reaches a degree of virulence 
comparable to that of wild epidemic polioviruses. The success of the entire live approach 
therefore turned on proving that any cases of poliomyelitis were not caused by the vaccine 
reverting back to virulence after multiplication in the host. 
 
Melnick found that live vaccine virus passaged through children was sometimes virulent 
enough to paralyze monkeys (Carter 1965:381). This caused serious concern, but there was 
no way in which a test could show that a given case of poliomyelitis in humans had been 
caused by the live vaccine, even if the victim was struck by poliomyelitis shortly after 
taking a live vaccine. If virus recovered from the victim resembled the wild type, one could 
suppose that it had taken over the intestines, and driven away the vaccine virus, before 
causing the disease (wild type-induced disease). Alternatively, one could decide that the 
vaccine virus had changed to resemble the wild type and become virulent, thereby causing 
vaccine-induced disease. Either way, testing primary isolates would not be able to prove a 
vaccine guilty. 
 
This made choosing between the alternative operational trajectories on any kind of 
objective basis of safety technically difficult. However, this did not prevent the two 
 137 
different operational principles being perceived differently as more or less risky41. And 
closely tied with these perceptions were the assumptions of the designers, embedded in the 
operational principles, about the social context in which their designs would be used. The 
next section shows that safety, as a relative measure, became more readily observable as 
protagonists argued risks and benefits in different contexts. 
 
6.6.3 Vaccines as part of a public health system 
 
The continued existence of distinct operational trajectories was dependent on different 
social contexts and the success of their protagonists in ‘suiting’ their vaccines to them. This 
is because notions of vaccine safety, and indeed other attributes of the vaccines, are relative 
measures which protagonists can highlight as merits in different social contexts (or as 
drawbacks by opponents in others). 
 
Due to the safety concerns, testing problems, and the use of Salk’s vaccine, all described 
above, Sabin was forced to look abroad to conduct large scale trials. In 1958, 200,000 
children in a Singapore trial received Sabin’s live vaccine in an effort to curtail their 
epidemic (Paul 1971:454). By 1960, approximately 100 million people in the former USSR 
and Eastern European countries had received the vaccine. By the end of the year enough 
evidence had been established to secure licensure in the US for Sabin’s live vaccine42 (Paul 
1971:456). 
 
However, the success of one vaccine over the other depended on the social context of its 
use. As a Soviet public health official remarked, ‘Our inoculation program was a public-
health measure, not a field trial. It was designed to suit our medical services. In attempting 
                                                 
41
 Tommy Francis saw the operational trajectories differently. ‘The two outlooks are, then, simply, this. 
Inactive virus is apparently a test of the straightforward hypothesis that antibody induced by the 
administration of antigen can provide protection without subjecting the recipient to harmful effects of even 
apparent infection. The other, through the use of modified active virus, seeks to induce antibody formation but 
wishes to add some undesignated advantage derived from assumedly harmless infection (I am not certain that 
any significant infection may not create undesirable tissue reactions…). Which of these approaches to 
poliomyelitis will be the more effective is, then, not a decision to be arrived at by authority and debate but 
by… making the observations. When the conditions are appropriate, tests should be made. This is the 
beginning not the end…’ (Carter 1965:357). 
42
 Thus, just over a decade after concerted efforts to strengthen the testing regime began; not one but two 
effective vaccines against poliomyelitis were available for general use. 
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to inoculate a population the size of ours, could there be any serious confusion about 
whether to give away candy drops, when the alternative was injection requiring so much 
more apparatus and personnel? Our work with the Sabin vaccine must be viewed in terms 
of public health and not as a strictly controlled scientific experiment’ (Carter 1965:359). 
 
If the Sabin vaccine could actually be shown to cause paralytic poliomyelitis, the finding 
would have been more significant for the US than for the Soviet Union. The Soviet Union 
was suffering poliomyelitis incidence rates of 94 per million (Carter 1965:363), much 
higher than that of the US, so any vaccine that could reduce that figure would be allowed 
the deficiency of a few vaccine-caused cases. It simply represented one dimension in a 
broader set of criteria for the health system as a whole. 
 
The protagonists of each vaccine worked hard to promote their interests and preferred 
choice43. Cox was benefiting from an aggressive publicity campaign by Lederle touting its 
advantage of a single dose vaccine that still protected against all three strains (trivalent) 
(Carter 1965:365). Koprowski managed to trial his vaccine in 9 million people but had his 
vaccine turned down by the US government because it caused some lesions in monkeys 
(Paul 1971:454). Salk argued that his vaccine was effective and that they needed to wait 
longer, without introducing other vaccines, to see definitive results of an imperfect 
vaccination program. And Sabin’s appeared to be the newer more modern vaccine with 
which the public health service could have a second chance of executing a vaccination 
program of more complete coverage (Carter 1965:372). Sabin’s field trials in the Soviet 
Union were even doubted, and it took a report by Hortsmann, who was dispatched there by 
the WHO, to verify the standards and evidence (Paul 1971:455; Robbins 2004:20). 
 
                                                 
43
 Salk describes his changing experience of attending poliomyelitis conferences. ‘It was like sitting in on the 
plans for one’s own assassination. The atmosphere of intrigue and hostility was even more intense than in 
1953 and 1954. In those years mine was the only vaccine in the picture. But now you had Sabin and his 
vaccine, Koprowski and his vaccine, Herald Cox and his Lederle vaccine, and each of them had their coterie. 
There were actual plots hatched to keep one or another vaccine report off one or another scientific program. 
And, long before a particular report was read, you heard a dozen whispered allegations about the lies 
contained in it and the number of deaths unmentioned by it. It was like Lisbon during the war’ (Carter 
1965:364). 
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The ensuing history of the changing relative merits and drawbacks of the Salk and Sabin 
vaccines is considerably well discussed but much of this lies outside the scope of this 
chapter (Blume and Geesink 2000a; Blume and Lindner 2004; Blume 2005). It is worth 
noting, however, that as incidence of poliomyelitis decreased in the US over the next thirty 
years, the perception of risks and benefits changed and so the choice of vaccine changed 
too. ‘The conclusion [of a comparative analysis of live and killed vaccine] is heavily 
dependent on assumptions of risk of exposure to wild virus in the US. Major declines in 
risk of exposure… could alter the balance significantly’ (Hinman, Koplan et al. 1988:295). 
Despite the high costs of switching from live to killed vaccine, the Advisory Committee on 
Immunisation Practices recommended the change in 1996 and US vaccine policy delivered 
killed vaccine exclusively from 2000 onwards (Plotkin and Orenstein 2004:1484). 
 
6.7 Summary 
 
The development of vaccines was dependent on a vision. This vision needed to be 
convincing not just for the community of technological practitioners, but also for wider 
society. It was constructed by key actors from different communities. Landsteiner may have 
shown an infectious agent to which inventive vaccine efforts could be directed, but the 
social landscape was undoubtedly reshaped by President Roosevelt. The relationship 
between scientists as technological-producers, and the public as ‘science’-consumers, was 
not forged until a specific and dedicated mediating organisation, the Foundation, was born 
to ensure the cumulative growth of technological knowledge. 
 
The path to two poliomyelitis vaccines required the development of a testing regime, and 
the Foundation played important governance roles in setting that up. The Foundation 
facilitated research by finding specific researchers to do the work and provided them with 
funds, virus, tissue and reagents. It cultivated an atmosphere that ensured there would be 
people to test on, as well as an immensely supportive public tolerant of failures (such as 
those by Brodie-Kolmer and Cutter Laboratories). 
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But the Foundation played a yet more active role in vaccine development than that. It 
fostered communication across research groups and in doing so gained an overview of what 
was needed for innovation. It directed technological research in critical areas that were seen 
by scientists as unstimulating. It mediated between personal agendas, conflicts of interests, 
and managed differences of opinion. It even displayed the leadership to make the uncertain 
and unpopular decision to enter field trials with Hammon and Salk vaccines. 
 
Once culturing techniques were developed, a steady supply of monkeys was secured and 
the results of a virus typing project were established, ideas could be tested quickly and in 
varying conditions. The Foundation then turned its attention to transforming subjective 
issues of vaccine design into more specifiable, objective criteria for vaccine use in human 
conditions (rather than in laboratory monkeys). 
 
In doing so, the Foundation played a central part in the choice of operational trajectories. 
The antagonism between the orthodoxy, of which Sabin and Enders were part, and 
newcomers such as Salk, might have mired development efforts were it not for a mediating 
organisation. The fact that the patterns of institutional rewards and credit accorded to Salk 
and Sabin differed so significantly44 suggest that elegant science and urgent technology 
development do not always sit comfortably next to each other.  
 
The Foundation also co-ordinated with many different actors to ensure that the field testing 
of vaccines ran smoothly. Clinical trials were greatly facilitated because the Foundation 
ensured officials from health departments across the country were on board. They provided 
local knowledge and support when the Foundation needed to navigate through the sensitive 
issue of using placebos in the trials for the first time. In addition, the prevailing and very 
eugenically oriented medical ethics of the first half of the 20th century (see for example 
Martin 1998), which considered mentally and physically handicapped children and 
                                                 
44
 Salk was a household name but his colleagues in the world of science never afforded him the recognition 
and awards accrued to Sabin (Oshinsky 2005:270). Although Salk received the Congressional Gold Medal 
and other such public medals, Sabin was lauded by fellow scientists, elected to the National Academy of 
Sciences and embraced by virologists worldwide. ‘Many attributed the professional discrimination against 
Salk to the flamboyant backing of O’Connor and the resultant media frenzies, which were offensive to ‘pure 
scientists’’ (Katz 2004:187). 
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prisoners to be the subjects of choice for medical experimentation, undoubtedly had the 
effect of strengthening the testing regime by providing easy access to accurate testing 
models. 
 
The cumulative growth of knowledge emerging from these field trials was ensured by 
providing scaffolding, or knowledge infrastructure. This took the form of careful trial 
design, indices of immunity, graded scales of poliomyelitis diagnosis, and finding critical 
viral infection doses. 
 
The Foundation had at its core a public mandate whilst creating an atmosphere that was 
conducive to technological research and development. The fact that volunteers for trials 
were so willing and abundant made the introduction of double-blind, placebo-controlled 
clinical trials possible. Such protocols indicate an emphasis on the role of trials as rigorous 
testing rather than as experimental treatments; it is an example of how well the Foundation 
juxtaposed public concerns with those of the scientists. The design and timing of clinical 
trials most likely had a lasting effect on the characteristics of the Salk vaccine when it was 
licensed. 
 
The Foundation’s concerns did not stop at the development of the Salk vaccine. By 
providing purchase guarantees before the vaccine was even finished, the Foundation 
managed some of the uncertainties involved in industrial production and facilitated prompt 
distribution by ensuring manufacturers were ready to produce as soon as possible. It also 
turned its attention to the development of a second vaccine that had developed under the 
strengthened testing regime. However, the Sabin vaccine faced a scarcity of resources that 
forced it abroad. The different decisions taken by the public health authorities suggest that 
the efficacy of vaccines is heavily dependent on the context in which they are used. 
 
The following chapters will show how AIDS vaccine research and development was 
presented with many challenges that were, in some ways, similar to those described above. 
However, the researchers, faced with a much weaker testability regime, have so far been 
less successful than their poliomyelitis vaccine predecessors. 
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Chapter 7 
 
Dead-ends and Detours in the Road to HIV Vaccines 
 
This chapter proceeds in four sections. The first section describes how the emergence of 
AIDS was generally met with antipathy, making visions for a vaccine weak. Uncertainties 
about the origins and causes of AIDS exacerbated problems in drawing wider support to 
develop measures against it. The second section explains why characteristics of the HIV 
virus make the establishment of a strong testing regime difficult, and the third section 
shows that there have been strategic efforts to strengthen the testing regime. The fourth 
section concludes the chapter. 
 
7.1 The beginnings of a testing regime 
 
In contrast to poliomyelitis, where certainties about its origins and causality enabled a 
shared technical vision of a vaccine solution to be formed quickly, AIDS vaccine 
development was burdened with uncertainties from the outset. It took the best part of a 
decade to attain consensus over what caused AIDS (Epstein 1996). The relative newness of 
the AIDS virus and its unclear origins made visions of a vaccine hazier still1. In addition, 
the groups that were emerging as most at risk from AIDS (homosexuals, injecting drug 
users and sex-workers) were already subject to heavy social prejudices (Fee and Fox 1988; 
1989). 
 
7.1.1 The origins of HIV and the cause of AIDS 
 
Although there is agreement that HIV arose from SIVcpz in chimpanzees in Africa and SIV 
in monkeys (Weiss 2003; Keele, Van Heuverswyn et al. 2006), how the viruses crossed 
over to human beings is debated. The most prevalent theory is that SIV was transferred as a 
                                                 
1
 Notwithstanding the fact that the earliest case of AIDS is now thought to be that of a man in Kinsasha in 
1959 (Carlsen 2001), the perception of a virus-related public health risk requiring government action, came 
decades later. 
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result of primates being eaten, or their blood entering wounds or cuts in a human hunter. 
Others have argued that mass injection campaigns during the 1950s not only accelerated the 
spread of virus but also contributed to its transformation from SIV to HIV by a process of 
‘serial passage’ in weakened immune systems2 (Chitnis, Rawls et al. 2000; Carlsen 2001). 
In contrast, Hooper (1999; 2000) argued that the epidemic began because Hilary 
Koprowski’s experimental live poliomyelitis vaccine, which was tested in Africa in 1957-
60, was contaminated with SIVcpz3. 
 
The first well-documented AIDS case was discovered in late 1980, by an immunologist at 
University of California teaching hospital, who came across previously healthy young men 
dying from everyday infections that normally only claim the immuno-suppressed (CDC 
1981b; CDC 1981a; Shilts 1987:47). Medical researchers quickly focussed on the men’s 
status as homosexuals4 and hypothesised that the syndrome was linked to ‘some aspects of 
homosexual lifestyle’ (CDC 1981b:252). Although Gottlieb later reported cases of the 
syndrome in exclusively heterosexuals, and others reported the syndrome in injecting drug 
users, attention in the medical literature remained fixed on the male homosexual sufferers 
(Shilts 1987; Oppenheimer 1988). Speculation about cases proceeded from the premise of 
the centrality of male homosexuality. 
 
Although the US Congress repeatedly offered more money for AIDS management (and 
R&D) than the Reagan administration requested in the budget (Shilts 1987:493), powerful 
                                                 
2
 The virus adapts to its host through mutations, becoming stronger before it is passed on, until it eventually 
becomes more virulent, lethal and transmittable. Simian viruses have been made 1000 times more pathogenic 
by serial passaging in as little as 3 monkeys (Carlsen 2001). Jim Moore argued that during colonial rule in 
Africa, many people were placed in labour camps with poor sanitation, scarce food supply and extreme 
physical demands. To improve productivity, they were immunised against smallpox with the same syringe 
allowing for ‘serial passage’. The conditions were sufficient to create poor health in anyone, so SIV could 
have exploited their weakened immune system to become HIV (Chitnis, Rawls et al. 2000). 
3
 Hooper provides convincing circumstantial evidence: for example, the timing and location coincide and the 
fact that other monkey viruses have been known to pass to humans from poliomyelitis vaccines, one of which 
was harmful (SV40) (Sweet and Hilleman 1960). The vaccines were given to infants so the SIVcpz could 
adapt in an under-developed immune system into HIV. However, evolutionary analysts have dated the HIV to 
1930 plus or minus 15 years (Korber, Muldoon et al. 2000) and others examined old samples of Koprowski’s 
vaccine to find no DNA from chimpanzee cells, no genetic material from SIVcpz and none from HIV either 
(Cohen 2001a). This makes Hooper’s theory extremely unlikely. However, such theories probably 
exacerbated the anti-vaccination forces (Blume 2006). 
4
 AIDS was initially called GRID (Gay-Related Immune Deficiency) (Shilts 1987:121; Oppenheimer 1988; 
Epstein 1996:50). 
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groups consistently opposed any funding for AIDS management on moral grounds. For 
example, senator Helms declared “Let’s talk about who’s causing this, caused this from the 
very beginning [my italics]. I’ve never heard once in this chamber, anybody say to the 
homosexuals, ‘Stop what you’re doing.’ …No federal funds can be used to encourage or 
promote homosexual, sexual activity” (Barker 2004:45). 
 
Framing the disease as a ‘gay disease’ and as a lifestyle problem distorted its public health 
significance for the population as a whole, and led to a lacklustre political and scientific 
response. Transcripts of White House Press Briefings reveal that in the years 1982-84, the 
Reagan administration viewed the AIDS problem with indifference. Even when it was 
brought up in terms of possible epidemics, the press officer treated the topic as unworthy of 
serious attention and laughed-off questions from journalists (See appendix for transcripts). 
Reagan did not say the word ‘AIDS’ in public for the first seven years of his presidency 
because, as his policy adviser reveals, he was ‘irrevocably opposed to anything having to 
do with homosexuality’ (Kramer 2005). 
 
The moralising wasted time and resources because a central question of early AIDS 
research was whether the disease was caused by an infectious agent or by the excesses of 
lifestyle choices. The answer to that highly contested question drove the degree to which 
society organised itself for the development of technologies such as vaccines, rather than 
measures to adjust social behaviours. For a long time, the latter dominated. The newness of 
the syndrome placed further special concern on ‘deviant’ social conditions of those that 
were affected and did not encourage the search for a technical solution. This history of 
events indicates the importance of support from the wider community outside of science. It 
bears close resemblance to the theories put forward by Rosenberg (2002) about the 
reorganisation of social resources around a disease diagnosis.  
 
The possibility of an AIDS vaccine as an operational principle became much more 
compelling when it was shown to be caused by viral infection. Epstein’s (1996) study 
explores how that causality came to be slowly established over time. The ‘immune 
overload’ hypothesis represented the initial medical frame for understanding the epidemic, 
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by claiming that hedonistic lifestyles were subjecting the immune system to too many 
sexually transmitted diseases and recreational drugs all at once and essentially pushing the 
immune system to give up (Epstein 1996:48). 
 
The search for a causal agent of AIDS was guided by a well known set of causation 
criteria5. ‘Implicitly or explicitly, researchers had Koch’s postulates – or similar criteria – 
in the backs of their minds’ (Epstein 1996:88). They provided a common reference point 
for considering the causation of AIDS and were a core part of the operational principle. 
(This principle was defined as how the parts of a technology come together to serve its 
purpose.) Luc Montagnier’s group at the Pasteur Institute, Paris, and Robert Gallo’s group 
at the National Cancer Institute, Washington DC, isolated the HIV virus and linked it to 
AIDS6. 
 
Proponents of the immune overload hypothesis argued that HIV did not fulfil all of Koch’s 
postulates whilst critics argued that, for contemporary biomedical research, the exact 
relevance of the postulates were questionable, especially for viruses, which were 
undiscovered in Koch’s time (Epstein 1996). They suggested researchers nowadays tacitly 
work with ‘modern’ or revised interpretations of the postulates, and have argued that Koch 
himself did not intend them to be followed rigidly (Gallo 1991:277). As more was 
discovered about HIV and more evidence of its presence in AIDS patients was gathered, 
the immune overload hypothesis was eventually discredited. 
 
In the scientific community, Gallo led the charge for HIV’s causal role in AIDS (Blattner, 
Gallo et al. 1988; Cohen 1994b) against Peter Duesberg’s claims which argued that HIV 
did not cause AIDS (Duesberg 1995; 1996; Duesberg and Rasnick 1998). Gallo’s 
                                                 
5
 Koch’s postulates of disease causation (see section 5.4.2). 
6
 The assignment of credit for this discovery was disputed and later developed into a protracted legal case that 
was eventually settled in 1987 involving the two heads of state, Reagan and Chirac. Although interesting, it 
lies outside the scope of this chapter. I offer as a rather coarse simplification that Montagnier discovered a 
novel virus, whilst Gallo established its association with AIDS. (See back to back articles by Montagnier, 
Gallo, and Gallo and Montagnier in Science 2002, Vol 298, pages 1727-1731.) 
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autobiography included an entire chapter entitled ‘About Causes of Disease (and, in 
particular, Why HIV is the Cause of AIDS)’ (Gallo 1991:276).7 
 
As Gallo and Montagnier gained ground in the debate, a vision of a vaccine started taking a 
hold. In 1984, the US Health Secretary, Margaret Heckler, announced with little mention of 
the French group led by Montagnier, “Today we add another miracle to the long honour roll 
of American medicine and science…. The probable cause of AIDS has been found” (Shilts 
1987:451). In response to widespread complaints of inactivity on AIDS by the Reagan 
administration, Heckler added, “Those who have said we weren’t doing enough have not 
understood how sound, solid, scientific medical research proceeds” and declared that  “a 
vaccine would be ready within two years” (Shilts 1987:451). 
 
The prediction was similar to that of Flexner’s, the poliomyelitis researcher, in its optimism 
and confidence about the possibility of a vaccine. Unlike poliomyelitis researchers, 
however, Gallo had never made a vaccine before (Gallo 1991). He reflected on the vaccine 
prediction with a reporter (Cohen 2001b:8), “I just said, ‘I think, you know, due to the fact 
we have an unlimited amount of virus now and we’re sure it causes the disease, I can’t 
think that this should take that long.’ I didn’t perceive the difficulties. You can’t imagine 
the level of my own feeling of confidence at that time. There was so much data pouring in 
that I, too, thought – probably believed – we could have solved the whole bloody thing, you 
know?” (Cohen 2001b:8). 
 
The announcement was a turning point and marked a start for the search of an HIV 
vaccine8. Almost as soon as the cause of the disease was perceived to have been 
established, talk of a vaccine followed. 
                                                 
7
 In response to critiques that he was not offering an alternative hypothesis, Duesberg later aligned himself 
with the ‘immune overload’ hypothesis. His credibility was used most notably by South African President 
Thabo Mbeki, who, in November 2007, admitted that he is ‘still an AIDS dissident’ (McGreal 2007). More 
accurately, Mbeki is an HIV dissident. At the International AIDS Conference of 2000, held in Durban, South 
Africa, Mbeki opened with HIV denial, “It seems that we cannot blame everything on a single virus” (Barker 
2004; http://virusmyth.net/aids/news/durbspmbeki.htm). 
8
 ‘Regardless of the political settlement concerning who discovered the AIDS virus, and who will garner 
Nobel prizes or public opprobrium, the May 1984 acceptance of [HIV] as the cause of AIDS irreversibly 
changed the nature of managing the epidemic. Prior to that time AIDS research was groping: now it had 
direction. Scientists could go on to real targeting of specific tests and prevention strategies’ (Panem 1988:30). 
 147 
 
7.1.2 Testing for HIV: diagnosis and surrogate markers 
 
The FDA approved the first blood test to screen for antibodies to HIV in 19859 (Gallo 
1991:205; Kates 2006). ‘From that precise moment when the blood test became available, 
AIDS became a problem that could be measured and scientifically evaluated’ (Gallo 
1991:206). The enzyme-linked immunosorbant assay (ELISA) test was an important 
development because it allowed researchers to track the spread of the infectious agent 
through a population. Before, epidemiology could only chart the course of the epidemic 
through full-blown AIDS cases, which meant that researchers were in effect following the 
route the virus had travelled several years behind. This is because of the long and varied 
incubation period between HIV infection and symptoms of AIDS, which can range from a 
few years to a decade. Some people do not seem to progress to AIDS at all (Johnston 
2000). 
 
The tests helped to quickly associate cases of AIDS with HIV, and hence establish a 
stronger link between the two. It also served to establish AIDS in social groups other than 
homosexuals and injection drug users, such as ‘ordinary’ heterosexuals, haemophiliacs and 
children10. The US health secretary, Margaret Heckler, made a key note address at the first 
International AIDS conference in 1985 that marked a change in tone. She said that AIDS 
was “our number-one public health priority until it has been conquered” and added that, 
“we must conquer AIDS before it affects the heterosexual population and the general 
population [italics added]… we have a very strong public interest in stopping AIDS before 
it spreads outside the risk groups, before it becomes an overwhelming problem”11 (Shilts 
1987:554). 
 
                                                 
9
 http://www.fda.gov/oashi/aids/miles81.html 
10
 The tests also served to highlight tensions between public health and civil liberties (Gostin 2006). For 
example, there were concerns about how insurance companies might use the data to shield themselves from 
expensive treatment costs (Shilts 1987:469). Test results effectively became a decisive marker of a person’s 
identity because no treatments existed. 
11
 Activists were quick to point out firstly, that AIDS was already an overwhelming problem, and secondly, 
that homosexuals, intravenous drug users, and people with AIDS were also among the ‘general population’. 
Furthermore, it is notable that the first technology to emerge was a blood test which was of no help to those 
already with AIDS, and only made it possible for them to be cordoned-off from the ‘general population’. 
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Even though the blood test allowed the scale of the problem to be more accurately 
perceived by indicating who was infected, it did not represent an instrument which could 
provide a way to gather knowledge about disease progression by varying learning 
conditions (Plotkin and Orenstein 2004:1220). Such knowledge would be needed to 
evaluate whether a vaccine that did not prevent infection was still of any value in slowing 
disease progression or reducing the intensity of disease symptoms (see section 8.2). 
 
Many indicators of disease progression, apart from death, were developed. The problem 
was that within a few years too many of these new indicators, or surrogate markers, began 
to emerge. In addition to neutralising antibodies, the list of other possible markers was 
long, including: viral counts, viral RNA, CD8 cell counts, CD4 cell counts, p17 antigen, 
p24 antigen, β-microglobulin or neopterin levels (Plotkin and Orenstein 2004:1220). 
 
The wide range of potential markers reflected the uncertainty about what was actually 
going on in the progression to AIDS. But part of the diversity in markers reflected 
differences in emphasis on what vaccines against AIDS should aim to do. For example, 
activists emphasised quality of life and argued for markers of apparent health, such as a 
doctor’s ranking of the patient’s overall state of being. In deciding which surrogate marker 
to use for developing tests, there was a challenge for the accumulation of knowledge. There 
needed to be some co-ordination, standardisation and common agreement about these 
definitions so that technologists knew what would be counted as ‘working’ by the rest of 
society. This is an institutional role, where the ‘objectivity’ in stable definitions of markers 
is established to enable further knowledge accumulation (Eichler, Pignatti et al. 2008:820). 
 
A good marker was agreed to be one with ‘face validity’ and ‘biological relevance’; terms 
that refer to how easily, reliably and objectively measurable they are (Moss 1990). Epstein 
(1996:270) provides a historical account of how the markers were contested through NIH 
conferences with titles such as ‘Surrogate end-points in evaluating the effectiveness of 
drugs against HIV infection and AIDS’. Although debate remains, it seems to have 
stabilised around CD4-cell counts (also known as T-cell counts) and viral load as measured 
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using polymerase chain reaction techniques (see for example Gallo 2005; Johnston and 
Fauci 2007). 
 
These now most likely form part of what Rosenberg (2002:238) calls the ‘predictable 
course’ of a disease that a patient expects their life to take when they discover they have 
been infected by HIV. In the contest to define what AIDS is, immunologists seem to have 
dominated. The progressive deficiency in the immune system is characterised by low CD4 
counts as opposed to, say, a doctor’s assessment of how often a patient suffers opportunistic 
infections, the latter being too variable and dependent on idiosyncratic patient behaviour or 
subjective observations. 
 
The blood test and the issue of surrogate markers represented the beginnings of a testing 
regime. Firstly, the blood test formed was a key diagnostic instrument which helped track 
the spread of AIDS. Secondly, for the spread of AIDS in individuals, various surrogate 
markers needed to be developed to represent discrete and different conditions in disease 
progression. The triad is completed when the social co-ordination and decision making 
process to set standardised markers is included in the analysis. 
 
Such a synthesis allowed the problem to then be set in technical terms: a problem with a 
virus target. Numbers could be applied to the scale of the problem and patterns could be 
studied in how the virus spread through the population and in individuals. A specifiable aim 
was for a vaccinated person to be able to take a blood test after exposure, and return a 
negative result. For that, an acceptable testing regime, and a pass-mark, was required. 
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7.2 Difficulties in strengthening the testing regime: A virus of ‘outstanding success’ 
 
By 1985 a causal agent of AIDS was found, a blood test could detect HIV, and viral 
markers were being understood to represent different sets of conditions in the progression 
of AIDS. The goal now was to develop a vaccine that could return a negative test result 
after exposure to the virus12. However further developments in the testing regime stalled, 
and part of the reason was the virus itself. 
 
‘In Darwinian terms, the recent emergence of HIV is an outstanding success’ (Weiss 2003). 
As researchers have learnt more and more about HIV, it is not surprising that Weiss and 
many others have expressed sentiments of respect and admiration for the virus’ ability to 
survive. The virus has two important characteristics: its extreme variation and its ability to 
evade ‘natural sterilising immunity’. These two properties make ideas relating to an HIV 
vaccine harder to test and make devising operational principles for vaccination problematic. 
This consequently placed greater emphasis on safety issues in testing regimes compared to 
poliomyelitis, many of which have not been resolved even today. 
 
7.2.1 Extreme variation of HIV creates moving goalposts 
 
The ways in which HIV attacks its host and causes disease are extremely diverse and 
complex. In addition to HIV targeting the immune system cells that are supposed to protect 
the host from the virus, the virus also possesses elaborate means for escaping detection by 
the immune system13 (Nabel 2001; Girard, Mastro et al. 2004). Perhaps the most important 
of them is its genetic and antigenic variation which makes HIV extremely adaptable. In 
chronic infection, HIV variants with mutations at every (single nucleotide) point in the 
genome, are believed to arise thousands of times per day (Johnson and Desrosiers 2002). 
Influenza is thought of as a highly variable virus, ‘yet the HIV population present in a 
single individual six years after infection can be as great as the global variation for an 
influenza outbreak’ (Weiss 2003:12). The swarm of viruses within an individual are so 
variable they are known as ‘quasi-species’ (Cichutek, Merget et al. 1992). Klein and Ho 
                                                 
12
 Rather than wait ten or so years for identifiable clinical symptoms to develop (see chapter 9 for more on 
‘end points’). 
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(2000:304) think that HIV may be ‘the most adaptive and genetically variable virus 
discovered to date’. 
 
Two of the most significant sources of variation lie with HIV’s low fidelity through 
replication cycles and extremely high turnover rate. In one day, 1x1010 virus particles are 
produced (Ho, Neuman et al. 1995). Like other retroviruses, HIV genome exists as RNA14. 
It uses reverse transcriptase15 to convert its viral RNA into DNA, which is then integrated 
into the host genome. This enzyme, reverse transcriptase, is highly error prone and the 
absence of ‘proofreading’ safeguards means that, on average, one mutation is introduced 
every replication cycle (Letvin 2006). In addition to these two factors, HIV also has a 
strong propensity to genetically recombine with itself and other quasi-species (Garber, 
Silvestri et al. 2004). When two viral particles with different genetic sequences enter the 
same cell; they can both integrate and produce entirely new viral RNA genomes. 
 
The result is that only about a third of nucleotide positions in the coding sequence of HIV 
are invariant (Alberts, Johnson et al. 2002:1450), which stands in contrast with the finding 
that humans and chimpanzees are 99% invariant (Wildman, Uddin et al. 2003). Nucleotide 
sequences in some parts of the viral genome, such as env gene, can differ by as much as 
30%. Even conserved parts, such as gag gene, differ by up to 20% (Letvin 2006:936). By 
comparison, amino acid changes of only 2% between a vaccine strain and wild types of 
influenza virus necessitate a change in vaccine strain and the formulation of a new 
influenza vaccine each year (Garber, Silvestri et al. 2004:405). 
 
Attempts to get around the variability of HIV by targeting functional, more conserved, 
regions, such as the critical binding site, have been foiled so far because HIV’s highly 
                                                                                                                                                     
13
 For example, HIV has evolved mechanisms that disrupt the Major Histocompatibility Complex proteins, 
the antigen-presenting proteins that T cells rely on to recognise foreign antigens on the cell surface. One of 
these mechanisms involves HIV’s nef gene product, which down-regulates expression of CD4 and class I 
MHC cell surface proteins that are essential for T-cell recognition of cells that harbour virus (Girard, Mastro 
et al. 2004). 
14
 RNA is inherently less stable than DNA due to the 2'-OH group on the ribose sugar, giving it the ability to 
be more chemically reactive and change its genetic bases. It is therefore yet another source of variation. 
15
 The discovery of reverse transcriptase earned Baltimore, Temin and Dulbecco a Nobel Prize because it 
challenged the central dogma of molecular biology that all genetic information exists in the more stable DNA 
form that Watson and Crick outlined. 
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glycosylated, hypervariable16 loops serve to shield and cloak its more conserved functional 
regions (Garber, Silvestri et al. 2004:399; Girard, Osmanov et al. 2006:4065). Antibodies 
are physically occluded17 from ‘where the action is’; whilst the regions that antibodies can 
reach are changing too quickly to be recognised for infection to be blocked. 
 
Given that HIV is so much more variable than influenza, and influenza is too variable to 
eradicate through vaccination, one might be led to assume that the same applies to HIV. 
However, a key difference is that HIV is far harder to transmit than influenza. HIV can only 
be transmitted in two ways: sexual or blood contact18 (Bloor 1995). This means that a 
rapidly executed mass immunisation programme, with a fact-acting vaccine, could control 
the HIV pandemic before the virus mutates too much. This implication for HIV vaccine 
design is explored further in the section below (7.2.3). 
 
Rapid evolution of a pathogen complicates whether to progress with prototypes. One 
effective strategy against a pathogen that evolves so rapidly is to develop multiple targets 
and take aim at all of them at the same time. This means that in order for the virus to 
survive, viral mutations need to confer resistance to all of the attacks at the same time. 
Although this is less likely to happen than mutation conferring resistance to only one form 
of attack, it does, however, raise the theoretical possiblity that a strain could arise which is 
resistant to all form of attacks presented to it (McMichael and Rowland-Jones 2001). 
Therefore, there is a strategic aspect to vaccine design, as there is in drug design, that 
involves gambling on how many targets represents ‘enough’ to ensure that completely 
resistant strains will not emerge. As Smith puts it, ‘It becomes a moral issue of whether or 
not to wait for better vaccine candidates or to move ahead with the ones showing at least, 
some promise’ (Smith 2002:108). 
 
                                                 
16
 ‘Hypervariable loops mask the critical receptor binding sites’ and ‘viral escape is facilitated by changes in 
glycosylation’ (McMichael and Hanke 2003:875). 
17
 In addition to hypervariable loops and glycosylation, conserved regions are also protected because they are 
embedded deep within the inside surfaces of envelope proteins that are arranged in trimeric (3xgp160) sets of 
heterodimers (gp120 and gp41) (McMichael and Hanke 2003:875; Girard, Mastro et al. 2004:399). 
18
 (Blood contact includes mother to child transmission.) The fact that there are so many people who are 
living with, or have died from, HIV/AIDS, despite the HIV network having only two avenues for growth, 
suggests that HIV is incredibly well suited to modern society and can be considered a highly human virus in 
the sense that it taps in to the most human of behaviours and relationships. 
 153 
In describing the results of a failed monkey experiment, one reviewer reports, ‘The 
researchers discovered that the SHIV [discussed later] had mutated its way around the 
killer-cell response. It’s an ominous development, Letvin thinks, because it threatens in 
time to undermine every vaccine that relies on the killer cells alone’ (Cohen 2002c:2325). 
Letvin here is suggesting that a multi-pronged approach will be necessary without defining 
the extent of the multiplicity required. 
 
The extent of multiplicity required is another inherently empirical question that requires the 
ability to test ideas against reality frequently and easily. Similarly, in discussing how 
closely to match the virus in the vaccine with the wild type virus, McMichael and Hanke 
(2003:878) write, ‘Intuitively, it seems preferable to match as closely as 
possible…[because] interactions are very sensitive to change… [but] The danger of too 
narrow a response is that escape mutants could be easily selected for by the vaccine, 
particularly if protection is incomplete.’ 
 
In summary, the extreme variation of HIV causes uncertainties in the vaccine innovation 
process. There is uncertainty in whether, firstly, the prototype is still relevant to tackling 
wild strains, and secondly, if the prototype has attacked enough targets to be effective. 
However, these are known uncertainties, and so the ability to test ideas frequently and 
easily means that robust knowledge may be gathered to address them. This requires a 
strengthened testing regime. 
 
7.2.2 Humans lack natural sterilising immunity against HIV 
 
The lack of natural sterilising immunity, the ability of the immune system to teach itself 
protection against a virus, is another unusual aspect of HIV. People who recover from an 
infection are often immune from subsequent attack by the same pathogen, and previously 
this has provided clues in the development of vaccines. This is not so for HIV because no 
one is known to have recovered from, and completely cleared, acute infection, let alone 
developed natural immunity to re-infection (McMichael and Hanke 2003; Garber, Silvestri 
et al. 2004; Girard, Mastro et al. 2004). ‘Natural infection with HIV does not result in virus 
clearance by the host immune system and the development of natural immunity to re-
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infection’ (Girard, Osmanov et al. 2006:4065). Humans can therefore be said to lack natural 
sterilising immunity to HIV. 
 
In spite of intense and sustained immune responses, HIV is able to resist eradication. Even 
when treatment reduces the viral load to undetectable levels19, the virus still remains and 
can continue depleting immune system cells, eventually leading to AIDS (Johnston and 
Fauci 2007). Since natural immunity to re-infection is not seen in HIV infections, it is not 
surprising to find that superinfection with a second HIV isolate20 can readily occur in 
infected persons. A lack of natural sterilising immunity therefore exacerbates the inherent 
variability of the virus by having multiple variants in the body at the same time, leading to 
the emergence of recombinant virus variants and generating increased virus diversity 
(Altfeld, Allen et al. 2002). 
 
Theoretically, even if the virus was completely cleared, the virus could return from latency. 
To prevent the ‘return’ of virus, any cells with the provirus integrated within the host 
genome, along with all of the copies of the cell after it was infected, would need to be 
identified and killed. It has been calculated that it would take up to 60 years to eradicate a 
reservoir of as few as 1x105 latently infected cells (Gallo 2005; Girard, Osmanov et al. 
2006). This suggests aiming to completely cure AIDS by clearing HIV infection is not 
feasible, and that it may be better to try and prevent infection. 
 
The lack of natural sterilising immunity against HIV means that ‘the potential correlates of 
protection are not known, leaving us without a definite model of protective HIV immunity 
to emulate through vaccination’ (Garber, Silvestri et al. 2004:398). This situation contrasts 
strongly with the challenge poliomyelitis researchers faced, as Albert Sabin succinctly put 
it, ‘The objective is clear: to imitate what nature does for 99-99.9% of the population but 
without incurring the 1-0.1% risk of paralysis which in many parts of the world is the price 
for acquiring immunity to poliomyelitis’ (Carter 1965:180). 
 
                                                 
19
 Treatment is by a combination of antiretroviral drugs collectively known as cocktail therapy or (HAART). 
Undetectable levels are <50 RNA copies per millimetre (Johnston and Fauci 2007:2704). 
20
 HIV from another source. 
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Maurice Hilleman (1992:1054), who has made many vaccines, laments, ‘The time proven 
approach of trying to mimic the immune response to natural infection makes little sense for 
a virus to which the natural immune response by the host fails and is ineffective’. One 
famous AIDS researcher said that the AIDS vaccine field was ‘flying without a compass’ 
(Cohen 2005:99). 
 
This has led some commentators to identify natural sterilising immunity as the major 
criteria for judging whether a vaccine is possible or not. ‘It is now theoretically possible to 
develop a safe and efficacious vaccine against any infectious disease to which natural 
specific immunity develops on recovery from infection’ (Andre 2001:2207). It is a 
declaration that carries great promise and excitement for vaccine development efforts 
against the many diseases where natural sterilising immunity can be seen. It is also a 
disheartening one for the diseases that are most in need of vaccine development (AIDS, 
tuberculosis and malaria), where natural sterilising immunity is not seen. 
 
7.2.3 Implications for vaccine design: A small window of opportunity 
 
Extreme variation and lack of natural sterilising immunity have immediate implications for 
the establishment of operational principles in vaccine design. 
 
From the moment of transmission into a host, the window of opportunity in which chronic 
HIV infection might be prevented by a vaccine is very small. Nearly all CD4 helper T-cells, 
the immune system’s cells that HIV attacks, are located in mucosal tissues such as those 
lining the vagina, airways and gut to provide mucosal protection. Only two per cent of CD4 
cells are estimated to actually circulate in the blood (Aldhous 2006). This highly skewed 
distribution of CD4 cells is possibly because pathogens typically enter the body through 
such tissues. And yet, despite this, infections acquired by this route have historically been 
difficult to prevent through vaccination (Klein and Ho 2000:305). 
 
Most HIV infections are transmitted sexually through the mucosal surface (Hilleman 
1992:1055), so a protective vaccine will probably have to provide ‘mucosal immunity’ in 
addition to immunity in the blood. This is difficult because, to provide mucosal immunity, 
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the induction of specific immunoglobulin (Ig)A antibody is needed in the thin layer of fluid 
at the mucosal interface. IgA neutralisation of the virus must occur at this narrow interface 
between the mucosa and the circulation. If neutralisation does not occur, the virus can 
easily encounter lymphocytes or macrophages and cause infection long before traditional 
IgG and IgM antibodies can respond in the bloodstream (Schultz 1996). In short, the virus 
has to be tackled effectively at the body’s first line of defence. 
 
But even a functional mucosal antibody would not be enough because HIV can be 
transmitted within cells as well as outside of them. So a protective vaccine would need to 
prevent cellular transmission. The fact that the virus can be transmitted either free of cells 
or within cells led Albert Sabin, the poliomyelitis vaccine developer, to suggest that an HIV 
vaccine is impossible (Sabin 1992). As chapter 8 will show, researchers came to realise that 
the operational principle of an effective vaccine would need to be more than a functional 
antibody response to kill the virus. A cellular immune response would also be required to 
clear any infected cells and prevent further cellular transmission. 
 
Mucosal surface transmission and intracellular transmission are not the only reasons the 
window of opportunity is narrow. Graham explains that once the virus enters the 
bloodstream, rapid evolution of HIV and the lack of natural sterilising immunity come into 
play and severely reduce the chances of a vaccine working effectively. ‘The timing of the 
immune response with respect to initial virus infection and spread is particularly important 
in the case of HIV infection. One reason is that the longer HIV replicates in the host, the 
more diverse variants evolve, which may allow the virus to escape immune responses. In 
addition, once HIV resides in the extracellular space of lymph node germinal centers and in 
latently infected cellular reservoirs, or is sequestered in the central nervous system and 
other sites that are relatively protected from immune responses, it probably cannot be fully 
eliminated from the host.’ Thus the confluence of these factors serve to reduce the window 
of opportunity such that, ‘the success of vaccination may hinge on altering events that 
occur in the early hours following HIV exposure’ (Graham 2002:209). 
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HIV poses some unique challenges (see table 8). The lack of natural sterilising immunity 
leaves vaccine designers few clues with which to design operational principles. The 
pathogen diversifies quickly due to the lack of immunity against super-infection and the 
virus’ inherent variability. This means that the operational principle has to get to work 
quickly in order to fulfil its purpose. The pathogen is usually transmitted through the 
mucosal surface, either within cells or outside of them. This means that the operational 
principle must prompt mucosal, cellular and humoral immunity. 
 
Table 8: A summary of technical obstacles to HIV vaccine development 
Common elements in vaccine 
preventable disease 
Some unique attributes of HIV infection 
Virus shows limited antigenic variation, if 
any 
Hypervariability of antigen specificity 
Spontaneous recovery is the normal event No, or extremely rare, spontaneous 
recovery from natural infection 
Genetic integration is not part of virus life 
cycle 
Obligatory integration of virus into host 
cell genome where the infection may be 
silent/latent and immunologically 
undetectable 
Virus does not destroy immune system Infection and progressive destruction of the 
immune system itself 
Transmission of disease is by free virus 
Transmission of disease is non-mucosal 
Transmission of infection by virus hidden 
inside cells as well as by free virus 
Transmission of infection by mucosal route 
Vaccine efficacy is by induction of 
neutralising antibody and sometimes 
cytotoxic T cells in addition 
Appropriation of infection in the CNS, 
where it is inaccessible to a peripheral 
immune response 
Viral antigens presented to immune system 
by Major Histocompatibility Complex 
Down-regulation of MHC class I antigens 
by viral gene product (nef) 
Sources: (Hilleman 1992:1054; Girard, Mastro et al. 2004:1220) 
 
These are formidable design specifications, but they have been established through a 
collective judgement, experience and understanding21. They have become increasingly 
well-known uncertainties (as opposed to unknown uncertainties) about the development 
                                                 
21
 There are a few individuals who offer further ways forward. A small cohort of sex workers in Nairobi has 
been found to be exposed but uninfected; however, their immunity seems dependent on continued exposure 
(Nabel 2001:1002; McMichael and Hanke 2003:875). There are also some infected people who have managed 
to fend off the onset of AIDS for more than a decade, known as long term non-progressors or elite controllers 
(Johnston 2000:268). A highly focussed, co-ordinated and well-resourced effort to find, and study, such rare 
individuals may help provide a ‘roadmap’ to inducing immune resistance. 
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process. This places heavy pressure on the need to test designs against these specifications 
to show that they are robust enough to meet them. Test-results need to be incorporated in a 
systematic way that allows incremental accumulation of knowledge. 
 
Sophisticated testing regimes allow the development of technologies through intermediate 
conditions to provide varying degrees of indirectness to real technological conditions. One 
such set of intermediate conditions is provided by the use of animals as a stepping stone to 
dealing with the problems posed in humans by the HIV virus. Ideas can be tested, shared 
and refined with careful use of animals as an indirect representation of conditions in 
humans. However, the next section shows their use for testing and refining ideas is 
contingent on the creation of these conditions through instrumentalities, and is in no way 
inevitable. 
 
7.3 Efforts to strengthen the testing regime with animals 
 
This section will show that there have been strategic efforts to strengthen the testing regime 
in the field of animal modelling. The section organises these efforts into the three 
constituent parts of the testing regime, explained in section 3.4. 
 
Animals provide an important environment from which novel hypotheses can emerge, in 
which new ideas can be tested, and which allows dead ends to be eliminated and new leads 
to be built on. But such a drive for animal-led HIV vaccine research and development has 
been problematic for a number of reasons. Foremost is that HIV is a primate virus capable 
of infecting only few animal species. Although HIV infects chimpanzees, the virus 
replicates to a lesser extent than in humans, the virus does not congregate and 
systematically destroy the lymph node architecture as in humans, and does not culminate in 
disease (Klein and Ho 2000; Nath, Schumann et al. 2000; Van de Perre 2000). By 1999, 
over 150 chimpanzees had been infected but only one was reported as progressing to AIDS 
(Koopman, Haaksma et al. 1999). 
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In reviews of HIV vaccines, few fail to readily acknowledge the lack of an animal model as 
a significant obstacle to vaccine development (Nabel 2001; Letvin 2005; Singh, Jeang et al. 
2005; Slobod, Bonsignori et al. 2005; Johnston and Fauci 2007; Titti, Cafaro et al. 2007). 
‘Another roadblock encountered in HIV vaccine research is the lack of a truly 
representative animal model in which to gauge the effectiveness of vaccine strategies’ 
(Klein and Ho 2000:304). ‘A second obstacle to an HIV-preventive vaccine is that we have 
no truly useful small animal model for studying HIV infection’ (Gallo 1991:1894). 
 
And yet, for all researchers who have commented on the unsuitability of animal models in 
mimicking real world conditions, the majority of the scientific literature I have reviewed 
has discussed data derived from animals. Nath et al (2000:430) conclude that ‘primates 
have provided a great deal of information that has significantly advanced vaccine design.’ 
There is an inconsistency between the complacency about animals and the use of animals. I 
suggest the phrasing in the quotes above by Klein and Ho and by Gallo, using verbs such as 
‘lacking’ or ‘having a useful model’, are passive descriptions or observations of the state of 
the natural world as it is. They have the tendency to downplay the role of human agency in 
the use and interpretation of animal models to mimic real world conditions as much as is 
technically possible. Girard et al. (2006:4066) expresses the difficulties more actively by 
using the word ‘developing’, ‘A significant obstacle in HIV vaccine research has been the 
difficulty in developing an appropriate animal model.’ This choice of words reflects more 
of the human effort that is expended in ‘making the best of what we’ve got,’ in moulding 
what is provided in the real world to our technological needs. 
 
Unlike the construction of prototypes and testing chambers in engineering, which are seen 
as clearly man-made endeavours, the use of animals as ‘testing chambers’ is quite rightly 
not seen in this way because animals are not man-made. But scope for man-made 
interventions that structure the environment provided by animals do exist, and this role is 
perhaps somewhat underestimated when barriers to vaccine innovation are being explicitly 
articulated. 
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Chapter 6 showed that monkeys were used to guide the way to poliomyelitis vaccines 
despite the fact that they did not closely mimic what happened in humans. Monkeys do not 
normally become infected with poliomyelitis, but when injected directly into their brains 
the virus is infectious and able to paralyse, thus giving an animal model with clearly visible 
test results. Isabel Morgan’s experiments thus facilitated the development of monkey 
models such that they could become incorporated into an effective testing regime. Similar 
efforts to achieve this seem to be underway for HIV models. 
 
7.3.1 Learning conditions in animals 
 
These efforts are considerable and are what consume much of the debates in the literature. 
The first issue is in our understanding of the conditions represented by animal models. 
Despite the shortcomings of the chimpanzee model, it is still useful to researchers, provided 
they know what aspects of the vaccine they are testing for. For example, since chimpanzees 
do not readily progress to AIDS in a human-like way (Klein and Ho 2000; Nath, Schumann 
et al. 2000; Van de Perre 2000), using it to study how a vaccine might reduce disease 
progression would not be as helpful as say, testing vaccines that prevent infection outright. 
Feinberg and Moore explain, ‘For instance, a virus that replicates very poorly in a host [as 
is the case with HIV-in-chimpanzee models] may be misleadingly easy to protect against 
by vaccination, and is of little value for studies of viral pathogenesis…’ 
 
‘…Conversely, vaccine studies that employ particularly virulent viruses, as is the case with 
SHIV-in-macaques [discussed below], or experimental challenges delivered at high doses 
via intravenous inoculation may underestimate the potential protective efficacy of some 
vaccine strategies’ (Feinberg and Moore 2002:207). Thus the usefulness of a model 
depends both on our understanding of the conditions that the model presents us with and on 
our ability to standardise what we are testing for. 
 
In the case of HIV, some researchers express extreme uncertainty about our understanding 
of these testing conditions and suggest reluctance to draw interpretation, ‘Even a vaccine 
that has 100% efficacy in all three [animal] challenge models discussed here might still be 
ineffective in humans. Conversely, a proficient vaccine developed in humans might never 
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show benefit in the animal models’ (Nath, Schumann et al. 2000:430). Similarly Feinberg 
and Moore (2002:209) caution interpretation of data arising from animals, ‘Animal models 
cannot determine whether a vaccine will be effective against HIV infection of humans; only 
Phase III trials in humans will do so.’ However, they also note that they can be used to 
‘explore the potential protective efficacy of vaccine concepts’ (:207), ‘add important 
insights’ (:209), and that ‘it is essential for models to be improved [my italics] so as to 
mimic, as closely as possible, the actual circumstances of HIV infection in humans.’ 
 
7.3.2 Animals as instruments 
 
The second issue involves the craft of developing animals as instruments. It is evident that 
researchers do not simply ‘make the best of what they’ve got’. They actively construct 
models and techniques to use them. This can be illustrated by the two main animal models 
used in HIV vaccine development (a third less used model is the chimpanzee): SIV and 
SHIV in monkeys. 
 
Shortly after HIV was discovered, SIV was also discovered as researchers in primate 
centres noticed that Asian monkeys (macaques) were dying of an illness which bore 
remarkable similarity to the newly observed AIDS syndrome that was killing young men 
(Gardner 1996). The causative agent of this simian AIDS was found to be SIV, a virus 
closely related to HIV in gene sequence homology. SIV is naturally found in African 
monkeys (sooty mangabeys), to which it does no harm but quickly causes AIDS in Asian 
monkeys, none of which are infected in the wild (Gardner 1996; Smith 2002). Smith says 
that ‘…several different, but closely related, strains (including SIVmac, SIVsm, and 
SIVmne) of SIV were developed for research purposes’ (Smith 2002:101 [my italics]). 
 
With respect to the first issue of understanding modeling conditions outlined above, the 
development of SIV-caused AIDS in macaques was quickly recognised as providing, ‘the 
flexibility to test not only potential vaccines but also to test and verify theories of 
pathogenesis or immunological correlations with disease. Accordingly, there are a 
multitude of pathogenic and non-pathogenic viral strains that can be used in therapeutic and 
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challenge studies to answer such questions as correlates of protection or progression to 
disease’ (Nath, Schumann et al. 2000:429). 
 
The SIV model was developed further when an SIV genome was engineered to carry the 
env gene22 from an HIV isolate. These SIV/HIV chimera (hybrid viruses) became 
instruments known as SHIVs (Johnston 2000). SHIVs can replicate in macaques and, after 
serial passages in the animal, eventually lead to the emergence of highly pathogenic 
variants that are capable of decimating CD4 T cell population of the animal within a few 
weeks of infection and generating a lethal AIDS-like syndrome within a year (rather than 
the ten or so years often needed for HIV) (Girard, Osmanov et al. 2006). 
 
The use of multiple SIV ‘strains of differing virulence’ (Feinberg and Moore 2002:207) 
allow researchers to control iterations between stricter, more real world conditions and 
lenient, simplified laboratory conditions. And the use of different chimeric SHIVs provides 
even more control over the opportunities to examine and test particular issues in the 
development of vaccines. For example, one notable difference between SIV and HIV is 
when and which of the two seven-transmembrane chemokine receptors CCR5 and CXCR4 
on CD4 cells, the virus binds with for viral uptake into cells (Nath, Schumann et al. 2000; 
Girard, Osmanov et al. 2006). In about half of HIV infected humans, HIV that binds to 
CCR5 predominates early and throughout the asymptomatic phase, but a shift towards 
binding to CXCR4 is observed as these humans progress to AIDS. This shift in tropism to 
CXCR4 has not been reported in SIV infected macaques (Johnston 2000). SHIVs provide 
an opportunity to take a controlled look at each of these tropisms in turn. 
 
The great variety of animal models that have been developed allow researchers to firstly 
examine different aspects of infection in turn, for example ‘R5’ and ‘X4’ receptor tropisms, 
and secondly adjust testing conditions to slowly iterate towards more and more real world 
conditions. For example, by using more or less virulent strains, varying challenge route and 
dose, and using more or less genetically diverse strains between vaccination and 
                                                 
22
 rev, tat, and vpu genes are also used in the chimera (Nath, Schumann et al. 2000; Feinberg and Moore 
2002). 
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challenge23. Thus, as instrumentalities help provide controlled variation of conditions, 
knowledge may grow reliably. 
 
7.3.3 The need for institutions and R&D governance 
 
As noted in the theory chapters, reliable knowledge gathered in an array of conditions may, 
however, remain fragmented. This effect may be particularly acute in a research 
environment that rewards individual achievement and relies on competition to drive 
forwards. In contrast, for robust technological knowledge to accumulate, it needs to be not 
only true but also shared and integrated. This can be facilitated by agreeing on which 
intermediate conditions to set experimental standards around. Thus, it is the inter-
relationships between different groups of knowledge producers that are most important for 
technological development. 
 
As Norley and Kurth point out, ‘There are a number of [primate] models available, each 
with its advantages and disadvantages, and unfortunately the model selected can have a 
large impact on the result. Which model is the most relevant is therefore a matter of debate’ 
(Norley and Kurth 1996:537). This would seem something of an understatement when 
compared to the account of a journalist, Cohen, on animal use, ‘Salk’s chimpanzee data [for 
AIDS vaccine candidates] were peculiar for several reasons, not the least of which was the 
way in which he attempted to use animal studies to gain support for human experiments he 
had already quietly begun. It would become an all too common gambit: rather than having 
animal experiments guide them in developing an AIDS vaccine, Salk and other researchers 
would use experiments ex post facto to justify the paths they had already chosen’ (Cohen 
2001b:88). 
 
When primate models are used in this way, or without coordination between research 
groups, commensurability between the results of testing becomes problematic. For 
example, ‘With the variety of challenge viruses and primates, comparison of one study to 
                                                 
23
 At 2002, all SHIV challenges employed vaccine immunogens that are genetically identical (or nearly so) to 
the challenge virus, yet a single amino acid change was reported to be sufficient to enable SHIV to escape 
from immune containment (Feinberg and Moore 2002). 
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another is often not possible’ (Smith 2002:107) and ‘These [SIV] species differ 
substantially. Since each of these SIV strains produced similar disease in a given macaque 
species and no macaque/ SIV model was clearly more relevant than another, researchers 
chose to study different SIV strains in different species of macaques. The resulting 
experiments, of course, often make direct comparison impossible. Additionally, researchers 
have now begun using SHIV as the challenge virus…’ (Smith 2002:101). 
 
To ensure that results between different groups are comparable would require a carefully 
planned strategy for co-operation. The very factors that provide researchers with flexibility 
and the ability to adjust testing conditions incrementally would need to be set constant and 
agreed for cumulative learning. This is needed in addition to careful documentation and 
understanding of the conditions used in tests and experiments. Thus, governance is required 
to ensure co-ordination and transparency. 
 
‘Comparative studies of candidate vaccines in animal models have been proposed as an 
approach to determining which candidates are most worthy of accelerated development. For 
example, comparison of viral vectors would require that the candidates express identical 
HIV genes, be of similar quality and be evaluated using the same protocol with the same 
challenge virus, route of challenge and endpoints’ (Johnston 2000:269). Such a 
comparative study does not seem to have been undertaken (Cohen 2001b). It would 
therefore seem that there has been a significant failure in the organisation of HIV vaccine 
R&D since such grand experiments have been designed and executed before (chapter 6). 
 
7.3.4 Some costs of not having wider support for a vision 
 
Attempts to shape the testing regime in such a direct and deliberate way has ethical 
implications. For example, attempts at creating HIV strains that were capable of not only 
infecting chimpanzees but also killing them caused concern. These lethal virus strains, 
previously not lethal to chimpanzees, would be undeniably man-made and, for some, their 
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creation and introduction marked an exploitation of our relationship to the animals24. Major 
meetings were convened for such debates (Gardner 1996). 
 
Smith (2002:101) notes, ‘macaque studies are expensive, and the supply of macaques is 
limited’ but relative to chimpanzees they are cheap and abundant. ‘It can cost more than 
$100,000 to care for a single [chimpanzee] animal’ (Nath, Schumann et al. 2000:428). In 
addition, as a rare species, chimpanzees are protected by a 1975 international treaty that 
allows them to be used for research only if they are bred in captivity and not caught from 
wild. This restricts supply much more than macaques. Macaques, in contrast, cost about 
$2000 each (Cohen 2001b:80) and, once infected, die from AIDS; unlike chimpanzees 
which need longer term care. Furthermore, chimpanzees can weigh up to 80 kilograms and 
possess strength three times that of an adult human male. Enclosures that can hold 
chimpanzees need to be made from durable steel and therefore add to the expense and 
difficulty of their use in vaccine testing (Nath, Schumann et al. 2000:428). 
 
These practical, legal, ethical and cost obstacles to the use of primate models in AIDS 
vaccine development led to a shortage in supply. For example Gallo is quoted to have said, 
“To do the studies I would like to do over the next two years, I need 75 chimps, but I will 
be lucky to get two or three” (in Cohen 2001b:83). Gallo goes so far as to say, “It is 
conceivable that we may already have an effective vaccine, but we will never know unless 
we can get the chimps to fine-tune different dosages of different compounds” (in Smith 
1990:397). Smith says, ‘Macaque studies are expensive and the supply of macaques is 
limited. Therefore, most macaque studies involve small numbers, usually well less than 20 
total, of animals’ (Smith 2002:101). 
 
                                                 
24
 Jane Goodall, a prominent anthropologist, was a vocal advocate for chimpanzee welfare and their right to 
be free from testing. Using her well known studies of chimpanzees in Tanzania, she wrote, for example, to 
Science journal, ‘…it is their humanlike behaviors that most fascinate people: their tool-using and tool-
making abilities; the close supportive bonds among family members, which can persist throughout a lifetime 
of 50 or more years; and their complex social interactions - the cooperation, the altruism, and the expression 
of emotions like joy and sadness. It is our recognition of these intellectual and emotional similarities between 
chimpanzees and ourselves that has, more than anything else, blurred the line, once thought so sharp, between 
human beings and other animals’ (Goodall 1998:2185). 
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The existence of strong leadership and co-ordination has been shown to ameliorate such 
problems with solutions such as the dedicated breeding programme O’Connors set up for 
poliomyelitis vaccine research. Similarly, strategic research can be supported to strengthen 
the testing regime in other ways. This section has shown that researchers have already been 
active in developing animal models, but has suggested that in the presence of strong 
support and co-ordination, researchers explicitly dedicated working on developing animal 
models may have made more breakthroughs. This includes the possibility of developing 
smaller animal models such as rabbits or rats. 
 
7.4 Summary 
 
This chapter has shown how visions for an AIDS vaccine were constructed in a 
considerably different way to that for poliomyelitis vaccines. It was dependent on the 
establishment of HIV as its cause, but uncertainties about the virus and the lack of wider 
support further weakened this vision and allowed other competing visions to draw 
resources away from co-ordinating efforts. Nevertheless, development of a blood test 
marked an important starting point in the search for a vaccine. 
 
This chapter has also reviewed the properties of the AIDS virus and its behaviour in 
animals so that their implications on vaccine design and development can be considered. 
The next chapter will examine how they have affected the development and selection of 
various approaches to AIDS vaccination in more detail. 
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Chapter 8 
 
Which HIV Vaccine? Competing directions of technical change 
 
This chapter explores the role of the testing regime in selecting between competing 
operational trajectories. It seeks to establish the notion that some operational principles are 
less likely to come about due to testing difficulties, and therefore that the direction of 
innovation is influenced by the testing regime. This idea complements the previous chapter 
which argued that the biological features of HIV, in comparison to other viruses for which 
vaccines have been found, requires the development of a far more sophisticated testing 
regime. This chapter continues by showing how, within the biological parameters of HIV, 
the testing regime can continue to shape progress in and direction of science and 
technology. 
 
The first section describes the operational trajectory that most AIDS researchers were 
forging and explains its relative popularity. The second section describes some of the 
experiences of small companies in the private sector and seeks to explain their choice of a 
new operational trajectory. The third section explains how and why the strength of the 
testing regime may support the development of some trajectories over others. The fourth 
section examines yet more operational trajectories that emerged in the 1990s. The fifth 
section describes how a weak testing regime may have contributed to the ‘closure’ of older 
vaccine approaches, apart from considerations of their effectiveness. A sixth section 
concludes the chapter. 
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8.1 Whole-virus vaccines making way for viral-subunit vaccines 
 
In the 1980s two approaches were available to AIDS researchers: live-attenuated and killed 
vaccines. These were the same options as when the poliomyelitis vaccines were being 
researched half a century earlier. But with the advent of biotechnology, AIDS researchers 
now have other approaches open to them. 
 
8.1.1 Safety in reductionism and efficacy in empiricism 
 
Live and killed vaccines present a modified version of the whole virus to the immune 
system. A new approach was to present proteins, or bits of protein, from the virus. This is 
known as the subunit approach. The idea of using genetically engineered proteins to make 
vaccines was elegant in its use of science and understanding, and seductive in its use of 
recently developed basic technologies in molecular biology. It has dominated AIDS vaccine 
research and development (see for example, Gallo 2005:178; Johnston and Fauci 2007). 
 
Whilst the live and killed vaccines ‘worked because they worked’, it was felt a subunit 
approach was possible based on newer understandings about the virus1, 2. The NIH’s 
leading AIDS vaccine researcher, Gallo, favoured this more refined approach (Fischinger, 
Gallo et al. 1986), “What can be done with a killed whole can be done with a protein and a 
little brains… The country has enough brains to do it. Let people who can’t do it with their 
own abilities or brains work with it as killed whole, and let the rest of the country figure out 
how to do it with proteins, and don’t stop either one” (in Cohen 2001b:44). 
                                                 
1
 Although it is debated how much HIV vaccine development should be empirically driven, there is no doubt 
that vaccines developed in the past have involved a considerable degree of empirical art. For example, 
Bolognesi, who has followed a not-so-empirical approach to making HIV vaccines, acknowledges that, ‘The 
science of vaccinology has been largely empirical. The use of vaccines based on selected components of a 
pathogen is only a recent development and the efficacy of these vaccines is still being evaluated. The 
underlying principles of vaccination are poorly understood despite vaccines’ successes, particularly against 
viruses’ (Bolognesi 1990:41). 
2
 With the benefit of several decades of hindsight, the words of poliomyelitis researcher Hilary Koprowski 
seem almost ironic as he predicted a diminishing role for empiricism in vaccine development. ‘And soon the 
dispute between the killed- and live-vaccine schools will be ancient history. Now that it is becoming possible 
to isolate and purify and even synthesize the viral protein that confers immunity, the infectious part of the 
virus becomes unnecessary. Perhaps undesirable. Why introduce viral infection – even supposedly harmless 
infection – when you can supply the specific antigenic protein you need for immunization?’ (Carter 
1965:355). 
 169 
 
Jonas Salk made his poliomyelitis vaccine using the whole-killed approach and he favoured 
the same approach to developing an HIV vaccine (Carter 1965; Salk 1987; Cohen 2001b). 
He saw contemporary visions of the subunit vaccine as hopelessly reductionist and 
unsubstantiated compared with the successes of the whole-killed approach in developing 
vaccines for poliomyelitis, influenza, pertussis, plague, typhoid, cholera and rabies, many 
of which are effective with little understanding of their disease causing mechanisms3 
(Plotkin and Orenstein 2004). Salk was of the view that understanding form and function, 
should come second to getting the vaccine to actually work. 
 
Gallo (2005), and others, argued that using genetically engineered protein was safer 
because, as happened in the Cutter incident of 1955, whole virus may not be killed properly 
during manufacture. Since genetically engineered vaccines feature only a small part of the 
organism and crucially none of its genetic material, they can never cause the disease they 
are trying to prevent. 
 
Another whole approach that was severely undermined by the safety issue was the live-
attenuated vaccine, where the virus is alive but is weaker and cannot cause disease4. If the 
whole-killed approach was met with safety concerns, the live-attenuated approach was met 
with ridicule. Plotkin, who had made other vaccines using this approach, was repeatedly 
turned down for grants on the basis that developing an HIV vaccine this way was too risky. 
Gallo says in an interview in 1990, “I think I would argue to put people in jail who did it, 
OK? This would be so seriously nuts, beyond belief” (Cohen 2001b:48). 
 
Gallo and some prominent colleagues expressed three key criticisms (Fischinger, Robey et 
al. 1985). Firstly, there was the risk that the weakened strain of HIV could cause cancer 
through a process called insertional mutagenesis, where viral genes cause problems when 
                                                 
3
 For example, vaccines against smallpox and rabies were developed before their causal agents were even 
fully identified (Chase 1982:167, 172; Plotkin and Orenstein 2004). 
4
 One advocate for this approach was Stanley Plotkin, a prominent vaccinologist who had made vaccines for 
rubella and rabies. Like AIDS, rabies is also a disease for which humans have no (or very little) natural 
sterilising immunity. He had also developed a live varicella chickenpox vaccine, and a live poliomyelitis 
vaccine that never came to market. He co-authored an important medical textbook, Vaccines, featuring a 
chapter on each vaccine (Plotkin and Orenstein 2004). 
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they integrate with DNA in the host cell. Secondly, with such extreme variation, the 
weakened HIV could revert back to virulence. Thirdly, the weakened HIV virus might 
cause AIDS at a slower pace than the wild type virus with vaccinees developing AIDS 
thirty years after infection rather than ten years. These are all difficult criticisms to deal 
with because to respond effectively would require testing to prove that something does not 
happen. And, in the last case, testing for at least thirty years. 
 
In addition to these criticisms, there was concern about the reaction of an increasingly 
reluctant public to a vaccine that was developed using the live approach. ‘The public fear 
associated with vaccinating individuals with living HIV make using live-attenuated virus an 
unattractive prospect from the perspectives of marketing and compliance’ (Klein and Ho 
2000:308). ‘Although most of the population has accepted [live] vaccines, the fear of AIDS 
is powerful, and even a l-in-a-million chance of contracting the disease from the vaccine is 
too great a public safety risk’ (Klein and Ho 2000:309). 
 
The whole virus approaches, both live and killed, were seen as old fashioned and unable to 
stand up to the challenge of a dangerous new pathogen (Cohen 1992a). Gallo insists that 
‘An HIV vaccine cannot consist of attenuated, actively replicating (live) HIV, even though 
the best vaccines for other viral diseases have usually used live viruses. There is inherent 
danger that attenuated HIV would cause AIDS. Killed whole virus, usually the next best 
approach, might also be precluded both because of the hazard (one cannot be certain that all 
virus particles would be inactivated), and because killed whole HIV has worked poorly in 
animal tests…we are restricted by the need to use one or more HIV proteins or peptides 
(subunit vaccines)’ (Gallo 2005:1894). 
 
8.1.2 Testing regimes and vaccine approaches: Inter-relationships 
 
Of the three approaches (live-attenuated, whole-killed and subunit), subunit was the 
dominant approach both in the public sector, represented by Gallo’s group at the NIH, and 
in the private sector (described in the section below). In the previous chapter, the testing 
regime was characterised as weak because of the lack of natural sterilising immunity 
(inability to clear virus), high variation of HIV, and limited scope for animal models to act 
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as intermediates to human testing. This section shows that these features have different 
implications for the different vaccine designs. It emphasises a lack of evolved capabilities, 
experience and skills in the testing regime. 
 
As discussed at the end of chapter 5, the design of a vaccine based on viral pieces or 
fragments faces the challenge of finding out which pieces are the most important for the 
immune system to recognise HIV correctly and accurately ( for example Eggink, Melchers 
et al. 2007). Then, even once the right protein or pieces of it have been selected for a 
vaccine; there is the worry that HIV’s extreme variation would allow it to evolve resistance 
to the vaccine (see section 7.2.1). There would also be manufacturing challenges in either 
cloning enough copies of the protein (in vivo) or synthesising pieces of it in a machine 
accurately (in vitro). These issues are inter-related with the testing regime because they are 
design uncertainties which need to be addressed through repetitive testing in varying 
conditions. 
 
The whole virus approaches face different obstacles to the subunit approach, particularly 
related to the issue of conducting tests with a deadly virus and without a reliable animal 
model. Advocates claim whole virus approaches rely on careful, ‘rational 
empiricism…based on hard data’ (Hilleman 1998:788). However, the lack of natural 
sterilising immunity and the lack of well developed animal models both result in a testing 
regime that is weak, and makes collecting ‘hard data’ on effectiveness difficult. 
 
Hilleman notes that vaccines have been developed without animal models, and vaccines 
have also been developed for very dangerous pathogens, but for HIV, the two hurdles 
exacerbate each other: ‘There are no meaningful animal models for measles, mumps, 
rubella, human adenovirus and varicella, but clinical tests of attenuated live virus vaccines 
could be carried out in human beings by a ‘guts and judgement’ approach and without prior 
animal safety studies because these diseases are not usually life threatening in their natural 
occurrence. Poliomyelitis, Hepatitis A and B, are potentially very dangerous, but it was 
possible to develop in vitro markers and tests in susceptible animal models… [for] safety 
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and protective efficacy… before initiating first clinical investigations’ (Hilleman 1989, 
quoted in Grady 1995:96). 
 
So unlike measles, mumps, rubella, diphtheria, pertussis, smallpox and many other vaccine-
preventable diseases for which humans have some form of adaptive immunity, and animal 
models, HIV had neither. This combination of difficulties represented a major problem for 
all vaccine approaches, but dealt its heaviest blow to empiricist methods which formed the 
basis of previous whole vaccine development methods. 
 
Capabilities, skills and experience evolved through successful use of whole vaccine 
approaches in the past; one might refer to them as part of a path-dependent technological 
paradigm. The paradigm has benefited from the development of ever more sophisticated 
testing regimes with key social elements. 
 
Piot et al. (2001:972) note, ‘Smallpox vaccination seems the ultimate ‘magic bullet’ — an 
example of a purely medical technology resulting in the total eradication of disease. But 
even the response to smallpox cannot escape its social determinants, such as the 
observation of natural immunity in cow-herding communities, the power relations that 
enabled vaccine testing, and the 200 years of social, political and economic organization 
required for vaccination to occur globally.’ 
 
Grady also uses the smallpox example to suggest that strong understanding may not be 
necessary for innovation, but emphasises that this is the case only if natural sterilising 
immunity can be observed (1995:95). ‘At the 1977 smallpox conference, 200 years after the 
first effective vaccine was used, researchers still did not understand the correlates of 
immunity. A major difference exists, however, between previous efforts at vaccine 
development and efforts at developing an HIV vaccine… Previous vaccine work almost 
always started with an empirical observation about natural protection (sometimes without 
understanding much about the microbe, for example, even though correlates of immunity 
were not known, it was observed that exposure to cowpox protected people from smallpox, 
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and this observation is what led Jenner to try his experiments), followed by attempts to 
copy or elicit the same type of protection using various vaccine preparations.’ 
 
8.2 Selection of the subunit approach by the private sector 
 
As noted in section 2.4.1, firms associate their market opportunities with their knowledge 
environment through their ‘core competences, ‘core rigidities’ and ‘dynamic capabilities’ 
(Leonard-Barton 1992; Henderson and Cockburn 1994; Prahalad and Hamel 1994; Teece, 
Pisano et al. 1997). These capabilities are acquired through time, as argued by evolutionary 
theories reviewed in chapter 2. Thus, for firms, the relationship between the testing regime 
and vaccine approaches is examined in this section by analysing not only their experiences 
of pursuing an HIV vaccine, but also some previous experiences. 
 
As noted in chapter 5, most private sector vaccine innovation capabilities resided with a 
few major pharmaceutical firms. However, they had declared their disinterest in the AIDS 
vaccine from the outset because of concern about longer development times, increased 
liability, and smaller profit margins, compared to therapeutic drugs (Chase 1984; see also 
chapter 5). The market was left to smaller biotechnology firms who drew investments by 
riding on the wave of optimism generated by genetic engineering. The few firms that did 
enter the race adopted the subunit approach to developing an HIV vaccine5. The associated 
lack of capabilities is noted in this section. 
 
8.2.1 Chiron 
 
A considerable degree of credibility for the subunit approach stemmed from Merck’s recent 
Hepatitis B vaccine, which was the first genetically engineered vaccine (Vagelos and 
Galambos 2004). 
 
                                                 
5
 This approach appealed more to venture capitalists and the novel techniques were also creating excitement 
in other projects (Thomas 2001). 
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Initially the Hepatitis B vaccine was based on a surface protein of the virus, recovered from 
the blood of Hepatitis B carriers. Manufacturing it in this way was not only laborious and 
expensive, because it involved extensive separation and purification, the process was also 
vulnerable to contamination from other viruses in the blood, such as HIV. 
 
Merck invested in several groups in order to find a better way (Vagelos and Galambos 
2006). One of those was an academic laboratory of the University of California run by 
William Rutter. He was the first to clone a human gene, the insulin gene (Cordell, Bell et 
al. 1979), but genetic engineering caused much concern in the general public. Rutter is 
quoted as saying “I became very concerned about developing a model that demonstrated 
the benefit over risk [of recombinant DNA technology], I thought vaccines would be a 
tremendous model” (Cohen 2001b:52). Rutter and his colleagues established a firm called 
Chiron in 1981 (Chiron 2006). By cloning Hepatitis B surface antigen, Chiron simplified its 
production. 
 
Chiron does not appear to have arrived at a vaccine approach by testing different strategies, 
comparing them and selecting the best one6. Rather, given Rutter’s agenda of promoting the 
uses of genetic engineering and Chiron’s experience with a subunit vaccine for Hepatitis B, 
it is likely that they sought to repeat the success for HIV, by cloning an HIV gene which 
codes for a surface glycoprotein7. 
 
Chiron quickly faced difficulties with this approach however. Whereas for Hepatitis B the 
epitope was already known, for HIV it was not certain which one would elicit the strongest 
immune response. Being a large glycoprotein on the HIV’s surface, it was guessed that 
gp120 would be the most immunogenic. 
 
Manufacturing gp120 in yeast raised problems (Pantophlet and Burton 2006). The protein 
yielded was not coated with carbohydrates; whereas it was in the wild (Wyatt and Sodroski 
1998). This difference between the wild type and vaccine contravened a basic principle of 
                                                 
6
 Searches of the ISI Web of Science in 2006, and the accounts of Cohen (2001b) and Thomas (2001), have 
not returned any evidence of Chiron attempting to pursue whole vaccine approaches to HIV. 
7
 A glycoprotein is a protein coated with small carbohydrate chains. 
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designing vaccines, which is to mimic the natural infection in order to elicit the strongest 
possible response from the immune system when it comes across the wild type virus8 
(Burton 1997). 
 
A further problem with using this epitope is that truncated surface proteins unwind. Loss of 
conformational integrity is extremely important because protein recognition processes are 
highly discriminatory and specific to shape and form (Huang, Barchi et al. 1997; Stryer 
1997). Antibodies would learn to recognise the unwound version, but remain less effective 
against the tightly coiled versions found on the wild type virus itself. 
 
Despite these problems, Chiron had set itself along a subunit trajectory as it sought to 
emulate its previous market successes. 
 
8.2.2 Genentech 
 
Genentech was also looking to emulate Merck/Chiron’s Hepatitis B vaccine by focussing 
genetic engineering techniques on envelope proteins of herpes simplex virus and HIV. 
Genentech was already a highly successful firm9, and entered the vaccine business mainly 
through the research interests of its scientists rather than from a ‘top down management 
strategy’ (Thomas 2001:44). 
 
In keeping with their popularity with the stock market10, Genentech’s strategy decisions 
were based firmly around profitability (Bass 1985; Stipp 2003). Genentech refrained from 
entering the vaccine market and emphasised therapeutic drugs because ‘pills taken daily 
will earn more than vaccines every few years’ (Thomas 2001:43). 
                                                 
8
 However, staying too close to a wild type means that that the immune system is being prepared for a very 
specific response, which may be a disadvantage against a virus that varies rapidly (see also section 6.2.1). 
9
 In 1972, biochemist Herbert Boyer of California University was working on restriction enzymes and 
geneticist Stanley Cohen of Stanford University was working on bacterial plasmids. Together they pioneered 
the recombinant DNA technology field (Cohen, Chang et al. 1973; Banting 2000). Boyer founded Genentech 
in 1976 with venture capitalist Robert Swanson (Genentech 2006). Within Genentech’s first year, the 
company engineered the first human protein, somatostatin. The following year it engineered the hormone 
somatostatin regulates, human growth hormone (Bass 1985). 
10
 Within an hour of Genentech’s initial public offering in 1980, the stock jumped from $35 per share to $89 
per share (Bass 1985). 
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Genentech’s initial attempts were therefore focused on an AIDS therapy based around 
competitive inhibition of the gp120 receptors (Berman and Lasky 1985). The idea was to 
block the gp120 from docking with the CD4 immune system cells by flooding it with 
dummy docking stations. The rationally-engineered ‘Soluble CD4’ gave good results in the 
test tube and Genentech hailed it as, ‘one of the most important steps we have ever been 
able to take’ (Thompson 1988). But the approach did not work in vivo conditions because 
the virus could ‘recognise’ the difference and could selectively dock with genuine receptor 
sites (Berman and Lasky 1985). In this case, animals had provided a crucial change of 
conditions. 
 
In the early 1980s it is likely that most of Genentech’s resources were focussed on bringing 
their next big project to fruition, engineering human insulin. When they succeeded in 
bringing it to market, it was the first recombinant DNA drug and was licensed to Eli Lilly 
(Genentech 2006). Similar to Rutter’s concerns about the public image of genetically 
engineered products, Genentech were concerned about their human growth hormone and 
insulin. Since they were used in young children, ‘they needed them to appear as safe as 
milk’ (Thomas 2001:34). 
 
As such, Genentech did not want genetic engineering being linked with pathogenic viruses 
and did not allow HIV virus into their premises. One Genentech scientist recalls, “There 
was never any virus here, it was always the [harmless] nucleic acid. It was like we were 
fighting the battle with HIV with one hand tied behind our back” (Thomas 2001:34). All 
HIV research needed to be conducted in an annex (Thomas 2001). As was the case in 
poliomyelitis research, this scarcity of testing resources could only have hampered research 
efforts. 
 
However, even with such top level discouragement from HIV vaccine research, some 
Genentech scientists pursued their own interests anyway and followed up with a vaccine 
similar to Chiron’s gp120 vaccine. However, unlike Chiron who developed gp120 from 
yeast cells, Genentech used animal (Chinese Hamster Ovary) cells. This use of different 
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instrumentality resulted in the gp120 being glycosylated more accurately. Genentech found 
early success with the virus being neutralised in test tube and in inoculated mice. Phil 
Berman, scientist at Genentech, said, “It worked great in small animals and in test tube 
experiments, and then we rushed to test it in chimpanzees” (Thomas 2001:39).  
 
The rushed experiment failed to protect against viral challenge. Despite a clear progression 
through intermediate conditions, learning in test tubes and mice, testing in the more 
realistic conditions of chimpanzees failed due to poor instrumentalities (instruments, skills 
and techniques). First, it is possible that the gp120 was not pure enough. Scaling up to 
chimpanzees meant that more gp120 was needed placing more demand on the purification 
process. Second, there was not enough time between doses according to Salk (Lasky, 
Groopman et al. 1986). HIV is quick to adapt and a partial immune system response is 
likely to have been evaded easily. Leaving more time between the doses might have given a 
stronger immune response. 
 
The rush to move to testing on more chimpanzees was probably influenced by two broader 
factors. Firstly, Gallo published a study at the time that seemed to show chimpanzees to be 
a realistic animal model, where the human pathogen caused signs and symptoms that mirror 
human disease11 (Alter, Eichberg et al. 1984). Despite the failure in chimpanzees, the 
results from preliminary tests in mice were enough to retain the attention of scientists 
working in a firm whose management focussed its interests elsewhere. 
 
Secondly, there was a lack of skills and capabilities in testing vaccines in chimpanzees. 
Reflecting on their failure to schedule the immunisations and challenges correctly, the 
Genentech scientists said, “There were not more than a handful of people around who 
really had serious vaccine experience… we were just young and foolish and in competition, 
rushing blindly ahead. That was the whole spirit of the early days of biotechnology” 
(Thomas 2001:42). 
                                                 
11
 But, as section 7.3 showed, problems would emerge with the model later on, which meant that the model 
was not as ready-made as Gallo’s study initially suggested. Results from the model need to be moderated 
because chimpanzees are more resilient to HIV infection and AIDS than humans (Koopman, Haaksma et al. 
1999). 
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This feeling would seem consistent with the views of other commentators who criticise a 
broader ignorance of vaccinology and a loss of crucial competences and tacit skills 
(Goldberg and Salk 1984; Gandy and Zumla 2003). ‘Expertise has been lost; the last 
generation of truly experienced ‘field hands’ are leaving the scene, lost to age and disuse. 
They are being replaced both in the West and in the research centers of the tropics by the 
‘molecular types,’ more concerned with the exquisite intellectual challenges of modish 
science than with seeking practical solutions. The razzle-dazzle and promise of 
biotechnology….’ (Desowitz 1991:16). The view that infectious disease had been defeated 
in principle was becoming prevalent in institutions of science and medicine, despite 
contrary warnings from many public health officials (Gandy and Zumla 2003). 
 
Berman and his colleagues realised that the experiment could have yielded better results, so 
they persisted and tried again. The second was devised without the knowledge of 
management and, with the help of Jonas Salk from the older generation, the gp120 
glycoprotein was purer and the immunisation schedules were less rushed. The vaccine was 
more successful as it managed to protect12 chimpanzees from infection (Lasky, Groopman 
et al. 1986). 
 
However, the vaccine received criticism on several issues. First, a less virulent HIV strain 
was used to challenge the inoculated chimpanzees. Second, the validity of the chimpanzee 
model was brought into question since they were found to be better than humans at fighting 
off HIV infection (Alter, Eichberg et al. 1984; Saxinger, Alter et al. 1987). These problems 
meant that the chimpanzee model was not as ready-made as Gallo’s study initially 
suggested. Instrumentalities were required in executing the tests, and interpreting the results 
required skill. Results needed to be moderated to take into account that chimpanzees are 
more resilient to HIV infection and AIDS than humans (Koopman, Haaksma et al. 1999). 
 
                                                 
12
 Although the vaccine was protective, it provided only transient protection (Lasky, Groopman et al. 1986). 
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Genentech felt that even with these problems, the candidate held promise either as a 
therapeutic (treatment) or prophylactic (preventative) vaccine, and set itself on a subunit 
trajectory. 
 
8.2.3 Other entrants and summary 
 
Companies such as Vical, Oncogen, MicroGeneSys, Repligen, Virogen were all small 
biotechnology companies who were trying to establish their ‘dynamic capabilities’ (Teece, 
Pisano et al. 1997) around new emerging platform technologies. They were looking to 
apply their new techniques to attractive markets such as cancer or diabetes, and were 
willing to hope for a little luck in HIV research along the way. None of the entrants had the 
exclusive aim or dedicated goal of developing an HIV vaccine and few had any experience 
in developing vaccines (see also Batson and Ainsworth 2001). 
 
In this setting, Salk’s views and ideas were not generally received well13. To Salk, the 
human body was infinitely complex and the goal of science was to understand only what 
was needed to be known to solve problems and improve life for humans (Carter 1965; 
Goldberg and Salk 1984; Cohen 2001b). His intellectual curiosity in HIV did not reach 
beyond developing a way to stop it; just as his interest for poliomyelitis was intensely 
focussed on practical, pragmatic, technological concerns. His approach was seen as crude 
and perhaps out-dated by the scientists adopting the subunit approach. Largely on the 
strength of his name, Salk quickly raised $20m to start a biotechnology company of his 
own, focussed entirely on developing an HIV vaccine14. On its initial public offering, 
Immune Response Corporation managed to generate $100m (Thomas 2001:54). It was a 
seemingly large amount, but the company still needed to operate in the same, expensive, 
testing regime that other companies and public actors were working in. 
                                                 
13
 However, they were received well by activists who wanted to see a sense of urgency in scientists’ 
endeavours. For example, one activist newsletter contended, ‘in the context of a raging epidemic… How 
much does one have to know about the scientific nature of combustion when the house’s burning down?’ 
(quoted in Epstein 1996:272). 
14
 Salk began with an idea to immunise seropositives (people who had already been HIV infected) on the 
suspicion that a vaccine might boost their immunity to the virus (Salk 1987). This effect had been shown for 
rabies infection by Pasteur over a century ago (Plotkin and Orenstein 2004). The company today has several 
whole-killed HIV preparations in Phase II trials intended to boost the immunity of those who are HIV infected 
patients (ImmuneResponseCorporation 2006). 
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8.3 Why did gp120 rise above the other approaches? 
 
One might expect all of the various approaches to have been developed somewhat evenly 
until formalised testing revealed that one approach was better than the other. But this does 
not seem to have been the case15. Chapter 7 discussed weaknesses in the testing regime in 
HIV vaccine development. Section 8.1 explained how these weaknesses dealt their heaviest 
blows to whole-virus approaches. Section 8.2 suggested that there was a lack of cumulative 
and shared knowledge growth between Chiron and Genentech. This meant that, in the 
absence of incremental improvements driven by regular comparative testing, other factors 
helped select the subunit approach, and along with it gp120 as its operational principle. 
This section discusses these factors. 
 
Previewing the next chapter, it is worth noting here that whilst weaknesses in the testing 
regime at early stages of the vaccine development cycle allowed gp120 to establish 
dominance, it was recognised as ineffective and dropped later in the vaccine development 
cycle, when it encountered a stronger testing regime. But by this stage, considerable time 
and resources had been wasted.  
 
The rise of the subunit approach is even more striking given that the only vaccine that had 
hitherto followed this approach was for hepatitis B16. All other vaccines have been made 
using whole approaches, as noted in section 8.1. One historical achievement was given 
preference over others on the basis that it was ‘newer’ technology. Other approaches were 
untestable due to safety concerns and were given little credence. ‘The rapid development of 
an AIDS vaccine seemed a realistic goal in light of the remarkable advances in molecular 
biology…The highly effective hepatitis B vaccine…seemed to be the natural model for a 
vaccine…Unfortunately extrapolation from the hepatitis B model proved to be 
                                                 
15
 See also Klein and Ho (2000:308), who note, ‘The possibility of using inactivated virus as the source of an 
HIV vaccine has been insufficiently investigated.’ 
16
 The subunit approach has been used to develop an effective influenza vaccine as well, but it is not as good 
as other influenza vaccines, and is only used in children who may be at more risk to adverse reactions. 
Hepatitis B is still widely regarded as being ‘the landmark example of a subunit vaccine’ (Klein and Ho 
2000:308). 
 181 
inappropriate because hepatitis B surface antigen is conserve’ (Hilleman 1995:1126). The 
previous chapter showed that HIV’s surface antigens were known to undergo extreme 
variation and such an approach was unlikely to work because the vaccine would be too 
different from the wild type pathogen. 
 
Nevertheless, the period of 1984-1995 was characterised by an almost exclusive focus on 
the subunit approach17. Extreme viral variability was the eventual downfall of the approach, 
but many researchers still held the notion that a non-variable region could be found, 
especially in the V3 loop, a neutralising domain of the virus. Targeting this loop was a form 
of ultra-reductionism, given that the V3 loop is only 35 amino acids long18 (Catasti, 
Fontenot et al. 1995). The belief in the subunit approach, and consequent focus on the V3 
loop, has implications for HIV even today because the V3 loop is the basis of the existing 
typology of HIV variants (discussed later). 
 
Although the early exclusive focus on the subunit approach is acknowledged, Klein and Ho 
(2000:308) are amongst those who try to justify it19, ‘Initial HIV vaccine design focused on 
the proteins expressed on the virus surface (V3 loop, gpl20, and gpl60). This was a logical 
first choice, because… targeting surface antigens was highly effective in producing the 
Hepatitis B vaccine.’ Hilleman (1998:787) says that ‘the zeal’ of the subunit approach 
overlooked strain diversity at its peril, and that the failure of the V3 approach was 
‘predictable’ given experiences with the diversity of influenza surface antigen. 
 
Viral diversity and the lack of natural sterilising immunity affected the various approaches 
differently. The lack of natural sterilising immunity undermined the safety of whole-virus 
vaccines. In contrast, the subunit approach was safer because it relied on small antigenic 
                                                 
17
 Hilleman (2000a:352) calls it ‘a near exclusive’ search for ‘antibody against the hypervariable surface 
antigens of the viral envelope.’ 
18
 The 1st and 35th amino acids are invariable cysteine residues forming a disulphide bridge between the two 
ends of the loop. The rest of the structure seems conservative relative to other parts of the virus, but is still so 
variable that up to 12 different amino acids may be found in any one position within the sequence (Klein and 
Ho 2000). 
19
 Many other researchers invoke the success of Hepatitis B vaccine (see for example Moore and Anderson 
1994). 
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parts of the virus, but it was most susceptible to ineffectiveness through viral diversity and 
hypervariablity. 
 
Whilst problems of safety and the lack of sterilising immunity were acknowledged by those 
pursuing whole-virus approaches (discussed later), problems of diversity were downplayed 
in several ways by advocates of the subunit approach. One was a belief that a conserved 
region would be eventually found but another was that subtype diversity was 
geographically specific so different vaccines could be made for different geographical 
regions. Both of these assumptions were unprecendented in vaccine development for other 
viruses. ‘Because phylogenetically diverse HIV subtypes are prevalent in different 
geographic locations, the use of HIV subtype-consensus sequences as vaccine immunogens 
have been proposed as a scientifically justifiable and feasible approach toward trying to 
diminish the problem that diversity poses against selecting relevant antigens for inclusion in 
candidate AIDS vaccines’ (Garber, Silvestri et al. 2004:405). 
 
In addition to global health equity implications20, this raised the prospect of needing to 
achieve the ‘impossible’ not once but several times. The answer to this - somewhat 
optimistically – was that the subunit technology might find a way of provoking an immune 
response strong enough to deal with the diversity problem. ‘This misguided choice of target 
antigen’ coupled with ‘the unfortunate intent to achieve a high level humoral antibody 
response’ meant that ‘the pursuit of the AIDS vaccine was one of initially serious flaws’21 
(Hilleman 2000a:352). 
 
Meanwhile, there were reasons to think whole-virus approaches might prepare the immune 
system for diversity better than subunit approaches. However, the development of such 
                                                 
20
 This had rather worrying implications for developing countries. The head of AIDS vaccine development at 
WHO, Joe Esparza, warned that developing countries would need products designed specifically for them, 
‘There’s a need here to encourage manufacturers to make strain specific vaccines’ (Cohen 1993a:981). 
Advocates such as IAVI further argued that whilst R&D incentives for an HIV vaccine were weak generally, 
they were woefully inadequate or non existent in poorer countries. 
21
 Hilleman (1998:786) goes so far as to call it a ‘spurious dedication to achieving humoral response against 
surface antigen.’ As explained in chapter 5, the humoral antibody response deals neutralises pathogens 
outside of cells, before cells might be infected. 
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approaches were stalled because the testing regime was particularly ill-equipped to deal 
with the safety issues raised by the lack of sterilising immunity (discussed later). 
 
8.4 Chasing the cellular response: second round approaches to the HIV vaccine 
 
Even with highly successful vaccines complete sterilising immunity is seldom achieved, 
and some cells become infected and must be removed. ‘Because some HIV variants might 
escape our best efforts at sterilising immunity, and a low level infection could occur, a cell-
mediated immune response that generates killer T cells that can eliminate the few infected 
cells should be part of the vaccine strategy’ (Gallo 2005:1897). ‘Although vaccines that 
stimulate the cellular arm of the immune response are not expected to provide protection 
against infection, they should allow vaccinees who get infected to control virus replication 
and reduce viral loads, thus resulting in lower probability of virus transmission to 
seronegative partners’ (Girard, Osmanov et al. 2006:4068). 
 
By the late 1990s, the rationale for a cellular response had become strong and widely 
recognised22. This section describes attempts to address the cellular response. The essence 
of the problem was to find a delivery vehicle that could enter into cells, carrying the kinds 
of materials that would trigger an immune response to kill infected cells. Rather than lead 
to more intense development of whole-virus approaches, as Hilleman had hoped23, this 
process led to even more sophisticated recombinant techniques; and amongst these, the 
subunit approach still reigned. 
 
                                                 
22
 This contrasts with aiming for a very strong humoural antibody response alone and hoping that no cells 
would be infected at all. ‘The period 1994-1995 gave belated recognition to the role of CD8+ T lymphocytes 
in destroying virus infected cells and in suppression of viral replication by cytokines’ (Hilleman 1998:787). 
23
 Hilleman wrote in 1995, ‘The tool of molecular genetics, which had been the central driving force in 
vaccine research in its decade, has now become subservient to the larger view of the biology of AIDS.’ 
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8.4.1 Vical and DNA Vaccines 
 
In 1987 Vical was established as a spin-off from University of California on the basis of a 
new idea at first derided24 but one which Vical now refers to as its ‘core technology’ (Vical 
2006b). It was initially developed to improve gene therapy (Felgner 1997), particularly for 
cancer, but there have been toxicity problems for the development of any oral drug 
possibilities (Filion and Phillips 1998). 
 
The aim was to package specific bits of DNA, using a positively charged fat vesicle as 
carrier, so that it would be drawn towards negatively charged membranes, and thereby into 
cells (Duzgunes and Felgner 1993). However, it was realised that DNA was being drawn 
into cells without the need for such packaging. 
 
Once inside the cell, the DNA could be expressed as protein and transported back to the 
cell surface. Although the amounts of expressed protein were not enough to treat diabetes 
or cystic fibrosis, it was thought possibly enough to stimulate a cellular immune response 
(Cohen 1993b; McDonnell and Askari 1996; Weiner and Kennedy 1997). 
 
When it was confirmed that DNA, on its own, could be drawn into cells and stimulate a 
response (Vical 2006a), Vical believed they were on the cusp of developing a new vaccine 
delivery method and quickly filed for a patent25 (Wolff, Malone et al. 1990; Tang, DeVit et 
al. 1992). However, Vical encountered problems when they needed further finance to 
develop the operational principle. ‘Any company that we went to had to be interested in 
developing vaccines, and there weren’t that many’ (Thomas 2001:63). 
 
                                                 
24
 “We were considered out on the fringes of science,” and “People would laugh at us, or abuse us publicy for 
our presentations.” (DNA vaccine researchers, quoted in Thomas 2001:74). 
25
 Vical’s scientist said, “As soon as we got the naked DNA results, we knew that this was quite different 
from a business and from a patent perspective. Nobody was doing anything with naked DNA, so we had a 
blocking position that was very broad. And when you start a biotechnology company, that’s what you’re 
looking for” (Thomas 2001:56). Such defensive patenting strategies have been noted and discussed (Freeman 
1982). For this analysis however, it serves to show that biotechnology companies were more concerned with 
their own survival through the establishment of platform technologies, than with HIV vaccine innovation. 
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They approached Merck whose vaccine division was headed by the well established 
vaccinologist Maurice Hilleman26 (Galambos and Sewell 1995:238). With Merck’s 
funding, Vical began developing the new vaccine approach. Vical scientists immunised 
mice with influenza genes, looked for immune responses and then challenged them with 
influenza virus. The reason they used influenza genes and virus was because mice resist 
infection with HIV. As Thomas (2001:58) puts it, ‘nature has made mice safe from AIDS.’ 
 
The experiment was successful, in protecting mice against influenza virus better than 
control mice, but convincing Merck to continue support was difficult (Ulmer, Donnelly et 
al. 1993). ‘One reason it took so long was that [Vical and Merck] were on different coasts. 
It’s much easier to show somebody how to do it than to describe how to do it27’ (Thomas 
2001:69). Even after achieving successful replication of the mice experiments, there was 
still not much to suggest that the approach would work with influenza in humans, let alone 
with HIV in humans. The fact that there were no tests using primates or HIV meant that the 
effectiveness of the approach could not be compared to the dominant subunit approach, 
which at the time was being tested in macaques by Chiron and in chimpanzees by 
Genentech, itself another issue of comparability. 
 
Chapter 7 took a different position to Thomas in arguing that animal models need not be 
seen as unchangeable ‘nature has made’ models, but as man-made technologies that can be 
deliberately developed and refined. Even without resorting to the use of chimpanzees or 
monkeys, efforts to develop a mouse model that was more suitable (for example by making 
it HIV-infectable) might have made judging the potential of this approach as compared to 
the subunit approach easier. 
 
Instead, Vical faced intra-firm competition for resources as a new drug, a protease inhibitor, 
was being developed at Merck. There was a large incentive for a new drug because of 
increasingly apparent shortcomings of AZT, the reverse transcriptase inhibitor (Epstein 
                                                 
26
 Hilleman’s enthusiasm for eliciting both cellular and humoral immune responses was critical in Vical 
striking a deal with Merck. “If he had been against it, we definitely would not have gone ahead, that’s for 
sure. But he was really keen on it, and that’s what it took at Merck Vaccine at the time” (Thomas 2001:68). 
27
 The experimental procedure clearly contained tacit knowledge that was difficult to codify (Senker 1995). 
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1996:241), including severe side effects and that it did not work in a growing number of 
people. Merck’s new drug was going through clinical trials, the most expensive phases of 
drug development, (Young, Anderson et al. 1990; Wlodawer and Vondrasek 1998), and 
most likely used much of its AIDS budget with little left over to develop Vical’s approach. 
 
8.4.2 Viral Vaccine vectors 
 
Vaccination with vaccinia28 virus was directly responsible for smallpox eradication 
(Levine, Kaper et al. 2004). Its potential use as a carrier for delivering foreign genes was 
explored in 1979 by Paoletti and Panicali in a New York state laboratory29. The idea was to 
insert cloned HIV genes into the viral vector as a delivery mechanism to cells in order to 
elicit an immune response. 
 
The approach held theoretical and practical advantages (Panicali and Paoletti 1982). The 
theoretical advantage was the greater likelihood of prompting a cellular response30. The 
practical advantage was that engineered vaccinia injected into the body could make the 
HIV protein inside human cells, rather than in yeast or hamster cells. So there was no need 
for separation or purification in the production process. Furthermore, the protein would be 
glycosylated in its native configuration, helping to provide a more effective immune 
response. 
 
Paoletti and Panicali did not, however, have access to HIV – it was a scarce testing 
resource, a weakness of the testing regime identified earlier (6.6.1). As with Vical, 
researchers had to progress with the development of the new approach on non-HIV 
pathogens. These viruses, more feared by the public at the time, were herpes (Panicali and 
                                                 
28
 Vaccinia can be thought of as the Escherichia coli of viruses. It has been the workhorse of virology and has 
been much manipulated and studied (Stryer 1997; Plotkin and Orenstein 2004). 
29
 The application of this new technique had been delayed because the regulatory framework governing 
genetic engineering was so poorly formed. Boyer-Cohen’s experiments were only six years old at the time, 
and fears about the technology were precautionary (Thomas 2001:83). 
30
 because proteins would be made inside cells and exported to cell surface. 
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Paoletti 1982), influenza (Panicali, Davis et al. 1983), and hepatitis B (Paoletti, Lipinskas et 
al. 1984)31. 
 
The New York Health Commisioner, David Axelrod, hailed the new approach a result of 
the state’s long term investment in basic biomedical research. Axelrod helped set up a spin 
off, called Virogenetics, to claim patents and exploit the technology further. However, with 
only incomparable results on viruses other than HIV, the firm struggled to find finance. 
 
Paoletti and Panicali sought to set up a collaborative agreement in which they could find 
finance and could access cloned HIV genes to splice into vaccinia. They tried to source 
some from Montagnier, the French discoverer of HIV at the Pasteur Institute, but he 
declined to share his clones for the new vaccine idea32. Paoletti said, ‘It wasn’t that they 
didn’t want to deal with Americans, it was that they wanted the vaccine to be a French 
effort’ (Thomas 2001:88). In terms of virus and finance, the firm remained undercapitalised 
for several years. This, coupled with regulatory system delays, meant that progress was 
slow and allowed others to become involved in the development of the technology. 
 
One of those who was quick to appreciate the potential of vaccinia was Lok Hu. Hu had 
just been recruited by Oncogen, a subsidiary of Genetic Systems Corporation, and his remit 
was to develop novel diagnostics and treatments for cancer. However, he did not have a 
project ready to get involved with, so he worked with what was at hand. By chance, the 
Pasteur Institute had sent Genetic Systems their gp160 clones to develop and market its 
version of the HIV blood test. ‘These were the very HIV genes that Paoletti had tried and 
failed to obtain from Montagnier’ (Thomas 2001:89). Hu inserted the gp160 into vaccinia 
constructing an impromptu HIV vaccine candidate. Oncogen’s entry into the HIV vaccine 
                                                 
31
 Infact the possibility for delivering genes from multiple pathogens in one vaccine, making vaccinia a 
polyvalent vector, made the technique very popular and excited public health officials (Perkus, Piccini et al. 
1985). 
32
 Although Paoletti does not mention it, it is possible that the French American dispute between Gallo and 
Montagnier over the ownership of credit for HIV discovery and patent rights had a bearing on Montagnier’s 
decision to decline. 
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sector was thereby circumstantial and could be described, at best, as researcher motivated33 
rather than part of a corporate strategy, or indeed any form of R&D governance. 
 
Similar to the Vical-Merck case above, Oncogen’s vaccine approach faced intra-
organisational barriers as Genetic Systems allowed Lok-Hu to follow his interests initially, 
when resource requirements were minimal, but were mainly interested in targeting the 
cancer market. The success of Genetic Systems in the cancer drugs market however 
attracted the pharmaceutical firm, Bristol Myers Squibb, to purchase the company, along 
with its subsidiary, Oncogen. Hu made it clear that Bristol was not keen on his project in 
later interviews with journalists (Cohen 2001b:55; Thomas 2001:90), but the 
pharmaceutical company did let the project continue alongside his principal work on cancer 
vaccines34, 35. 
 
To develop the vaccinia approach further though, the developers would need to resolve 
testing problem related to its past use. The successful smallpox eradication programme had 
already introduced vaccinia to much of the world, and it was possible that people who are 
smallpox immunised might still mount an antibody response to it. Thus, the materials 
relevant to stimulating an HIV immune response (the vaccine) might be stifled by an 
antibody response to vaccinia (the carrier). 
 
So the test needed to be designed so that it included people who were smallpox immunised 
and those who were not (Corey, Collier et al. 1989). They also needed to give the smallpox 
vaccine to half the volunteers and the trial vaccine to half so that they could distinguish 
how much of the immune response was to vaccinia (the carrier) and how much was to the 
gp160 (the vaccine) (Corey, Collier et al. 1989). 
                                                 
33
 See also Augdorfer’s (1996; 2005) analyses of bootlegging in R&D. 
34
 “Bristol has all along taken a semi-interested [position], tolerated more than anything else. We’re just a 
bunch of guys fooling around. We clearly generate publicity based on our work, but does Bristol need that? I 
doubt it. Number two, it might not want it. But really, it comes down to a bottom line with vaccine: because 
of the liability and because of the business of vaccines in general, big companies like Bristol, for that matter 
most of the companies shy away from it” (Hu, quoted in Cohen 2001b:55). 
35
 Hu published his findings extensively, and perhaps made it harder for Bristol to terminate the project. His 
initial monkey experiments showed T-cell responses that were strong enough to support a clinical study 
(Chakrabarti, Robert-Guroff et al. 1986; Hu, Kosowski et al. 1986; Zarling, Morton et al. 1986; Hu, Fultz et 
al. 1987). 
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The results were encouraging enough to be reported in the Lancet favourably, but it was not 
the blockbuster the researchers hoped for (Cooney, Collier et al. 1991). The vaccine 
managed to stimulate a transient cellular immune response but no antibody response at all 
in vaccinia-primed subjects. A significantly stronger cellular immune response was 
observed in vaccinia-naïve subjects but again, no antibody response was detectable and the 
cellular immune response was transient. However, when followed with gp160 subunit 
vaccine in a prime-boost immunisation schedule, antibodies were stimulated. 
 
The vaccine was concluded to be of value only to a vaccinia-naïve population (Cooney, 
Collier et al. 1991). Considering that the smallpox eradication programme had so 
successfully managed to immunise a large number of people, this fact served to shrink an 
already small potential market for investors. Furthermore, there was concern that the 
vaccinia vector may become virulent and re-introduce smallpox, despite there being little 
evidence from the vaccine trials to support this possibility. 
 
It would seem then that unfavourable issues can emerge even from a programme widely 
acknowledged to be a success, like the smallpox eradication programme. Indeed it is 
precisely the success of the programme that made, firstly, so many people vaccinia primed 
and, secondly, the risk of reverting to virulence loom so large for potential investors. At this 
point Bristol withdrew its support for the project36. 
 
Other viral vectors were searched for, with special consideration given to the viruses that 
were unable to replicate in humans to allay fears of any vector virulence. In 1986, Axelrod 
and Paoletti managed to persuade Charles Merieux of the Pasteur Merieux Institute to 
invest in the undercapitalised Virogentics37. With the new money Paoletti and his team 
                                                 
36
 However, as the years after smallpox eradication passed, the proportion of the population who would be 
vaccinia naïve would also be increasing, making this approach one that would not be forgotten. Swedish 
researchers have recently run a vaccinia based prime-boost HIV vaccine through Phase I with strong results 
(MedicalNewsToday 2006). 
37
 The Pasteur Merieux Institute bought out 51% of Virogenetics (Cohen 2001b:237). In 1989, Pasteur 
Merieux increased its share to 85%. 
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explored other vectors such as fowlpox, and canarypox38, 39 (Cox, Tartaglia et al. 1993; 
Paoletti 1996). 
 
In 1989, Pasteur Meriuex acquired Connaught Laboratories to become the world’s largest 
vaccine company37. This resulted in Pasteur Merieux’s HIV vaccine project portfolio 
increasing from one to four. The increase in resource competition, coupled with Axelrod’s 
death in 1989, deteriorated relations between Pasteur Meriuex and Virogenetics. 
 
Pasteur Meriuex Connaught’s director, Stanley Plotkin, believed that the viral vaccine 
vector technology could only work in a prime-boost approach where, following canarypox 
immunisation, a gp120 boost would also be administered (Salmon, Excler et al. 1994). 
Pasteur Meriuex Connaught’s strategic priority, to the frustration of Virogenetics40, was to 
keep options open and wait for NIH to fund clinical trials into one of the approaches rather 
than to invest in comparing and selecting any single approach. 
 
                                                 
38
 Fowlpox was safer than vaccinia because it could not replicate in humans, and could be more lucrative in 
the veterinary sector. Similarly canarypox was also safer and expressed more antigen. 
39
 The US Army, in the interest of protecting troops, provided New York State university with a grant to study 
the Venezuelan Equine Encephalitis (VEE) virus as an alternative vector to vaccinia (Thomas 2001). VEE 
might have been appropriate for two reasons (Johnston, Johnson et al. 2005). Firstly, the virus stimulates an 
immune response in mucosal surfaces. Secondly, it has a high affinity for lymph nodes, which correlates with 
a response from both arms of the immune system. For safety concerns, they made the vector unable to 
replicate (Grieder and Nguyen 1996; Caley, Betts et al. 1999). This resulted in a lower antibody response than 
that of the replicating version. Furthermore, the word encephalitis in the vector was thought to have 
exacerbated concerns about the vaccine’s public image (Caley, Betts et al. 1999:108; Thomas 2001). So the 
project was denied further money and the researchers following this approach found no other sponsors 
(Thomas 2001). 
40
 There were arguments about the viability of the prime boost approach because Paoletti wanted to test 
canarypox without the subsequent boost because he felt it was not necessary. Plotkin was convinced that both 
humoral and cellular responses would be needed in a successful HIV vaccine. There were also arguments 
about evaluating the results of experiments and arguments about manufacturing (Thomas 2001). 
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8.4.3 Summary 
 
The private sector efforts to develop an HIV vaccine were lacklustre and narrowly focussed 
on biotechnological processes. ‘An aggressive effort would test and adapt many AIDS 
candidate vaccines in parallel. However, few companies were pursuing multiple options 
and a number of approaches appeared to be shelved before their potential value had been 
determined’ (Batson and Ainsworth 2001:724). 
 
To explain the investment decisions, one needs to examine, as this thesis does, the technical 
problems faced by the companies and their previous experiences. Market pull explanations 
are particularly weak in such situations because if these problems are perceived by the 
companies, correctly or incorrectly, to be intractable, the size of the reward becomes 
irrelevant. 
 
Similarly, if the perceived time to commercial revenue is long and far away, any rewards 
that may accrue is substantially discounted, thus relegating market characteristics and 
policies when considering investment. Accordingly, even by 1998, ‘fewer than 200 
scientists in the private sector were dedicated to work related to HIV vaccines, and some of 
them were probably supported by grants from the public sector. The private funds dedicated 
annually to R&D on AIDS vaccines were estimated to be between $50m and $124m’ 
(Batson and Ainsworth 2001:722). 
 
Although the more standard approaches to developing a vaccine had been claimed by 
Chiron and Genentech, small biotechnology companies continued to come up with new 
approaches. Two key technologies were naked DNA vaccines and viral vector vaccines, but 
the companies involved were severely constrained by the scarcity of testing resources, in 
terms of access to plentiful virus and animals as well as money. The lack of organised 
comparability between preliminary experiments most likely hampered the ability to sell 
their approaches to investors despite the stock market’s fondness for biotechnology 
companies at the time. In addition, the vaccinia-based approach faced some unusual 
challenges of previous vaccinia use. It was also a time of biotechnology company take-
overs by large pharmaceutical houses and with this, companies such as Vical, Oncogen and 
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Virogenetics had their aspirations for developing the new vaccine approaches quashed by 
the larger firms who were much clearer and more explicit about avoiding high-risk, low-
return projects such as HIV vaccine research. 
 
Despite belated recognition of the need for a cellular response, and the potential of these 
refinements to the subunit approach to provide a cellular response, the original gp120 
subunit approach was still the one that reached clinical efficacy trials. This is discussed 
further in the next chapter. With little comparability between the approaches, and few 
instruments to learn safely, gp120 vaccines remained in the milieu. The next section shows 
how the other approaches would effectively drop out of the running. 
 
8.5 The subunit approach becomes the last approach standing: selection by testing? 
 
The dominant approach was centred on the hope that genetically engineered pieces of the 
HIV virus would be enough to trigger an immune response, perhaps with the help of a 
vector. As discussed, live-attenuated and whole-killed vaccine approaches were not 
commonly considered as feasible options. However, in the early 1990’s, two research 
groups were developing vaccines that caused a rethink: James Stott’s whole-killed vaccine 
and Desrosier’s live-attenuated vaccine. 
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8.5.1 The whole-killed approach is killed off 
 
The UK Medical Research Council co-ordinated a programme between two primate 
research groups run by James Stott and Martin Cranage41 (Stott, Chan et al. 1990; Cranage, 
Stott et al. 1994). They were developing a whole-killed SIV vaccine with monkeys and 
found considerable success as their vaccine prevented infection from an intravenous 
challenge with SIV (Stott, Chan et al. 1990). They then pushed the vaccine further by 
testing in more rigorous conditions. It withstood more realistic situations as rectal challenge 
and mismatched strains42. Even without the confidence that comparative testing brings, 
most considered this vaccine to have provided much better results than subunit vaccines 
(Cohen 1992a). 
 
Stott’s vaccine was developed by growing SIV in human cells and then killing the whole 
mixture. Compared to separating the virus out from the cells they were grown in, then 
purifying the virus, and then killing the pure batch of virus, this was a much cruder one-step 
approach (Stott 1991). The resulting vaccine was essentially human cells with killed SIV. It 
was unlikely to be deemed clean enough to consider for human use, but the protection it 
achieved in monkeys was exceptionally good43. 
 
Then the group gave control monkeys human cells alone, with no SIV in them. The results 
astonished them so much that they wrote to Science noting, ‘We are performing definitive 
experiments to confirm these observations…In the meantime, we wish to publish our 
unexpected findings quickly so that others working with SIV in macaques or HIV in 
chimpanzees can evaluate their results in the light of this information’ (Stott 1991:393). 
                                                 
41
 Hollingsworth’s (1986) study of medicine in Britain and America notes differences in the styles of medical 
research between the two countries. Over the course of the twentieth century British research has been 
smaller, more centralised, more co-ordinated, and less competitive. Since the National Health Service came 
into existence research has also been more tightly linked with clinical practice (Hollingsworth 1986:222; see 
also Hopkins 2004). James Stott was based at the National Institute for Biological Standards and Control in 
Hertfordshire and Martin Cranage, at the Centre for Applied Microbiology and Research in Salisbury. 
42
 Rectal challenge is innoculation of HIV through the rectum after vaccination (see also Sabin 1992). The 
term mismatched strains refers to conditions where the strain used in the vaccine is different to the strain used 
to challenge. 
43
 Stott’s previous publications indicate a background in developing veterinary vaccines where such an 
approach would be more acceptable (Brown, Newman et al. 1974; Nyack, Willard et al. 1981; Osburn, 
McGowan et al. 1981; Osburn, Stott et al. 1982; Stott, Scibienski et al. 1987; Angel, Stott et al. 1991). 
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What they found was that two doses of the vaccine protected three of four monkeys against 
subsequent SIV challenge. But crucially, two of four control monkeys did not become 
infected either (Stott 1991). The key principle that allows us to understand this result is that 
immune systems, whether they are of humans or monkeys, develop the strongest reactions 
to the things that are most foreign to them. This meant that the monkeys developed a strong 
antibody response to human cells, and since this was given to both test and control 
monkeys, both groups were primed in this way. So when control monkeys were 
subsequently challenged with human cells containing SIV, they were partly protected, 
albeit not as strongly as vaccinated monkeys. 
 
Stott repeated the experiment with purified virus (virus with no human cells), but still got 
the same finding. This was because the virus was grown in human cells and it incorporated 
human cell proteins into its own structure44. 
 
The New Scientist’s report on these results did not shy away from declaring the 
implications (Brown 1991; Maddox 1991). The control monkeys’ antibodies explained 
away the protection seen in all vaccines where the virus had been grown in human cells. 
And since all primate researchers grew SIV this way, it brought into question all SIV 
vaccines. They were all contaminated. Its opening sentence, ‘The search for an AIDS 
vaccine was thrown into disarray with the disclosure of stunning findings..’ (Brown 
1991:14) and the article’s accompanying cartoon reflected a mood of disorganisation 
(figure 7). 
 
                                                 
44
 The protein shells (capsids) of SIV and HIV contain pieces of the host cells which they infect. As these 
viruses infect a cell, they abandon their capsid and inject their genetic material. The genetic material then 
integrates with the human cell’s chromosome and codes for new viral proteins to be synthesised. These 
proteins assemble into a new virus which buds from the cell surface. During exocytosis, the virus incorporates 
some of the cell’s proteins into its capsid. The virus therefore has both viral proteins and cellular proteins in 
its capsid regardless of whether it is purified afterwards or not. 
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Figure 7: SIV shock 
 
Source: taken from Brown (1991). 
 
Jonathan Weber45, said he was ‘gobsmacked’ by the findings but, in response to criticisms 
about the MRC’s overemphasis on the study of monkeys, defended the MRC, ‘These 
findings prove there is a point to animal models. Although this hiccup is extremely 
important it is better that it happened in animals than in man’ (Brown 1991:14). After 
testing in animals, Weber was perhaps hoping for incremental improvements and 
redirection of the approach rather than a response of abandonment. 
 
Other scientists were angry that the vital control experiments had not been done earlier but 
Stott countered that everyone tries to minimise the number of monkeys they use, ‘It’s 
terribly easy to say that afterwards, it would have been such a bizarre experiment to 
suggest. You have to try and save animals’ (Brown 1991:14). Similar to Weber’s hope for 
refinement, Stott cautioned, ‘Some people will view this negatively; I think it is also 
opening things up. The new finding could turn out to be very important…’ (Brown 
1991:14). Stott’s and Weber’s comments illustrate the importance of having firstly, access 
to cheap testing, and secondly well developed animal models. These issues were flagged in 
the theoretical framework of chapter 3, also emerged in the account of poliomyelitis 
vaccine development provided in chapter 6. 
                                                 
45
 Jonathan Weber is a Professor of communicable diseases at St Mary’s Hospital in London and directed 
Britain’s only human trial of a potential AIDS vaccine (Brown 1991). 
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Subunit researchers, such as Bolognesi’s group, promptly capitalised on Stott’s findings 
(Langlois, Weinhold et al. 1992). They analysed antibodies in blood from 200 monkeys 
used in vaccine experiments and showed high levels of human cell antibodies in those that 
had received whole-killed vaccines. After acknowledging that ‘whole-killed SIV 
preparations induce the strongest and most consistent protection thus far experienced in 
experimental animal studies,’ the paper concluded that more research was necessary into 
understanding how protection induced by inactivated SIV preparations was achieved 
(Langlois, Weinhold et al. 1992:293). 
 
An alternative reaction to Stott’s results would have been to harvest SIV in monkey cells 
and use the resultant virus both to make whole-killed vaccines and challenge stock (Cohen 
2001b). This monkey-monkey approach to vaccinating and challenging would represent 
technological conditions more accurately. This is because if a whole-killed vaccine was to 
be used in humans, it would be made by growing HIV in human cells whilst the wild type 
virus that exists out there to ‘challenge’ the immune system would also be grown in human 
cells. 
 
In order to pursue this approach, however, there was an instrumentality problem that 
needed to be resolved. Techniques for growing virus rely on immortalised cell lines. These 
cell lines carry mutations that make them more like cancer cells than normal cells in that 
they live longer and copy faster (see section 5.4.2). These characteristics are required for 
growing SIV because the cells need to replicate faster than the SIV can kill them. Many 
such cell lines exist based on human cells, but none existed for monkeys. This is the reason 
why all the vaccines featuring SIV had been grown in human cells. 
 
Stott and Cranage did subsequently manage to grow some SIV in monkey cells, but only to 
use it to challenge monkeys vaccinated with human grown SIV (Cranage, Polyanskaya et 
al. 1993; Stahlhennig, Voss et al. 1993). It served only to emphasise their results more 
severely as they did not take the opportunity to vaccinate with monkey-grown virus. It is 
possible they did not have enough monkey-grown SIV to do both vaccination and challenge 
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because growing SIV in monkey cells is a difficult task without an immortalised monkey 
cell line. 
 
These experiments, and also those of Le Grand, Vogt et al. (1992), confirmed the idea that 
earlier attempts were successful largely because of antibodies to the human cells. But the 
experiments effectively obscured the need for the monkey-monkey challenge and 
contributed to a sense that the whole-killed approach was no longer worth pursuing. My 
searches from 1984-2007 have not returned any records of a full scale monkey-monkey 
SIV vaccine experiment (see also Cohen 2001b). 
 
Another scientist, Murphey-Corb, recounted her attempt to conduct a monkey-monkey 
experiment without the aid of an immortalised cell line (Cohen 2001b:126). After nearly a 
year of hoarding the spleens of SIV infected monkeys that died from AIDS, she had enough 
to make a vaccine. “I spent a considerable fortune and time trying to make virus.” But it 
was too impure and the resultant vaccine “was really crap” to even stimulate an immune 
response. Murphy-Corb soon gave up and changed research focus46. 
 
The way in which the Stott paper was handled suggests that a stronger testing regime was 
needed. More liberal use of monkeys might have allowed the vital control experiment to be 
conducted earlier. Instrumental research issues such as the development of a monkey cell 
line for the purposes of harvesting SIV might have been made an explicit priority, in order 
to make comparisons and draw out implications for human vaccines. These are specifiable 
goals and are therefore amenable to strategic contracting. Since monkeys have been farmed 
before and many cell lines have been developed before, they are likely to be feasible too. 
The failure to overcome such hurdles suggests that the testing regime is inadequate, making 
                                                 
46
 Murphy-Corb says “I didn’t want to be sacrificed. Everyone took Stott’s work and said, ‘OK, this vaccine is 
not doable.’ You have to respect their opinion. I abandoned my whole-killed vaccine work. Tons of stuff 
never got published. I literally wiped off three years of my life…I’ve always had a personal sense that I 
should have hung on longer” (Cohen 2001b:126). 
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it harder to evaluate progress regularly through a reliable, comparative and iterative process 
of testing various operational trajectories47. 
 
8.5.2 The social framing of contaminants and populations 
 
One group of researchers, led by Arthur, raised the possibility of a new vaccine approach. 
They found the surfaces of HIV and SIV had more cellular proteins than viral proteins, 
explaining why cellular proteins had played such a significant role in Stott’s results (Arthur, 
Bess et al. 1992)48. But rather than considering them contaminants, cellular proteins could 
serve as a critical part of the operational principle, because HIV will contain human 
proteins that may stimulate an immune response in other humans49. 
 
Re-framing the contaminants, Arthur vaccinated two monkeys with only human cellular 
proteins and then challenged them with SIV grown in human cells (Arthur, Bess et al. 
1992; Arthur, Bess et al. 1995). They found that monkeys did not show signs of infection. 
This implied that a human vaccine could be made using cellular proteins rather than just 
viral protein gp120. 
 
However, the monkeys’ immune systems were more likely to have been responding 
because the proteins were from a different species (humans). Thus, to explore the potential 
of this approach further, a testing regime with humans was required. Otherwise, the species 
difference is likely to be the cause of the immune response more than anything else. The 
scope for intermediate conditions is very small in this operational trajectory. Another 
                                                 
47
 Stott and Cranage continued to pursue the whole-killed SIV vaccine (Almond, Kent et al. 1995) but the 
approach was dogged by criticism about its safety and unworthiness as a human trial candidate (Baba, Liska 
et al. 1995; Ruprecht, Baba et al. 1995). 
48
 The number of gp120 molecules on the surface of each virus had already been estimated at 216 (Racz, 
Dijkistra et al. 1991 cited in Arthur, Bess et al. 1992). These proteins were viral because they were produced 
along with the rest of the virus inside the cell. Arthur’s paper, however, asked how much cellular protein was 
incorporated into the surface of the virus during or after exocytosis. After purification and separation they 
found ‘that there are between 375 and 600 molecules of β2m and HLA DR (α and β chains) per virion’ 
(Arthur, Bess et al. 1992:1936). 
49
 Arthur’s conclusion indicated that this result could be taken as the basis for the design of a new operational 
principle. ‘cellular proteins [are] an integral functioning part of the viral envelope… which should be 
considered in the elucidation of steps involved in infection, design of vaccines, preparation of experimental 
virus-challenge stocks’ (1992:1938). 
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alternative might have been to use proteins from a different monkey, but as already noted, 
instrumentalities for growing SIV in monkey cells had not been developed. 
 
There was also a theoretical problem with this approach that involved how vaccine 
designers frame the broader needs of populations to be vaccinated. Organ transplants can be 
problematic because people’s immune systems reject the transplanted tissue as foreign. 
Injecting people with this kind of vaccine would severely limit their options if they needed 
a transplant because their immune systems would be primed to attack any new substance or 
proteins from other humans. However, Shearer et al. (1993) pointed out that ‘in some parts 
of the world, effective immunisation against HIV infection might take precedence over the 
unlikely prospect of a future organ transplant.’ 
 
Shearer et al. cited a study amongst prostitutes in Kenya who were exposed but uninfected 
by HIV (Fowke, Nagelkerke et al. 1996; Rowland-Jones, Dong et al. 1998). The extremely 
rare protein on their blood cells, Shearer et al. posited, allowed them to elicit a stronger 
than normal immune response when confronted with the cellular proteins on the virus of an 
average person. They implied that it was a target model on which they could base vaccine 
design. 
 
So there existed not only animal, but human data suggesting that this idea is at least 
promising. But the approach succumbed to testing constraints. The idea was not integrated 
into a co-ordinated research programme and attempts to explore further the potential of the 
approach by strengthening the testing regime were not undertaken. For example by 
reframing safety risks (Institutions), or developing monkey grown SIV (Instrumentalities). 
Of course, it is possible that, even then, the idea would not have been successful. The point 
here is that it failed because it could not be tested and developed. 
 
8.5.3 The live approach struggles to stay alive 
 
One of the key protagonists for the live attenuated approach was Desrosiers. His group 
reported remarkable work on a weakened version of the complete virus in a landmark paper 
(Daniel, Kirchhoff et al. 1992). It arrived at crucial juncture, when researchers were reeling 
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from the Stott results, and when it was becoming clear that sleek recombinant methods 
were not yielding vaccines readily. This approach had always been criticised as being too 
dangerous, but in this article Desrosiers reported immunity which was the longest lasting, 
strongest protection in any HIV vaccine experiment so far. 
 
Desrosiers was unimpressed by the whole-killed approach but he was even less so by the 
recombinant approach, ‘The whole, inactivated virus vaccine approach has been largely 
unsuccessful against SIV grown in rhesus monkey lymphocytes’. This suggests that 
Desrosiers believed that the excitement for the approach was unjustified given that a 
monkey-monkey approach has not yielded protection (Daniel, Kirchhoff et al. 1992:1938). 
He goes on to say, ‘Priming with vaccinia recombinants followed by boosting has protected 
rhesus monkeys against challenge by homologous cloned SIV, but little or no protection 
has been observed against homologous uncloned SIV. Tests of several products have 
shown only limited success in chimpanzee trials. What is most disappointing about these 
studies is that the numerous failures have occurred despite extensive efforts to maximise, in 
an unrealistic fashion, the likelihood of vaccine protection. The vast majority of studies 
have used a minimal dose of challenge virus, matched to the strain used for vaccination, at 
or near the peak of vaccine-induced immune response’ (Daniel, Kirchhoff et al. 
1992:1938). 
 
Desrosiers’ reference to lenient testing conditions highlights that early stage vaccine 
development involves the creation of highly artificial conditions50, created by a range of 
instrumentalities, so that inferences can be made for learning. But by the same token such 
conditions make it highly difficult to predict whether the vaccine will be effective as a 
technology in the real world. Thus, Desrosiers argues not only that his results show 
protective effects stronger than those achieved with other approaches, but also that the 
conditions he achieved them in represent closer to real world conditions than tests in other 
approaches. 
 
                                                 
50
 Conditions range from weak challenge virus, low challenge dose, homologous strains and relaxed challenge 
timings etc. (See table 2 at the end of this chapter). 
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Desrosiers did not abandon recombinant techniques altogether though. He used the 
technique to remove a gene from a highly virulent SIV strain51. The excised gene was nef, 
and although its function was not well understood, they knew it was not required to 
replicate so it would not affect the vaccine’s durability. He injected this constructed SIV 
into six monkeys and gave the control group of twelve monkeys an intact version of SIV. 
2.25 years later, all of the control group were ill or dead, but all of the nef-deleted group 
were healthy with normal CD4 counts and low virus counts. 
 
The monkeys were then challenged, along with four new controls, with complete versions 
of SIV. Note that ‘no booster immunisations of any type were used.’ By 36 weeks, the 
controls were dead (or killed when moribund) and the inoculated group were all healthy. 
Polymerase Chain Reaction analyses found no virus indicating that they resisted infection 
effectively. Even with a hundred times higher challenge dose, the monkeys did not show 
signs of infection. 
 
The findings amazed other researchers. ‘This is a significant advance’ said Fauci, director 
of NIAID, and Schultz, chief of NIAID’s vaccine branch added that ‘this is three orders of 
magnitude better than any protection we’ve seen.’ Bolognesi called the data ‘head and 
shoulders above everything else’ (quotes in Cohen 1992a:1880). The comments did not 
mean, however, that Desrosiers had their full support. It is more likely that they saw 
Desrosiers’ work as useful in contributing to their understanding of what the different 
components of HIV do by removing them one by one52. 
 
Subunit researchers such as Bolognesi and Gallo viewed Desrosiers’ live virus work as part 
of the journey towards understanding which immune responses could be correlated with 
effective protection. The rationale was that understanding what effective protection is, in 
                                                 
51
 Although not explicitly acknowledged in the paper, I assume that the vaccine strain was grown in human 
cells but unlike Stott and others, the two challenge stocks were both grown in monkey cells: ‘In both cases, 
virus stocks were prepared in primary rhesus monkey peripheral blood mononuclear cell (PBMC) cultures’ 
(Daniel, Kirchhoff et al. 1992:1939). PBMCs are mixtures that include CD4 cells, the cells that HIV infect. 
52
 For example, Almond, Stott and Cranage defended the work against Ruprecht et al.’s (1995) criticisms by 
writing, ‘We agree with Ruprecht and colleagues that ‘it is premature to consider nef-deleted viruses as 
candidate AIDS vaccines.’ Nevertheless, we believe that the study of live, attenuated SIV will provide vital 
clues in the development of an effective AIDS vaccine’ (Almond, Cranage et al. 1995:178). 
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the way that Hammon did for poliomyelitis, would enable them to design their subunit 
vaccine better. Unfortunately Desrosiers’ paper did not offer any such correlates, it merely 
suggested that their ‘live attenuated HIV-1 may be the most potent, effective vaccine for 
the prevention of AIDS53’ (Daniel, Kirchhoff et al. 1992:1941). 
 
The high degree of protection afforded by the attenuated SIV could not be readily explained 
with neutralising antibodies of such low levels. Other vaccines which had triggered much 
higher levels of antibodies still failed to reach the kind of protection Desrosiers achieved. 
Attempts at making comparisons with other approaches were made explicitly, ‘These are 
the most impressive protective effects we have seen in any vaccine experiments, including 
those with inactivated whole virus, recombinants expressing SIV env, vaccinia 
recombinants, and vaccinia recombinants priming followed by SIV particle boosting’54 
(Daniel, Kirchhoff et al. 1992:1940). 
 
Desrosiers’ vaccine was never taken seriously due to the safety concerns raised by the 
prospect of a live-attenuated vaccine55. Desrosiers acknowledged ‘Concern for safety is 
likely to be the key issue for the eventual development of this approach’ (Daniel, Kirchhoff 
et al. 1992:1941). He argued that by removing more and more components from the virus, 
the risk of reversion back to virulence would be minimised. ‘In addition to nef, other 
genetic elements can be deleted from HIV-1 to help ensure long-term safety…The use of 
deletion mutations is an important part of this strategy [which] eliminates the possibility of 
reversion.’ The use of the word strategy reflects the need to compromise for a less effective 
vaccine, but that was a balance that needed to be explored (see table 9)56. 
 
                                                 
53
 ‘Most viral vaccines currently in use in humans are of the live attenuated variety. It is simply difficult to 
match [other vaccine approaches with] live virus infection for strength, breadth, nature, and duration of the 
immune response that is generated’ (Daniel, Kirchhoff et al. 1992:1939). 
54
 The quote has been repeatedly truncated, but I do not believe I have altered its essential point. 
55
 The safety concerns were, and still are, most vociferously led by Gallo (Fischinger, Robey et al. 1985; 
Gallo 2005). They focussed on three main areas: insertional mutagenesis, reversion to virulence and delayed 
onset of AIDS (see section 8.1.1). 
56
 Desrosiers also countered that the link between cancer and the retrovirus family was weak, and not well 
understood. In addition, the attenuated virus did not replicate much making cancer less likely. The delayed 
onset of AIDS was merely a reason to work faster and take candidates to testing earlier, because the lead 
times for developing such a vaccine would be long, including 15 or so years of safety testing. 
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Table 9: A balance between safety and efficacy 
High level of attenuation  Low level of attenuation 
Safe: low probability of 
reverting back to virulence  
  
Risky: high probability of reverting 
back to virulence  
Less effective: at stimulating an 
immune response and less 
recognition of other strains in 
the field  
  
Effective: elicits strong immune 
response 
 
In this approach, the compromise that scientists arrived at would presumably reflect 
assumptions about the way they frame different populations’ social needs. The evaluation 
and communication of desired risk/efficacy was never going to be a simple task, but the 
criticisms aimed at Desrosiers work seemed to lack any acknowledgment that, for some 
people57, the risks of such a vaccine might be worth taking, particularly if their behaviours 
and lifestyle were difficult to change (drug addiction, poverty etc) resulting in high 
probability of HIV exposure. 
 
Such calls for pragmatic re-framing of social assumptions bear strong resemblance to 
Shearer’s assertion, reviewed in the earlier section, that for some people the prospect of 
organ transplantation is not as important as effective HIV protection. Even if attaining 
widespread consensus over ‘objective’ risk-benefit analyses were not feasible for vaccines 
with triple or even quadruple deletions, Desrosiers was effectively calling for a 
strengthening of the institutions part of the testing regime, so that the live attenuated 
approach could proceed purposefully to address the safety issue with as much data as 
possible. A more nuanced debate of needs and risks would require better governance. 
 
Desrosiers acknowledged that the results were based on pure empiricism. ‘We do not know 
the mechanisms that are responsible for the protective immunity observed in these 
experiments’ (Daniel, Kirchhoff et al. 1992:1940). Desrosiers was faced with two options 
                                                 
57
 This was the basis for the WHO’s decision to support efficacy trials of gp120 (see later chapter). See also 
Blower et al. (2001) who develop a theoretical framework predicting that live vaccines would reduce AIDS 
death rate in Zimbabwe (where transmission is higher), but increase it in Thailand (where transmission is 
lower). In short, different countries require different solutions, which is in keeping with evolutionary theories 
of technical change. 
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for further research directions. He could either search for other possible explanations for 
protection, the most obvious candidate being the cellular immune response, or he could 
push forward with the deletions. The former appeals to more rationalist inclinations of 
explaining what is needed and then designing a vaccine that works. The latter is an option 
that places the search for an effective vaccine as a priority over gains in theoretical 
understanding. Desrosiers had little faith that a rationalist approach would work on its own, 
and he says “I just kind of chuckle at it. It’s dreaming that science can do more than it can. 
It’s a worthy concept, but dream on” (Cohen 2001b:130). Desrosiers concentrated on the 
more technological exercise of engineering SIV’s and HIV’s with more and more deletions, 
and evaluating how well they worked in chimpanzee challenges. 
 
Cohen (2001b:130) points to an experiment with monkeys that could suggest causal 
mechanisms. If the hypothesis were true that killer cells were responsible for protecting the 
monkeys, then it follows that researchers should be able to bleed the animals, separate out 
those killer cells (or whatever they suspect is causing immunity), and inject them into 
unvaccinated monkeys58. If the monkeys that received the transplanted killer cells could 
resist infection after a challenge with SIV, that would provide evidence that they were a 
correlate of protection. 
 
However, there was again an instrumentality problem hindering the creation of the required 
experimental conditions. The monkey receiving the cells would mount an immune response 
against the transplanted cells because they are ‘non-self’. Identical twins, which can freely 
share cells, offer a way around this problem. They are an important instrumentality that 
changes conditions, such that growth of knowledge becomes feasible. 
 
Desrosiers searched for identical twin monkeys in captivity but found none (Cohen 
2001b:131). The next step might have been to recruit assistance from reproductive 
endocrinologists, who have learned much about how to manipulate multiple births. But 
                                                 
58
 In passive immunisation, previously made antibodies injected into a subject can provide protection or 
treatment (see section 5.4.3 or 6.4). 
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such an effort to bring together the required capabilities and resources was not made 
(Cohen 2001b:131). 
 
With no correlates for protection in sight, and safety fears emphasised repeatedly, the live 
approach attracted little further support. 
 
8.5.4 Summary 
 
Perhaps the learning conditions provided by Stott’s crucial control experiments would have 
been created earlier if monkey supply was as closely monitored as Basil O Connor’s 
efforts. Even when Stott’s results were out, efforts to strengthen the testing regime were not 
made. For example, monkey cell lines to facilitate monkey-monkey tests were not a 
priority. Some researchers such as Arthur and Shearer found promising research avenues 
with Stott’s result, but efforts to test their approach based on cellular proteins were 
thwarted by a reluctance to re-frame the need for and risks of organ transplanting. 
Similarly, the risks of a live-attenuated approach were not re-evaluated, even when data 
existed showing Desrosiers’ vaccine to be highly promising. Instead, the strong results were 
used to pursue other (recombinant) vaccine approaches. 
 
Lack of comparability between the approaches resulted in the entrenchment of researchers 
into vaccine approach ‘camps’ where researchers like Murphy-Corb were made to ‘switch 
camps’ for lack of support. If researchers were not communicating freely, this is likely to 
have affected the knowledge flows that were identified as being important in chapter 2. 
 
A way of improving the live vaccine was held back by the lack of monkey twins to test a 
major hypothesis in. This represented a failure in co-ordinating access to important testing 
instrumentalities in terms of failing to bring the skills and capabilities of an endocrinologist 
to bear on the problem. Monkey twins may have provided a critical set of intermediate 
conditions for learning. 
 
Despite these problems of underdeveloped instrumentalities, and the comparability 
problems of weak R&D governance, Desrosiers was able to have his vaccine labelled as the 
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best effort so far. In doing so he highlighted how researchers developing other approaches 
had used purified - but unrealistic - laboratory conditions. This supports the notion that 
vaccine development progresses through an iterative process of testing ideas in 
incrementally tougher and more realistic testing conditions. 
 
8.6 Conclusions 
 
The popularity of biotechnology and the fondness for applying it, coupled with a paucity in 
traditional vaccine development skills and capabilities, contributed to a heavy emphasis on 
the subunit approach that may have had an excluding and detrimental effect on the other 
approaches. The subunit approach focussed on the development of hepatitis B vaccine as if 
it were a predecessor model and used its recent success to downplay the problem of 
variation in HIV. Advocates of the subunit approach were convinced that a conserved 
region could be found, and that separate vaccines could be developed for different 
geographical regions. 
 
After the need for cellular immune responses were belatedly recognised, new approaches 
emerged in small biotechnology companies. However, the weak testing regime meant that 
preliminary tests lacked immediate commensurability to the other approaches. The 
companies failed to attract further investment with which to develop their ideas and the lack 
of commensurability probably contributed to this. The small companies were taken over by 
large pharmaceutical firms who had already clearly expressed their intentions to refrain 
from AIDS vaccine development, if not all vaccines generally. The takeovers led to 
tensions and intraorganisational problems in the development of these new approaches. 
 
This left Chiron and Genentech with the subunit approach in the private sector alone, 
against the whole-virus approaches led, for example, by Stott and Desrosiers in the public 
sector. Stott’s and Desrosiers’ data showed how poorly deviation away from the dominant 
model was managed. Stott and Desrosiers produced strong vaccine candidates but found it 
difficult to explicitly compare with recombinant approaches, and faced a lack of testing 
resources (monkeys) and instrumentalities (cell lines and twins). In addition, they faced 
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heavy criticism about safety and a testing regime with institutions reluctant to engage in 
governing or mediating any risk discussions. 
 
This chapter has shown that many potential operational principles emerged after a decade 
of AIDS research. However, selecting an operational trajectory was difficult (discussed in 
next chapter) because the wide variety of laboratory practices remained largely ungoverned 
(see table 10 below). As such, developments in many of the operational trajectories could 
not be related or compared with others. Greater standardisation would have allowed 
researchers to make comparisons with more confidence, identify strong vaccine candidates 
more easily, and focus resources. Instead, scarce resources were scattered across many new 
vaccine approaches, and the uncertainties permeating vaccine development were perhaps 
greater than they were ever before. 
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Table 10: Variation in vaccine development 
A list of operational principles to 
select from 
 A list of laboratory practices left 
unstandardised across operational 
trajectories 
• Whole, killed  • Use of HIV, influenza or herpes 
for ‘proof of concept’ 
• Live, attenuated; with varying 
number of deletions 
 • Species of test animal; mice, 
chimpanzees, monkeys 
• Recombinant envelope 
proteins; e.g. gp120, gp160 
 • Immunisation schedules 
• Mixtures of core (e.g. p17, 
p27) and envelope proteins 
 • Route of challenge: rectal, 
mucosal, intravenous, foetal 
• Naked DNA; with cationic 
liposomes 
 • Dose of challenge 
• Live vectors to express and 
deliver different proteins; e.g. 
vaccinia, venezuelan equine 
encephalitis, canarypox, 
fowlpox 
 • Strains of challenge; virulent 
primary isolates taken from 
patients or weaker laboratory 
adapted strains 
• Prime with live vector 
vaccine, then boost with 
recombinant protein 
 • Assessment of antibody 
neutralisation; neutralisation 
judged at 50%, 90%, 95%? 
• Cellular proteins mixed with 
recombinant viral proteins 
(e.g. gp120, gp160, p17, p27) 
 • Assessment of protection; 
sterilising immunity, delayed 
onset of disease 
Source: compiled from chapter 8. 
Knowledge growth remains fragmented unless standards are set across the dimensions 
listed on the right hand column. In this environment it is difficult to bring new knowledge 
to bear on the process of selecting putative operational principles for further, focussed 
development because it is not stable and shared. A strong testing regime may assist in 
deciding when to winnow down the options in the left hand column, and when to continue 
developing in parallel. 
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Chapter 9 
 
Testing Times for an AIDS Vaccine: Testing regimes in clinical development 
 
The progression of a vaccine candidate from the laboratory to the market is long, and 
becomes increasingly complex and expensive as tests are conducted closer to their intended 
operating conditions. Following studies in laboratories and animals, candidates are tested in 
phase I clinical trials for short-term safety and immunogenicity in a small number of 
humans. In phase II, these attributes are examined in hundreds of people, and the trials also 
seek to determine the immunisation doses, routes and schedules to use (Pocock 1996; 
Plotkin and Orenstein 2004). 
 
This chapter explores the role of the testing regime in the decision to move to phase III 
trials. These trials seek to establish the efficacy of the vaccine by testing in thousands, or 
tens of thousands, of people. Establishing efficacy in the field is more difficult than the 
other phases of testing because of the interaction of other influences (Levine, Kaper et al. 
2004). Fewer variables can be controlled, so the concern for vaccine designers is much 
more about ‘does it work?’ than it is about ‘how does it work?’ Consequently they are the 
longest of the tests, lasting several years and are the most expensive, costing millions of 
dollars (see section 5.2.2). 
 
With such large stakes, the decision to move to phase III can be arduous, contested and 
conspicuous. This chapter explores how without a strong testing regime in place, processes 
to legitimise the selection of operational trajectories become more difficult and less likely 
to be widely acceptable. This affects the take-up of knowledge generated in the trials and 
makes it less likely to be shared, integrated and added to previous knowledge. Cumulative 
technological knowledge growth is unlikely if the knowledge is not seen to have been 
produced through institutional processes that make it robust. This chapter therefore argues 
that clinical trials require a strong institutional presence with leadership, management and 
co-ordination. 
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Section 9.1 describes how the funds for testing one vaccine were politically allocated 
despite serious doubts in the scientific community. Section 9.2 examines how, for a 
different approach, scientists struggled to reach consensus on whether to move into phase 
III and how weaknesses in the testing regime were partly responsible. Sections 9.3 and 9.4 
examine the consequences of a decision not to proceed and the implications of an 
alternative decision to proceed with the trial. Section 9.5 concludes the chapter by 
exploring the possibility of a new vaccine paradigm. 
 
9.1 Pork-barrel science 
 
Along with Salk’s Immune Response Corporation, MicroGeneSys was the only other 
company whose sole activity and aim was the development of an AIDS vaccine (Batson 
and Ainsworth 2001). 
 
In September 1992, the US Department of Defense annual budget appropriated $260bn, but 
the Senate also passed a relatively minor $20m amendment to the appropriation (Hines 
1993). The amendment ordered the Army to spend the money on a ‘large-scale… clinical 
investigation of the gp160 vaccine’ referring to Microgenesys’ ‘VaxSyn’ product (Watson 
1992:94). Although medical research priorities are often set by Congress following 
lobbying, this allocation was significant because lawmakers had earmarked funds for a 
specific product without the explicit backing of federal researchers from either the NIH or 
FDA. Even the Army were unaware of the proposed amendment until it was passed (Hines 
1993). 
 
The decision aroused considerable anger in the AIDS research community. Martin Hirch, 
director of the AIDS program in Massachusetts, said that ‘new money for work against 
AIDS is always welcome, but there are many AIDS vaccines being studied at the moment 
and there is nothing to suggest that this one is better than the others’ (Meier 1992). 
Bernadine Healy, director of the NIH, called it ‘a backdoor channel’ and added ‘there are 
others that may be as good if not better’ (Anon 1992). She cited it as an example of ‘law 
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pre-empting science and scientific judgement’ (Watson 1992:94). David Kessler, 
commissioner of the FDA, had ‘serious concerns about sidestepping the normal peer review 
process, especially on something as important as the AIDS vaccine’ (Meier 1992). 
 
Microgenesys was well connected to political power and employed highly influential 
lobbyists(Anon 1992; Cohen 1992d). There was little doubt about how the $20m 
amendment came to be after the senators proposing the amendment credited well known 
lobbyists for bringing VaxSyn to their attention (Cohen 1992b; Meier 1992). 
 
The idea behind the VaxSyn product was that a vaccine could not only protect healthy 
people but might also serve as a form of therapy for those already infected - but few 
researchers felt that the product was ready for trials. Army researcher, Robert Redfield, lent 
the product much needed scientific credibility whilst his study, published in the New 
England Journal of Medicine, showed that VaxSyn was ‘safe and immunogenic’ in thirty 
volunteers (Redfield 1993:1677). But the study did not suggest the product was effective as 
judged by the surrogate marker, CD4 cell counts. For example, only six out of fourteen 
volunteers needing treatment1 responded to the gp160. 
 
However, the lack of evidence regarding efficacy was not enough to overturn the 
considerable public attention that had gathered momentum, particularly because the vaccine 
candidate offered hope to activists who were often already HIV infected. Many advocates 
argued that it would be better to take the $20m and spend it on the vaccine than lose it 
altogether (Kolata 1996). Healy reconciled, “we hate the process, but we’re focussing on 
what to do with the money” (Watson 1992:94). 
 
The Department of Defense changed its unilateral strategy, and brought itself in line with 
the NIH and FDA in agreeing that ‘[VaxSyn] should be tested only in trials that include 
other vaccines and that otherwise the $20m should be spent on basic AIDS vaccine 
research’ (Meier 1993). Since VaxSyn was also a therapeutic drug, the FDA convened a 
                                                 
1
 16 out of the 30 volunteers were healthy and sought protection (>600 cells per ml) and 14 were unhealthy 
needed treatment (<600 cells per ml) (Redfield 1993:1677). 
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committee of antiretroviral drugs experts. The committee found that the VaxSyn data did 
not merit a large scale trial and they unanimously agreed that the money would be much 
better spent if it went towards a more expensive trial that compared several candidates 
where industry contributed to the remaining costs (NYTimes 1994; Cohen 2001b). 
 
This comparative trial seemed like a reasonable compromise for all parties concerned. 
However Microgenesys, resisted with a variety of reasons, claiming that a comparative trial 
would dilute and delay the results of a VaxSyn trial (Squires 1993b), allow its competitors2 
to ‘catch up’ and then finally Microgenesys claimed it could not afford to pay for the 
experimental vaccine (Squires 1993a). Microgenesys wanted half of the $20m to be spent 
on purchasing vaccine for the comparative trial whilst other companies, like Chiron and 
Genentech, would have to pay for their own vaccine. When Chiron and Genentech 
reluctantly obliged, Microgenesys still withdrew from the comparative trial anyway. 
 
In a highly critical article in Nature, John Moore labelled VaxSyn as the worst possible 
choice amongst the vaccine candidates, “Obviously they fear a comparison trial. They 
probably prefer to play with their friends than with people of objectivity” (Moore, Lewis et 
al. 1993; Cohen 2001b). Microgenesys said the charge was ‘preposterous’ and that they 
withdrew from the trial because they ‘disagreed with the primary and secondary end 
points3’ (Macilwain 1993). The NIH was also incensed by the withdrawal, ‘This was the 
only study giving direct comparability between rival vaccines. But put yourself in their 
shoes: why would you want to help generate data showing that their vaccine offers less 
immunogenicity than the others?’ (Macilwain 1993). 
 
The $20m was redirected to basic research projects and the Army used its own budget to 
run VaxSyn slowly through its original five year plan for phase III trials (Cohen 2001b). In 
                                                 
2
 Jonas Salk’s Immune Response Corporation, for which he raised $20m very quickly, had pioneered the 
therapeutic vaccine approach since the late 1980s. Chiron and Genentech were also pursuing therapeutic 
applications of their gp120 products. The Austrian company Immuno AG was also pursuing the gp160 
approach. (See chapter 7). 
3
 These terms refer to the clinical symptoms or indications needed to be observed so that a trial may be 
considered a failure or success. See the section 8.5 for more details. 
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April 1996, the Army announced that it had completed the trial and the Department of 
Defense press release stated: 
 
‘While gp160 was hoped to slow the progression of the disease, unfortunately, results from 
the study show no clinical improvement that could be attributed to the vaccine used as 
adjunct therapy for HIV infection’ (Defense 1996). 
 
The company’s press release stated that the vaccine ‘did not demonstrate statistically 
significant benefit’ (Proteinsciences 2006). The company later changed its name, its CEO 
and turned its attention to influenza vaccines and, lately, SARS vaccines (Kolata 1996). 
 
9.2 After MicroGeneSys: how strong was the rationale to back its rival over other 
alternatives? 
 
The Microgenesys trials with gp160 briefly diverted attention away from gp120 and 
possibly slowed its route to clinical efficacy trials. Just as it was for Microgenesys, a 
complex mix of scientific, organisational, financial and ethical factors pushed the gp120 
vaccines made by Chiron and Genentech ahead of the rest. In isolation, none of these 
factors made a compelling case that gp120 vaccines held substantially more promise than 
the other ones being developed. But collectively, they managed to beat the other vaccines to 
being considered for the final stages of testing: the phase III efficacy trial. 
 
The NIH was tasked with judging whether the gp120 vaccines held enough merit to warrant 
the expense of designing and conducting efficacy trials. They faced significant arguments 
for and against going ahead with Phase III trials because the testing regime was weak. It 
was difficult to interpret how realistic the conditions were when experimental results were 
being discussed, instruments and standardised conditions were not well developed by 
institutions, so conditions could not be changed easily and knowledge could not be shared 
and accumulated easily. There was an acute shortage of accumulated technological 
knowledge. 
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9.2.1 Arguments for proceeding with efficacy trials 
 
a) Antibodies offer poorly understood protection 
 
The main argument in favour of the gp120 vaccines centred on a mechanistic perspective of 
the role of antibodies. The basis for injecting lots of it into a person was that the gp120 may 
either, by itself inhibit the binding process through competitive inhibition (also a basis for 
therapy), or it may stimulate the production of antibodies which could block the viral 
envelope glycoproteins docking with CD4 sites and prevent infection. Similar to  
arguments in poliomyelitis vaccine development, prior to Hammon’s results, the role of the 
antibody in immunity was frequently argued to be unclear and, as such, its use in 
determining the value of a vaccine candidate was debated (Fauci 1991; Sabin 1992). 
 
Regardless of exactly how antibodies might protect against HIV, evidence existed to show 
that antibodies alone could do it in some conditions. For example, researchers had injected 
chimpanzees with antibodies taken from HIV-infected humans and then showed that the 
animals resisted infection from challenges (Prince 1991). In addition, Genentech had 
published in Nature to show that their recombinant gp120 could protect chimpanzees from 
an HIV challenge whilst gp160 (the complete envelope protein used by MicroGeneSys and 
Immuno) could not (Berman, Gregory et al. 1990). 
 
Don Francis of Genentech questioned the necessity of understanding the role of antibodies 
in immunity in the face of such results. But the results did not convince everyone because, 
although many antibodies were known to bind to HIV, only those that prevented the virus 
from infecting cells were deemed neutralising antibodies. These experiments showed 
immunity with antibodies, which can bind to HIV, but not necessarily immunity with 
neutralising antibodies, which can bind and prevent infection. 
 
For Francis, a vaccine’s ability to induce antibodies capable of neutralisation was not a 
criterion that should be used to judge the vaccine’s worth. The vaccine was able to induce 
immunity, and it involved antibodies somehow – and that was enough. Debates over 
whether neutralisation had occurred were irrelevant (discussed further in part a, section 
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9.2.2). He highlighted the fact that sera taken from vaccinated animals failed to neutralise 
the virus in the laboratory, even when sera were taken from animals that were protected 
against a ‘whopping dose’ of challenge virus. “Anybody in their right mind would have 
known that the neutralising antibody was not predictive of protection” (Thomas 2001:201). 
 
b) An opportunity to learn and retain industrial involvement 
 
The purpose of the trial was also argued to be a means for learning rather than simply being 
a test for efficacy. This perspective emphasises that putative operational principles are not 
merely tested, they are corroborated through repeated testing and they evolve through 
incremental refinements in the testing regime. However, to do so at this stage is expensive, 
slow to feed back and possibly even unsafe. 
 
Jack Obijeski, who ran Genetech’s AIDS vaccine project, argued that the efficacy trial 
would be a way of generating ‘the next big increment of knowledge’ (Thomas 2001:200). 
Scientists would be able to evaluate their laboratory results against what happened in the 
field and if the trial went well, they might know what immune response a successful 
vaccine would need to elicit (Ada, Koff et al. 1992). Even if the trials did not show 
complete success, it was argued that unsuccessful trials hold clues to improvements in 
vaccine design, dosing and immunisation schedules. New data acquired at government 
expense could stimulate industry to develop more and better products. 
 
Clinical evidence was claimed to be ultimately more meaningful and relevant than 
laboratory results. However, this claim relies on whether the clinical evidence is derived 
from a product that has been brought reasonably close to working order through the testing 
regime. Complete failure would offer little information and so a reasonable chance of 
success is necessary in order for this ‘learning’ justification to be valid. 
 
Batson and Ainsworth (2001:723) call this particular testing issue a ‘vicious circle’, where 
failure to undertake phase III trials can perpetuate the lack of knowledge that underlies 
industry’s reluctance to invest their resources in the first instance (see figure 8). They seem 
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to think that frequent iterations and the ability to move back and forth between different 
conditions is an important factor in innovation. Chapter 2 theorised that these conditions 
can be more or less suited to learning on the one hand, and more or less relevant to 
technological use on the other. It added that these degrees of variation in conditions may be 
controllable through the governed use of instrumentalities. 
 
Figure 8: The vicious circle: scientific barriers make industry reluctant to invest in the phase III trials 
that may be required to solve them 
 
Source: Reproduced from Batson and Ainsworth (2001:723). 
 
Another factor was the perceived need to protect industry involvement. Large 
pharmaceutical companies were avoiding AIDS vaccine research, leaving it to small 
biotechnology companies that lacked capabilities and money, such as MicroGeneSys, 
Repligen and Vical. Chiron and Genentech were different. These companies had strong 
scientific reputations; their scientists had integrated themselves into the AIDS vaccine 
network, collaborated with other scientists, published in the best journals, and even 
published negative data like the primary isolate study done by Chiron (see below). So NIH 
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and NIAID staff did not want to alienate the most attractive industrial partners they had 
when it came to deciding which candidates to consider for funding through efficacy trials. 
 
Genentech’s Obijeski expected public health urgency to drive candidates forward into trials 
and was furious when he realised that the trials may be in jeopardy, particularly as many of 
the necessary testing resources were already in place. For example, he complained that they 
had already manufactured 200,000 doses of vaccine under the impression that the NIH had 
made a commitment to move forward into efficacy trials. “To leave that vaccine on the 
shelf, something that might help someone, we think that’s ridiculous… it’s a monumental 
disincentive for Genentech…NIH [should] not dwaddle about, one step forwards, one step 
back. That’s what makes CEO’s nervous” (Cohen 1993a:981). Chiron was in a similar 
position needing commitment to move forward. 
 
If the NIH did not move forward, it would discourage any further industry involvement. 
One scientist commented, “If they get the sense that this is not an area of fertile investment, 
I think you are going to see a lot of little companies disappear, and a source if potential 
future vaccines disappear. That’s not a threat, it’s just a fact. The community will react… 
with some fear and panic with regards to decisions made here, should they be… negative” 
(Cohen 2001b:235). The larger firms and more established biotechnology companies were 
also nervous. Genentech’s Don Francis said, “If you do this to us, we’re telling you that the 
corporate decision is going to shut us down” (Thomas 2001:204). Merck’s Hilleman also 
offered the same warning more moderately, and added “it’s not bad enough not to 
consider” (Thomas 2001:205). 
 
c) Other reasons 
 
There were other reasons, discussed in chapters 7 and 8, to proceed with efficacy trials. A 
recombinant Hepatitis B vaccine developed by Chiron heralded new hope for subunit 
vaccine researchers. Scientists also believed that the subunit approach was less risky simply 
because there was less of the virus in the vaccine. In addition AIDS activists had 
constructed considerable expertise and had established themselves as an important 
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stakeholder group in decision making processes (Epstein 1995). Although they focussed 
most of their attention on the development of new treatments, they also applied significant 
pressure to move forward with vaccine clinical trials because it offered a chance to ‘do 
something,’ even if the chances of success were low. For example, Pinching, an 
immunologist, believed that in licensing the antiretroviral AZT, the US authorities 
‘extrapolated’ beyond the limits of legitimate scientific deduction and had been led by ‘the 
widespread desire to see progress achieved and the wish to be seen to have made such 
progress’ (Pinching 1991:158). 
 
9.2.2 Arguments against proceeding with efficacy trials 
 
There were strong arguments against going forward with Phase III trials. 
 
a) Primary isolates problem 
 
To ascertain whether a vaccine can induce neutralising antibodies, there are tests which mix 
HIV with blood taken from vaccinated individuals. But these tests, or assays, were much 
debated because there were many differences in techniques (Hanson 1994). Some used 
undiluted sera whilst others used various dilution factors, and there were differences in the 
growth media used to grow isolates in. Different investigators obtained their virus from 
different sources, which mattered because the kind of strain used affected results. There 
was no way of knowing how the strains compared to each other in terms of virulence. 
Furthermore, titrations differed because some considered neutralisation to have occurred if 
50% of the HIV was disabled whilst others held out until 90% (Hanson 1994). 
 
However, the high variation within the assay techniques, and resultant lack of 
comparability between them, was not their most significant drawback. These assays rely on 
HIV that is grown in immortalised laboratory cell lines and, even though antibodies may 
(differentially) protect against such laboratory-adapted viruses, they may be ineffective 
against a real-world strain of HIV. A more stringent test would be to use HIV that has been 
freshly harvested from patients because these ‘primary field isolates’ are believed to be 
much closer to the type of HIV that would infect a vaccinated person. 
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David Ho and others had gathered evidence to show that primary isolates (virus taken 
directly from patients) behaved very differently from laboratory adapted strains (Daar, Li et 
al. 1990). Many investigators, including Chiron themselves, also published studies showing 
antibodies capable of neutralising primary isolates of the virus could not be found in blood 
taken from people who had received vaccines from many different companies (Hanson 
1994; Matthews 1994). Although even more variation existed in these more stringent tests, 
because the characteristics of the fresh blood cells would vary4, the key finding of many 
independent tests was that primary isolates were not being neutralised5 (Matthews 1994). 
 
So whilst the tame laboratory adapted strains were being neutralised, the more virulent 
primary isolates taken from patients were not being neutralised. It has been suggested that 
this may be because proteins in the primary isolates are more tightly coiled, whilst those in 
laboratory strains unwind in the absence of selective pressures and lose their shape, or 
‘conformational integrity’ (Matthews 1994). The inability to neutralise primary isolates 
brought into question the quality of the antibody response the vaccine might induce and 
stood alongside the fact that this vaccine approach cannot6 induce a cellular response at all 
(Letvin 1993; Klein and Ho 2000). 
 
b) Animal model problem 
 
The lack of consensus over which animal models to use has meant that animal experiments 
have played a somewhat confusing role in AIDS vaccine development.  
Genentech built its research programme around its chimpanzee results and promoted them 
as a success. However, closer inspection (see table 11) reveals more limited success. 
 
                                                 
4
 For example, some blood cells would be more susceptible to infection than others, or some would grow 
faster than others. 
5
 There was only one single exception where blood from one vaccine injected person neutralised a field 
isolate (Matthews 1994). 
6
 Because this type of vaccine antigen does not enter the MHC class I pathway after administration, so cannot 
induce a cellular response (Letvin 2006). 
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Table 11: Problems with Genentech’s gp120 
• Chimpanzees are better than humans at fighting off HIV infection  
• The vaccine only worked in chimpanzees, failed in monkeys’ SIV model 
• The immunisations needed to be tightly scheduled in order to work 
• They used so few chimpanzees that the study lacked statistical significance  
• The route of the challenge, an intravenous injection, might not reflect what 
happens during sexual exposure 
Source: Based on chapter 8. 
 
Following the initial results with the chimpanzees, the logical experiment would have been 
to design similar conditions with monkeys or to repeat with more chimpanzees in order to 
reach statistical significance. However, expense and logistics make adequate chimpanzee 
studies too risky for a company to undertake and represent a major testing constraint. ‘To 
really test efficacy in chimpanzees, one would have to inoculate animals at the mucosal 
surfaces with small amounts of virus. Given that most of them would not become infected 
even without a vaccine, the experiment would require approximately 100 vaccinated 
compared to 100 unvaccinated chimpanzees in order to reduce the infection rate in the 
vaccinated group to about 2 in 100 from about 8 in 100’ (Grady 1995:99). At 
approximately $70,000 per chimpanzee this study would be a sizeable [$14m] outlay 
(Grady 1995:99). 
 
The success of the experiments was also undermined because comparing them to monkey 
experiments conducted by other groups, which may have used different routes of challenge 
or immunisation schedules, was difficult. Uncertainties could have been reduced if 
organised groups ensured their experiments were comparable, even if they were not 
statistically significant. 
 
Some members of the NIH, such as Alan Schultz, recognised the difficulty the companies 
were in, “If in fact this group or some decision-making group would say, ‘if you did this 
experiment and if you got that result, we will do the trial,’ then, in fact, I think maybe those 
experiments would get done.” He went on to say that the current message being conveyed 
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was, “Well go ahead and spend half a million on a couple of chimpanzees, show us the 
results, and we’ll think about it” (Cohen 2001b:253). 
 
c) Challenge stock issues  
 
One of the advantages to the vaccines developed by Chiron and Genentech was that they 
used more common strains (HIVSF2 and HIVMN) whilst others used laboratory adapted 
strains to make their vaccines (Berman, Matthews et al. 1992; Steimer, Yoshiyama et al. 
1993). But Genentech’s experiments on chimpanzees, described above, was with their 
earlier version of the vaccine, which was made from HIV3B (a less common strain). 
Moreover, they only challenged the HIV3B vaccine with HIV3B (a homologous challenge). 
A real-world vaccine would have to work against a variety of strains. 
 
The number of strains a vaccine is effective against can be considered a secondary 
performance criterion which might be incrementally improved as it is tested against more 
and more strains. But there were hurdles in broadening the reach of gp120 vaccines to other 
strains because of limited challenge stocks (Cohen 1991). Challenge stock is a batch of 
virus that scientists have characterised by determining the precise dose needed to infect an 
animal (Cohen 1991). 
 
Although challenge stock existed for HIV3B, Genentech did not want to test this against its 
HIVMN vaccine because the result might be misleading: even if the vaccine failed to protect 
against the distantly related HIV3B, the preparation still might have an impact in parts of the 
world where HIVMN – and other similar strains – predominated. So ideally the company 
wanted to test against an HIVMN challenge stock, but HIVMN had not been characterised in 
chimpanzees (Cohen 1991; Palca 1992). 
 
Challenge stock is a crucially important aspect of the testing regime, a shared resource 
which allows others to accumulate knowledge by testing prototype vaccines in conditions 
that can be related to the tests of other groups. It is an example of the knowledge 
infrastructure flagged in chapter 3. However, this knowledge infrastructure was not 
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provided for a range of HIV strains by government. One possible reason is that developing 
challenge stock is expensive and of little scientific interest. 
 
To make challenge stock, scientists must test various doses of the virus in several 
chimpanzees to determine the amount needed to cause an infection, an experiment that in 
the early 1990s could cost up to $0.5m (Cohen 1991). In addition to expense, companies 
that needed challenge stock had to find someone with chimpanzees who would run the 
experiment. Jorg Eichberg, a veterinarian who managed one of the largest private 
chimpanzee colonies in the US, turned down several requests to make challenge stocks, 
describing it as “scientifically unexciting work and you’re really burning up animals” 
(quoted in Cohen 1991:519). Eichberg, who had performed more chimpanzee challenges 
than any researcher in the world, agreed with many of his colleagues that government 
should do this type of work. Government, however, was not forthcoming on this (Palca 
1992). 
 
The problem of challenge stock has been identified more recently by Johnston, who goes 
on to suggest, in the manner of chapter 8, that this characteristic of the testing regime may 
affect the choice of operational principle. ‘[Disadvantages to using the chimpanzee 
model]…include the difficulty and expense of developing reproducible mucosal challenge 
stocks, particularly those that address clade [genetic subtypes] issues, and the expense, 
which limits the number of animals that can reasonably be employed. Thus, the use of 
chimpanzees to evaluate HIV vaccines will probably remain limited to those experiments 
that cannot be adequately carried out in the macaque model. These might include, for 
example, evaluating the safety of a live-attenuated HIV candidate…’ (Johnston 2000:268). 
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d) Virus typing 
 
The way in which virus typing for HIV was done stands in stark contrast to the way it was 
done for poliomyelitis. The classifying method involved studying commonalities of amino 
acid structure in 245 different HIV isolates. This put HIVMN as the most prevalent, HIVSF2 
as the next most, and HIV3B as less prevalent7 (LaRosa, Davide et al. 1990:935). 
 
However, there were two major limitations. Firstly, the study was conducted with isolates 
that were not ‘fresh’ primary isolates, they had 14 days in which to become more ‘tame’ 
laboratory-adapted isolates. ‘To obtain the PND8 sequences, we collected PBMCs9 from 
133 HIV-1-infected donors and co-cultured these cells for 14 days with uninfected PBMCs 
(113 donors) or with H9 or CEM cell lines (20 donors)’ (LaRosa, Davide et al. 1990:932). 
Consequently, the ranking of strains by prevalence is open to some question since primary 
isolates could look completely different. In other words, a vaccine made with HIVMN may 
not necessarily elicit antibodies with the anticipated breadth of efficacy. 
 
Secondly, the typology relied on a view that reduced the potency of the entire HIV virus to 
a small part of its structure, the V3 loop, introduced earlier in section 8.3. It was hoped that 
antibodies directed to this short segment might neutralise the virus, so only those 35 amino 
acids were sequenced and classified in the sample of 245 isolates. The rest of the HIV 
structure was completely disregarded from the typology. 
 
Such was the belief that the V3 loop would be decisive in immunity that the study proposed 
a theoretical structure of the consensus sequence, ‘C-β strand-type II turn-β strand-α helix-
C’ (LaRosa, Davide et al. 1990:933), analysed the character of the conserved amino acids 
‘nonpolar, polar or charged’ (LaRosa, Davide et al. 1990:935), and whittled the binding site 
down to just six amino acids ‘this suggests that, for example, an antibody that binds 
                                                 
7
 The study’s authors included influential authors such as Bolognesi, Emini, Putney, and Matthews. 
8
 LaRosa et al (1990:932) refer to the V3 loop as a primary neutralising determinant, or PND. (See section 8.3 
for further details of V3 loop). 
9
 Peripheral blood mononuclear cells (PBMC’s) are a fraction of the blood that contains T cells, the cellular 
targets of HIV infection. 
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GPGRAF as contained in the gpl20 glycoprotein will neutralize roughly 60% of randomly 
selected virus isolates’ (LaRosa, Davide et al. 1990:934). 
 
Moreover, the typology was not tested using animals. In contrast, the poliovirus typing 
project centred on the observed immunological responses of lots of monkeys, and 
consequently the typology was based on the whole virus. There are testing regime barriers 
to typing HIV in an analogous way. As noted in chapter 7, monkeys are not infectable by 
HIV. Chimpanzees can be infected by HIV, but, when they are infected, do not neutralise 
the virus or develop AIDS readily. Furthermore, they are, compared to monkeys, very 
expensive. 
 
A practical alternative could have been to analyse the genetic and amino acid structure 
similar to the LaRosa et al study. Instead of restricting it to the V3 loop of laboratory 
adapted isolates, typing could have encompassed the whole virus in primary isolates. This 
would have been an enormous project, perhaps 80 times larger than the V3 loop approach10. 
But this scale has been reached before in that the virus typing project for poliovirus was a 
multi-university, multi-year and multimillion dollar project. Such projects need institutional 
leadership and co-ordination to recognise and exploit strategic opportunities for 
strengthening knowledge infrastructure. 
 
e) Path-dependency problems 
 
One of the arguments put forward was that the phase III trial in question could be used as a 
learning experience specifically to improve a low efficacy vaccine candidate. However 
there are several path-dependent risks with going ahead on a candidate vaccine that is 
expected to be of low efficacy. 
 
Any efficacy trial requires many volunteers, but if the vaccine is of a low level of efficacy 
then only very large studies are statistically sensitive enough to detect such vaccines. This 
                                                 
10
 This would be a larger project but not impossible because the HIV genome is only 9749 nucleotides long 
(Alberts, Johnson et al. 2002), about 80 times larger than its V3 loop. 
 225 
meant that there was a need to consider if the gp120 trial would use up most of the potential 
volunteers in the US, a valuable testing resource. As a result, there may not be enough 
volunteers left for future studies of products that might be more effective. 
 
The future of the AIDS vaccine ‘pipeline’ was considered important because, as discussed 
in section 8.4, the gp120 vaccines barely stimulated cell-mediated immunity at all. Vaccine 
research shifted to a focus on cellular responses suggesting that this was suspected to be 
where the problems lay. New vaccine approaches developed at the time all aimed to 
address this directly, so phase III testing resources might have been better saved and 
deployed later in the testing of these newer operational principles. 
 
One such candidate was the vaccinia vector based vaccine known as the prime boost 
approach (discussed in section 8.4.2) which had encouraging results but was not ready to be 
considered for efficacy trials. Using volunteers for the gp120 trials could ruin the chances 
for later candidates such as the prime boost. This is because those volunteers would be 
primed to respond to gp120, so if they are given gp120 again as part of the prime boost 
approach, it would cross react with those pre-existing antibodies. Furthermore, the vaccinia 
vector caused problems because it could only be used on people who were not smallpox 
vaccinated (section 8.4.2), since they too would cross-react with pre existing antibodies 
induced by smallpox vaccine. 
 
Lastly, introducing low efficacy products means that future products will be compared to 
this standard. Evaluating the efficacy of future products is likely to be more complicated 
when the controls are people vaccinated with an older vaccine. It would require an 
inordinately large number of volunteers (or years) in order to detect any incremental 
improvements in efficacy. Therefore deciding to move to efficacy trials is not simply a 
question of the available of volunteers without pre-existing immunity, but also the 
opportunity costs of testing one concept over another. 
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f) Ethical restrictions 
 
In accordance with ethical guidelines dictating that current best preparations be made 
available to all participants, the control is often not an inert placebo (Grady 1995). The 
implications of contending with a low efficacy control vaccine were considered above to be 
a complicating factor. But there were other ethical concerns as well. 
 
Administering an injection, whether a placebo or a vaccine of low efficacy, may influence 
the participants towards higher risk behaviour. This may well be countered by educating 
participants about risk reductive behaviours. However, the tone and strength of the 
education programme would add another layer of statistical complication in examining 
vaccine efficacy. The underlying issue was inescapable: in order for efficacy to be shown, 
some people (in the control arm) needed to get infected and die. 
 
In addition, it was becoming apparent that cocktail drugs were extremely effective in 
reducing viral loads (to undetectable levels11) and allowing patients to resume normal lives. 
Ethical restrictions meant that participants who became infected during a trial would need 
to be offered antiviral therapy. But these therapies were expensive and would add to the 
cost of trials. 
 
There were important analytical consequences to such provision too. If everyone who 
became infected during a vaccine trial quickly began taking antiretroviral drugs, it would be 
impossible to tell whether the vaccine had delayed the disease. In such a setting, some of 
the vaccine’s potential benefits may go undetected. Even increasing the length or size of the 
trail may not clear up that kind of analytical problem. Thus, the licensing of antiviral drugs 
like AZT, in one fell swoop, had completely invalidated existing testing procedures and 
protocols, and served to increase the difference between ethical treatment conditions and 
effective learning conditions. 
 
                                                 
11
 Less than 50 RNA copies per millimetre (Johnston and Fauci 2007). 
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9.2.3 A Phase 2½ trial 
 
Given the difficulty of choosing whether to go ahead or not, one option considered by NIH 
Committees was the possibility of an intermediate clinical trial in between phase II and 
phase III to indicate whether the expense of a full efficacy trial was justified. This midsize 
trial would bear the advantage of being less risky, and initially cheaper and quicker; but 
since a full efficacy trial would be needed to clear FDA regulations, collectively the trials 
would be dearer and longer. Furthermore, the initial midsize trial would lack the statistical 
power to detect low efficacy rates, and so moderately effective vaccines might go 
undetected. 
 
9.3 The NIH’s decision to not proceed to Phase III 
 
In June 1994, the NIH decided not to go ahead with trials in the US (Moore and Anderson 
1994). As predicted, the NIH’s negative decision triggered an industry withdrawal. By 
1997, Bristol Myers Squib, British Biotech and Immuno AG were no longer conducting 
research into AIDS vaccines and no new companies expressed interest in the field (AVAC 
1998). 
 
Chiron stock price dropped and became 49.9% owned by Novartis, a large pharmaceutical 
company. It scaled back its vaccine programme and shifted its priorities to less problematic 
and more lucrative pathogens (AVAC 1998; Batson and Ainsworth 2001). To make matters 
worse, Chiron’s head of HIV vaccines, Kathy Steimer, died in 1996 (Thomas 2001). The 
NIH brokered a deal that brought together Pasteur Merieux Connaught and Chiron in a bid 
to develop the prime boost approach discussed in section 8.4 (Excler, Duliege et al. 1996). 
 
Genentech responded by taking its case to Congress and the Executive branch in an effort 
to override the NIH decision (Cohen 1994a) but, after the MicroGeneSys affair, few were 
willing to take their case up. Genentech’s management withdrew completely from HIV 
vaccines, shutting down the division and reallocating its staff to other projects (Thomas 
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2001). Only Don Francis remained, saying “we’ve got a vaccine that deserves to be tested” 
(Cohen 1994a:1839). 
 
VaxGen was spun off solely to stage efficacy trials for Genentech’s product, with 
‘epidemiologist Don Francis [as] president and sole employee of Genenvax12’ (Holden 
1996:1237). Genentech offered VaxGen $1m starting capital and would offer another $1m 
and exclusive rights to the vaccine if the company could raise $18m on its own (Gershon 
1996). With biotech start-up expert Robert Nowinski13, Francis promoted VaxGen across 
the country to private investors saying “it’s a social experiment [that directly asks the 
public whether it is] willing to invest” in a vaccine (Holden 1996:1237). They succeeded in 
raising $27m by March 1997 (Thomas 2001:361). 
 
In October 1994, only four months after the NIH decision, the world’s public health 
officials and scientists met in Geneva to discuss whether the WHO should approve of 
efficacy trials being undertaken generally. The WHO Committee came to a different 
decision. It recommended that ‘any decision to go ahead with a trial of any product must be 
made by the government of the country hosting a trial and… the governments concerned 
will have the full support of the WHO when they make a decision that is most suitable for 
their populations taking into account the benefits and chances of success, and the 
consequences of failure’ (Moore and Anderson 1994:314). 
 
Public health officials and epidemiologists emphasized that AIDS is different across the 
world in its burden, its HIV genetic subtypes, and its most common transmission modes. In 
some parts of the world the public health need to try something was dominant and gp120 
was seen as the best candidate. The WHO recommendation gave VaxGen confidence and 
credibility in fundraising. The NIH’s rejection together with WHO’s recommendations 
forced manufacturers to consider other subtypes that affected poorer countries (Moore and 
Anderson 1994). 
                                                 
12
 VaxGen was initially known as Genenvax. Genenvax was required to change its name because it was too 
similar to the naked DNA vaccine’s trade name Genevax (Thomas 2001). Incidentally, a Nature Medicine 
article (Gershon 1996) made this very mistake when it misspelled Genenvax as Genevax. 
13
 Nowinski was known as a man with ‘a Midas touch who has helped bring in hundreds of millions of dollars 
for other start ups, earning him the nickname ‘No-lose-ski’’ (Holden 1996:1237). 
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Thailand had favourable characteristics for staging efficacy trials. Foremost was its high 
infection rate. After the first cases of AIDS were reported in Thailand in 1985, rates of new 
HIV infections were relatively low (Phanuphak, Locharernkul et al. 1985). But between 
1988 and 1989, HIV prevalence amongst injecting drug users and sex workers rose 
dramatically, from almost zero to 40% (Weniger, Limpakarnjanarat et al. 1991). These 
were amongst the highest infection rates in the world (UNDP 2004; WHO/UNAIDS 2006). 
There are many studies showing benefits of a low efficacy vaccine to countries that have 
high infection rates (see for example Farlow 2006). There was also a history of Thai 
collaboration with Chiron, the US Army, and Genentech (Barker 2004). 
 
There were several disadvantages to holding the trial in Thailand. Physical trial 
infrastructure would need to be set up in Thailand in order to recruit and track volunteers, 
costing over $100m. VaxGen also needed to modify their vaccine to include the clade E 
strain prevalent in Thailand (Batson and Ainsworth 2001:724; Thomas 2001:362). Some 
claimed that it was exploitative to go to the developing world to run trials of a vaccine that 
was previously rejected in the US (Lurie and Wolfe 1997). Others questioned whether 
clinical trial participants should have access only to the best local treatment rather than the 
best treatment available universally (Bloom 1998). The latter would imply the provision of 
cocktail drugs, which would dramatically increase the costs of the trial and impact on the 
interpretation of the results as discussed above (Varmus and Satcher 1997). Medical 
ethicists were sharply divided on these questions. For example, one author in the New 
England Journal Medicine even compared the trials to the Tuskegee study of untreated 
syphilis14 (Thomas and Quinn 1991; Angell 1997). 
 
The Thai government approved the trial of VaxGen’s modified vaccine, called AIDSVAX. 
Their decision, along with the WHO recommendations, contrasted with the NIH’s decision. 
Risks were judged more in their social and economic context. This recognition was what 
                                                 
14
 The Tuskegee study was sponsored by the US Public Health Service from 1932 to 1972 and is the longest 
non therapeutic experiment on humans in medical history. It observed poor African-American men with 
syphilis to determine the ‘natural history’ of the disease, even after penicillin had proved effective and had 
become widely available (Thomas and Quinn 1991; Angell 1997). 
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Desrosiers was implicitly calling for within the NIH about the development of his live 
attenuated vaccines (discussed in section 8.5.3). Not only was risk judged differently but 
the Thai government was also deciding whether to allow somebody else to spend their 
money running trials as opposed to justifying the expenditure of government funds. This 
latter factor seems crucial because, later, a trial of AIDSVAX was also approved in the US. 
 
9.4 The results of the trial 
 
The trial of gp120 vaccine went ahead in 1999 and the results were released in 2003. The 
vaccines failed to protect healthy subjects from HIV infection (Johnston and Fauci 
2007:2076). ‘The complete lack of efficacy of antibody responses raised by monomeric 
gp120 vaccines in protection against HIV infection has been proven beyond any doubt in 
the world’s first Phase III clinical trials of AIDS vaccines’ (Girard, Osmanov et al. 
2006:4064)15. 
 
Many scientists expressed their lack of surprise at the results. ‘The vaccine did not provide 
any protection against infection and did not lower viral loads… it is no surprise that the 
VaxGen gp120 vaccine failed’ (Desrosiers 2004:222). ‘Most investigators involved in HIV 
vaccine development were not surprised by the outcome of this trial’ (Letvin 1993:932). 
 
The only success left to celebrate was simply that VaxGen managed to mount and complete 
a Phase III trial. ‘Regardless of the ultimate results, just completing the study marks a 
significant achievement’ (Cohen 2003c:1663). Some recognised this but it did not change 
the result. ‘Although these studies were successfully mounted, they both very clearly 
showed the complete lack of efficacy of the recombinant monomeric HIV-1 envelope 
gp120 vaccine (AIDSVAX; VaxGen Inc, Brisbane, CA, USA) tested… Given the difficult, 
and as yet unresolved, challenge to elicit antibodies by vaccination that are capable of 
                                                 
15
 Initially, VaxGen thought there was a mistake because they admitted to finding ‘absolutely no difference 
between the vaccine and placebo groups’ (Cohen 2003b). The use of placebos made interpreting the results 
quite clear. But VaxGen tried to salvage something from the trial by splitting the participants into ethnic 
subgroups in order to find statistical significance in the results. Statisticians subsequently showed that 
applying more accurate techniques of analysis made the results lose their significance (Cohen 2003a). 
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neutralizing primary HIV-1 isolates, these negative results were expected by many 
investigators in the field’ (Garber, Silvestri et al. 2004:397). 
 
9.5 What can be gained by trialling ineffective vaccines? 
 
The decisions to move gp160 and gp120 into phase III trials were the result of a mix of 
political, financial, ethical and historical factors. In the case of gp160, the lack of 
legitimacy and credibility emerged principally because it was felt that the candidate had not 
been put through a progressive programme of testing and iterative improvement. It had 
unfairly queue-jumped. 
 
In the absence of a co-ordinating organisation, Microgenesys was able to bypass earlier 
phases of the testing regime. It failed to do the proper learning needed to move itself 
towards increasingly realistic, and expensive test, conditions. Ultimately, the entire gp160 
operational trajectory failed to acquire legitimacy and credibility because, as the theory 
chapter suggested, vaccine development is necessarily cumulative and the knowledge 
acquired by undertaking a phase III trial on gp160 did not have an adequate base to build 
on. Trail and error is a learning tool only as long as the research process can incorporate the 
lessons of the error in a repeated game (otherwise it is just failure); and for this, sound 
governance of the testing regime is needed. 
 
The case of gp120 displayed some differences however. The companies involved in this 
operational trajectory had progressed through the testing regime, but its problems 
highlighted weaknesses in different parts of the testing regime. It meant that whilst they had 
observed efficacy in some conditions and not in others, they were not able to interpret the 
significance of those changes for real-world use. The lack of knowledge infrastructure, such 
as standardised challenge stocks, virus types and antibody neutralisation protocols, served 
to exacerbate uncertainty. 
 
The combination of uncertainty and inability to readily access instruments and testing 
resources such as tissues, primary isolates, monkeys, chimpanzees created a ‘vicious 
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circle’. It introduced an element of gambling when one thought one had a good enough 
hand. Costs increased further when the development of antiviral treatments, such as AZT, 
emerged. Non-pecuniary, but path-dependent, costs such as the consumption of available 
human test subjects also needed to be considered in the decision to gamble forwards. 
 
The NIH’s decision meant that the vicious circle was not broken, and private investments in 
the AIDS vaccine dried up. However, VaxGen managed to attract some new investment 
following the WHO’s encouragement and declaration of support for phase III trials. The 
contrasting decisions of the NIH and WHO reflect some similarity to the decisions taken by 
USA and USSR regarding choice of poliomyelitis vaccines discussed in section 6.6.3. 
 
As decisions were increasingly made in the context of the vaccines’ planned use, broader 
public health issues, such as safety, needs and costs, were likely to have had a more 
subjective bearing, resulting in more heterogeneous outcomes. As Jasanoff (in Epstein 
1996:277) notes, the experts on these sorts of panels ‘seem at times painfully aware that 
what they are doing is not ‘science’ in any ordinary sense, but a hybrid activity that 
combines elements of scientific evidence and reasoning with large doses of social and 
political judgement.’ This indicates that the institutional aspects of the testing regime 
become increasingly important towards the innovation end of the development process. In 
this sense, social visions return to the fore. 
 
But there are important differences between the poliomyelitis and HIV cases. The 
USA/USSR divergence occurred after standards of clinical efficacy had been established in 
trials whilst the NIH/WHO divergence occurred before phase III trials had been 
undertaken. The fact that such divergences occurred in both instances, when there was low 
and high uncertainty about the vaccine efficacy, before and after innovation one might say, 
suggests that socio-economic forces do not act on vaccines only after they have been 
innovated. Sociological and economic enquiries into vaccine choice, and vaccine product 
demand are therefore likely to be missing important dynamics that explain heterogeneity in 
vaccines. 
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The divergent decisions also indicate that phase III trials do not answer questions of how to 
proceed in the face of the vast diversity of operating conditions around the world. It 
suggests that there can be no one single testing regime capable of encompassing all possible 
technological needs, requirements and values in its evaluation. Consequently, there is little 
point in trying to find a technology that is ‘best’ or ‘optimal’ for everyone in every 
situation. 
 
Because the gp120 vaccine candidate fared so poorly, the results of the phase III clinical 
trial seem to have been largely free from debates about its success, which would typically 
have asked questions such as ‘on what basis do we choose a significance level?’ and 
‘exactly how successful was it?’ These questions dogged the Salk and Sabin vaccines long 
after their respective clinical efficacy trials, well after they were introduced, and the debates 
continued long after data started to be collected about their real-world use (Carter 1965). 
 
Similar to the Hammon trials (see section 6.4), these trials may be forgotten in future 
historical accounts of the development of an HIV vaccine. Whilst Hammon demonstrated 
that a ‘low concentration of antibodies will protect man’ (Hammon, Corriel et al. 
1953:1283), the HIV phase III trials did the opposite. They confirmed that an antibody 
response was not enough to confer protection against HIV infection. This affected future 
decisions about which operational trajectory to pursue. At the recent International AIDS 
Conference, the global health director of the Gates Foundation said, ‘The road to success is 
littered with failure, we have to be unafraid to fail’ (Picard 2008). 
 
In addition, the clinical trials helped to establish field-based testing capabilities. For 
example, they prepared activists and patients for placebo controlled trials. As was the case 
in the Salk trials, many objected to the use of ‘sacrificial lambs’ or ‘death by placebo’ 
(Epstein 1996:214)16. Without their co-operation and the compliance of trial subjects, test 
results could not be shared, related and interpreted. 
 
                                                 
16
 One subject who had discovered he was in the placebo arm commented, “Fuck them. I didn’t agree to 
donate my body to science, if that is what they are doing, just sitting back doing nothing with me waiting until 
I get PCP [Pneumocystis carinii pneumonia] or something” (quoted in Epstein 1996:214). 
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For HIV/AIDS, clinical trial designers and activists were brought together to negotiate 
aspects of the trials and learn from each other. For example, such discussions yielded 
grounded and tacit knowledge about the conduct of clinical trials. Fauci said that activists 
often had ‘an extraordinary instinct… about what would work in the community and 
probably a better feel for what a workable trial was than the investigators [had]’ (quoted in 
Epstein 1996:249). 
 
For activists and participants, trials represented a means of early access to new 
technologies. However, their position began to shift to one where they acknowledged that 
placebos were sometimes in the participants’ individual and collective long-term interest, 
‘whether they realise it or not, and no matter how many signs they paint and march around 
with’ (Byar in Epstein 1996:250). 
 
Clinical trial designers exclude certain population groups to remove extraneous variables 
and yield ‘clean data’ (Epstein 1996:253). Activists often objected, seeing the exclusions as 
arbitrary. The trade off was one where ‘strict entry criteria promised an efficient trial, but 
one that might lack generalisability; and broad criteria meant that findings would be 
generalisable but that the trial would be less efficient in the short run’ (Volderberg in 
Epstein 1996:256). In the terms set out in chapter 3, the conditions of the trial could be 
institutionally set to either facilitate learning more, or represent real-world conditions 
more17. 
 
Building field test capabilities is a large, but necessary, undertaking which requires 
considerable co-ordination and institutional guidance (see figure 9 below). It ensures that 
clinical trials are feasible and can be conducted where participants conform to expected 
behaviour. The prescribed and constrained behaviour during clinical trials are a legacy of 
the last set of ‘relevant’ conditions in the testing regime where technological knowledge 
was accumulated, typically characterised by phase I or II safety trials. 
 
                                                 
17
 Contaminants could be re-framed as virtues and warrants of validity. They were difficult real-world 
conditions, not artificially pristine laboratory ones. 
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In the cases of the gp160 and gp120, it fell on the shoulders of industrial scientists to 
negotiate with the governments of the US and Thailand, and to build the needed capabilities 
for clinical trials. However the activity yields little theoretical or scientific knowledge, and 
may be less attractive for academic scientists. It then effectively becomes a market-driven 
process, with consequent limitations in the way that the field trial can inform the overall 
research challenge. 
 
Therefore, poor candidates, such as gp120, and even weaker candidates, such as gp160, 
may reach expensive clinical trials when the testing regime is weak. It struggles to 
differentiate between other candidates tested in cheaper learning conditions, and to 
accurately predict effectiveness of the operational principle. The testing regime influences 
field trials and the subsequent capacity of the research community to learn from them 
because, as summarised in figure 9, there may be constraints the design of trials, changing 
ethical and social norms, and the goals of the vaccine being tested. The relationship 
between the testing regime and the goals of vaccine design is discussed further in the next 
section. 
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Figure 9: Clinical trials require coordination 
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9.6 From HIV vaccine to AIDS vaccine: admitting defeat? 
 
9.6.1 A new vision 
 
Since the late 1990s, expectations of a vaccine against HIV shifted to a new perspective. ‘It 
is not time to give up on HIV vaccines but to change the way we pursue them’ (Gallo 
2005:1898). Scientists had known that, ‘the window of opportunity to clear HIV and 
prevent long term, established infection may close permanently once a pool of latently 
infected cells is in place’ (Johnston and Fauci 2007:2074). Aiming to prevent the ‘latent 
infection’ that Johnston and Fauci refer to, sets the standard for an effective HIV vaccine 
very high. It not only needs to provide high levels of protection, it needs to do it very 
quickly. Achieving such a standard is unprecedented as Johnston and Fauci (2007:2074) 
explain. ‘This aspect of HIV infection puts it in sharp contrast with almost all other viral 
infections, in which the initial rounds of viral replication do not establish a permanent 
reservoir of infection. For this reason, HIV poses a greater challenge to the classic 
vaccination paradigm in which prevention of clinically relevant infection ultimately leads 
to the eradication of the microbe, even though initial rounds of viral replication may occur.’ 
 
Graham makes a similar point but suggests that we need to aim for other, lower, goals. ‘It is 
unlikely that vaccine-induced immune responses will be able to prevent the establishment 
of [HIV] latency… A more realistic initial goal for HIV vaccine development is to dampen 
the initial viremia in an infected individual, maintain a low virus load, and prevent 
progression to AIDS’ (Graham 2002:208). 
 
Desrosier’s inability to explain his finding of live vaccine protection (section 8.5.3), and 
Stott’s (section 8.5.1) explanation of killed vaccine protection in his controls, together with 
the phase III results of the subunit vaccine all ushered in a new mood that protective 
efficacy simply could not be achieved. The question of aiming for a lower standard of 
delaying or preventing disease became more pertinent. 
 
I refer to the shift in emphasis away from infection and onto disease progression as a shift 
away from hoping for an HIV vaccine to developing an AIDS vaccine. Smith crystallises 
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such a shift in a short sentence, ‘vaccination, which may not affect the infection rate, may 
prevent disease’ (Smith 2002:107). Preventing progression to disease, however, was not the 
only reason for a shift towards an AIDS vaccine. Other benefits of an AIDS vaccine which 
lowers virus load are that it could also reduce transmission within the population18, 
diminishing the spread of the epidemic. These side-benefits had now become re-framed as 
more central virtues. 
 
The technological vision outlined in section 7.1 was re-shaped into a new, more modest but 
more complex, form19. The new vision implied that whilst HIV infection may not be 
prevented, the onset of AIDS could be prevented or delayed, symptoms made less severe, 
and the prospect of HIV transmission to another person could be vastly reduced. Vaccines 
need no longer be seen as the traditional injection that provided complete invulnerability to 
a disease environment. They were a substance that exploited the immune system for some 
kind of perceived or actual benefit that blurred the lines between a preventative 
prophylactic and a therapeutic treatment20. The prospect of an AIDS vaccine gave rise to a 
new choice between normal treatment drugs for an infected population, and a vaccine-drug 
for a healthy population to slow disease progression should they become infected. 
 
Thus the testing regime worked to some extent in that it forced researchers to confront 
more honestly the formidable biology of HIV. The testing regime helped recognise that any 
vaccine that might appear soon would not act fast enough to protect the body from 
infection. The lesson was that complete protective efficacy would have to wait; perhaps 
until a low efficacy vaccine could be used as a stepping stone to accumulate further 
technological knowledge. As IAVI’s vaccine blueprint notes, ‘The next major advance on 
the way to the ultimate goal will be the first demonstration that a candidate benefits 
humans, by delaying the onset of disease… This intermediate achievement, even if it does 
not lead directly to a licensed vaccine, would help solve key riddles that have impeded 
                                                 
18
 Efficiency of transmission is directly related to plasma virus levels (Johnston and Fauci 2007). 
19
 Pondering a question as fundamental as whether we are developing an HIV vaccine or and AIDS vaccine 
after a decade of effort reflected the fading overconfidence with which scientists began the vaccine search 
when Margaret Heckler famously predicted it would take only two years (see section 7.1.1). 
20
 This has given rise to the exciting concept of cancer vaccines, where the immune system is primed to 
identify and kill only cancer cells and not healthy cells. 
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advances, give researchers a platform on which to improve, and attract investment and 
creative energy to the field’ (IAVI 2008a:1). 
 
9.6.2 Rigidities in and around the testing regime 
 
With respect to the new vision outlined above, there were several rigidities in the testing 
regime that had formed around the original HIV vaccine vision and the notion of a 
traditional vaccine. Firstly, the MicroGeneSys debacle most likely damaged the credibility 
of any vaccine approaches focussing on disease expression for the foreseeable future. Such 
effects indicate that the testing regime is part of a path-dependent search, where altering 
entrenched goals and mismanaged tests of the past may incur additional costs in the present 
or future. 
 
Secondly, other findings in the 1990s also prompted concern over the goal of the vaccine. 
Vaccinated monkeys who had failed to resist challenges and became infected often fared 
better than the unvaccinated controls in terms of suffering fewer opportunistic infections, 
less pervasive SIV infections (for example lymph nodes only and not blood infected), lower 
viral loads, and generally staying alive for longer (Shafferman, Lewis et al. 1992; 
Shafferman, Lewis et al. 1993). 
 
This new emphasis called for a lot of old data to be reanalysed, but in many cases the 
monkeys had died, or the surviving ‘failed’ monkeys had been killed off. Even for the 
monkeys that were still alive, researchers would need more resources such as laboratory 
space, extra cages, and more personnel to care for the monkeys. These are practical issues 
one might call ‘research infrastructure’ and they are critical in making a testing regime 
strong. A scientist-led funding environment that calls for new and more research is likely to 
overlook this by favouring requests that detail new research ideas rather than proposals that 
ask for more resources to strengthen infrastructure. 
 
Thirdly, if an AIDS vaccine candidate (rather than an HIV vaccine) were to reach clinical 
efficacy trials, there would be difficulties in setting an end point to the trial. The often long 
incubation period (decades) between infection and disease means that staging a trial with 
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disease as the clinical endpoint would require many more years and many more people to 
reach a statistically significant answer21. Participant retention may be challenging and 
costly. In cases where disease does occur, examining whether symptoms are more or less 
severe would require considerable re-conceptualisation of what is and what is not feasible 
in clinical efficacy trials. Few tests exist to detect subtle but important changes in patients 
that may occur. All of these issues suggest that new ways of looking at the virus also 
demand new ways of looking at the testing regime.  
 
This shows how the complexities of the testing regime shapes the characteristics of the 
technology being tested, the characteristics in this case being prevention of or delayed onset 
of disease or symptom alleviation. The rigidities of the clinical trial design had a direct 
influence on the goals and aims of HIV (or AIDS) vaccine research and development. 
Constructing a testing regime that is sensitive enough to detect a non-traditional vaccine 
may be prohibitively expensive. 
 
These deductions arrive at a peculiar conclusion: aiming for a vaccine of lower efficacy 
could cost more to develop due to testing requirements. This finding is likely to be 
generalisable to developing vaccines against other pathogens too. Thus, the move from 
laboratory idea to clinical efficacy trials and use in public health is a multifaceted and 
complex transition that begins from the early evolving technological vision of the vaccine 
and its testing regime. 
 
Fourthly, even if such an AIDS vaccine was accepted through clinical trials, Johnston and 
Fauci contemplate further implications of disseminating such a vaccine. ‘[These] vaccines 
represent uncharted territory, and their use may have outcomes that challenge researchers 
and regulators alike. If proven successful, a disease-modifying [AIDS] vaccine would also 
present new challenges for the entire public health community, since it would not be a 
stand-alone preventive measure, as are most classic preventive vaccines. Instead, it would 
                                                 
21
 This assumes that the rate of new infections is constant. The length of the trial, the clinical end point 
chosen, the rate of new infections and the number of participants are four variables which are all closely inter-
related. Changing one directly impacts on the others (interdependencies are depicted in figure 9). 
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need to be delivered in the context of a comprehensive HIV-prevention program’ (Johnston 
and Fauci 2007:2073). 
 
A low efficacy AIDS vaccine runs the possibility of misleading some people into a false 
sense of security, and influencing them to employ other means of protection less often or 
less consistently. Practicing more risk behaviour, rather than less, could limit the impact of 
the vaccine somewhat. Also, the existence of a moderately effective vaccine could make 
future testing of other, possibly more effective vaccines much more difficult and less of a 
priority. 
 
Many scientists now believe that an HIV vaccine in its traditional sense is impossible or 
unlikely (Connor and Green 2008). Some retain hope that an imperfect or low efficacy 
vaccine is possible. These kinds of vaccines are likely to be of significant value to public 
health in contexts where infection rates are high and ‘herd immunity’ may be achieved 
(Mclean and Blower 1993; Garnett 2005; Farlow 2006). However, this section has 
suggested that the possibility of a new paradigm of vaccination, led by a putative AIDS 
vaccine with treatment and prevention blurred, also needs attention to the development of a 
relevant testing regime, as have previous vaccine paradigms. 
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Chapter 10 
 
Conclusions 
 
This chapter summarises the main outcomes of the research and discusses implications for 
theory and policy. It also makes some recommendations for future research and discusses 
limitations of the study. 
 
10.1 Summary 
 
This thesis has been concerned with the rate and direction of vaccine innovation. Technical 
change in vaccines is widely recognised as requiring urgent policy attention. The analysis 
in chapter 2 found that current policies towards this are implicitly based on what may be 
termed as ‘demand-pull and science-push’ models of innovation. It was argued that these 
approaches, whilst beneficial in thinking of an overall policy set, are likely to understate the 
inherent uncertainty involved in vaccine innovation. An implication of this, is the 
importance of infrastructure that allows researchers to learn. The chapter located the idea of 
‘testing regimes’ within theoretical perspectives on science and technology policy. 
 
The thesis introduced and developed concepts of the testing regime, operational principle, 
and social vision. As discussed in chapter 3, they draw on evolutionary theories of technical 
change, engineering studies, and social theories of technology respectively. It is argued that 
these concepts, by providing greater insight into the knowledge and innovation process, 
may help develop better policies in conjunction with prevailing sociological, political and 
industrial perspectives. 
 
The testing regime is argued to be a set of governed instrumentalities that create 
intermediate conditions central for learning and technical development. The thesis shows 
how testing regimes, when set in the context of social visions, can be a useful lens for 
tracking and exploring the development of operational principles in the innovation process. 
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It suggests that the emergence of certain vaccines is dependent on the ability to test and 
learn, and on an infrastructure that facilitates cumulative knowledge growth. It argues that 
these are important issues about the production of technological knowledge, as distinct 
from scientific knowledge, that need to be addressed for innovation to proceed. 
 
Chapters 4 and 5 emphasised the importance of analysing these issues in sufficient detail, 
and in cases of failure as well as those of success. As such, the study undertook a survey of 
historical and scientific literature about a case where multiple vaccines were developed and 
another case where a vaccine was not developed, despite significant investments. 
 
The concepts of testing regimes, social visions and operational principles were applied in 
the empirical chapters of the thesis (6, 7, 8 and 9). They show that vaccine research into 
poliomyelitis and HIV have been led by contrasting social visions, features of the testing 
regime and development of operational principles. These points are elaborated below. 
 
10.1.1 Poliomyelitis vaccine innovation 
 
Chapter 6 argued that a strong and inclusive social vision was necessary before a significant 
technological effort could begin. Crucial to initiating the innovation process was an 
increasingly specific characterisation of the condition as a disease, eventually named as 
poliomyelitis, after a series of previous names which reflected different characterisations. 
As Rosenberg (2002) suggested, once a predictable life course was outlined for the disease, 
it organised social and economic resources around the particular phenomenon of 
poliomyelitis. 
 
By identifying an infectious agent, Landsteiner’s cause specification allowed the technical 
community to rally around a vision for a vaccine. Flexner’s optimism about the possibility 
or expectation of a vaccine was publicised to the wider community just as a major 
poliomyelitis epidemic was taking hold. The affliction of Roosevelt added to the perceived 
importance of conquering the disease. Together, these factors helped to mobilise resources 
and attention to poliomyelitis. However, Roosevelt’s involvement in setting up an 
organising foundation was perhaps more significant in the development of a testing regime. 
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As a result, the search for a poliomyelitis vaccine was uniquely led by non-private 
administration – this is likely to have affected the norms and values of the vaccine 
developers. 
 
The Brodie-Kolmer failures were perhaps indicative of these norms, which valued urgency 
and immediacy of testing. But the failed trials indicated that the testing regime was initially 
weak. Researchers had not learnt enough about the virus, instrumentalities were poorly 
developed and efforts were not well co-ordinated. 
 
In order to accumulate technological knowledge, the National Foundation for Infantile 
Paralysis adopted a leading role to ensure certain features of the testing regime were 
developed. The need for virus and monkeys was met by supporting the development of 
tissue culturing and the establishment of a monkey farm. This allowed more tests to be 
done in intermediate conditions and their results to be fed back quickly. A large project to 
type polioviruses was also undertaken to provide crucial knowledge about which strains the 
vaccine would need to provide protection against. 
 
The Hammon trials strengthened the testing regime by continuing the effort to turn 
subjective design aims into objective specifications. Thus qualities such as strength and 
durability of immunity were translated into measures of antibody concentration. The trials 
also improved field-based capabilities for more scale-intensive testing. Various indices 
were developed1, and these scales formed an important part of the standardised knowledge 
infrastructure against which field tests could be evaluated. The Foundation strengthened its 
administrative capacity for coping with the logistics of large scale immunisation and co-
ordinating the supply of testing resources. Fostering public support was important for 
ensuring that there were enough volunteers and gamma globulin to test with. The trials 
provided all vaccine designers with an important correlate for immunity, a design standard, 
by showing that relatively little antibody was needed for efficacy. 
                                                 
1
 Firstly, an index was developed to gauge how much antibody was needed for immunity in monkeys. 
Secondly, the trials allowed a similar index to be constructed for humans, which addressed crucial questions 
about the longevity and efficacy of neutralising antibodies for human immunity. Thirdly, graded scales were 
developed to measure varying degrees of severity in the symptoms of poliomyelitis. 
 245 
 
The availability of disabled children and prisoners (and lower ethical standards than apply 
today) helped Salk and Sabin to test early versions of their vaccines. The operational 
trajectory forged by Salk went against scientific orthodoxy, and the Foundation mediated 
differences of opinion about efficacy, safety and when to test. One principal means for 
doing this was to strengthen the test by insisting on an unprecedented placebo arm, against 
the wishes of the main vaccine developer2. 
 
Sabin developed a different operational trajectory, but faced a scarcity in testing resources 
in the wake of the Salk trials. Although Sabin found significant sums of money to fund 
research, the number of remaining vaccine volunteers in the US were limited and he had to 
conduct tests of his vaccine in the Soviet Union. Testing in a different country emphasised 
the relative components of successful innovation because the conditions in, and the 
requirements of, the Soviet Union were significantly different. 
 
As technological knowledge accumulated, the testing regime needed to adapt to ensure that 
test-results remained stable and conclusive. However, this was not the case, and there was a 
weakening of the testing regime in the face of technical advance. As tests became less 
conclusive, different researchers began to promote their respective vaccines. At this stage, 
the institutions in the testing regime played more dominant roles because conditions of use 
are less shared than they were in the development stages. The USA and USSR are different, 
but their laboratories were probably less so. 
 
10.1.2 HIV/AIDS vaccine innovation efforts 
 
Chapter 7 argued that the initial rate of technical change in HIV vaccine development was 
slow because there were competing social visions about how the disease should be 
addressed. Its association with drug users and homosexuals led to the absence of co-
ordinating visions. Even for the technical community who wanted to pursue a vaccine, 
there remained competing visions about which approach should be used, despite a wide-
                                                 
2
 Salk described the placebo arm as a ‘fetish of orthodoxy’ (Carter 1965:192). 
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scale dominance of the reductionist sub unit approach using molecular biology (chapter 8). 
The scope for multiple competing visions remained large well into the development 
process, and mechanisms for resolving them suffered from difficulties in characterisation 
and causes of the disease, resulting in widely varying expectations of what a vaccine could 
or should do. 
 
Characterisation of the illness was difficult because deaths were due to indirect causes3, 
and all that was initially known was that the immune system was somehow weakened. The 
disease was originally overshadowed by its social interpretation and the illness was 
connected to homosexuality (GRID). The deaths were subsequently connected to a broader 
pattern and renamed as a less specifiable syndrome (AIDS). Thereafter, the origins and 
cause of AIDS remained unclear for a decade, and many contested the identification of 
HIV as the cause of AIDS. For those in the technical community who felt that AIDS was 
adequately characterised and HIV was sufficient as its causal explanation, the expectations 
of a preventative vaccine were publicly optimistic, as they were for poliomyelitis. But for 
many in the wider community, there was apathy for those most at risk to AIDS. Many felt 
little or no imperative to act, despite optimistic forecasts. 
 
Part of the shift to a broader and more stable perspective of the syndrome was facilitated by 
the development of HIV diagnostic tests and surrogate markers. The use of diagnostic tests 
strengthened the case for HIV as the cause for AIDS, whilst prompting stronger concerns 
about its spread through to the ‘general population’. However, the vast range of surrogate 
markers indicated that AIDS remained poorly characterised and required shared knowledge 
growth. Visions for what a vaccine should achieve struggled to find common ground 
beyond the basic premise that a diagnostic blood test should remain negative after a 
vaccinated person has been exposed to the virus. Nevertheless, it was an instrument that 
provided a crude but tangible goal for vaccine designers. 
 
Strengthening the testing regime was hindered by two salient characteristics of the virus. 
Firstly, the virus exhibits extreme variation. This placed great pressure to design a vaccine 
                                                 
3
 Patients succumbed to a variety of opportunistic infections. 
 247 
that gets to work quickly before the virus has time to change. After an individual is 
infected, the window of opportunity is very small within which an effective immune 
response must be mounted before the virus becomes too varied and sequestered. Rapid 
evolution of the pathogen also introduced a strategic element in vaccine design that centred 
on the question of how many targets represent ‘enough’ to overcome the possibility of viral 
resistance. 
 
Secondly, humans lack sterilising immunity for HIV and cannot clear the virus after 
infection. Natural sterilising immunity would provide research clues from the body’s 
immune response to the virus. This means that researchers lacked a natural mechanism to 
mimic for vaccine design. It also made testing prototypes in humans dangerous and 
precluded a lot of early stage trial and error learning. These two characteristics of the virus 
have imposed difficult vaccine design constraints. 
 
Chapter 7 described the representation of animals as intermediate conditions, a part of the 
testing regime that allows changes to the operational principle to be tested for reliability 
and relevance. Animal models were described as stepping stones to vaccine trials in 
humans. In this way, they have provided a solution to the problem of trialling vaccines 
against pathogens to which humans do not have any natural sterilising immunity. For other 
diseases4, where animal models have not provided adequate intermediate conditions, it was 
still possible to forge ahead with a ‘guts and judgement’ approach for those viruses because 
natural sterilising immunity existed in humans. 
 
The problem in the case of HIV was that both hurdles need to be crossed: a lack of natural 
sterilising immunity and a lack of animal models. This combination, the thesis argues, is a 
key element in explaining the lack of success in HIV vaccine innovation that has been 
overlooked in previous studies of vaccine innovation (for example Archibugi and Bizzarri 
2004; Blume and Lindner 2006; Chataway, Brusoni et al. 2007). 
 
                                                 
4
 For example, measles, mumps, rubella, and varicella (see section 8.1.2). 
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However, chapter 7 noted that focusing solely on these hurdles is an over-simplification. 
Whilst natural sterilising immunity is an exogenous constraint, the lack of animal models is 
not necessarily so. Animal models did not simply appear ready-made to be taken ‘off the 
shelf’ to provide intermediate conditions. Their use as ‘models’ was dependent on a 
considerable body of knowledge. Animals were used in conjunction with techniques, skills 
and instruments and were thus moulded into standardised conditions from which shared 
interpretations and inferences could be made about realistic operating conditions. 
 
Animals were, in this sense, fabricated through the use of techniques such as genetic 
engineering. They needed to be supplied, fed, observed and looked after. They needed to be 
selected for their appropriateness because, for example, monkeys offer different 
possibilities than those offered by chimpanzees. In short, there was considerable scope for 
variation in the use and manipulation of animals for the purposes of technological 
development. 
 
This variation in experimental conditions was a key reason why institutional guidance was 
required to co-ordinate and standardise R&D efforts towards technological, rather than 
solely scientific, goals. Such an instrumental perspective of animals meant that governance 
was also required to mediate concerns about animal rights with those of technological 
development. 
 
10.1.3 The direction of inventive efforts in HIV/AIDS vaccine innovation 
 
Chapter 8 showed that a weak testing regime could impact on the selection and 
development of operational trajectories. The combination of both a lack of suitable animal 
models and a lack of natural sterilising immunity impacted on not only the rate but also the 
direction of innovation because the combination had differing implications for differing 
vaccine approaches. 
 
For whole-virus approaches, the inability of humans to clear HIV infection accentuated 
safety concerns and emphasised the need to develop a vaccine through intermediate 
conditions provided by animals. However the lack of animals, or instrumentalities for 
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developing them into good models, meant that such intermediate conditions were not 
forthcoming. In the laboratory, conditions were too artificial to develop efficacy by trial-
and-error; whilst in humans, there was too little room for error in order to learn safely. This 
favoured operational trajectories that were seen as more rational, less dependent on 
intermediate conditions, and altogether safer regardless of how tried and tested other 
approaches proved to be in the past. 
 
The subunit approach suffered from a lack of vaccine knowledge for other viruses. All 
vaccines in the past have used whole viruses, with only a single exception where a subunit 
was used. Scientists and companies pursuing this approach lacked skills and acquired 
capabilities. Most private actors adopted the subunit approach as part of a broader effort to 
develop a platform of biotechnology competences from which they could launch into other 
markets. 
 
Viral diversity and the lack of natural sterilising immunity also affected the various 
approaches differently. Whilst the lack of natural sterilising immunity undermined the 
safety of whole vaccines, it drew attention to the increased safety of an approach that relied 
on only small antigenic parts of the virus. However, the efficacy of such an approach was 
most susceptible to viral diversity precisely because it only relied on small antigenic parts 
of the virus. Viral diversity meant the subunit approach needed highly specific instruments 
and techniques to facilitate efforts to find conserved non-variable regions, such as the V3 
loop. This places greater pressure on policy to support the development of a different set of 
instruments than in other approaches. 
 
The trajectory also raised the possibility of having to find different conserved regions for 
strains of viruses in different parts of the world. This exacerbated concerns about global 
inequities in the development of, and access to, new health technologies. This also raised 
additional policy questions about the testing regime and its impact on the direction of 
innovation for certain groups of people compared to others. 
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Later, the importance of another approach came to the fore. In addition to requiring 
antibodies to protect cells from being infected, it became clear that a cellular immune 
response would also be needed to deal with cells that were infected. This implied that 
researchers thought that a vaccine may not be able to prevent infection completely and 
vaccine efforts were increasingly viewed in terms of ‘damage limitation’. The issue was 
that the subunit approach was not very good at stimulating a cellular immune response, 
especially when compared to the live vaccine approach. Rather than defer to the 
development of live vaccines, private sector researchers attempted to develop new 
approaches. 
 
Private sector efforts were lacklustre and narrowly focussed on biotechnological 
approaches. They suffered from takeovers from large pharmaceutical firms, faced intra-firm 
competition for resources and an overall lack of finance. The problem of designing an 
effective vaccine was perceived as being extremely difficult, and any solutions to be a long 
way off. Market rewards were thus heavily discounted and most likely played little role in 
firms’ investment decisions. Firms faced a scarcity of testing resources, in terms of animals 
and virus, their work was fragmented due to a lack of organised comparability, and there 
were testing constraints due to the effects of prior smallpox vaccination. 
 
The subunit approach remained dominant, as live and killed vaccine approaches were 
stalled due to weaknesses in the testing regime. Problems in the killed vaccine approach, 
when Stott used monkeys as intermediate conditions, may have been identified earlier if 
more monkeys were made available. The opportunity to improve learning conditions with 
better instrumentalities seems not to have been taken. Monkey cell lines were not 
developed to allow monkey-monkey tests, where SIV grown in monkeys (rather than 
humans) is used both for vaccination and subsequent challenge. Attempts to re-frame the 
problem as the basis for a new operational trajectory were thwarted by limited scope for 
creating intermediate conditions. Furthermore, central to the approach was a relativistic and 
differentiated view of the need for, and risks of, organ transplanting around the world. 
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The live vaccine approach seemed promising, even in conditions that were more stringent 
and realistic than those of subunit approach tests. But, again, there was a reluctance to 
consider risks in relative terms. And the skills of endocrinology were not called upon to 
develop the instrumentality of monkey twins. Technological development thereafter 
evolved along a path-dependent ‘subunit-approach’ trajectory. 
 
10.1.4 HIV vaccines in clinical efficacy trials 
 
Chapter 9 discussed the role of the testing regime in deciding at which point in a trajectory 
its operational principle should be subjected to large scale efficacy testing. The case of 
MicroGeneSys showed that a poor vaccine candidate could not be easily eliminated from 
others for phase III testing because the testing regime was weak. MicroGeneSys’s vaccine 
performed poorly and the trial indicated how urgently institutional leadership and guidance 
was needed to mediate conflicting interests over the terms of the test. For example, 
MicroGeneSys resisted comparisons to other vaccines, and contested the controls and the 
end points of the trial. 
 
Chapter 9 argued that the way in which phase III trials were staged showed that the subunit 
vaccine was selected and developed in a weak testing regime. The move to large scale 
field-tests of poliomyelitis vaccines was also difficult, but the uncertainties about the 
subunit HIV vaccine seems to have been more problematic. 
 
There were arguments to proceed with the trials. Antibodies were thought to provide 
protection, but their mechanism was poorly understood. Industrial actors stressed a ‘vicious 
circle’ in which most, if not all, of their commitment to HIV vaccine development was 
staked on their ideas thus far being tested in phase III trials. The subunit approach was not 
thought to pose a significant safety risk to volunteers and past experience with hepatitis B 
had been positive. The trials were an opportunity to be seen ‘doing something’. 
 
There were arguments against going ahead with the trials. Antibody titrations were often 
not conducted in a standardised and comparable way, and test conditions were too varied. 
Crucially, the titrations relied on laboratory-adapted viruses rather than primary isolates. 
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Laboratory-adapted viruses represented artificial conditions, whilst primary isolates 
represented more realistic conditions. Results of tests with monkeys were difficult to 
interpret because they dealt with SIV rather than HIV. Tests on chimpanzees were done 
with HIV but, owing to their expense, such tests were few and far from systematic. 
 
Such tests also suffered from two examples of weak knowledge infrastructure. Firstly, 
challenge stock was poorly developed. Researchers inferred that it took more HIV to infect 
a chimpanzee than humans, but they were not certain how much more. They were not 
certain how critical HIV infection dose varied by animal species and virus type. Secondly, 
virus type was not catalogued systematically by observing different immune responses in 
animals (as was done for poliovirus), but rather proxied by deviation from the V3 loop, an 
extremely small fragment of HIV. Such extrapolation undoubtedly saved animals and 
expense, but added considerable uncertainty. 
 
The NIH decided not to proceed with the trials. But public health officials at the WHO 
made a contrasting recommendation. The WHO committee emphasised that risks and 
benefits can be different for different countries around the world. They endorsed trials in 
Thailand, but did not offer further guidance on the tests’ difficult ethical and analytical 
issues regarding access to cocktail drugs for trial participants. The vaccine was 
unanimously accepted as ineffective. 
 
The trials served to strengthen the field-based testing regime, playing a similar role to 
Hammon’s trials of poliomyelitis vaccine. The HIV trials confirmed that antibodies on their 
own cannot confer immunity (Hammon confirmed that they could for poliovirus). The early 
trials were similarly useful for capability-building. The need for placebo trials was 
affirmed, and the chance to renew and build skills for designing, administering and 
executing a large scale test was taken. 
 
The differing decisions taken by the US and Soviet Union, and the NIH and WHO, suggest 
that a single phase III trial is not capable of accommodating the vast diversity of 
technological needs and values around the world. There can be no best or optimal 
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technology for all people in all situations and vaccine choice in the latter stages needs to be 
a more socially inclusive process that is likely to stress institutions more. 
 
Chapter 9 also suggested that the testing regime had locked researchers into aiming for a 
standard of vaccine that is higher than widely desired or expected. This refers to the lower 
goal of an AIDS vaccine that slows down disease through an immune response, and to the 
higher goal of an HIV vaccine that triggers an immune response which completely prevents 
infection. The chapter argued that testing constraints and rigidities make it more expensive 
to focus vaccine development efforts on an AIDS vaccine. The chapter suggested that this 
may be a potentially new paradigm of vaccine innovation and deployment, but it is unlikely 
to emerge in the current testing regime. 
 
10.2 Theory and policy implications 
 
There is a strong and urgent need for an AIDS vaccine and substantial investments have 
been made to encourage its innovation. However, there is large variance in vaccine 
innovation, and various explanations and policy recommendations have been forwarded by 
sociologists, economists, and scientists. 
 
This thesis has focused more squarely on the knowledge production stage and identified a 
missing dimension in existing explanations. This draws on the idea that innovation requires 
technological knowledge, taken from literature on technological change, histories of 
technology and studies in engineering. 
 
The empirical chapters supported the idea that vaccine design cannot be simply deduced 
from scientific principles. It supported the notion that the design of operational principles 
can follow different technological trajectories, such as the subunit vaccine approach, and 
that these trajectories can then be refined into yet more technological sub-paradigms, such 
as vector-based subunit approaches. 
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The thesis used the testing regime lens to argue that vaccine innovation has become 
increasingly indirect and iterative. This resonates with recent evolutionary theories about 
the increasing prevalence of ‘offline’ testing (Nelson 2008a; Nelson 2008b). The thesis has 
added to theory by showing how the testing regime is an environment in which the 
manipulation of intermediate conditions (rather than offline or online), with well-developed 
instruments and tacitly acquired skills, is a governed process that leads to the accumulation 
of technological knowledge. 
 
The thesis has suggested that in testing regimes, deadlocks in the growth of knowledge may 
be released with the development5 of instruments and skills because they can help make 
critical changes in testing conditions. However, the thesis has also emphasised that the 
inter-relationships between newly acquired findings are as important as the findings 
themselves. Findings in monkeys, need to be related to findings in chimpanzees, which 
both in turn need to be related to humans. The thesis concludes that the production of 
technological knowledge requires institutional guidance in order to encourage cumulative 
growth and limit fragmented growth. 
 
The thesis has suggested that the growth of robust knowledge is scaffolded through projects 
such as virus typing and developing challenge stock. Although the validity of knowledge is 
enhanced through testing in varied conditions, governance is also needed to set standards 
that make the findings of one research group more relevant to another. It is in these 
institutionally standardised conditions that reliability is then established through repetitive 
and intensive tests, such as phase III clinical trials. In this sense, socially produced 
knowledge becomes stabilised technological knowledge when it is true, shared and 
integrated. 
 
The empirical chapters also suggested that as products emerge from testing regimes, and 
are anticipated to enter the real world, competing social visions return to the fore. In this 
phase of product development, the way in which a number of features are socially framed 
becomes important. 
                                                 
5
 Development may simply mean making old instrumentalities more widely available. 
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These findings can be generalised across fields such as biopharmaceuticals (defined in 
section 2.5), where contexts of technological application are highly systemic, and the 
systems (such as human bodies) are non-linear, non-decomposable and non-scalable. The 
generalisations are limited however when one ventures into fields where technical experts 
play a less central role, and users are more prominent in shaping technical change. Sectors 
where users play important roles extend beyond craftwork, to increasingly lucrative 
industries such as computer video games, music and fashion tailoring (von Hippel 2005; 
NESTA 2008). In such contexts, users may be subject to more varied modes of governance 
and institutional norms than required in a testing regime. Moreover, the indirect 
environment afforded by a testing regime becomes a disadvantage, in that it is more likely 
to result in innovations that users are dissatisfied with. The findings of this thesis do not 
generalise to such fields where users play more active inventing roles and, at the very least, 
conclusions derived in this thesis should be extended with extreme caution with respect to 
how instrumentalities are employed in less institutionalised environments. 
 
Some critical policy steps can be identified from the testing regime framework presented in 
the thesis. Instrumentalities, which are made up of instruments, skills and capabilities, need 
to be nurtured and developed because they are essential to the manipulation of conditions 
for learning. Institutions, which govern vaccine research and development, are needed to 
accumulate knowledge for innovation. 
 
This may take the form of ensuring the plentiful supply of reagents, monkeys, chimpanzees, 
test-subjects, and instruments. The work will require highly skilled personnel, so HIV 
vaccine development needs to attract experienced vaccinologists, who can also offer 
technological training to younger researchers well-versed in scientific methods. This is 
likely to require stable, consistent and non-contingent institutional funding. 
 
Policy makers should also consider offering contracted research grants as a complement to 
investigator-initiated research. This is because the development of new instruments, 
techniques and knowledge infrastructure may require targeted strategic attention. Well 
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funded investigator-initiated research may yield exquisite science, but contracted grants 
will ensure mundane research is undertaken systematically. It is likely that both will be 
essential for innovation. 
 
Strengthening the overall testing regime by undertaking these steps is likely to accelerate 
vaccine innovation. However, strengthening different elements of the testing regime may 
have uneven effects on the rate of innovation, the direction of innovation, and the decision 
to test in clinical efficacy trials (suggested by chapters 7-9 respectively). So improving the 
supply of animal models may have stronger effects on the rate of innovation, developing 
instrumentalities may have a stronger effect on the direction of innovation, whilst 
improving governance, co-ordination and leadership may exert its strongest effects in 
clinical trials and the later stages of vaccine development. It should be noted however, that 
these are merely differences in emphases of various policy options. Each policy option is 
likely to have overlapping and helpful outcomes. 
 
10.3 False dichotomies and technological knowledge 
 
A number of policy dichotomies misrepresent the role of technological knowledge 
accumulation as examined in this thesis. Economists argue that well funded market policies 
will induce vaccine innovation whilst scientists assert that laissez-faire science push 
policies will eventually deliver a vaccine. Both neglect the role of technological knowledge 
in innovation. Market policies may play a more important role later in the innovation 
process, but they are less relevant at this stage because many companies perceive 
innovation to be so far away, or even impossible (Batson and Ainsworth 2001). Thus, 
market rewards become heavily discounted or even irrelevant. 
 
This thesis has contributed by showing that focussing on examples of centralised research 
successes or failures, such as the Manhattan Project or the Virus Cancer Program, misses a 
very significant issue for innovation. Wilson et al.’s (2007:35,36) conclusion that ‘mission 
mode is appropriate only when the path to success is relatively clear’ and that ‘what matters 
is whether rapid progress in following up on existing ideas is more important than 
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generating new ideas’ implies the important question is when should research be co-
ordinated or decentralised. This thesis has suggested that certain kinds of research activities 
generate technological knowledge needed for innovation. These activities require 
governance to set up and maintain throughout the innovation process.  
 
Similarly, attempting to distinguish between basic and applied science (see Calvert 2001), 
neglects the role of technological knowledge in innovation. Stokes’ (1997:73) influential 
framework attempts to reduce the tendency of policy makers to pit basic and applied 
research against each other. He suggests that the spectrum be orthogonally split into a two 
dimensional grid where the motivation to improve understanding lies on one axis and the 
motivation to improve use lies on the other. This gives rise to four quadrants, one of which 
accommodates concerns for both use and understanding (labelled as ‘Pasteur’s quadrant’). 
This thesis provides examples of research that might fall into Pasteur’s quadrant with its 
detailing of cases such as the virus typing project and development of challenge stock. 
 
However, Stokes’ reconciliation does not seem to be borne out by HIV/AIDS vaccine 
scientists, many of whom find notions of use an encroachment on academic freedom. For 
example, a renowned biochemist working on HIV wrote ‘We do not need an ‘AIDS 
Manhattan Project’, the centralisation of the atomic bomb had more to do with national 
security reasons than with scientific ones. What we do need is an emphasis on small basic 
research projects aimed at better understanding HIV’s interactions with the human body; 
such projects are already underway…’ (Moore 1993). 
 
Moore also wrote, ‘This approach is contrary to the way in which all great scientific 
discoveries have been made – free spirited questioning of the unknown in investigator-
initiated research projects. To apply office-management techniques to the utterly different 
discipline of the laboratory displays a profound ignorance of scientific research’ (Moore, 
quoted in Cohen 2001b). 
 
In defending academic freedom, Moore neglects the ultimate issue, which is one of 
technological innovation and not ‘scientific research’. A linear model appears to underlie 
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his comments, where technological innovation is believed to inevitably follow scientific 
progress. Issues such as testing resources, instrumentation, animal models, and knowledge 
infrastructure do not feature in his policy prescriptions. The HIV/AIDS vaccine problem for 
Moore, and those who share his view, is clearly one of not enough ‘free-spirited’ science6. 
 
Vaccines have been critical to the elimination of disease at global and local levels. But what 
emerges clearly from this thesis is that they are difficult to develop, and they need to keep 
up with evolving disease ecology and changing social contexts. A system is needed that can 
not only develop vaccines for an array of diseases, but can achieve this again and again. 
This thesis has argued that vaccine innovation should be examined as a process of 
accumulating knowledge, one that is embedded in a social system. 
 
However, these contemporary debates tend to view vaccine innovation as a one-off event 
that is framed by dichotomous explanations. So vaccine innovation may be induced by 
market forces or deduced from scientific understanding, or it can be leveraged by altering 
the balance of basic or applied science, or it may be brought about by encouraging free- 
spirited investigation or establishing strategic targets. Focusing on the accumulation of 
technological knowledge, this thesis reveals not only how arbitrary these segregations can 
seem, but it also shows that establishing a sustainable vaccine innovation system is - more 
importantly - what is at stake. 
 
The testing regime lens highlights parts of the public infrastructure needing investment and 
maintenance if we are to create a vaccine system that is responsive, adaptable and prepared 
for infectious disease outbreaks such as ‘swine flu’ or ‘bird-flu’7. Preparedness for such 
contingencies is likely to be affected by the provision of stable funding for building a 
skilled workforce that can use instruments in a variety of ways, alongside effective 
                                                 
6
 See the Myth of Unfettered Research (Sarewitz 1996). 
7
 I am aware that investments to mitigate infectious disease outbreaks outside the vaccine system altogether 
may be just as effective and equitable for public health (if not, more so). For example, investing in more 
sustainable agricultural systems in developing countries, or in countries such as China and Mexico where 
‘swine flu’ and ‘bird flu’ are thought to have originated, may prevent or reduce the frequency of such 
outbreaks. Preventative strategies mean that everyone benefits, without having to consider who might have 
access to newly developed vaccine technologies. 
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governance mechanisms that are capable of coordinating and identifying strategic priority 
research areas. 
 
10.4 Final Conclusions 
 
This thesis has used evolutionary theories of innovation to show that vaccine development 
is a highly uncertain and groping process. It has contributed to theory by showing how 
these uncertainties are reduced incrementally, purposefully, and indirectly within well-
developed testing regimes. Policy makers should acknowledge that investing in a dedicated 
testing regime, alongside science investments, is an expensive and long-term endeavour8. 
 
This thesis has indicated that policy makers should be sceptical about the idea that vaccine 
development is very different from other complex technological processes, and should not 
assume that scientific knowledge from academic institutions will lead to a clear, certain and 
costless path to a vaccine. If potential problems in the accumulation of technological 
knowledge are not understood, anticipated and addressed, then progress towards sustained 
innovation will stall, whether one is considering vaccines or any other complex technology 
that requires multiple scientific advances. This thesis concludes that the social imperative 
for an HIV vaccine could be more quickly met through carefully designed science and 
technology policies to address current barriers in the accumulation of technological 
knowledge. 
 
                                                 
8
 Suggesting that the process of accumulating technological knowledge is long and expensive is consistent 
with the fact that two thirds of R&D costs are spent on the D part (Rosenberg 1994:13). 
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Appendix 
 
THE WHITE HOUSE 
Office of the Press Secretary 
PRESS BRIEFING BY LARRY SPEAKES 
October 15, 1982, 12:45pm EST 
The Briefing Room 
Q: Larry, does the President have any reaction to the announcement - the Centers for Disease Control in 
Atlanta, that AIDS is now an epidemic and have over 600 cases? 
MR. SPEAKES: What's AIDS? 
Q: Over a third of them have died. It's known as "gay plague." (Laughter.) No, it is. I mean it's a pretty serious 
thing that one in every three people that get this have died. And I wondered if the President is aware of it? 
MR. SPEAKES: I don't have it. Do you? (Laughter.) 
Q: No, I don't. 
MR. SPEAKES: You didn't answer my question. 
Q: Well, I just wondered, does the President - 
MR. SPEAKES: How do you know? (Laughter.) 
Q: In other words, the White House looks on this as a great joke? 
MR. SPEAKES: No, I don't know anything about it, Lester. 
Q: Does the President, does anyone in the White House know about this epidemic, Larry? 
MR. SPEAKES: I don't think so. I don't think there's been any - 
Q: Nobody knows? 
MR. SPEAKES: There has been no personal experience here, Lester. 
Q: No, I mean, I thought you were keeping –  
MR. SPEAKES: I checked thoroughly with Dr. Ruge this morning and he's had no - (laughter) - no patients 
suffering from AIDS or whatever it is. 
Q: The President doesn't have gay plague, is that what you're saying or what? 
MR. SPEAKES: No, I didn't say that. 
Q: Didn't say that? 
MR. SPEAKES: I thought I heard you on the State Department over there. Why didn't you stay there? 
(Laughter.) 
Q: Because I love you Larry, that's why (Laughter.) 
MR. SPEAKES: Oh I see. Just don't put it in those terms, Lester. (Laughter.) 
Q: Oh, I retract that. 
MR. SPEAKES: I hope so. 
Q: It's too late. 
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THE WHITE HOUSE 
Office of the Press Secretary 
PRESS BRIEFING BY LARRY SPEAKES 
December 11, 1984,12:03 p.m. EST 
The Briefing Room 
MR. SPEAKES: Lester's beginning to circle now. He's moving in front. (Laughter.) Go ahead. 
Q: Since the Center for Disease Control in Atlanta (laughter) reports... 
MR. SPEAKES: This is going to be an AIDS question. 
Q: that an estimated 
MR. SPEAKES: You were close. 
Q: Well, look, could I ask the question, Larry? 
MR. SPEAKES: You were close. 
Q: An estimated 300,000 people have been exposed to AIDS, which can be transmitted through saliva. Will 
the President, as Commander-in-Chief, take steps to protect Armed Forces food and medical services from 
AIDS patients or those who run the risk of spreading AIDS in the same manner that they forbid typhoid fever 
people from being involved in the health or food services? 
MR. SPEAKES: I don't know. 
Q: Could you - Is the President concerned about this subject, Larry 
MR. SPEAKES: I haven't heard him express... 
Q: ...that seems to have evoked so much jocular 
MR. SPEAKES: ...concern. 
Q: reaction here? I - you know –  
MR. SPEAKES:: It isn't only the jocks, Lester. Has he sworn off water faucets? 
Q: No, but, I mean, is he going to do anything, Larry? 
MR. SPEAKES: Lester, I have not heard him express anything on it. Sorry. 
Q: You mean he has expressed no opinion about this epidemic? 
MR. SPEAKES: No, but I must confess I haven't asked him about it. (Laughter.) 
Q: Would you ask him Larry? 
MR. SPEAKES: Have you been checked? (Laughter.) 
 
(Source: Cohen 2001; taken from The Reagan Library, Press Office Transcripts). 
 
 
 
 
 
 
 294 
 
